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Abstract 
The thesis is focused on the design and synthesis of 3-D fragments to explore new areas of 
pharmaceutical space. Chapter 1 provides an overview of fragment-based drug discovery 
including, fragment design, screening and synthesis. The diastereoselective synthesis of nine 
pyrrolidine and piperidine fragments A-I is described in Chapter 2. These fragments were 
identified as suitable 3-D fragments based on a 3-D shape analysis using principal moments 
of inertia. The key step in the synthesis of the 2,3-disubstituted pyrrolidines was the 
stereoselective reduction of the dihydropyrrole to afford the cis-diastereoisomer, with the 
trans-isomers accessed via epimerisation. The piperidines were synthesised via 
hydrogenation of the pyridine to give the cis-diastereoisomer as the major product, with the 
trans again access via epimerisation of the methyl ester. Chapter 3 covers of methodology 
for the synthesis of all 20 regio- and diastereosiomers of piperidines J. The syntheses were 
completed using three main types of methodology: pyridine hydrogenation, epimerisation 
and lithiation-trapping of N-Boc piperidines. 
 
In Chapter 4, a different approach to 3-D fragment design and synthesis was developed.  
Here, the focus was on the identification of synthetic methodology that would allow the 
incorporation of different scaffolds and a range of aromatic/heteroaromatic groups. Ester 
enolate α-arylation and α-alkylation were the two approaches used to design fragments K 
and L which had their shapes analysed, with the most 3-D fragments selected and 
synthesised.  
 
Finally, the entire York 3-D fragment library was compared against a set of commercial 
fragment libraries to evaluate their usefulness in drug discovery, with the analysis fully 
summarised in chapter 5. 
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Chapter 1 Introduction 
1.1 Fragment Based Drug Discovery (FBDD) 
1.1.1 Introduction 
The emergence of fragment based drug discovery (FBDD) over the last 20 years has opened 
the door for medicinal chemists to explore more challenging biological targets for the 
development of new drugs.1 The first notion of fragments goes back to 1981, with Jencks’ 
work on the attribution and additivity of binding energies. In that work, it was proposed that 
a molecule can be considered as containing two or more smaller molecules (fragments) 
which have the ability to bind to a target.2 Over 10 years later, the technology behind FBDD 
started to be shaped by Fesik et al. from Abbot Pharmaceuticals. They developed a NMR-
based method to determine structure-activity relationship (SAR) which offered the ability to 
screen a large quantity of fragments against a target protein.3 The binding interactions of low 
affinity fragments could be detected at adjacent binding sites and structural information such 
as the binding region and the orientation of the bound fragment could be determined from 
the NMR spectrum. Once two fragments were determined to bind to the target at adjacent 
binding sites, they could then be linked to produce a higher affinity binding ligand. 
FBDD offers a different approach to previous drug discovery methods such as high 
throughput screening (HTS), which is widely used by pharmaceutical companies to obtain 
lead compounds for their drug discovery programs.4 HTS libraries often contain 100,000s of 
drug-like molecules, broadly obeying Lipinski’s ‘Rule of five’, which have been adopted as 
a guideline for orally available drugs.5 The rules are used as a general guide and consist of 
four parameters: molecular weight (MW) ≤ 500, ClogP ≤ 5, hydrogen bond donors ≤ 5 and 
hydrogen bond acceptors ≤ 10, where ClogP is a measure of the lipophilicity expressed as a 
ratio of octanol solubility to aqueous solubility. These rules were proposed based on the fact 
that 90% of orally active drugs in phase II clinical trials at the time were within these 
parameters, meaning that the molecules show acceptable solubility and intestinal 
permeability, so that they can enter the bloodstream. In comparison, fragments are often 
defined as obeying the ‘Rule of three’ with MW ≤ 300, ClogP ≤ 3, hydrogen bond donors ≤ 
3 and hydrogen bond acceptors ≤ 3.6 Researchers at Astex have since refined these guidelines 
and proposed that fragments should ideally have MW between 140-230, heavy atom count 
(HAC) 10-16 and ClogP 0-2.7 Molecular weight and ClogP typically increase in size during 
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the optimisation of the fragment to a more lead-like compound before ultimately reaching 
the optimal drug-like space (Figure 1.1).  
 
Figure 1.1 – Drug-like chemical space, which generally could be defined within the red dotted oval. As MW 
and ClogP increases (arrow), a suitable starting point would be the fragment space region of the graph (small 
blue circle).8 
1.1.2 High Throughput Screening versus Fragment Based Drug Discovery 
High throughput screening (HTS) is a highly successful method for initiating drug discovery 
and involves the screening of typically 100,000 or more lead-like compounds (MW > 350 
typically). The advantage of this method comes from the high binding affinities that can be 
achieved, which removes the need for sensitive screening methods. However, the 
disadvantage of this approach is that the compounds being screened are complex and often 
non-drug-like with poor physicochemical properties, thus requiring further optimisation. 
The size of the molecules means that the potential chemical space is vast, with an estimated 
1060 organic molecules possible with a MW < 500. As a result, HTS libraries containing 
100,000 compounds seem extremely small compared to the large amount of chemical space 
that remains unoccupied with these libraries.9  
For comparison, Reymond et al. computationally analysed the chemical space of molecules 
with a HAC of ≤ 17 i.e. within fragment space.10 With the use of mathematical graphs, 
geometrical strain and functional group criteria, to ensure that the produced molecules made 
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chemical sense, they enumerated 166 billion different organic molecules containing carbon, 
nitrogen, sulfur, oxygen, fluorine, chlorine, bromine and iodine.11–13 Therefore, the sampling 
of chemical space is more efficient with fragments, compared to molecules within HTS 
libraries, which makes them more appealing as a starting point. Another consideration is the 
simplicity of fragments and their lack of molecular complexity compared to larger molecules 
which may lead to higher hit rates with fragments. Hann et al.14,15 studied the correlation 
between molecular complexity and the probability of finding hit compounds. A simple 
molecular interaction model was used based on the assumption of two types of interactions. 
If the receptor and the ligand are mismatched, then this indicated no affinity of the ligand to 
the receptor. A series of simulations was run using these assumptions to predict the 
probability of a ligand with a pre-determined number of interaction features binding to a 
receptor with a random sequence of interaction features. The results showed that as 
molecules increase in size, then the probability of measuring the binding interactions 
increased, but the probability of finding a hit decreased, as there are fewer ways of obtaining 
favourable interactions (Figure 1.2). Therefore, the probability of useful events (purple line) 
describes an interaction that is both favourable and measurable. The maximum can be seen 
to peak at about 5 interaction features. Thus, smaller fragments with lower complexity and 
fewer points for interaction should be able to bind to a greater number of sites and as a result 
lead to higher hit rates. 
 
Figure 1.2 – The graph shows the probability of a match vs probability of measuring binding, which is 
represented by the probability of a useful event (purple line).15 
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Hann’s molecular complexity model also highlights one of the main disadvantages with 
FBDD, namely that weaker binding affinities are observed with smaller molecules. The 
binding affinities are usually in the region of mM or high μM. Therefore, there is a 
requirement to use sensitive screening methods such as NMR-based approaches and X-ray 
crystallography, which can be more time consuming.7 Despite this, FBDD has been a huge 
development for the discovery of lead compounds for a variety of diseases and has already 
led to the discovery of new drugs. 
1.1.3 Fragment Based Drug Discovery Successes 
The first drug which emerged from FBDD was Vemurafenib (Zelboraf), which is a treatment 
for late-stage melanoma.16 The drug targets BRAFV600E, a kinase found in many types of 
cancer. Preclinical studies showed that proliferation of melanoma could be stimulated by 
BRAFV600E, with its suppression leading to the regression of the tumour.16 A fragment library 
of 20,000 compounds was initially screened against a family of five kinases. This screening 
identified 238 compounds for follow-up studies. The use of 3-dimensional structural analysis 
enabled scaffold selection based on the number of sites for chemical growth, along with the 
position and interaction within the binding pocket. This was accompanied with biological 
assays that allowed selection of a series of potent compounds. Vemurafenib was selected 
after optimisation of binding affinity, selectivity and pharmacokinetics. Vemurafenib was 
optimised starting from a 3-substituted 7-azaindole initial fragment hit 1 (Scheme 1.1). 
 
Scheme 1.1 
The route that was developed for the synthesis of Vemurafenib for preclinical research is 
shown in Scheme 1.2.17 The first step involved sulfonylation of aniline 2 to afford 
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sulfonamide 3. Formylation to give aldehyde 4 was achieved using ortho-metallation of the 
aromatic ring using LiHMDS and a morpholine amide under microwave conditions. 
Addition of the 3-substituted aza-indole 5 was achieved by nucleophilic attack of the aza-
indole onto aldehyde 4 and then rearomatisation to give alcohol 6. Finally, oxidation of the 
secondary alcohol in 6 to the ketone using DDQ gave the desired Vemurafenib.17       
 
Scheme 1.2 
The second drug to be discovered using FBDD was Ventoclax, which has been approved in 
the USA as a treatment for chronic lymphocytic leukaemia.18,19 Ventoclax was found to be 
an inhibitor of proteins in the B cell CLL/lymphoma 2 (BCL-2) which are key in the 
apoptotic process. The initial fragment hits were the two aromatic rings highlighted in Figure 
1.3.  
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Figure 1.3 – Ventoclax, an approved treatment for chronic lymphocytic leukaemia. 
The original route to Ventoclax, started with the conversion of β-ketoester 8 into enol triflate 
9. Next, Suzuki-Miyaura cross coupling to give 10 followed by reduction of the ester with 
LiBH4 furnished primary alcohol 11. Mesylation and then subsequent nucleophilic 
substitution with N-Boc piperazine and Boc group removal gave intermediate 12 (Scheme 
1.3). 
 
Scheme 1.3 
A SNAr reaction of intermediate 12 with 7-azaindole 13 then afforded disubstituted 
piperazine 14, which underwent ester hydrolysis to afford carboxylic acid 15. The final step 
of the synthesis involved amide coupling of carboxylic acid 15 with sulfonamide 16 using 
EDC to give the desired drug molecule Ventoclax (Scheme 1.4). 
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Scheme 1.4 
As of July 2016, along with Vemurafenib and Ventoclax, there were a further 30 lead 
compounds which were in either phase I or II clinical trials.1 For example, Astex developed 
a drug candidate, which was in phase II clinical trials, targeting the Aurora and JAK2 
kinases.20 The initial target was the Aurora kinase which consists of the two isoforms, Aurora 
A and B, which are linked to the regulation of mitosis. As a consequence, drugs targeting 
the inhibition of the Aurora kinase have become popular anticancer treatments. Astex’s 
initial fragment hit was pyrazole-benzimidazole 17, which showed high affinity towards 
Aurora A. The key interactions were the three-hydrogen bonds with the carbonyl of an 
alanine residue and the NH of a glycine residue within the hinge region. Installation of the 
basic morpholine group on the benzimidazole core, combined with the para-
fluorobenzamide, afforded a ten-fold increase in affinity for Aurora B. Replacement of the 
amide linker with the urea offered a folded conformation, placing the urea substituent closer 
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to the benzimidazole. Finally, optimisation led to the inclusion of a cyclopropane which kept 
the proximity to the benzimidazole and reduced the lipophilicity of the molecule (Scheme 
1.5). 
 
Scheme 1.5 
The remaining 27 lead compounds included four where the structural information had not 
been shared within the public domain. However, analysis of the remaining 23 compounds 
revealed that they contained between 2-5 aromatic rings, with some of the compounds 
containing relatively few sp3 centres (Figure 1.4). 
 
Figure 1.4 – Lead compounds with one, two or four sp3 centres. 
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Despite the high number of aromatic rings, 16 of the lead compounds also contained 
saturated heterocycles. Over half of the current lead compounds derived from fragments 
incorporated morpholine, pyrrolidine, piperazine, piperidine, lactam, cyclohexane and 
tetrahydropyran (THP) saturated rings; selected examples are shown in Figure 1.5.  
 
Figure 1.5 – Lead compounds containing saturated heterocycles, such as piperidine (red), morpholine (blue) 
and piperazine (pink). 
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1.2 ‘Escape from Flatland’ 
‘Escape from Flatland’ is part of the title of a paper published by Lovering et al. in 200921 
which describes an analysis of molecules as they proceed through the different stages of the 
drug discovery process. Specifically, the analysis explored the correlation between 
molecules making it through clinical trials and how this related to the number of sp3 
hybridised carbon atoms and stereogenic centres within the molecule. 
Traditionally, the properties assessed during the discovery-to-drug process focused on polar 
surface area (PSA), MW, rotatable bonds and hydrogen bond donors and acceptors. 
However, the complexity of the molecules was not considered. Lovering proposed fractional 
sp3 (Fsp3) as a descriptor for the saturation of a molecule, which could be used as a measure 
of molecular complexity. Fsp3 is defined as the number of sp3 hybridised carbon atoms 
divided by the total number of carbon atoms within the molecule. Lovering proposed that an 
increase in molecular complexity and saturation may offer the ability to access a wider region 
of chemical space which may not be accessible with flat aromatic rings. Therefore, this could 
lead to an increase in the selectivity and potency of the drug.  
The paper analysed all of the compounds, in the period 1980-2009, which have either been 
reported to have biological activity or were described within a medicinal chemistry patent. 
The results showed a correlation between increasing Fsp3 and the progression of a drug 
candidate through clinical studies, with a 31% increase in saturation when comparing 
discovery molecules to drugs. The second method they used for accessing molecular 
complexity was the presence of stereocentres. The paper revealed a 33% increase in the 
number of stereocentres when comparing discovery molecules to drugs. 
Finally, the effect of increased saturation on the physical properties such as solubility and 
melting points of the compounds were compared. There was a correlation between increased 
Fsp3 and increased solubility, with a reduction in melting points. The improved solubility 
for molecules with increased saturation and complexity could be attributed to the observed 
trend, as molecules with high solubility are more likely to succeed as suitable drug 
candidates. 
A further study reported by Ritchie et al.22 focused on the number of aromatic rings within 
drug molecules and whether that was detrimental to drug design. The study selected 
compounds within the GlaxoSmithKline pipeline over a period of time and revealed that the 
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average number of aromatic rings in a compound at the preclinical stage was 3.3. The 
number then decreased to 2.3 for compounds that were in proof-of-concept trials. The 
decreasing trend in the number of aromatic rings as a drug got closer to the market suggested 
a detrimental effect on the number of aromatic rings within drug molecules. However, there 
are benefits for inclusion of aromatic rings, as they can offer an increase in the ligand-
receptor binding energy, due to the fewer degrees of freedom that aromatic rings possess. It 
has also been shown that aromatic rings do have an effect on the physical properties of the 
drug molecule. Ritchie et al. analysed over 26,000 compounds within the GlaxoSmithKline 
compound library and were able to show a correlation between the number of aromatic rings 
and ClogP. It was found that the inclusion of an aromatic ring gave a significant increase in 
ClogP, with fewer compounds having ClogP ˂ 3 upon addition of an aromatic ring. 
Decreasing the starting ClogP value is an important feature as, increasingly, there have been 
studies showing a trend in logP drift owing in part to the difficulties associated with polar 
molecules and the dearth of methodology available to synthesise such molecules.8  
The studies from Lovering and Ritchie demonstrated the improvement in progression of a 
molecule through clinical trials, when the molecule contained an increased amount of sp3 
centres and fewer aromatic rings. These papers are both focused on the progression of drug 
candidates through clinical trials and support the idea that by increasing the 3-D shape of 
drug candidates, the likelihood of the molecule making it through clinical trials could be 
increased. 
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1.3 Characterisation of 3-D Molecular Shape 
Lovering et al. used Fsp3 as a method to assess molecular complexity, proposing that it 
would enable the design of out-of-plane substituents and, in that respect, increase the 3-D 
shape of a molecule. However, Fsp3 has limitations, as it does not characterise whether or 
not the sp3 carbon is connected to a bond which deviates from the molecule in a way that 
increases the 3-D shape. Furthermore, a molecule containing no sp3 carbon centres does not 
necessarily adopt a flat 2-D structure, which is an assumption made with using Fsp3. 
Sauer and Schwarz, introduced principal moment of inertia (PMI) plots as an alternative 
method for classifying the shapes of molecules.23 Their aim was to develop a method that 
would allow analysis of the shape diversity between compound libraries of varying size and 
complexity. With the aid of a 3-D descriptor they wanted to show the benefits of having a 
library containing multiple scaffolds versus a library derived from a single scaffold, which 
it was proposed would have limited shape diversity. 
A PMI plot is created in the following way. To start with, using molecular mechanics 
typically within conformation generating software, the conformations of a molecule are 
computationally generated and used to calculate the three principal moments of inertia I1, I2 
and I3. The values are then normalised by dividing the two smaller values I1 and I2 by the 
largest value I3 to obtain two normalised principal moments of inertia (NPR1 and NPR2) for 
each molecule. Normalising the values eliminates variation arising from the size (or MW) 
of the molecule. The two normalised values NPR1 and NPR2 are then plotted onto a 
triangular plot. The plots can be used to visualise the degree to which a molecule is rod-, 
disc- or sphere-shaped. The top left apex represents rod-like molecules such as bis-alkynes 
with coordinates (NPR1 = 0 , NPR2 = 1), the bottom apex shows disc-like compounds such 
as benzene (NPR1 = 0.5 , NPR2 = 0.5) and the top right apex represents sphere-like 
molecules such as adamantane (NPR1 = 1 , NPR2 = 1) (Figure 1.6). The PMI plots can then 
be analysed to determine the overall 3-D shape of a compound collection. The rod-disc axis 
will contain molecules which are more 2-D in character with compounds becoming more 
3-D in shape as they occupy the region towards the right apex.  
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Figure 1.6 – PMI plot with the top left apex, bottom apex and top right apex representing rod-like, disc-like 
and sphere-like molecules respectively. 
In order for Sauer and Schwarz to determine whether a small library containing multiple 
scaffolds was more 3-D shaped than a single scaffold library, they created three different 
libraries to analyse. The first library contained a single scaffold (benzodiazopine) with 13 
diverse functional groups to afford a library of 2197 molecules. The second library contained 
the same single scaffold, but this time incorporated 50 diverse functional groups to afford 
125,000 molecules. The final library increased the number of scaffolds to 50 but retained the 
initial 13 functional groups from the first library. Analysis of their respective PMI plots 
revealed that a single scaffold had access to a limited region of chemical space, and that a 
combination of a smaller library consisting of multiple scaffolds produced a library with 
higher levels of shape diversity and coverage. This study highlighted the potential usefulness 
of using PMI plots to assess 3-D shape. 
Prior to the introduction of PMI analysis, an alternative descriptor of 3-D shape was 
proposed by Meyer. In 1985, Meyer described a computational procedure for predicting 
volumes, surface areas and cross-sectional areas of molecules. The data can then describe 
molecular globularity using the visual descriptor of globularity.24 The theory is based on the 
radii of three spheres around the molecule to give a ratio RM. The first sphere of radius R1 
corresponds to a sphere that is equal in volume to the van der Waals volume. R2 is the radius 
of the sphere which has a volume equal to the molecular volume and R3 is the radius of the 
sphere that encapsulates the whole molecule. The shape descriptor is then defined by RM = 
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(R3 ‒ R2) / (R2 ‒ R1), with smaller values of RM corresponding to the molecule being more 
spherical.  
A new 3-D shape analysis tool, the plane of best-fit (PBF), was developed in 2012 by Firth, 
Brown and Bragg. In order to differentiate between flat and non-flat molecules, the following 
descriptions were employed: 1-D molecules consist of all the heavy atoms lying in a straight 
line; 2-D molecules have all of their heavy atoms in the same plane. Therefore, they proposed 
to describe and define how 3-D a molecule was by measuring how much it deviated from 
the 2-D plane.25  
The molecules were assessed using CORINA to generate a single reference conformation.26 
The coordinates calculated for each conformer are used to determine the plane-of-best-fit 
which is solved using a least squares-method.27 The equation of best-fit can then be used to 
give the distance, Δ, of each heavy atom from the plane-of-best-fit. The PBF score is then 
given as an average of all these distances measured in Å. The values can range from 0 to ꝏ, 
but values ranging from 0-2 are expected for small drug-like molecules. Some examples of 
molecules with differing PBF values are shown in Figure 1.7. The molecule which deviated 
the most from the PBF was sulfonamide 18, which highlights the issues with Fsp3 as a 3-D 
descriptor, as the molecule only contains two sp3 carbons compared to morpholine 19 which 
deviated less from the plane but contains nine sp3 carbons. The 3-D shape of the sulfonamide 
18 arises due to the sulfonamide linker, which causes the molecule to fold back in on itself. 
The next most 3-D molecule was morpholine 19, followed by bicycle 20 where the 3-D 
shape was directed by the ortho methyl group which rotates the biaryl bond. As expected, 
planar monocyclic aromatic fragments were completely flat. For example, amidine 21 had a 
PBF score of 0 Å. 
 
Figure 1.7 – Plane-of-best-fit values for four molecules contained within the Institute of Cancer Research 
(ICR) fragment library 
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The PBF approach was then applied to nine diverse compound libraries ranging from small 
fragment libraries to larger compound libraries and then compared against PMI and 
molecular globularity. The results showed good correlation with molecular globularity and 
PMI. Hence, PBF can also be considered a useful tool for analysing the 3-D shape of 
molecules within compound libraries. The one drawback with PBF is that larger molecules 
tend to have larger PBF values, which can make comparisons across different classes 
difficult. 
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1.4 Brief Overview of Fragment Libraries  
Library design is an important aspect of FBDD. In terms of fragment properties, the ‘Rule 
of three’ (MW < 300, HBD < 3, HBA < 3 and ClogP < 3) is important, but there are other 
considerations which need to be taken into account. Fragment libraries should contain a 
diverse set of scaffolds which may allow for better sampling of chemical space.28 Synthetic 
tractability is also an important feature, along with the ability to grow the fragment with 
suitably accessible growth vectors. A final consideration is the avoidance of highly reactive 
functional groups such as acyl chlorides, anhydrides, aziridines and epoxides, which can 
produce false positives in biochemical assays.29,30  
One of the early approaches to library design, was detailed by Fejzo et al. from Vertex with 
their SHAPES library.31 The library was developed to comprise shapes that would represent 
frameworks most commonly found within drug molecules and as a result should have 
favourable physicochemical and biological properties. Commercially available therapeutics 
were analysed and broken down into rings, linkers and sidechains. The rings were classified 
as an array of cyclic atoms, with the linkers being the bonds connecting the rings. Overall, 
the rings and linkers were classified as frameworks with some examples represented in 
Figure 1.8.  
 
Figure 1.8 – Examples of frameworks used for the SHAPES library. 
Within the SHAPES library, focus was placed on the cost, synthetic tractability, solubility 
and separation of the signals in 1H NMR spectra of the frameworks. The fragments were 
screened by 1H NMR spectroscopy to determine any weak affinity binding. Any hits could 
then be used to bias the filtering of a larger chemical database to select a large group of 
molecules for purchase or synthesis followed by HTS. The one drawback with using 
frameworks from commercial therapeutics is the lack of IP and novelty, which leads to 
regions of chemical space being unexplored and not exploited. 
Fragment libraries designed for screening by NMR spectroscopy have been widely 
employed due to the high screening sensitivity of the technique and the ability to screen 
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multiple fragments at once. In 2004, Vernalis developed four libraries consisting of 
commercial fragments for screening by NMR spectroscopy.32 The four main library design 
aspects were: fragments should have good aqueous solubility for the binding experiments; 
fragments needed to be stable in stock solution and should not degrade over time; fragments 
should show chemical diversity and fragments should contain points for diversification for 
growth of the fragments into potential lead or drug candidates. The four designed libraries 
were to be used within their SeeDs (Selection of Experimental Exploitable Drug Starting 
Point) strategy which covers fragment selection, NMR spectroscopy screening and 
determination of the X-ray crystal structure of the fragment bound to the protein. The 
information obtained from the crystal structure can then be used to direct the evolution of 
the fragment into a higher affinity hit. The four designed libraries contained 1315 
compounds and were selected with the help of in silico filters to remove undesirable 
functionality, along with the help of medicinal chemists to remove any likely insoluble 
fragments.  
Another approach to library design is to consider the synthetic tractability of the fragments. 
Novartis previously published their approach to designing fragment libraries for screening 
by NMR spectroscopy.33 However, a few years later, they reported the design of a third 
generation library which offered improved chemical tractability. Functional groups in 
fragments offer potential binding interactions and points for diversification and elaboration 
of the fragment. However, modification of the functionality can cause a reduction in the 
binding interaction of the linked fragments. Therefore, it may be necessary to have fragments 
which have multiple functional groups to allow for fragment linking without loss in potency. 
The other solution is to have a masked functional group, which would resemble the group in 
the linked fragment. Functional group masking has already been applied by Ellman et al. 
with the development of the first highly selective inhibitor of c-Scr which is a key signalling 
kinase in cancer.34,35 The aldehydes were masked with O-methyl oximes via a condensation 
reaction to resemble the functionality in the linked fragment (Figure 1.9) 
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Figure 1.9 – Example of masked functional groups for a fragment linking stratergy. 
Therefore, Novartis developed a fragment pair approach, where fragments would be 
screened with masked functionality, closely resembling the group in the linked fragment.36 
The two fragments would include the ‘masked screening fragment’ which would be 
derivatised with a simple and low MW group, and the ‘synthesis fragment’ which would be 
the main building block. The ‘synthesis fragment’ can contain reactive functional groups to 
allow for a range of chemistry to be undertaken to improve the binding interaction. Examples 
of the types of ‘synthesis fragments’ and ‘screening fragments’ included within the library 
are shown in Figure 1.10. In the first example, the piperazine is masked as the acetamide for 
screening, whereas in the second example the acyl chloride is masked as a secondary amide. 
 
Figure 1.10 – Examples of ‘synthesis fragments’ and ‘screening fragments’. 
In recent years, pharmaceutical companies have been reviewing their fragment libraries to 
try and improve hit rates. In 2009, AstraZeneca reported the design of two generic fragment 
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libraries, one containing 20,000 fragments, and another focused on NMR screening and 
containing 1,200 fragments.37 More recently, AstraZeneca have further re-evaluated their 
fragment library.38 The library re-design has constituted the removal of compounds which 
have been found to decompose, cause assay interference or had poor aqueous solubility, 
which would not suit screening by X-ray, NMR or surface plasmon resonance (SPR). In the 
ten years since the first-generation library was designed, synthetic methodology has evolved 
significantly and, as a result, new fragments were added. Recently, attention has turned to 
evaluating 3-D molecular shape of the fragments in the library, with the use of methods such 
as PMI and PBF. Analysis of their library revealed gaps in the chemical space coverage of 
the current library, which were filled using shape analysis to identify new fragments. In total, 
the second-generation library contained over 15,000 fragments which all largely obeyed the 
‘Rule of three’. 
A comparison of 3-D and 2-D fragments embedded within drug molecules was carried out 
by Chan et al. who took account of different ring sizes and structures.39 A 2-D fragment was 
defined as having no sp3 hybridised carbons, with a 3-D fragment having at least one sp3 
hybridised carbon within the ring. 1297 Drug molecules were analysed and showed a total 
of 433 unique ring fragments, with 101 2-D and 322 3-D fragments. The fragments showed 
a variety of ring sizes with the most common being the 5- and 6-membered rings, with the 
most-used ring systems being bicyclic and spirocyclic fragments. The 3-D fragments showed 
a good distribution of 3-D shape, supporting the theory that 3-D fragments allow for the 
sampling of a larger region of chemical space.  
In Chan’s study, a fragment target class analysis was also carried out, comparing the 
difference in binding between the 2-D and 3-D fragments against 15 different targets e.g 
GPCRs, ion channels and nuclear receptors. The findings showed that for fragments derived 
from nuclear receptors, 92% were 3-D fragments. The 3-D fragments were also found to 
have a high percentage (86%) in cellular proteins. Perhaps the most interesting finding was 
that the 2-D fragments failed to show a higher percentage contribution for any of the 15 
target classes, underlining the potential benefit of 3-D fragments.    
In 2013, in order to take advantage of the potential of 3-D fragments, a 3-D Fragment 
Consortium was set up. The consortium consists of not-for-profit organisations, and they 
outlined their goal of developing a fragment screening library which would have enhanced 
3-D character.40 The aim was to create a library of between 500-3000 fragments which would 
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contain fragments from current libraries and fragments which had enhanced 3-D shape. It 
was proposed that the flatness of current fragment libraries may be a reason for their poor 
success rate for certain protein targets.  
To start with, the 3-D Fragment Consortium analysed a current fragment library consisting 
of 1000 compounds supplied by one of the members of the consortium, and compared them 
to fragments which are embedded in drug compounds which have been evaluated in humans 
(Figure 1.11). The two sets of data were evaluated using a PMI analysis. The results showed 
that the 1000 fragments occupied the region of the PMI plot along the rod-disc axis with 
limited spread across the plot (Figure 1.11a). This contrasted with the PMI plot shown in 
Figure 1.11b, which contained fragments which are embedded in current drug candidates.  
a)                                                                      b) 
 
 
 
 
 
Figure 1.11- PMI plot of 1000 fragments within a current fragment library (a) and fragments which are 
embedded in current drug candidates (b). 
The 3-D Fragment Consortium concluded that the different positional vectors that are 
possible with 3-D fragments might allow for alternative pharmacophore relations, which flat 
fragments cannot obtain. To selected 3-D fragments, the eMolecules and ZINC databases 
were combined to give a combined total of 13.4 million molecules. The molecules were then 
filtered to only include molecules with a HAC of 9-18, and to remove any undesirable 
functionality, which afforded 180,000 molecules. Then, 200 molecules were selected based 
on a 3-D shape analysis of the 180,000 molecules. After the removal of certain molecules 
due to supplier issues or failed quality checks, the library was reduced to 170 fragments. 
Three example 3-D fragments are shown in Figure 1.12.     
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Figure 1.12 – Three fragments inlcuded within the 3-D Fragment Consortium library. 
In the intervening five years, the consortium has grown the library to contain 609 fragments, 
which are publicly accessible via Diamond light source.41 In combination with the library, 
the consortium also designed and developed 3DFIT (3-D Fragment Idea Tool) which is 
computational software that enables users to evaluate the 3-D shape and predict 
physicochemical properties of molecules. The program predicts the seven lowest energy 
conformations for PMI analysis and flags up any parameters that lie outside the boundaries 
which have been established by the consortium. 3DFIT offers a quick and instant assessment 
of the suitability of the molecule, which can help guide synthetic work and offer a useful 
tool for fragment-based drug discovery.  
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1.5 Recent Approaches to Fragment Synthesis 
There is a growing interest in the development of 3-D fragment libraries and synthetic 
methodology related to 2-D and 3-D fragments. This section provides a detailed overview 
of the key work in these areas.  
One of the main disadvantages with FBDD often can be the ability to follow up hits, due to 
the limited availability of chemically accessible growth vectors for fragment elaboration. 
Therefore, Brennan et al. proposed the creation of a poised fragment library, which would 
allow for fast and effective fragment optimisation once a fragment hit had been identified.42 
A poised fragment was defined as a fragment which could be separated into two separate 
synthons linked via the formation of a ‘poised bond’. Chemically similar, commercially 
available synthons could then be bought, and in one synthetic step, follow-up fragment 
analogues could be synthesised and screened (Figure 1.13). 
 
 
Figure 1.13 – A schematic overview of the poised fragment approach, with an example of a poised fragment 
strategy. 
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The ‘poised bond’ forming reaction required reliable and robust chemistry in order to tolerate 
a wide variety of commercially available compounds. Suitable reactions were selected based 
on the ten most common reactions used by medicinal chemists, which included amide 
coupling, reductive amination and Sonogashira coupling.43 They also included 12 
heterocycle forming reactions and a new oxazole synthesis that had been developed within 
their group.44  
A library of 11,677 fragments from the Structural Genomics Consortium was collected from 
in-house libraries and collaborators. The fragments were then assessed based on poised 
fragments and prevalent synthons to create a library of 2347 fragments. To ensure diversity, 
a subset consisting of 407 poised fragments was identified. The 407 fragments were screened 
against pleckstrin homology domain interacting protein (PHIP), which had been identified 
as being overexpressed in metastatic melanomas, and against the PHIP(2) bromindomain 
using X-ray crystallography. For PHIP(2) bromindomain, three fragment hits were 
identified. The three poised fragment hits were in three different classes: thioureas, N-benzyl 
amides and oxazoles. Using the poised fragment strategy, a set of analogues for each class 
was synthesised (Scheme 1.6).   
 
Scheme 1.6 
In addition, Brennan et al. created a poised fragment library based on the 192,000 
compounds within the ZINC fragment-like library which was reduced to 41,271 when drug-
like property filters were applied. A poised fragment analysis was used and a library of 
28,438 fragments were selected. They were surprised to find that 68% of ZINC compounds 
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could be synthesised using 21 different reactions, which highlighted the limited amount of 
synthetic reactions used by medicinal chemists. 
Despite efforts to expand the scope of fragment methodology there are still issues with 
fragment-oriented synthesis. For example, Astex highlighted the issue of fragment 
elaboration and the need for synthetic methodology research to focus on fragment design 
and the elaboration of a fragment hit into a high affinity lead. As a representative example, 
they focused on dihydroisoquinolone 22, as it has ideal fragment properties with a MW = 
147, ClogP = 1.0 and one HBD and HBA. The synthesis of dihydroisoquinolone derivatives 
can be achieved using Rh C-H activation reactions. Rees et al. from Astex designed a series 
of dihydroisoquinolone derivatives, expanding on the current synthetic methodology to 
allow for the elaboration of the fragment to afford an array of near neighbours with 
alternative growth vectors (Figure 1.14).45 
 
Figure 1.14 – Potential fragment elaboration points of the dihydroisoquinolone. 
Starting from aryl-hydroxamate 23, dihydroisoquinolones were synthesised generally with 
high regioselectivity when reacted with monosubstituted alkenes. The mechanism for the 
reaction is believed to involve the coordination of the Rh to the nitrogen which directs the 
cyclometalation to the ortho C-H bond. Reductive elimination and N-O bond cleavage 
affords the dihydroisoquinolone product.46 Reaction of substituted alkenes enabled 
installation of protected polar functional groups which could facilitate future elaboration. 
The installation of monosubstituted alkenes largely afforded a single regioisomer. Insertion 
of the silyl protected alcohol afforded a 50:50 mixture of regioisomers which were separable. 
Despite the low regioselectivity, the route offered access to both regioisomers in good yields 
(Scheme 1.7).  
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Scheme 1.7 
Aryl substituted hydroxamates were also explored to give compounds with a bromide or 
methyl ester. Cyclisation of the meta-methyl ester afforded a single regioisomer, with the 
meta-bromide giving the desired product along with a small amount of the ortho-Br product 
(Scheme 1.8). Incorporation of heteroaromatics can modify the physicochemical properties 
of the fragments. Cyclisation was known with thiophenes and pyridines and the scope was 
expanded to include thiazoles, albeit in low yields. Cyclisation with chlorothiazole 
hydroxamate afforded an 80:20 mixture of regioisomers (Scheme 1.9). 
 
Scheme 1.8 
 
Scheme 1.9 
The products of the reactions shown in Scheme 1.8 and Scheme 1.9 are not considered to be 
fragments, but rather they are building blocks offering points for elaboration via cross-
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coupling or reduction. Thus, Rees et al. had been able to show that the dihydroisoquinolone 
fragment had the potential to be derivatised and elaborated by offering differing synthetic 
handles or regions for protein binding. However, the work undertaken to synthesise near-
neighbours for just the one fragment demonstrates the challenges faced by medicinal 
chemists and the need for newly designed fragments to incorporate accessible points for 
fragment elaboration. 
Fragment libraries often contain ‘privileged scaffolds’ derived from known drugs and this 
results in similar regions of chemical space being covered by the libraries. Another approach 
to fragment design would be to consider natural products, which have already been 
biologically validated in nature. Waldmann et al. outlined and demonstrated an approach 
towards the design and synthesis of a natural product inspired library.47 Natural products 
benefit from having a high number of sp3 centres and offer access to regions of chemical 
space currently unoccupied by commercial compounds. The natural product derived 
fragments would retain high numbers of sp3 centres and resemble natural scaffolds. Thus, 
fragmentation of natural products was undertaken with the position and substitution patterns 
retained from the natural product, but with an alteration of the functional groups. The 
deconstruction of Renieramycin P into five fragments is shown in Figure 1.15.  
 
Figure 1.15 – Deconstruction of Renieramycin P to afford five fragments. 
In total, 751,577 natural product derived fragments were generated and then filtered based 
on toxicity, stability and ‘Rule of three’ compliancy to afford roughly 160,000 fragments. 
To further refine the library, iterative clustering was performed to produce 2,000 clusters 
each showing high diversity and a richness in sp3 centres. The chemical space coverage of 
the natural product library was then compared to a commercial ZINC fragment library. 
Analysis of the two libraries revealed that the two shared little overlap in chemical space.  
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In order to demonstrate that the natural product derived library could be applied to a drug 
target, the fragments were screened against p38α MAP kinase. A subset containing 193 
fragments (or close analogues) was selected from the initial 2,000 fragments based on their 
availability. Screening of the library revealed unique binding to the allosteric pocket with 
bicyclic cytisine/sparteine derivatives, which offered a new starting point for future kinase 
inhibition. 
Fragments inspired by natural products have also been reported by researchers at Novartis 
with their development of a fragment library consisting of 3-D and nature-inspired 
fragments.48 An in-house library of 17,000 natural products was subjected to in silico 
fragment generation, yielding 66,000 fragments. Natural products were selected based on 
ease of cleavage, introduction of sp3 centres and potential rearrangements. The known 
degradation of Tacrolimus is an example of their fragmentation approach. Ozonolysis of 
Tacrolimus followed by reduction or oxidation yield aldehyde, alcohol or carboxylic acid 
fragments (Scheme 1.10). 
 
Scheme 1.10 
The method of deconstruction via known routes of degradation was applied to other natural 
products, affording a library of 150 3-D and natural product-like fragments. The library was 
then compared against a Novartis in-house library for 3-D shape and natural product-
likeness. The data revealed that the new library occupied novel areas of chemical space and 
showed a greater degree of natural product-likeness.  
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The biological relevance of sp3 rich fragments which are distantly related to natural products 
has been shown by Nelson et al. with their ‘top-down’ synthetic approach towards natural 
product-like frameworks.49 Starting from complex, but easily available intermediates, they 
synthesised 22 scaffolds which contained natural product-like features. The 22 scaffolds 
were then derivatised to create a library of 52 fragments, which were assessed against a 
commercial fragment library, showing increased natural-product likeness and greater shape 
diversity. In order to show the biological relevance of the fragments, they screened the 
library against three different protein targets, and obtained 17 hits (Figure 1.16 - ). Screening 
a conventional fragment library, containing 700 compounds, against one of the protein 
targets achieved nine hits compared to the seven hits achieved with their own library. Thus, 
a higher hit rate was achieved with the shape-diverse natural product-like fragments 
compared to the conventional flat fragment library. 
 
Figure 1.16 - Three shape-diverse natural product-like fragment hits. 
The work on fragments inspired by nature has indeed offered a greater coverage of 
biologically relevant chemical space. However, the synthesis of natural product-derived 
fragments remains challenging, with the development of novel and innovative chemistry 
often required to synthesise the fragments of interest. 
The ability to introduce diversity within fragment libraries can often prove challenging. 
However, there are synthetic strategies that have attempted to address the issue. For example, 
diversity oriented synthesis (DOS) can enable the synthesis of a series of compounds 
containing structural complexity and diversity.50 Starting from simple building blocks, 
molecular complexity and diversity can be introduced in four to five steps to create a library 
of fragment-sized molecules which have the ability to be further elaborated. In 2011, Young 
et al. reported the first example of a DOS approach to synthesise fragments which had 
structural and stereochemical diversity, focusing on bicyclic and spirocyclic systems.51 
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Young et al. started from a selection of proline building blocks such as cis-24, trans-25 and 
26 and the different stereoisomers were used to incorporate stereochemical diversity into the 
fragments that were synthesised (Figure 1.17).  
 
Figure 1.17– Examples of stereochemical diverse 3-D building blocks. 
Young’s strategy used proline-like building blocks cis-24, trans-25 and 26 as the starting 
point for a build/couple/pair approach. Starting with chemically diverse starting materials, 
coupling with differing functional groups would offer the diversity before the final ‘pair’ 
phase in which the molecules would be subjected to coupling conditions to afford a higher 
degree of complexity within the molecule. This led to small fused bicyclic fragments which 
all obeyed the ‘Rule of three’. Coupling of proline derivative cis-24 with N-Boc amino acids 
gave amides 27 and 28, whereas N-sulfonylation gave sulfonamides 29 and 30. The 
substrates all had varying alkyl chain lengths with terminal alkenes, allowing for subsequent 
ring-closing metathesis with Grubbs I or II catalyst. The esters were cleaved with TFA to 
afford carboxylic acids with a range of different fused ring systems (Scheme 1.11).  
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Scheme 1.11 
The fragments synthesised all had a high degree of complexity, with the DOS approach 
offering control of each position on the ring. An advantage of the approach is that 
derivatisation of the initial building block can access new derivatives without changing the 
overall synthetic route. In addition, increasing the number of sp3 centres could provide 
unique growth vectors and increased selectivity in protein binding. Finally, incorporation of 
polar functional groups can increase the solubility of the fragments which is important as 
high aqueous concentrations are necessary for protein screening. 
Young et al. analysed 35 of their 3-D fragments against a sub-set within the ZINC library 
(18,534 compounds). PMI analysis of the two libraries revealed that the 3-D fragments 
occupied a broader region of the plot, with the ZINC fragments largely focused around the 
rod-disc axis. In order to analyse a smaller subset of the ZINC library, the 3-D fragments 
were compared against the best-match ZINC fragments, regarding HAC and similar physical 
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properties. The two comparisons showed that the ZINC fragments occupied the region 
around the rod-disc axis and the top left apex. Therefore, the ZINC fragments could be 
considered less diverse compared to the more 3-D fragments synthesised using the DOS 
approach. 
Young’s group has also published work on the synthesis of enantiopure cis- and trans-2,3- 
and 2,6-disubstituted piperazines, sub-structures which are common in drug molecules. The 
outlined approach started from enantiopure amino acids, with the stereochemistry retained 
in the piperazines.52,53 The 2,6-piperazine synthesis involved amide coupling of amino acids 
to afford amides which were directly reduced with BH3 to afford protected diamines 31. 
Alkylation gave acrylates 32 which, after deprotection and neutralisation, cyclised to give 
mixtures of 2,6-disubstituted piperazines cis-33 and trans-33 (Scheme 1.12). The 
diastereoisomers were separable using chromatography and a further 13 amino acids (both 
(S) and (R)) were reacted affording 24 2,6-piperazine analogues as single enantiomers. The 
(S)- and (R)-phenylglycine products were the only examples where the starting 
stereochemistry was not retained with high ee in the final product.  
 
Scheme 1.12 
The synthesis of the 2,3-piperazines started from the reduction of the carboxylic acid in 
amino acids to the alcohol, followed by oxidation to the aldehyde and Wittig reaction to 
afford acrylates 34. Aza-Michael addition with hydroxy amine afforded alcohols 35, which 
then underwent N-protection and O-activation. Removal of the Boc protecting group allowed 
cyclisation to afford mixtures of 2,3-disubstituted piperazine 36. Protection of the nitrogen 
then aided separation of the two diastereoisomers affording piperazines cis-37 and trans-37, 
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with reactions of ten different amino acids (both (S) and (R)) giving 20 disubstituted 2,3-
piperazines (Scheme 1.13).  
 
Scheme 1.13 
A different example of the Base/Couple/Pair approach was used by Young’s group in a 
FBDD approach towards the inhibition of glycogen synthase kinase 3β (GSK3β), which had 
been found to be overexpressed in cancer and Alzheimer’s diseases.54 A series of fragments 
were synthesised starting from arylnitrofluoride 38 as the building block. SNAr reaction with 
a range of amino acids afforded the coupled products 39. The final step was the ‘pairing’ 
phase, with reduction of the nitro group giving an aniline which cyclised to afford the final 
amide fragments 40 (Scheme 1.14). 
 
Scheme 1.14 
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Using this route, a series of fragments (Figure 1.18) were prepared and screened against 
GSK3β. The DOS approach enabled the rapid derivatisation and variation of the amino acid 
to install different functionality into the piperazinone ring, which led to an increase in the 
binding affinity towards GSK3β. 
 
Figure 1.18 – Subset of eight fragments synthesised with differing aromatic groups. 
In recent years, new methodology and synthetic strategies have been developed to 
accommodate the need for fragments to have multiple, accessible growth vectors. Spring et 
al. reported a synthetic approach to sp3-rich fragments, focusing on partially saturated 
bicyclic heteroaromatics containing pyrazoles and pyridines.55 The route for the synthesis of 
the bicyclic pyrazole system is shown in Scheme 1.15. Pyrazole 41 was initially SEM-
protected and iodinated, allowing for Suzuki-Miyaura coupling which gave vinyl pyrazole 
42 in 85% yield. The SEM group was removed to reveal a pyrazole which then underwent 
N-alkylation to give an alkene. Ring-closing metathesis using Hoveyda-Grubbs II catalyst 
gave bicyclic pyrazole 43 in 45% yield. 
 
Scheme 1.15 
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With bicyclic pyrazole 43 prepared, a series of one-step reactions such as aziridination, 
dibromination, allylic oxidation, dihydroxylation, difluorocyclopropanation, 
hydroxybromination, epoxidation and hydroboration were performed on the alkene to 
introduce functionality at the 4-, 5- and 6- positions on the fused pyrazole system (Figure 
1.19). These fragments were also derivatised further to install bromine, fluorine and nitrogen 
substituents. Nucleophilic attack of the epoxide with hydride or fluoride offered fragment 
diversification. The nitro group could also be reduced to afford the amine which offers 
another synthetic growth vector for the fragments. The ability to quickly build up a fragment 
library using the pyrazole and pyridine building blocks via simple and direct introduction of 
new functionality makes the route very attractive. 
 
Figure 1.19– Example of eight products from one-step reactions to functionalise pyrazole 43. 
Using this approach, Spring et al. synthesised 42 fragments and analysed the 
physicochemical properties, with the mean value of the fragments being compared. The 
results showed that the fragment properties lay within the ranges set out by Astex, with MW 
between 140-230, hydrogen bond donors ≤ 3 and hydrogen bond acceptors ≤ 3. The ease of 
introducing functionality makes this route appealing, but some of the functionality in the 
fragments shown in Figure 1.19 such as epoxides and aziridines which are classed as reactive 
intermediates may not be suitable for use in drug discovery.  
Spring et al. have also developed a DOS approach, starting from α,α-disubstituted propargyl 
amino ester 44, for the synthesis of fragments which could feature 3-D growth vectors and 
allow the installation of polar functional groups.56 The aim was to create a library of 
nitrogen-containing fragments with quaternary centres which would be synthesised using 
known chemistry based on the reactivity of amines, esters and terminal alkynes. 
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Figure 1.20 – Synthetic versatility of α,α-disubstituted amino esters. 
One type of scaffold was prepared as shown in Scheme 1.16. Reaction of amine 44 with 
Boc2O and alkylation with propargyl bromide gave 45. Then, Co-induced [2+2+2] 
cyclotrimerization with benzonitrile afforded two bicyclic regioisomers, which were 
subsequently treated with TFA to afford 46 and 47. 
 
Scheme 1.16 
A different scaffold could be prepared from amine 44 using different reactions. After Boc 
protection, reduction of the ester afforded a primary alcohol which was O-alkylated with 
allyl bromide to give 48. Cyclisation of ether 48 via ring-closing enyne metathesis and Diels-
Alder cycloaddition with nitrosobenzene afforded oxepine 49 in 12% yield over the two 
steps (Scheme 1.17). 
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Scheme 1.17 
Alternatively, pairing of the amine and the ester was achieved either by alkylation and 
subsequent Dieckmann condensation to generate the cyclic compounds or by a Paal-Knorr 
reaction to generate a pyrrole. The Paal-Knorr reaction results in the alkyne functional group 
remaining intact, which can be further functionalised using 1,3-dipolar cycloadditions to 
install triazoles. From example, amine 44 was subjected to standard Paal-Knorr reaction 
conditions to afford pyrrole 50 which was then converted into triazole 51 (Scheme 1.18). 
 
Scheme 1.18 
Expanding on the methodology described in Scheme 1.17 and Scheme 1.18, 40 fragments 
were synthesised starting from α,α-disubstituted propargyl amino ester 44 in five or less 
steps. The molecular shapes of the 40 fragments were assessed using PMI analysis. The plots 
showed that the fragments occupied a wide region of chemical space and importantly 
avoided the rod-disc axis. A computationally derived library was also analysed, with the 
methyl group of the quaternary centre replaced with a phenyl substituent. Modification of 
the sp3 quaternary centre altered the coverage of chemical space of the 40 fragments, 
highlighting the potential ability to tune the 3-D molecular shape of the fragments.  
The approaches so far have addressed issues of elaboration, novelty and diversity. In the 
remainder of the chapter, methodology that affords compounds with suitable fragment 
properties will be presented. For example, AbbVie have recently published a paper focused 
on the design and synthesis of 3-D fragments, with the development of a stereoselective 
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route to 48 enantiomerically pure pyrrolidine fragments.57 The pyrrolidine scaffold is a 
popular moiety in drug molecules and natural products, and has the ability to access a wide 
region of chemical space due to the energetically accessible conformations arising from 
pseudorotation. AbbVie established a metal-catalysed asymmetric 1,3-dipolar cycloaddition 
with the incorporation of a chiral auxiliary and either Au(I) for endo-selectivity or Cu(I) for 
exo-selectivity (Scheme 1.19).  
 
Scheme 1.19 
The enantiomerically pure pyrrolidine scaffolds were then derivatised to incorporate a 
methyl ester group and primary alcohol substituent to afford the 48 pyrrolidine fragments. 
The fragments were designed to comply with Astex’s ‘Rule of three’, with the shape of the 
fragments analysed using PBF and PMI scores. The fragments were assessed based on Firth 
et al.25 description of 3-D space which had been defined as ƩNPR ≥ 1.07 and PBF ≥ 0.6, 
resulting in all but one of the fragments occupying 3-D space. It was shown that from a 
relatively simple pyrrolidine scaffold, a wide region of chemical space could be accessed. 
Willand et al. have also reported the synthesis of sp3 rich fragments, composed of spirocyclic 
isoxazoles. Isoxazoles are prevalent in many natural products and have been shown to 
exhibit activity against a broad range of biological targets.58 Spirocycles are popular drug 
scaffolds due to their conformational rigidity, which can potentially reduce off-target 
affects.59 A small library of 21 fragments were synthesised using a one-pot strategy which 
proceeded via chloro oxime 52, which underwent 1,3-dipolar cycloaddition with geminal 
disubstituted alkenes to afford substituted isoxazoles 53 (Scheme 1.20). 
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Scheme 1.20 
The work was then further expanded to spirohydrantoin fragments.60 The synthesis was 
achieved using microwave-assisted conditions. Cyclic ketones were reacted with (NH4)2CO3
 
and KCN in a 1:1 mixture of MeOH-H2O to afford the desired spirohydrantoins 54. The 
ketone was varied to include, 4-, 5- and 6-membered rings along with substituted and 
hindered ketones containing ester and ether functional groups. The presence of a substituent 
on the ring led to mixtures of diastereoisomers, but substituents at the α- or β-position to the 
carbonyl in the cyclohexane series afforded single diastereoisomers. Presumably, steric 
hindrance directed the nucleophilic attack of the cyanide to the least hindered face. N-
heterocycles were also attempted and tolerated under the same conditions. The 3-D shape of 
the 27 spirohydrantoin fragments were analysed using PMI plots, revealing that the 
fragments covered a broad region of chemical space. 24 of the fragments also showed 
suitable solubility with all the fragments fitting the ‘Rule of three’. 
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Scheme 1.21 
The Bull group have synthesised a library of 56 cyclopropanes using methodology 
discovered within the group.61 Co-catalysed cyclopropanation of phenyl vinyl sulfides with 
ethyl diazoacetate afforded access to a 50:50 mixture of cis- and trans-cyclopropanes. The 
diastereoisomers offer differing growth vectors and, once separated, allowed for orthogonal 
derivatisation of the ester and the sulfide functional groups. For example, the ester group 
was hydrolysed to afford the carboxylic acid which could then undergo amide coupling to 
afford a range of amides (Scheme 1.22). 
 
Scheme 1.22 
Oxidation of the sulfide using excess m-CPBA afforded a set of sulfones in quantitative 
yield. The sulfide could also be oxidised to a sulfoxide with 1.0 eq of m-CPBA which 
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allowed for sulfoxide-metal exchange reactions. Generation of the cis-/trans-cyclopropane 
Grignard intermediates were achieved with iPrMgCl and electrophilic trapping with 
aldehydes, halogens, acyl chlorides and boronates worked well (Scheme 1.23). Trapping to 
give a boronate allows for further functionalisation of the ring using Suzuki-Miyaura cross-
coupling. As expected, trapping of the cis-cyclopropanes with aldehydes was followed by in 
situ lactonisation to afford bicyclic lactones. 
 
Scheme 1.23 
The trans-cyclopropane Grignard intermediate was also transmetallated with ZnCl2 to 
enable Negishi cross-couplings. Thus, the trans-cyclopropane Grignard intermediate was 
charged with a mixture of Pd2(dba)3, (tBu)3P and ZnCl2 followed by the aryl/heteroaryl 
bromides. Electron donating and electron withdrawing groups on the aryl bromide both 
worked well (Scheme 1.24). 
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Scheme 1.24 
The MW and AlogP values of the synthesised cyclopropanes were analysed to assess their 
coverage of lead-like and fragment properties. The six cyclopropanes that contained iodides, 
aldehydes, boronates or ethoxysilanes were removed from the analysis due to the presence 
of reactive functional groups. The remaining 50 cyclopropanes showed a wide coverage of 
lead-like and fragment properties. The 56 cyclopropanes were also elaborated virtually using 
the Lead-likeness and Molecular Analysis (LLAMA) software developed by Nelson and 
Marsden.62 The elaboration was restricted to 44 reactions with a maximum of two reactions 
on the scaffold. The virtual elaboration generated 1187 compounds with 392 compounds 
having a MW < 300 and 1033 compounds having a MW < 500. The Bull group has also 
published methodology synthesising arylated 3,4-pyrrolidines and piperidines along with 
oxetane ethers, all of which afford interesting fragments.63,64,65  
The Marsden and Nelson groups have published methodology to access twisted bicyclic 
lactams containing a bridgehead nitrogen, which modulates the electronic properties of the 
amide, and could offer alterative interactions with proteins.66 Starting from N-Boc 
piperidine-3-one, reductive amination followed by ester hydrolysis, Boc removal and Sn-
mediated cyclisation gave access to bicyclo[3.3.1]nonane and bicyclo[4.3.1]decane bicyclic 
rings. Derivatisation of the amine was carried out using acylation and alkylation on both ring 
systems to afford a range of fragments. The amide could also be derivatised to afford 
amidines (Scheme 1.25). 
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Scheme 1.25 
Alternatively, condensation of N-Boc piperidine-4-one with pyrrolidine gave the enamine 
which was reacted with ethyl acrylate followed by lactam formation using the same 
procedure as above to afford bicyclo[3.3.1]nonane (Scheme 1.26). Lactam 55 could be 
derivatised to give a series of fragments. Au-catalysed hetaryl-annulation with 
propargylamine afforded pyrido-fused lactam 56. The amide could be functionalised through 
formation of the chloroenamine and subsequent Suzuki-Miyaura cross-coupling to afford 
57. Diastereoselective reduction of lactam 55 with NaBH4 occurred on the less hindered face 
to give alcohol 58 which was O-alkylated to furnish fragments 59 and 60 (Scheme 1.27). A 
diverse set of 22 bicyclic lactam fragments were synthesised with assessment of the 
fragment-like properties undertaken comparing the MW against AlogP. Analysis of the 
shape diversity using PMI plots revealed the bridged scaffold resulted in fragments with a 
high degree of 3-D shape.  
 
Scheme 1.26 
43 
 
 
Scheme 1.27 
In recent years, academic groups have responded to the need for more synthetic methodology 
focused on the synthesis of diverse and easily accessible fragments. Various approaches for 
accessing fragments have been undertaken, including the design of fragments to include 
predetermined growth vectors allowing for rapid fragment elaboration, the generation of 
fragments inspired by natural products and the use of DOS. The greater understanding of 
physicochemical properties and the need for fragments to have high aqueous solubility has 
led to an array of methodology being researched. This has led to the synthesis of small 
libraries of sp3 rich fragments which have favourable ‘Rule of three’ and solubility 
properties. 
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1.6 Previous Work on 3-D Fragments in the O’Brien Group 
Prior to starting the research described in this PhD thesis, work within the O’Brien group 
had led to the design and selection of a set of disubstituted pyrrolidine and piperidine 
fragments based on their 3-D shape. A previous member of the O’Brien group, Mary 
Wheldon, had created a protocol to analyse the 3-D shape of fragments and their 
conformations in order to identify suitably shaped fragments with a view to creating a library 
of 3-D fragments. In collaboration with Paul Bond and Rob Hubbard from the York 
Structural Biology Laboratory, Mary Wheldon developed a protocol within Pipeline pilot, 
using the BEST algorithm, to generate conformations and PMI data.67  To carry out PMI 
analysis, the SMILE files of the fragments were uploaded to Pipeline Pilot. The SMILE files 
contain SMILE strings for each fragment and all the conformations with a relative energy < 
7 kcal mol‒1 and root-mean-square deviation (RMSD) of 0 Å were computationally 
generated. The conformations each have different normalised ratios of the principal 
moments of inertia, NPR1 and NPR2, which were plotted on the x/y-axis to give a final PMI 
plot. As well as conformation generation, the predicted physicochemical properties of the 
fragments such as the number of HBD/HBA, HAC and AlogP were also generated in the 
Pipeline Pilot protocol.  
As an example, the protocol was applied to a commercial fragment library from Maybridge 
containing 1000 compounds obeying the ‘Rule of three’. A PMI analysis of this set of 
compounds would enable the 3-D shape of the fragments to be evaluated.68 The 1000 
compounds in the Maybridge fragment library were uploaded to the Pipeline Pilot protocol 
and a PMI analysis was carried out. The lowest energy ground state conformations of each 
of the 1000 Maybridge fragments are shown in the PMI plot in Figure 1.21. The large number 
of fragments being analysed meant that plotting all the conformations with a relative energy 
below 7 kcal mol-1 would have afforded a large number of points on the plot, making analysis 
of the PMI plot difficult. The PMI plot in Figure 1.21 shows that the majority of the 
fragments occupy the region along or very close to the rod-disc axis indicating that the 
library consists of 2-D fragments. The plot also shows that these ground state conformations 
occupy less than half of the 3-D chemical space. The most spherical fragment was tricyclic 
alcohol 61. However, despite its spherical shape, fragment 61 lacks certain functionality 
compared to the other fragments which contain at least two different moieties, offering 
diversity and easily accessible growth vectors for the fragment. The structures of three 
fragments lying on or close to the rod-disc axis, namely amine 62, amide 63 and methoxy 
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ether 64, indicated each contained an aromatic ring and they are 2-D shaped. The main 
conclusion drawn from PMI analysis of the Maybridge fragment library was the large area 
of chemical space currently unoccupied and therefore under-represented within the library. 
 
Figure 1.21 - PMI plot showing the ground state conformations of the 1000 Maybridge fragment library. 
In order to access the regions of chemical space unoccupied within the Maybridge library, 
the previous work in the group focused on the design and selection of disubstituted 
pyrrolidine and piperidine fragments using the protocol developed within Pipeline Pilot to 
select compounds with the most 3-D conformations. The pyrrolidine ring is the fifth most 
popular saturated nitrogen heterocycle in FDA approved drugs.69 Hence, pyrrolidines 
provide a good starting point for designing new 3-D fragments. For the initial set of 
fragments, the pyrrolidine scaffold was decorated with a methyl group and a methyl ester 
substituent. A methyl substituent provides a hydrophobic group and the methyl ester can 
engage in hydrogen bonding interactions, both of which could be important in protein-
fragment binding interactions. The approach adopted in our group was to enumerate all the 
possible isomers of the pyrrolidine with these two substituents and then to use PMI analysis 
to select compounds for the synthetic work. Excluding enantiomers, there are 14 different 
isomers of a pyrrolidine with methyl and methyl ester substituents (Figure 1.22). However, 
the plan was to synthesise racemic mixtures of the fragments, as this would increase the size 
of the library and remove the need for asymmetric fragment synthesis which could prove 
challenging.  
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Figure 1.22 - 14 Pyrrolidine isomers gives 56 compounds with four different nitrogen substituents. 
To introduce more structural diversity into the fragments, it was decided that the nitrogen 
would be functionalised in four different ways, so that the fragment would contain NH, NMe, 
NSO2Me and N(CO)Me groups. It was envisaged that substituents could be easily installed 
onto the nitrogen using protecting group removal, reductive amination, mesylation or 
acylation. These substituents also provide potential for additional binding interactions with 
proteins. For example, the sulfonamide and amide can be involved in hydrogen bonding 
interactions and the amine, which will be protonated at physiological pH, can interact via 
electrostatic interactions and/or hydrogen bonding. In total, 56 pyrrolidine 3-D fragments 
were enumerated. The physicochemical properties were assessed to check whether the 
enumerated pyrrolidine fragments fitted within the Astex ‘Rule of three’ guidelines (see 
Section 1.1.1). Indeed, all the pyrrolidine fragments were compliant with the guidelines, 
having MW < 300, HBD/A < 3 and ClogP < 3. The MW and ClogP values are likely to 
increase during a lead optimisation process, with high ClogP values leading to poor aqueous 
solubility. Therefore, ClogP values < 3 allow for greater elaboration of hit compounds during 
optimisation. 
The ground state PMI plot of the 56 pyrrolidine fragments are shown in Figure 1.23. The 
ground state conformations of the fragments are fairly spread over the plot, with few 
conformations in the top right apex which represents the most spherical fragments. Of note, 
none of the ground state conformations occupy the region near to the rod-disc axis which 
was the region densely occupied by the fragments in the Maybridge library (see Figure 1.21). 
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Figure 1.23 - PMI plot of the ground state conformations of the 56 pyrrolidine fragments. 
The 3-D shape of the pyrrolidine fragments was further analysed by considering a PMI 
analysis of all conformations with an energy of up to 1.5 kcal mol‒1 above the energy of the 
ground state conformation for each molecule. The energy difference was selected based on 
a Boltzmann distribution calculation at physiological temperature, which revealed that the 
probability of the compounds occupying a conformation with an energy difference > 1.5 kcal 
mol‒1 was < 8%. Considering conformations above the ground state conformation allows for 
conformational diversity and is appropriate since it is not necessarily the ground state 
conformation that will bind to the protein. The analysis gave a total of 582 conformations 
for the 56 fragments, which gave a wide spread across the PMI plot. The conformations did 
cluster near the top left apex suggesting that some of the conformations were flatter and 
possessed similar shapes (Figure 1.24). 
 
Colour       
Conformation energy 
difference (kcal mol‒1) 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
Figure 1.24 - PMI plot of the pyrrolidines with all conformations that have relative energy ≤ 1.5 kcal mol‒1. 
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These 582 conformations were then used to select compounds for synthesis. Our intention 
was to identify compounds which had conformations as far away from the rod-disc axis as 
possible. This would allow us to target areas of fragment space that are under-represented in 
current fragment libraries. To identify compounds, the PMI plot was divided into 10 sections 
with lines parallel to the rod-disc axis (Figure 1.25). The diagonal lines correspond to the 
sum of NPR1 and NPR2 (ƩNPR) with ƩNPR = 1.00 describing the most rod-disc-like 
molecules and the region between 1.90-2.00 containing the most spherical molecules.  
 
Figure 1.25 - PMI plot showing the ƩNPR values 
In order to select compounds for synthesis, the approach was to identity compounds with 
conformations in which the ƩNPR values were the highest. Figure 1.26 shows the 583 
conformations on a PMI plot with the 10 sections of ƩNPR values highlighted. This PMI 
plot was used to select compounds and since it was felt unnecessary to synthesise all 56 
compounds, a compromise between ƩNPR values and number of compounds was required. 
Thus, the region was analysed between ƩNPR values of 2.00-1.34. With ƩNPR ≥ 1.40, eight 
fragments would be selected for synthesis, which increased to 17 fragments when ƩNPR was 
set to ≥ 1.34 (Table 1.1). A closer inspection of the region between 1.40 to 1.34 was carried 
out in order to identify a suitable number of compounds for the initial synthetic work. 
Ultimately, an ƩNPR value of 1.36 was chosen and 14 fragments were selected, 
corresponding to 25% of the initially designed pyrrolidine fragments.         
Colour       
Conformation energy 
difference (kcal mol‒1) 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
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Colour       
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Figure 1.26 - 582 Pyrrolidine conformations with a relative energy ≤ 1.5 kcal mol‒1. 
ƩNPR value Number of Fragments 
≥ 1.40 8 
≥ 1.39 9 
≥ 1.38 9 
≥ 1.37 10 
≥ 1.36 14 
≥ 1.35 15 
≥ 1.34 17 
Table 1.1 - Analysis of ƩNPR pyrrolidine values. 
The selected 14 fragments have a total of 117 conformations with an energy of ≤ 1.5 kcal 
mol‒1 above the ground state energy for each fragment; the structures of the fragments 
together with their associated PMI plot is shown in Figure 1.27. Each fragment has at least 
one conformation with a ƩNPR value ≥ 1.36. The fragments incorporate a range of regio- 
and diastereoisomers, with each of the four different nitrogen substituents present. Overall, 
the 14 selected fragments showed positional, stereochemical and functional group diversity, 
despite the relatively simple design criteria.  
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Figure 1.27 - The selected 14 pyrrolidine fragments, and the PMI plot containing all of their 117 
conformations with a relative energy ≤ 1.5 kcal mol‒1. 
A similar design protocol and 3-D shape analysis was carried out with a set of piperidine 
fragments. In this set, the piperidine ring was decorated with a methyl group and a primary 
alcohol substituent. The primary alcohol was chosen instead of the methyl ester to help 
diversify the library, whilst keeping a hydrogen bonding group which would be useful for 
protein-fragment interactions. The piperidine scaffold was enumerated with the methyl and 
primary alcohol substituents to give 23 isomers. The nitrogen was substituted with NH, 
NMe, NSO2Me and N(CO)Me, which afforded 92 fragments (Figure 1.28). 
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Figure 1.28 - 23 piperidine isomers gives 92 with four different nitrogen substituents. 
The physicochemical properties were assessed, with the fragments all complying with the 
Astex ‘Rule of three’ guidelines. PMI analysis of the ground state energy of the 92 fragments 
(Figure 1.29) allowed comparisons to be made with the ground state conformations of the 
Maybridge library (see Figure 1.21). As with the pyrrolidine ground state conformations, 
none of the piperidine ground state conformations occupied the region along the rod-disc 
axis. The piperidine ground state conformations have a much more even spread across the 
plot compared to the ground state conformations of the 56 pyrrolidine fragments (see Figure 
1.23). The piperidine conformations with a relative energy of ≤ 1.5 kcal mol‒1 were assessed, 
which gave 373 conformations (Figure 1.30). 
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Figure 1.29 - PMI plot of the 92 ground state conformations. 
 
Colour       
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Figure 1.30 - PMI plot of the 373 conformations with relative energy ≤ 1.5 kcal mol‒1. 
With 52 conformations lying above a ƩNPR value of 1.30 the region between ƩNPR values 
of 2.00-1.34 was assessed. When the ƩNPR was set to ≥ 1.4, 18 fragments were selected 
which increased to 28 fragments when the ƩNPR was set to ≥ 1.34, as shown in Table 1.2. 
Closer inspection of the region between 1.4 to 1.34 led to a ƩNPR value of ≥ 1.39 being 
selected affording 19 fragments, which was 20% of the initially designed piperidine 
fragments (Table 1.2).        
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ƩNPR value Number of Fragments 
≤ 1.4 18 
≤ 1.39 19 
≤ 1.38 19 
≤ 1.37 23 
≤ 1.36 24 
≤ 1.35 26 
≤ 1.34 28 
Table 1.2 - Analysis of ƩNPR piperidine values 
The 19 fragments gave a total of 58 conformations with a relative energy ≤ 1.5 kcal mol-1. 
The 19 selected fragments show a similar structural diversity to that of the pyrrolidines (see 
Figure 1.27), with a range of regioisomers, diastereoisomers and N-substituents selected 
(Figure 1.31). 
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Figure 1.31 – PMI plot of the selected 19 pyrrolidine fragments and all the conformations with a relative 
energy ≤ 1.5 kcal mol‒1. 
In total, this PMI analysis led to 14 pyrrolidines and 19 piperidines being selected for 
synthesis and inclusion in the groups fragment library. Part of the work described later on 
within this PhD thesis is focussed on the development of synthetic routes to some of these 
pyrrolidine and piperidine fragments. 
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1.7 Project Outline 
The long-term aim of this project is to build a fragment library of ~300 3-D compounds with 
shapes in the under-represented areas of 3-D space and to ultimately evaluate their protein 
binding properties. Following on from the previous work in the group outlined in Section 
1.6, the design process will involve computational analysis of 3-D shapes using PMI plots 
to select compounds for synthesis. In order to occupy chemical space currently not covered 
by current fragment libraries, the plan was to select compounds with conformations which 
lie away from the rod-disc axis of the PMI plot. 
The initial focus was placed on the synthesis of disubstituted pyrrolidine and piperidine 
fragments of the types shown in Figure 1.32, since such heterocycles are the first and fifth 
most popular nitrogen-containing saturated heterocycles within FDA approved drugs.69 
Previous analysis of the pyrrolidine and piperidine datasets had revealed that, despite our  
relatively simple design criteria, a range of shape-diverse fragments could be identified. Out 
of the 14 pyrrolidine and 19 piperidine fragments that were selected by the analysis, we 
focused our attention on the synthesis of the three pyrrolidines trans-73, cis-74 and cis-75 
and the six piperidines cis-84, cis-85, cis-86, cis-87, trans-95 and trans-96 (Figure 1.33). 
The results of this part of the project are discussed in Chapter 2. 
 
Figure 1.32 – Disubstituted pyrrolidines and piperidines with four differing nitrogen substituents. 
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Figure 1.33 – Three pyrrolidine and six piperidine fragments. 
Alongside the synthesis of specific fragments, we also explored whether it would be possible 
to develop some simple and general approaches for the synthesis of all of the possible 20 
disubstituted piperidine regio- and diastereoisomers (excluding the geminal disubstituted 
piperidines). In the end, three different pieces of methodology were required to achieve our 
aim: pyridine hydrogenation, base-mediated epimerisation and lithiation-trapping and the 
results are described in Chapter 3. 
As the project evolved, we identified some limitations in our design process. As a result, a 
different approach was adopted where there was a focus on two key transformations that 
could be applied to a wide range of scaffolds. This approach delivered a significant number 
of novel 3-D fragments with interesting PMI plot profiles in a short period of time. A key 
aspect of these fragments was that they contained aromatic functionality as this can help in 
fragment screening using 1H NMR spectroscopy. An overview of our general approach is 
summarised in Scheme 1.28. The two main reactions that we focused on were ester enolate 
α-arylation and α-alkylation chemistry to install the required aromatic substituents. The 
results are presented in Chapter 4. 
 
Scheme 1.28 
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Finally, we analysed the physicochemical properties of all the fragments within the library, 
and then compared the data against current commercial fragment libraries focusing on MW, 
HAC, Fsp3 and ClogP. The main aim of our project was to design and synthesise fragments 
with shapes that are under-represented within current fragment libraries. Therefore, to 
validate the 3-D nature our library, we compared the PMI plot of our fragments with the PMI 
plots of commercial libraries, and other 3-D fragment libraries that were either commercially 
available or had been developed by academic groups. Our findings are described in Chapter 
5. 
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Chapter 2 Synthesis of Disubstituted Pyrrolidine 
and Piperidine Fragments 
In this Chapter, the development of methods for the synthesis of three of the designed 
pyrrolidine 3-D fragments and six of the designed piperidine 3-D fragments are described. 
The structures of the 3-D fragments that were the focus of our efforts are shown in Figure 
2.1. 
 
Figure 2.1 - Three pyrrolidine and six piperidine fragments. 
Chapter 2.1 covers the synthesis of the pyrrolidine 3-D fragments, including an overview of 
the relevant background literature on approaches to cis- and trans-2,3-disubstituted 
pyrrolidines. The synthesis of the piperidine 3-D fragments and the related literature are 
described in Chapter 2.2. For each set of fragments, reduction chemistry was optimised for 
access to the cis-diastereoisomers. This was complemented by an epimerisation strategy to 
synthesise the corresponding trans-diastereoisomers.  
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2.1 Synthesis of 2,3-Disubstituted Pyrrolidine Fragments 
The 14 selected pyrrolidine fragments were divided up for synthesis between the 3-D 
fragment team in the O’Brien group. The pyrrolidines that will be discussed within this 
section are the 2,3-disubstituted pyrrolidines cis-74, cis-75 and trans-73. The PMI plot of 
their conformations with an energy that is ≤ 1.5 kcal mol‒1 above the ground state energy is 
shown in Figure 2.2.  
 
 
 
 
 
Colour       
Conformation energy 
difference (kcal mol‒1) 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
Figure 2.2 – Conformations of cis-74, cis-75 and trans-73, which have a relative energy ≤ 1.5 kcal mol‒1. 
2.1.1 Overview of Previous Approaches for the Synthesis of cis- and trans-2,3-
Disubstituted Pyrrolidines 
The three target fragments cis-74, cis-75 and trans-73 all contain 2,3-disubstitution, with cis 
or trans relative stereochemistry. In this section, an overview of previously described 
syntheses of 2,3-disubstituted pyrrolidines is discussed.  
Sekiya et al. investigated a 1,3-dipolar cycloaddition route to N-acylated pyrrolidines and 
dihydropyrroles.70 Disubstituted pyrrolidines cis-98 and trans-98 were synthesised directly 
via the reaction of imine 97 with methyl acrylate after the generation of the 1,3-dipole 
reagent from N-acylation and desilylation. However, the stereoselectivity was poor and a 
55:45 mixture of pyrrolidines cis-98 and trans-98 was isolated in 80% yield (Scheme 2.1). 
An alternative two-step route is 1,3-dipolar cycloaddition with an alkyne to give a 
dihydropyrrole, which could be subsequently reduced to afford the pyrrolidine. This 
approach was also investigated and methyl propiolate was reacted with imine 97 to afford 
dihydropyrrole 99 in 26% yield. Reduction of dihydropyrrole 99 afforded a 60:40 mixture 
60 
 
of pyrrolidines cis-98 and trans-98 (Scheme 2.2).  
 
Scheme 2.1 
 
Scheme 2.2 
In 2004, Suresh and Periasamy reported a route for the synthesis of 2,3-disubstituted 
pyrrolidines such as cis-101 via the stereoselective cyclisation of γ-imino esters using 
TiCl4/Et3N.
71 γ-Imino ester 100 was formed by esterification and imine formation. 
Subsequent reaction of γ-imino ester 100 with TiCl4/Et3N gave pyrrolidine cis-101 in 75% 
yield over three steps (Scheme 2.3). This reaction presumably involves nucleophilic attack 
of a titanium enolate onto the imine. The cyclisation reaction was repeated with five imines 
with different aromatic rings containing electron donating and withdrawing groups, 
affording pyrrolidines in 64-76% yields. The reactions each time gave purely the 
cis-diastereoisomer, making it a very attractive route to such cis-pyrrolidines.  
 
Scheme 2.3 
Another route to 2,3-disubstituted cis-pyrrolidine uses the stereoselective catalytic reduction 
of dihydropyrrole 102 reported by Gardette et al.72 Hydrogenation of dihydropyrrole 102 
with 10% Pd/C was found to be very slow, with removal of the N-α-methylbenzyl group 
occurring faster than the rate of hydrogenation.  In contrast, use of PtO2 as the catalyst 
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afforded a 92:8 mixture of (S,S,S)-103 and (R,R,S)-103 in 90% yield (Scheme 2.4). 
 
Scheme 2.4 
Stereoselective routes to 2,3-disubstituted trans-pyrrolidines are also known. For example, 
Basu et al. reported a synthesis of pyrrolidine trans-106 in 21% yield over 13 steps starting 
from epoxide 104 (Scheme 2.5).73 The stereochemistry was set up at the start of the synthesis 
and retained throughout. Pyrrolidine formation was achieved through mesylation of alcohol 
105, followed by conversion of the azide into the amine and subsequent cyclisation to afford 
the trans-pyrrolidine. Boc protection of the secondary amine then gave pyrrolidine trans-
106. The main disadvantage of this synthetic approach is the length of the overall route.     
 
Scheme 2.5 
A different synthetic route to 2,3-disubstituted trans-pyrrolidines was published by Zhang 
et al. starting from a 2,3-disubstituted cis-pyrrolidine, which had been previously 
synthesised by Gardette et al. Nucleophilic attack of (S)-α-methylbenzylamine on 
cyclopropane 107 and subsequent condensation gave dihydropyrrole 102 in 70% yield. 
Then, stereoselective reduction of dihydropyrrole 102 was achieved with NaBH(OAc)3 to 
give the two cis diastereoisomers. Under these conditions, an 81:19 mixture of (S,S,S)-103 
and (R,R,S)-103 was obtained in 86% yield (Scheme 2.6). The diastereoselectivity of this 
reduction reaction is slightly worse than that reported by Gardette et al. (see Scheme 2.4). 
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Scheme 2.6 
In order to prepare the trans-pyrrolidine, pyrrolidine (S,S,S)-103 was epimerised in neat 
DBU at 100 °C, which gave an 83:17 mixture of pyrrolidines (R,S,S)-103 and (S,S,S)-103. 
Pyrrolidine (R,S,S)-103 was isolated in 47% yield, with hydrogenolysis using 10% Pd/C 
being used to cleave the N-α-methylbenzyl group to give amine trans-74 in 61% yield 
(Scheme 2.7). 
 
Scheme 2.7 
The routes summarised here represent the main approaches that have been previously used 
for the synthesis of the 2,3-disubstituted cis- and trans-pyrrolidines. The 1,3-dipolar 
cycloaddition route described by Sekiya et al. lacked diastereoselectivity. In contrast, the 
titanium enolate methodology reported by Suresh and Periasamy was highly 
diastereoselective. However, in both of these routes, the examples only include an aromatic 
substituent α to the nitrogen. The most versatile approach is the one that proceeded via 
dihydropyrrole 102. Using a combination of Gardette’s and Zhang’s work, access to both 
2,3-disubstituted cis- and trans-pyrrolidines is possible. In addition, use of the α-
methylbenzylamine chiral auxiliary would provide access to the enantiopure products and 
the methyl group α to the nitrogen in pyrrolidines (S,S,S)-103 and (R,S,S)-103 is exactly the 
substituent needed in the pyrrolidine fragments that were our initial targets. 
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2.1.2 Synthesis of Pyrrolidine Fragments 
Our initial plan for the synthesis of the target pyrrolidine 3-D fragments cis-74, cis-75 and 
trans-73 is set out in Scheme 2.8. It is based on the previous work reported by Gardette and 
Zhang. The route reported by Zhang et al. afforded the most promising route to the trans-
pyrrolidine, whilst also affording access to the cis-pyrrolidine. (S)-α-Methylbenzylamine 
had been used in order to access single enantiomers. However, we only required access to 
the racemic cis- and trans-pyrrolidines since this would mean that both enantiomers for each 
diastereoisomer would be available for fragment screening. Therefore, we proposed to use 
benzylamine. Nucleophilic cyclopropane ring opening with benzylamine followed by 
condensation should afford dihydropyrrole 108. Stereoselective reduction would hopefully 
give pyrrolidine cis-109 which we anticipated could be epimerised to trans-109 using 
Zhang’s DBU conditions. Hydrogenolysis or hydrogenolysis/N-methylation of pyrrolidine 
cis-109 should then generate fragments cis-74 and cis-75 respectively. Acylation of 
pyrrolidine trans-109 should give pyrrolidine fragment trans-73.  
 
Scheme 2.8 
The synthesis of pyrrolidines cis-74 and cis-75 was initially targeted. Thus, methyl 
acetoacetate was reacted with 1,2-dibromoethane and K2CO3 in refluxing MeCN, adapted 
from the procedure by Zhang et al.74 This afforded an 85:15 mixture of cyclopropane 107 
and enol-bromide 110 as determined by 1H NMR spectroscopic analysis of the crude reaction 
mixture. After purification, it was not possible to fully separate cyclopropane 107 and enol-
bromide 110 and an 85:15 mixture of cyclopropane 107 and enol-bromide 110 was isolated. 
Based on this ratio and the isolated mass, a 47% yield of cyclopropane 107 was calculated 
for this reaction. Pure enol-bromide 110 was also isolated in 3% yield (Scheme 2.9).  
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Scheme 2.9 
The observation of a reasonable amount of enol-bromide 110 indicated that the second 
alkylation was not going to completion. Attempts were made to force enol-bromide 110 to 
react further. For example, refluxing for 72 h or changing the base to Cs2CO3 was explored 
but this led to similar amounts of enol-bromide 110 being formed during the reaction.  
It is possible that reaction of enol-bromide 110 with benzylamine could afford 
dihydropyrrole 108, which would mean that its formation is of no consequence for the next 
step of the synthesis. To explore this idea, enol-bromide 110 was reacted with benzylamine 
under reflux. However, this failed to yield any of the desired dihydropyrrole 108 (Scheme 
2.10). Therefore, in the knowledge that enol-bromide 110 was unreactive with benzylamine, 
our attention turned to the next step, which was the nucleophilic ring-opening of 
cyclopropane 107 and subsequent condensation to afford dihydropyrrole 108. Reaction of 
benzylamine with the 85:15 mixture of cyclopropane 107 and enol-bromide 110 in refluxing 
toluene gave dihydropyrrole 108 in 72% yield, calculated based on the amount of 
cyclopropane 107 present in the starting material (Scheme 2.10). 
 
Scheme 2.10 
To streamline the synthesis of dihydropyrrole 108, the first two steps were re-investigated 
in order to determine whether the dialkylation and dihydropyrrole steps could be telescoped. 
Thus, the crude mixture of cyclopropane 107 and enol-bromide 110 after the dialkylation 
step was taken through and subjected to reaction with benzylamine. This afforded a 44% 
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yield of dihydropyrrole 108 over two steps. This two-step process represents an 
improvement in the overall yield and a reduction in the time taken to synthesise 
dihydropyrrole 108 (Scheme 2.11).  
 
Scheme 2.11 
Zhang et al. achieved diastereoselective reduction of dihydropyrrole 102 using NaBH(OAc)3 
(see Scheme 2.6). Therefore, dihydropyrrole 108 was treated with NaBH(OAc)3 in AcOH-
MeCN and this gave an 85:15 mixture of pyrrolidines cis-109 and trans-109 as determined 
by 1H NMR spectroscopic analysis. Purification by column chromatography gave 
pyrrolidine cis-109 in 65% yield along with a 65:35 mixture of pyrrolidines cis-109 and 
trans-109 in 17% yield (Scheme 2.12). The stereoselective reduction of dihydropyrrole 108 
can be explained by the formation of iminium ion 111 and preferential reduction on the face 
opposite to the sterically bulky methyl ester in 111 (Figure 2.3). The stereochemistry was 
proven by X-ray crystallography of a sulfonamide derivative synthesised from pyrrolidine 
cis-109 (see Figure 2.4).  
 
Scheme 2.12 
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Figure 2.3 – Stereoselective reduction via hydride addition on the opposite face to the ester. 
Hydrogenolysis of N-benzyl pyrrolidine cis-109 would afford the first 3-D fragment, 
pyrrolidine cis-74. Treatment of pyrrolidine cis-109 with 10% Pd/C and H2 in MeOH gave 
pyrrolidine cis-74. However, upon attempted isolation of pyrrolidine cis-74 in the work-up, 
we observed a low mass recovery. Given the low molecular weight of cis-74, we realised 
that it is likely to be somewhat volatile and was probably lost during the rotary evaporation 
step. Therefore, the hydrogenolysis was repeated and after removal of the Pd/C catalyst by 
filtration, a 2 M solution of HCl in Et2O was added and rotary evaporation gave pyrrolidine 
cis-74·HCl directly, which was isolated in 78% yield (Scheme 2.13). The cis relative 
stereochemistry in N-benzyl pyrrolidine cis-74 was proven by converting pyrrolidine cis-
74·HCl into a crystalline derivative. Reaction of pyrrolidine cis-74·HCl with mesyl chloride 
and Et3N afforded sulfonamide pyrrolidine cis-112 in 73% yield. A crystal of sulfonamide 
pyrrolidine cis-112 suitable for X-ray crystallography was grown and the cis-
stereochemistry was confirmed (Figure 2.4). 
 
Scheme 2.13 
 
 
 
67 
 
 
Figure 2.4 
Access to N-methyl pyrrolidine cis-75 was also required. Using a reductive amination 
procedure developed in the group, pyrrolidine cis-74·HCl was reacted with aqueous 
formaldehyde and NaBH(OAc)3 in the presence of MgSO4 to afford N-methyl pyrrolidine 
cis-75. However, due to the anticipated volatility of this compound, N-methyl pyrrolidine 
cis-75 was taken through after work-up and stirred in 2 M HCl in Et2O. This gave N-methyl 
pyrrolidine cis-75·HCl in 48% yield over two steps (Scheme 2.14). 
 
Scheme 2.14 
With the successful synthesis of the two cis-pyrrolidine fragments, our attention switched to 
the synthesis of pyrrolidine trans-73 for which, as outlined earlier (see Scheme 2.8), an 
epimerisation strategy would be explored. We decided to use the base-mediated 
epimerisation conditions outlined by Zhang et al. (see Scheme 2.7). In our hands, 3.0 
equivalents of DBU in xylene were used instead of neat DBU, due to the unworkably small 
quantity of DBU that would be required. Reaction of pyrrolidine cis-109 with DBU gave a 
55:45 mixture of pyrrolidine trans-109 and cis-109 (by 1H NMR spectroscopy of the crude 
reaction mixture). Unfortunately, it was not possible to separate the two diastereoisomers 
despite trialling multiple solvent systems (Scheme 2.15). 
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Scheme 2.15 
The difficulty in separation of the two diastereoisomers, and the poor diastereoselectivity for 
trans-109 after epimerisation, led us to use Zhang’s α-methylbenzylamine-derived 
dihydropyrrole 102. Thus, racemic α-methylbenzylamine was used as the nucleophile for 
the ring opening and subsequent intramolecular condensation. The telescoped two-step 
reaction afforded dihydropyrrole 102 in 44% yield (Scheme 2.16). 
 
Scheme 2.16 
Dihydropyrrole 102 was reduced using NaBH(OAc)3 under the standard conditions. The 
1H 
NMR spectrum of the crude product showed a 70:20:10 mixture of pyrrolidine (R,R,R)-103, 
(R,R,S)-103 and (R,S,S)-103 (Figure 2.5). The methyl ester singlet appears at 3.69 ppm peak 
for (R,S,S)-103, at 3.67 ppm for (R,R,R)-103 peak and at 3.63 ppm for (R,R,S)-103. 
Purification afforded a 45% yield of a 90:10 mixture of pyrrolidines (R,R,R)-103 and 
(R,R,S)-103, together with a 60:25:15 mixture of pyrrolidines (R,R,R)-103, (R,R,S)-103 and 
(R,S,S)-103 in 18% yield (Scheme 2.17). The stereochemistry of these three diastereoisomers 
was assigned by comparison of the NMR spectroscopic data with those reported by Zhang 
et al.74  
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Scheme 2.17 
 
Figure 2.5 – 1H NMR spectrum of a 70:20:10 mixture of (R,R,R)-103, (R,R,S)-103 and (R,S,S)-103. 
Epimerisation was then attempted by reacting the 90:10 mixture of pyrrolidines (R,R,R)-103 
and (R,R,S)-103 with neat DBU at 100 °C for 48 h. The crude reaction mixture contained a 
75:20:5 mixture of pyrrolidines (S,R,R)-103, (R,R,R)-103 and (R,R,S)-103, demonstrating 
that a good degree of epimerisation had occurred. Separation of the diastereoisomers via 
column chromatography was not straightforward and gave a 95:3:2 mixture of pyrrolidines 
(S,R,R)-103, (R,R,R)-103 and (R,R,S)-103, in 24% yield, and a 50:40:10 mixture of 
pyrrolidines (S,R,R)-103, (R,R,R)-103 and (R,R,S)-103, in 22% yield (Scheme 2.18). 
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Scheme 2.18 
The last two steps in the synthesis of pyrrolidine fragment trans-73 proceeded uneventfully. 
Hydrogenolysis with Pd/C and H2 in MeOH removed the α-methylbenzyl to give pyrrolidine 
trans-74·HCl as the major component after treatment with 2 M HCl in Et2O. Pyrrolidine 
trans-74·HCl was then acylated with acetyl chloride in the presence of Et3N, which gave N-
acyl pyrrolidine trans-73 in 42% yield over two steps (Scheme 2.19). 
 
Scheme 2.19 
An important consideration with fragments that are stored as part of a library is their long-
term stability in DMSO solution, as this is typically how they are stored. Thus, the stability 
of pyrrolidine fragments cis-74·HCl, cis-75·HCl and trans-73 was inspected by dissolving 
2 mg of each fragment in d6-DMSO (2 mL). The samples were then analysed by 
1H NMR 
spectroscopy every two weeks in order to explore whether any degradation due to instability 
had occurred. N-Methyl pyrrolidine cis-75·HCl and N-acetyl pyrrolidine trans-73 showed 
no stability issues after six weeks. However, on inspection of the sample of NH pyrrolidine 
cis-74·HCl in DMSO, after initially making up the solution, we noticed the presence of a 
small amount of a second methyl doublet (occurring at 1.22 ppm) in the 1H NMR spectrum. 
It was initially considered that this signal could be due to partial epimerisation of pyrrolidine 
cis-74·HCl to pyrrolidine trans-74·HCl. Therefore, for comparison, pyrrolidine trans-
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74·HCl was synthesised starting from pyrrolidine (S,R,R)-103. Hydrogenolysis of (S,R,R)-
103 with 10% Pd/C under H2, and subsequent treatment with 2 M HCl in Et2O gave 
pyrrolidine trans-74·HCl in 99% yield (Scheme 2.20). 
 
Scheme 2.20 
The 1H NMR spectra of the aged sample of pyrrolidine cis-74·HCl and the freshly 
synthesised trans-74·HCl were compared (Figure 2.6). For pyrrolidine trans-74·HCl, there 
was a methyl doublet at 1.34 ppm and the CHCO2Me appeared at 2.89 ppm. Both of these 
signals were not present in the aged sample of pyrrolidine cis-74·HCl which clearly indicated 
that epimerisation of cis-74·HCl had not occurred. 
 
Figure 2.6 - 1H NMR spectra of pyrrolidine cis-74·HCl (blue) and pyrrolidine trans-74·HCl (red). 
We also considered whether the instability of pyrrolidine cis-74·HCl was due to hydrolysis 
of the ester to a carboxylic acid. Analysis of the downfield region of the 1H NMR spectrum 
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of the aged sample of cis-74·HCl revealed that there were two signals at 9.74 pm and 8.80 
ppm corresponding to the two NH protons and a third signal at 12.91 ppm. The 12.91 ppm 
signal was found to integrate to 1H with the signal at 1.22 ppm set to 3H integration. Signals 
within this region are usually associated with the hydroxy group of a carboxylic acid, 
supporting the suggestion that cis-74·HCl had partially hydrolysed to the carboxylic acid 
(Figure 2.7).  
 
Figure 2.7 - The downfield region of the 1H NMR spectrum of 74·HCl showing the two NH protons right, 
and the hydroxy signal left. 
As a result of these findings, pyrrolidine fragments cis-74 and cis-75 were re-synthesised 
and converted into AcOH salts for long-term storage. In this case an 80:20 mixture of 
pyrrolidine (R,R,R)-103 and (R,R,S)-103 was reacted with H2 and 10% Pd/C followed by 
treatment with AcOH to afford pyrrolidine cis-103·AcOH in 96% yield. Reductive 
amination of pyrrolidine cis-74·AcOH gave pyrrolidine cis-74·AcOH in 57% yield (Scheme 
2.21). The stability of pyrrolidines cis-74·AcOH and cis-74·AcOH was assessed by 
dissolving 2 mg of each fragment in d6-DMSO (2 mL). Analysis of the 
1H NMR spectrum 
after six weeks showed that no ester hydrolysis or epimerisation of the pyrrolidines had 
occurred. 
 
Scheme 2.21 
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2.1.3 Conclusion 
Previous work by Gardette et al. and Zhang et al. had offered routes to access pyrrolidine 3-
D fragments cis-74, cis-75 and trans-73. Telescoping the first two steps to obtain 
dihydropyrrole 108 avoided the difficult separation of cyclopropane 107 and enol-bromide 
110 formed from the monoalkylation of dibromoethane. Hydrogenolysis or 
hydrogenolysis/N-methylation then gave the NH and N-methyl fragments, which were 
stored as the AcOH salts due to the volatility and stability issues we had encountered. 
The synthesis of pyrrolidine trans-73 used the base-mediated approach outlined by Zhang et 
al. Epimerisation with the inclusion of the N-benzyl substituent afforded marginal selectivity 
for the trans-pyrrolidine. However, the inclusion of the N-α-methylbenzyl substituent aided 
the separation of the diastereoisomers and gave pyrrolidine (S,R,R)-103 in 24% yield with 
95% purity. Hydrogenolysis, HCl salt formation and acylation gave pyrrolidine trans-73 in 
42% yield over the three steps (Scheme 2.22). 
 
Scheme 2.22 
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Synthesis of the three pyrrolidine 3-D fragments was possible using the route outlined above 
in Scheme 2.22. However, we observed that the reduction of N-benzyl dihydropyrrole 108 
gave a higher yield of pyrrolidine cis-109 compared to the reduction of N-α-methylbenzyl 
dihydropyrrole 102. Pyrrolidine cis-109 was isolated in 65% yield (see Scheme 2.23), 
whereas reduction of N-α-methylbenzyl dihydropyrrole 102 afforded a 90:10 mixture of 
pyrrolidine (R,R,R)-103 and (R,R,S)-103 in 45% yield. Therefore, a higher yielding route to 
the cis-pyrrolidine fragments was achievable using N-benzyl dihydropyrrole 108. 
 
Scheme 2.23 
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2.2 Synthesis of 2,5-, 2,3- and 2,6-Disubstituted Piperidine Fragments 
The 19 selected piperidine fragments were synthesised by different members of the O’Brien 
group.  In this section, the syntheses of disubstituted piperidines cis-86, cis-87, cis-84, cis-
85, trans-95 and trans-96 are discussed. The PMI plot for these six fragments (up to an 
energy of 1.5 kcal mol‒1 above the ground state) showed that all of their conformations 
occupied different regions of chemical space, suggesting broad shape diversity of the 
conformations (Figure 2.8). 
 
   
 
 
 
 
 
Colour       
Conformation energy 
difference (kcal mol‒1) 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
Figure 2.8 – Conformations of cis-86, cis-87, cis-84, cis-85, trans-95 and trans-96, which have a relative 
energy ≤ 1.5 kcal mol‒1. 
2.2.1 Overview of Previous Approaches to 2,3-, 2,5- and 2,6-Disubstituted Piperidines 
In this section, an overview of the synthesis of disubstituted piperidines with either a methyl 
group and a methyl ester/acid substituent, a methyl group and a hydroxyl methyl group or 
two esters in the 2,3-, 2,5- and 2,6-positions is provided (Figure 2.9). This included a 
summary of the previous synthetic routes to the cis and trans-diastereoisomers for these 
piperidines. 
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Figure 2.9 – Substitution patterns included in this section. 
The most widely used strategy for the synthesis of 2,3-disubstituted cis-piperidines is 
hydrogenation of substituted pyridines. For example, in 1990, Shuman et al. reported the 
hydrogenation of pyridine 113 using 44 mol% PtO2 at 60 psi to give piperidine cis-114                                        
which was isolated as the HCl salt (Scheme 2.24).75 Another example of the hydrogenation 
of pyridine 113 used 10% Pd/C in MeOH and HCl at 50 psi for 1 h, which gave a quantitative 
yield of piperidine cis-114.76 In a similar way, hydrogenation of 3-methylpyridine-2-methyl 
ester 115, reported by Subramanyan et al.,77 used 44 mol% PtO2 at 60 psi in EtOH with 
HCl(aq). This gave piperidine cis-116 in quantitative yield (Scheme 2.25). 
 
Scheme 2.24 
 
Scheme 2.25 
The hydrogenations shown in Scheme 2.24 and Scheme 2.25 were carried out under acidic 
conditions. However, pyridines can also be reduced in the absence of acid. For example, 
Whitten et al. reported the hydrogenation of 2,3-diester 117 using Pd(OH)2 at 50 psi, which 
gave piperidine cis-118 in high yield (Scheme 2.26).78 
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Scheme 2.26 
Hydrogenation of disubstituted pyridines offers high levels of cis-diastereoselectivity. 
Presumably, coordination of the pyridine ring to the surface of the catalyst results in 
hydrogen addition to one face of the pyridine ring to give the cis-piperidine as the major 
product. The minor trans-piperidine could result from the partially reduced pyridine ring 
dissociating from the catalyst surface and then re-coordinating on the opposite face. 
A non-hydrogenation route for the synthesis of a 2,3-disubstituted cis-piperidine was also 
developed by Whitten and co-workers. Deprotonation of iodide 119 using LDA at ‒78 °C, 
warming to ‒35 °C for cyclisation and quenching with 2,6-diisopropylphenol exclusively 
gave piperidine cis-120 in 65% yield (Scheme 2.27).78  
 
Scheme 2.27 
In 1998, Normant et al. designed a diastereoselective amino zinc enolate carbocyclisation as 
a route to piperidine cis-123. Subsequent epimerisation also allowed access to piperidine 
trans-123. Treatment of ester 121 with LDA followed by transmetalation with ZnBr2 gave 
zincate cis-122. Protonation of zincate cis-122 afforded piperidine cis-123 in 40% yield over 
three steps as a single diastereoisomer (Scheme 2.28).79 The cis stereochemistry is controlled 
via an intramolecular olefinic aldol reaction with the ZnBr2 enolate, which selectively gave 
piperidine cis-122 (Figure 2.10). Coordination of ZnBr2 with the olefin results in a 6-exo-
trig ring cyclisation affording the cis-stereochemistry. 
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Scheme 2.28 
 
Figure 2.10 – 6-exo-trig cyclisation and coordination of the Zn(II)Br enolate with the olefin.  
Epimerisation of piperidine cis-123 was achieved using LDA which gave a 65:35 mixture 
of piperidines trans-123 and cis-123. The diastereoisomers were separable and piperidine 
trans-123 was isolated in 57% yield (Scheme 2.29).  
 
Scheme 2.29 
Epimerisation of piperidine cis-123 affords piperidine trans-123 due to the 2,3-related 
substitution pattern. As shown in Figure 2.11, cis-116 is likely to adopt a conformation with 
the ester group axial and the sterically larger methyl group equatorial. Thus, upon treatment 
with base, enolate 124 will be formed and protonation could give either cis-116 or trans-
116. Since the substituents are 2,3-related then formation of trans-116 will be favoured as 
its conformation can have both substituents in equatorial positions. Thus, it would be 
expected that there would be a thermodynamic driving force for the formation of trans-116.  
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Figure 2.11 – Protonation of enolate 124 to give trans-116. 
The synthesis of the 2,5-disubstituted cis-piperidine methyl/ester system has also been 
reported using pyridine hydrogenation. For example, as reported in a patent, hydrogenation 
of pyridine 125 with 5 mol% PtO2 at 45 psi in AcOH/EtOH afforded an 80:20 mixture of 
piperidines cis-126 and trans-126 in quantitative yield (Scheme 2.30).80  
 
Scheme 2.30 
Hydrogenation of pyridine 125 was also reported in a further three patents using 10% Pd/C 
at H2 pressures of 45-200 psi.
81,82,83 In all cases, the reactions were carried out under acidic 
conditions. In addition, Medina et al. reported the hydrogenation of pyridine 125 using 5 
mol% PtO2 at rt and 60 psi for 4.5 h. This gave a 75:25 mixture of piperidines cis-126 and 
trans-126. Subsequent Cbz protection and separation of the diastereoisomers by 
chromatography afforded piperidine cis-127 in 65% yield over the two steps (Scheme 
2.31).84 
 
Scheme 2.31 
More recently, microwave hydrogenation conditions for the synthesis of 2,5-disubstituted 
piperidines have been developed by Taddei et al. (based on the initial microwave work by 
Vanier et al.).85,86 Hydrogenation of pyridine 125 with 10 mol% PtO2 at 120 psi and 80 °C 
under microwave conditions gave an 85:15 mixture of piperidines cis-126 and trans-126. 
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The hydrogenation of diester pyridine 128 was also studied and this gave a 90:10 mixture of 
piperidines cis-129 and trans-129 (Scheme 2.32).  
 
Scheme 2.32 
The synthesis of a 2,5-disubstituted trans-piperidine was reported by Chung et al. where the 
key step was a Mukaiyama aldol reaction of lactam 130 which installed the primary alcohol 
functionality.87  This afforded a 95:5 mixture of lactams trans-131 and cis-131 in 91% yield 
(Scheme 2.33). The preferred formation of piperidine trans-131 in the Mukaiyama aldol 
reaction can be explained by considering the steric hindrance between the carbonyl from the 
N-benzoyl and the methyl group. In order to minimise the A1,3 strain, the methyl group is 
placed axial and the aldol reaction then proceeds in a trans-diaxial fashion to give the trans 
stereochemistry (Figure 2.12). 
 
Scheme 2.33 
 
Figure 2.12 – Explanation of diastereoselectivity in the Mukaiyama aldol reaction to give trans-131.  
The same group developed a more cost-effective synthesis of piperidine trans-86·HCl which 
could be used in the manufacturing process (based on the work of Girardin et al.88). Single 
enzyme transamination gave a 50:50 mixture of lactams trans-132 and cis-132. Then, 
lactams trans-132 and cis-132 were saponified using NaOH followed by HCl to give 
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carboxylic acids. Crystallised-induced dynamic resolution of the carboxylic acid with 
methoxyethylamine gave a 96:4 dr of lactams trans-133 and cis-133 in 91% yield. Finally, 
reduction of lactams trans-133 and cis-133 with BH3·THF afforded piperidine trans-86·HCl 
(Scheme 2.34).89  
 
Scheme 2.34 
The main synthetic route used for the synthesis of 2,6-disubstituted cis-piperidines is also 
the hydrogenation of substituted pyridines. As early as 1961, Ryan and Ainsworth reported 
the hydrogenation of pyridine 134 using 5% Rh-alumina at 3960 psi, which gave piperidine 
cis-135 in 82% yield.90 Six years later in 1967, Crabb and Newton reported the 
hydrogenation of pyridine 134 using PtO2 in AcOH, although no yields or catalyst loadings 
were provided. The only observation noted was the selective formation of piperidine cis-
135.91,92 More recently, work by Hausch et al. described the hydrogenation of pyridine 134 
with PtO2 at 50 psi in AcOH. This gave piperidine cis-135 in 49% yield (Scheme 2.35).
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Scheme 2.35 
The hydrogenation of 2,6-diester pyridine 136·HCl was studied by Chênvert and Dickman. 
Using 10% Pd/C at 45 psi piperidine cis-137 was isolated in 74% yield (Scheme 2.36).94 
Taddei et al. had also studied the hydrogenation of the 2,6-diester pyridine 136 using their 
developed microwave conditions (see Scheme 2.32). Hydrogenation with 10 mol% PtO2 at 
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120 psi for 40 min afforded piperidine cis-137 in 78% yield as a single diastereoisomer 
(Scheme 2.37). 
 
Scheme 2.36 
 
Scheme 2.37 
A route to access 2,6-cis-disubstituted piperidines without using pyridine hydrogenation was 
developed by Somfai et al. The key step was an aza-(2,3)-Wittig rearrangement upon 
treatment of the aziridine with LDA at ‒78 °C to give piperidine cis-138 in excellent yield. 
Reduction of the alkene in piperidine cis-138 with 5% Rh/C in MeOH then gave the t-butyl 
ester piperidine cis-139 (Scheme 2.38).95 The explanation for the observed 
cis-diastereoselectivity in the aza-(2,3)-Wittig rearrangement was discussed in an earlier 
paper by Somfai et al.96 In order to facilitate bond formation, the t-butyl ester and the methyl 
group are cis with the enolate orientated to minimise steric interaction with the aziridine 
substituents (Figure 2.13). 
 
Scheme 2.38 
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Figure 2.13 – Model to explain the cis-stereoselectivity 
Blechert et al. has reported a stereoselective synthesis to access N-heterocycles via cross-
metathesis and subsequent reductive cyclisation.97 Cross-metathesis of methyl vinyl ketone 
with alkene-containing amino acid derivative 140 using 10 mol% Hoveyda-Grubbs II 
catalyst, afforded ketone 141. Reduction of ketone 141 with H2 and 5% Pd/C gave piperidine 
cis-142 as a single diastereoisomer in 85% yield (Scheme 2.39). This transformation 
involves several steps: alkene hydrogenation, Cbz protecting group cleavage, cyclisation to 
an imine and hydrogenation. The imine hydrogenation occurs from the face opposite to the 
methyl ester group due to steric hinderance and this places the methyl group and the methyl 
ester substituents cis to each other. 
 
Scheme 2.39 
In 1994, Momose et al. reported a route towards piperidine trans-147 starting from 
carbamate 143, which was synthesised from D-alanine. Asymmetric dihydroxylation gave a 
mixture of diastereoisomeric diols 144. Selective protection of the primary alcohol with 
TBDMSCl followed by reaction with MsCl gave carbamate 145. Then, hydrogenolysis of 
the Cbz group in carbamate 145 with Pd(OH)2 resulted in cyclisation via substitution of the 
mesylate group to give a 75:25 mixture of piperidines trans-146 and cis-146. Removal of 
the TBDMS protecting group and Cbz protection of the free piperidine allowed the 
separation of the two diastereoisomers, with piperidine trans-147 isolated in 50% yield 
(Scheme 2.40).98 The diastereoselectivity is controlled by the asymmetric dihydroxylation 
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reaction and stereospecific inversion of the stereochemistry upon substitution of the mesylate 
group. 
 
Scheme 2.40 
A related approach to 2,6-disubstituted trans-piperidines was report by Wasserman et al. in 
1988.99 Reaction of epoxide 148 with benzylamine in refluxing benzene gave oxatropane 
149 in 87% yield. Reduction of oxatropane 149 with NaBH4 gave a 90:10 mixture of 
piperidines trans-150 and cis-150 which were acetylated to enable separation of the 
diastereomeric piperidines (Scheme 2.41).  
 
Scheme 2.41 
In this approach, the stereochemistry was controlled by the A1,2-type strain between the 
substituent on the nitrogen and the primary alcohol (Figure 2.14). With a bulky N-benzyl 
group, the primary alcohol substituent will be orientated in an axial position 151 (rather than 
in an equatorial position 152) to minimise steric interactions. Axial attack of hydride on the 
iminium ion then leads to the observed formation of trans-150.100   
 
Figure 2.14 – Model to explain the formation of trans-150. 
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A  completely different approach to synthesise 2,6-disubstituted trans-piperidines is the 
lithiation-trapping of N-Boc 2-methylpiperidine 153 using conditions reported by Beak in 
1993.101 For example, Pissarnitski et al. treated N-Boc 2-methylpiperidine 153 with sBuLi 
and TMEDA at ‒78 °C. Subsequent electrophilic trapping with DMF afforded piperidine 
trans-154, which was reduced using NaBH4 to give alcohol trans-155 (Scheme 2.42).
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Scheme 2.42 
The trans-stereochemistry results from equatorial lithiation and subsequent trapping. Due to 
the Boc group, the C-2 substituent in N-Boc piperidine 153 is axial to reduce the A1,3-type 
strain between the two substituents. The Boc group also directs the deprotonation to the 
equatorial proton, via coordination of the carbonyl group to the sBuLi to give 156. Finally, 
electrophilic trapping proceeds with retention to give the two substituents trans to each other 
(Figure 2.15). 
 
Figure 2.15 – Lithiation-trapping to obtain the 2,6-disubstituted trans-piperidine.  
In summary, the most common method for synthesising the 2,3- 2,5- and 2,6-cis-
disubstituted piperidines is hydrogenation of the corresponding disubstituted pyridines. 
Typical reaction conditions use PtO2 under high H2 pressure and acidic conditions to give 
the cis-piperidines as the major products. In contrast, the trans-piperidines required 
individual routes to obtain the desired diastereoselectivity, and no overall general approaches 
for the synthesis of 2,3-, 2,5- and 2,6-trans-disubstituted piperidines have been reported. 
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2.2.2 Synthesis of 2,5-Disubstituted Piperidine Fragments 
The approach planned for the synthesis of the piperidine 3-D fragments cis-86 and cis-87 is 
shown in Scheme 2.43. We proposed to use hydrogenation of 2,5-disubstituted pyridine 125, 
which based on the literature precedent discussed in the previous section, should give 
piperidine cis-126 as the major product. To aid with the separation of the diastereoisomers a 
Boc group would be installed to give cis-157 and this should also allow access to both 
fragments. Chemoselective reduction of the ester in cis-157 to the primary alcohol should 
be possible using LiAlH4 at 0 °C
103 and subsequent removal of the Boc group would then 
afford 3-D fragment cis-86·HCl. In contrast, starting from N-Boc piperidine cis-157, 
reduction of the Boc group and methyl ester using LiAlH4 at reflux should give N-methyl 
piperidine cis-87. These planned syntheses would allow both fragments to be accessed in 
three steps starting from the corresponding pyridine 125.  
 
Scheme 2.43 
To start, 2-methylpyridine-5-methyl ester 125 was hydrogenated in AcOH using 5-20 mol% 
PtO2 and a H2 balloon at rt for 16 h. After filtration, with a CH2Cl2 wash, and work-up with 
NH4OH(aq), the crude product was analysed by 
1H NMR spectroscopy to determine whether 
the reaction had gone to completion and establish the ratio of piperidines cis-126 and trans-
126. The results are shown in Table 2.1. In each case, an 85:15 mixture of piperidines cis-
126 and trans-126 was observed, with the crude yield being reported as purification was not 
required. Confirmation that the major product was indeed cis-126 is provided in Scheme 
2.45. Using 20 mol% and 10 mol% PtO2, piperidines cis-126 and trans-126 were each 
isolated in 74% yield with no pyridine 125 remaining (entries 1 and 2). With 5 mol% PtO2, 
complete hydrogenation of the pyridine ring was observed after 16 h, to give piperidines cis-
126 and trans-126 albeit in a slightly lower 65% yield (entry 3). The reaction was repeated 
for scale up with 10 mol% PtO2 to ensure complete reduction of the pyridine ring after 16 h. 
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This gave a 76% yield of an 85:15 mixture of piperidines cis-126 and trans-126 (entry 2). 
As described above, the work-up for the reactions initially involved removing the PtO2 
catalyst by filtering through Celite and then washing the Celite pad with CH2Cl2 (entries 1-
3). We suspected that some of the product was sticking on the Celite pad. Therefore, the 
work-up was modified and the Celite pad was washed with MeOH instead of CH2Cl2. This 
increased the yield of piperidines cis-126 and trans-126 to 93% (entry 4), which represented 
the optimised conditions.  
 
Table 2.1 – Hydrogenation of pyridine 125 using different loadings of PtO2. 
 a) Ratio of diastereoisomers was determined by 1H NMR spectroscopy of the crude product; b) Yield of 
crude product; c) Reaction carried out on 13.2 mmol scale. (d) Celite pad washed with MeOH instead of 
CH2Cl2. 
Piperidines cis-126 and trans-126 could not be separated using column chromatography. 
Therefore, the crude 85:15 mixture of piperidines cis-126 and trans-126 was reacted with 
Boc2O and DMAP. Purification by column chromatography afforded Boc piperidine cis-157 
in 68% yield. In addition, a 60:40 mixture of Boc piperidines trans-157 and cis-157 (6% 
yield) and Boc piperidine trans-157 (6% yield) were also isolated (Scheme 2.44).  
 
Scheme 2.44 
Entry PtO2 (mol %) cis-126 : trans-126 a Yield (%)b 
1 20 85:15 74 
2 10 85:15 74 (76c) 
3 5 85:15 65 
4d 10 85:15 93 
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Piperidines cis-126 and trans-126 had been synthesised previously and full data had been 
reported with a Cbz group present on the nitrogen.84 The relative stereochemistry had been 
established using an X-ray structure of a cis-piperidine derivative bound to their target 
kinase. In order to compare the data, we synthesised the Cbz analogues for each 
diastereoisomer. The Boc group was removed with 2 M HCl in Et2O and the HCl salts were 
Cbz protected to afford the corresponding piperidines cis-127 and trans-127 in 26% and 
48% yields respectively (Scheme 2.45). Comparison of the 1H NMR spectra for cis-127 and 
trans-127 with the literature data allowed unequivocal assignment of the relative 
stereochemistry. 
 
Scheme 2.45 
With the relative stereochemistry assigned, the synthesis of the two 2,5-disubstituted 
piperidine 3-D fragments was completed. Reduction of the methyl ester in cis-157 was 
carried out with LiAlH4 at 0 °C for 2 h and 
1H NMR spectroscopic analysis after work-up 
revealed that no purification was required. Removal of the Boc group with 2 M HCl in Et2O 
afforded piperidine fragment cis-86·HCl in 97% yield over two steps (Scheme 2.46) 
Alternatively, N-Boc piperidine cis-157 was treated with LiAlH4 at 0 °C for 2 h to reduce 
the methyl ester and then refluxed for 16 h to reduce the Boc group to afford the N-methyl 
substituent. Purification by column chromatography gave N-methyl piperidine cis-87 in 42% 
yield (Scheme 2.47). 
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Scheme 2.46 
 
Scheme 2.47 
2.2.3 Synthesis of 2,6-Disubstituted Piperidine Fragments 
A pyridine hydrogenation route was envisaged for the synthesis of 2,6-disubstituted 
piperidines cis-84 and cis-85 as outlined in Scheme 2.48. Thus, hydrogenation of 2,6-
disubstituted pyridine 159 should afford piperidine cis-142 selectively based on literature 
precedent (see Scheme 2.37).90–93 Then, mesylation or acylation of cis-142 followed by ester 
reduction to the primary alcohol should give 3-D piperidine fragments cis-84 and cis-85. 
 
Scheme 2.48 
Starting from commercially available 2,6-pyridine methyl ester 159, hydrogenation with 10 
mol% PtO2 in AcOH gave, after work-up, the crude product which required no further 
purification. Analysis by 1H NMR spectroscopy showed that the crude product contained a 
95:5 mixture of piperidines cis-142 and trans-142 (92% yield) (Scheme 2.49). The 
stereochemistry of piperidines cis-142 and trans-142 was assigned based on 3JHH values of 
the protons at the C-2 and C-6 positions (Figure 2.16). The C-2 proton exhibited 3JHH values 
of 12.5 and 2.5 Hz (as well as coupling to the methyl group), which suggested that the C-2 
proton was axial. The C-6 proton showed 3JHH values of 11.0 and 3.0 Hz which suggested 
that it was also axial, thus confirming the cis-stereochemistry. Confirmation that the major 
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product was cis-142 was obtained by X-ray crystallography of the 3-D sulfonamide fragment 
cis-84 (see Figure 2.17). 
 
Scheme 2.49 
 
Figure 2.16 – Confirmation of stereochemistry via 3JHH coupling constants. 
With a view to completing the synthesis of 3-D sulfonamide fragment cis-84, the 95:5 
mixture of piperidines cis-142 and trans-142 was reacted with mesyl chloride and Et3N (0 
°C, 1 h). 1H NMR spectroscopic analysis of the crude reaction mixture revealed the 
formation of two main products. Purification afforded sulfonamide piperidine cis-160 in 
20% yield and what we initially suspected was the corresponding trans-diastereoisomer. 
However, mass spectrometry showed a mass ion of m/z 336, which did not correspond to 
sulfonamide piperidine trans-160. Analysis of the 1H NMR spectrum showed the presence 
of two doublets at 4.75 and 4.49 ppm which based on the m/z value, was consisted with a 
pair of diastereotopic CH2 protons adjacent to two sulfur atoms. This, together with full 
characterisation by 1H and 13C NMR spectroscopy indicated that bismethanesulfonamide 
piperidine cis-161 (assumed relative stereochemistry) had been formed and isolated in 30% 
yield (Scheme 2.50).  
 
Scheme 2.50 
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We suggested that there are two possible pathways in which bismethanesulfonamide 
piperidine cis-161 could be formed. The first starts with the formation of sulfonamide 
piperidine cis-160 which can then react with another equivalent of mesyl chloride to afford 
bismethanesulfonamide cis-161. The second involves the initial formation of sulfonylidene 
162, (precedented in the work of Shealy et al.104), which can then react with piperidine cis-
142 to afford bismethanesulfomaide piperidine cis-161 (Scheme 2.51). 
 
Scheme 2.51 
To investigate the first proposed route for the formation of bismethanesulfonamide 
piperidine cis-161, we re-subjected sulfonamide piperidine cis-160 to mesyl chloride and 
Et3N at rt for 16 h. 
1H NMR spectroscopic analysis of the crude reaction mixture revealed 
that no bismethanesulfonamide piperidine cis-161 was present, and the starting sulfonamide 
piperidine cis-160 was isolated in 60% yield after purification (Scheme 2.52). 
 
Scheme 2.52 
Therefore, we believe that the formation of bismethanesulfonamide piperidine cis-161 
proceeds via the second proposed route, with the initial formation of sulfonylidene 162. We 
presume that the sterically hindered nature of the amine, due to the 2,6-substitution, results 
in a slow mesylation, which allows for the formation of sulfonylidene 162. The proposed 
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mechanism for the formation of sulfonylidene 162 was reported in 1991 by Shealy et al.104 
Initial deprotonation of mesyl chloride affords sulfene 163 which then gets attacked by Et3N 
to give 164. Nucleophilic attack by 164 onto another molecule of sulfene 163, followed by 
proton exchange gives the Et3N adduct 165, which had been previously isolated by Opitz 
and Bücher in 1966.105 Subsequent elimination of Et3N then affords sulfonylidene 162 
(Scheme 2.53). 
 
Scheme 2.53 
To minimise the formation of bismethanesulfonamide piperidine cis-161 we decided to 
change the base to pyridine, which should prevent the formation of sulfene 162 as it is a 
weaker base than Et3N. Thus, pyridine was added to a CH2Cl2 solution containing a 95:5 
mixture of piperidines cis-142/trans-142 and mesyl chloride and stirred at rt for 1 h. 1H NMR 
spectroscopic analysis revealed an 80:20 mixture of sulfonamide piperidines cis-160 and 
trans-160 with no presence of bismethanesulfonamide piperidine cis-161. Purification 
afforded an 80:20 mixture of sulfonamide piperidines cis-160 and trans-160 in 26% yield. 
In addition, and rather unexpectedly, piperidine cis-142·HCl was isolated (50% yield) 
(Scheme 2.54). Thus, the use of pyridine had two effects: first, partial epimerisation occurred 
during the sulfonylation reaction and, second, the generated HCl protonated the starting 
amine and prevented the mesylation reaction going to completion.   
 
Scheme 2.54 
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In an attempt to optimise the formation of the desired sulfonamide cis-160, we decided to 
vary the reaction time, base and temperature using the results shown in Scheme 2.54 as the 
starting point (Table 2.2, entry 1). The relative amount of each product was determined by 
integration of the three methyl ester singlets in the 1H NMR spectrum of the crude reaction 
mixture. Reaction for 24 h gave no improvement in the overall yield of sulfonamide 
piperidines cis-160 and trans-160 (entry 2). Use of 3.0 eq for 24 h afforded a higher overall 
yield of sulfonamide piperidines cis-160 and trans-160 (37%, entry 3). The base was 
changed to 2,6-lutidine and this gave 28% yield of sulfonamide piperidines cis-160 and 
trans-160 (entry 4). Running the reaction in neat pyridine for 24 h and 72 h was then 
investigated (entries 5 and 6). After 24 h, we obtained a 45:10:50 mixture of cis-160, trans-
160 and cis-142·HCl (entry 5). When the reaction was left for 72 h, a 60:5:35 mixture of cis-
160, trans-160 and cis-142·HCl was achieved, with sulfonamide piperidine cis-160 isolated 
in 60% yield, along with a 90:10 mixture of sulfonamide piperidine trans-160 and cis-160 
in (4% yield) (entry 6). We also explored elevating the reaction temperature to 60 °C, 
although this did not lead to any improvement (entries 7 and 8). The conditions used in entry 
5 (neat pyridine, rt, 72 h) afforded the highest yield of sulfonamide piperidine cis-160 and 
these conditions were then scaled up to give sulfonamide piperidine cis-160 in 52% yield 
(entry 9). 
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Table 2.2 – Optimisation of the synthesis of piperidine sulfonamide cis-160. 
a) Ratio determined by 1H NMR spectroscopy of the crude product; b) % yield of cis-160 after 
chromatography; c) % yield of cis-160 and trans-160 after chromatography; d) Ratio determined by 1H NMR 
spectroscopy after chromatography; e) 2,6-Lutidine used; f) Scale-up reaction using entry 5 conditions. 
The final step to synthesise piperidine cis-84 was ester reduction to give the primary alcohol. 
Therefore, sulfonamide piperidine cis-160 was treated with LiAlH4 in THF at 0 °C for 2 h 
which gave sulfonamide piperidine 3-D fragments cis-84 in 78% yield (Scheme 2.55). The 
final product was crystalline and crystals suitable for X-ray crystallography were grown. The 
X-ray crystal structure of sulfonamide piperidine cis-84 (Figure 2.17) proved the cis 
stereochemistry. Interestingly, in the solid-state, the sulfonamide was planar (sp2 hybridised) 
with both substituents in axial positions that are tilted slightly outwards, presumably to avoid 
steric clashes with the sulfonyl group. 
Entry Time 
(h) 
Temp 
(°C) 
Base 
(eq) 
 cis-160:trans-160 
:cis-142a 
cis-160 
(%)b 
cis-160:   
trans-160 (%)c 
1 1  25 1  25:5:70 - 26, 80:20d 
2 24  25 1  20:5:75 19 3, 55:45d 
3 24  25 3  35:5:60 - 37, 80:20d 
4e 24 25 3 35:5:60 - 28, 80:20d 
5 24  25 Neat  45:10:45 43 4, 20:80d 
6 72  25 Neat  60:5:35 60 4, 10:90d 
7 16  60 Neat  45:5:50 - 38, 90:10d 
8 24  60 Neat  50:5:45 - 44, 90:10d 
9f 72  25 Neat  55:5:40 52 - 
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Scheme 2.55 
 
Figure 2.17 - X-ray crystal structure of sulfonamide cis-84. 
To gain access to acetamide piperidine cis-85, a similar route to that used to synthesise 
sulfonamide piperidine cis-84 was envisaged. The 95:5 mixture of piperidines cis-142 and 
trans-142 was reacted with AcCl and Et3N at rt for 16 h. Purification by chromatography 
afforded piperidine cis-166 in 74% yield, with no evidence of any epimerisation (Scheme 
2.56). Reduction of acetamide piperidine cis-166 with LiAlH4 at 0 °C for 2 h, led to reduction 
of both the ester and the acetamide, together with some epimerisation. 1H NMR 
spectroscopic analysis revealed that a 75:25 mixture of amino alcohols cis-167 and trans-
167 (53% yield) had been generated. To explain the facile amide reduction, it is possible that 
the carbonyl group of the amide is not fully conjugated with the nitrogen lone pair due to the 
steric hindrance cause by the 2,6-cis-disubstitution. As a result, this amide carbonyl group 
would be more electrophilic than typical amides and so readily reduced.  
 
Scheme 2.56 
In the reaction to form amino alcohol cis-167 and trans-167, it is assumed that the 
cis-diastereoisomer is the major product and, since some epimerisation was also occurring 
during the reduction, we decided to explore an alternative route rather than trying to optimise 
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the chemoselective reduction of the ester over the acetamide. The plan was to reduce 
piperidine cis-142 to afford amino alcohol cis-168. Then, acylation of the alcohol and the 
amine would afford the doubly acylated product, in which the more labile O-acyl group 
could be selectively removed to afford acetamide piperidine cis-85. Reduction of the 95:5 
mixture of piperidines cis-142 and trans-142 proceeded smoothly, to give, after purification, 
alcohol piperidine cis-168 in 76% yield (Scheme 2.57). 
 
Scheme 2.57 
Refluxing piperidine alcohol cis-168 with Ac2O in pyridine gave crude diacylated product 
cis-169, which was subsequently treated with K2CO3 in MeOH at rt for 2 h. Purification led 
to the isolation of the fully deprotected piperidine alcohol cis-168 in 66% yield (Table 2.3, 
entry 1).  The cleavage of both the amide and ester group was unexpected although the ease 
of amide cleavage in this case was at least consistent with its ready reduction described above 
(see Scheme 2.56). To address this issue, shorter reaction times were explored. In contrast 
to the 2 h reaction, reaction for 30 min led to a mixture of acetamide piperidine cis-85 and 
cis-168 isolated in 28% and 12% yields respectively (entry 2). With a 10 min reaction time 
the 1H NMR spectrum of the crude product showed formation of only the desired acetamide 
piperidine cis-85. Purification then gave acetamide piperidine 3-D fragment cis-85 in 60% 
yield (entry 3). 
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Entry Time (min) cis-168 (%)a cis-85 (%)b 
1 120 66 -c 
2 30 12  28 
3 10 -c 60 
Table 2.3 – Optimisation of the synthesis of acetamide piperidine 3-D fragment cis-85. 
 a) % yield of cis-168 after chromatography; b) % yield of cis-85 after chromatography; c) No product 
observed from the 1H NMR spectrum of the crude. 
2.2.4 Synthesis of 2,3-Disubstituted Piperidine Fragments 
Our proposed approach to access piperidine 3-D fragments trans-95 and trans-96 is 
summarised in Scheme 2.58. Hydrogenation of pyridine methyl ester 115 would give a 
mixture of piperidines cis-116 and trans-116 (presumably with cis-116 as the major 
product). Then, the conversion of this mixture into N-benzyl ester trans-123 would be 
investigated using base-mediated epimerisation with the formation of the more stable 
trans-diastereoisomer providing the driving force. There was literature precedent for 
epimerisation of NH and N-benzyl esters providing routes to 2,3-trans-piperidines79,106 and 
both approaches could be studies. Starting from N-benzyl ester trans-123, hydrogenolysis to 
remove the benzyl group, mesylation and reaction with LiAlH4 should give the 3-D 
sulfonamide fragment trans-95. The synthesis of the acetamide fragment would proceed 
using the route used to synthesis acetamide piperidine cis-85. Hydrogenolysis and ester 
reduction would afford the primary alcohol which would be doubly acylated. Removal of 
the more labile O-acyl group should then afford acetamide piperidine trans-96. 
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Scheme 2.58 
Hydrogenation of pyridine 115 was carried out with PtO2 in AcOH for 16 h using our 
standard conditions. An 85:15 mixture of piperidines cis-116 and trans-116 was generated 
as determined by 1H NMR spectroscopic analysis. This crude mixture was clean enough to 
react on without further purification (Scheme 2.59). With a view to exploring Normant el 
al.’s epimerisation method on N-benzyl piperidine esters cis-123 and trans-123 (see Scheme 
2.29), benzylation using reductive amination was carried out. Thus, reaction of PhCHO with 
the 85:15 mixture of piperidines cis-116 and trans-116, NaBH(OAc)3 and AcOH in  DCE 
gave, after chromatography, N-benzyl piperidine cis-123 (80% yield) and trans-123 (10% 
yield) (Scheme 2.59). 
 
Scheme 2.59 
The assignment of the cis and trans stereochemistry was assigned based on 1H NMR J-
values. The C-2 hydrogen had a 3JHH coupling constant of 9.0 Hz which supports the two 
hydrogens being in axial positions and therefore having the trans-stereochemistry. This 
99 
 
assignment meant that piperidine cis-123 could be inferred as the major product after 
hydrogenation (Figure 2.18). 
 
Figure 2.18 – Diagnostic 3JHH coupling constant in piperidine trans-123. 
N-Benzyl piperidine cis-123 was then subjected to the epimerisation conditions reported by 
Normant et al.79 A pre-made solution of LDA was added dropwise to a solution containing 
cis-123 in Et2O at ‒20 °C. The reaction was then warmed to rt over 20 min and stirred at rt 
for a further 20 min. After cooling to 0 °C, it was quenched with a 2:1 solution of sat 
NH4Cl(aq)-NH4OH(aq). The solution was then allowed to warm to rt and left to stir for 18 h. 
The reaction mixture was then worked-up and the crude product was analysed by 1H NMR 
spectroscopy, which showed a 50:50 mixture of N-benzyl piperidines cis-123 and trans-123. 
Purification afforded trans-123 in 34% yield and cis-123 in 31% yield (Scheme 2.60).  
 
Scheme 2.60 
Since these LDA epimerisation conditions gave a 50:50 mixture N-benzyl piperidines cis-
123 and trans-123, it was decided to carry out the alternative approach of epimerisation and 
then benzylation. In a 2010 patent, researchers at Merck had reported that epimerisation of 
2,3-piperidine ethyl ester cis-171 using NaOEt in EtOH at 50 °C for 24 h gave a 90:10 
mixture of piperidines trans-171 and cis-171.107 Since we had the methyl ester in hand, we 
decided to attempt the epimerisation using the NaOEt/EtOH conditions expecting that 
transesterification to the ethyl ester would occur to give the same products as reported by 
Merck. Thus, the 85:15 mixture of piperidines cis-116 and trans-116 was refluxed with 
NaOEt in EtOH for 24 h. This gave an 80:20 mixture of the ethyl ester piperidines trans-171 
and cis-171 with no methyl ester observed. As these piperidines were inseparable, the crude 
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reaction mixture was N-benzylated. After chromatography, N-benzyl piperidines trans-172 
and cis-172 were isolated in 34% and 10% yields respectively over the two steps (Scheme 
2.61).  
 
Scheme 2.61 
To remove the N-benzyl group from trans-172, transfer hydrogenolysis using 20% 
Pd(OH)2/C and NH4
+HCO2
‒ in EtOH was used. This afforded 2,3-piperidine trans-171 in 
62% yield. Subsequent sulfonylation with MsCl and Et3N for 16 h gave sulfonamide trans-
173 in 86% yield, with no epimerisation. Reduction of the ester with LiAlH4 at 0 °C for 2 h 
then gave sulfonamide piperidine 3-D fragment trans-95 in 94% yield (Scheme 2.62). 
 
Scheme 2.62 
The synthesis of acetamide piperidine trans-96 required repeating the NaOEt epimerisation 
shown in Scheme 2.61 to bring through more material. Unfortunately, using apparently 
identical conditions, we did not get the same outcome. It appeared that piperidine ester cis-
171 had hydrolysed to the acid, which was supported by the MS data. 1H NMR spectroscopic 
analysis of the crude reaction mixture also showed no evidence of the ethyl ester peaks. The 
NaOEt used was a commercial 21% solution in EtOH and, presumably in the time between 
doing the two experiments, water had been absorbed into the solution and this led to ester 
hydrolysis. As a result, we decided to use NaOMe which would also avoid the 
transesterification. 
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The 85:15 mixture of piperidines cis-116 and trans-116 was reacted with NaOMe refluxing 
in MeOH and the reaction was monitored by 1H NMR spectroscopy. After 24 h, the 1H NMR 
spectrum showed a 50:50 mixture of piperidines cis-116 and trans-116. The reaction was 
left for a further 40 h and the 1H NMR spectrum showed a 70:30 mixture of piperidines 
trans-116 and cis-116. The crude reaction mixture was N-benzylated to give piperidine 
trans-123 in a similar yield (38% over two steps) as observed in the original NaOEt route 
(see Scheme 2.61) and piperidine cis-123 in 6% yield (Scheme 2.63). 
 
Scheme 2.63 
Acetamide piperidine trans-96 was synthesised following the double acylation route 
previously discussed for acetamide piperidine cis-85 (see Table 2.2). The route avoided the 
possibility of any epimerisation and selective removal of the O-acyl group was established. 
Methyl ester piperidine trans-123 was treated with LiAlH4 at 0 °C for 2 h to give N-benzyl 
amino alcohol trans-170 in 99% yield. Transfer hydrogenolysis then afforded amino alcohol 
trans-174 in 58% yield (Scheme 2.64). Piperidine alcohol trans-174 was stirred with Ac2O 
and DMAP in pyridine to give amido ester trans-175. The crude product was treated with 
K2CO3 in MeOH which after 16 h, gave acetamide piperidine trans-96 in 71% yield (Scheme 
2.64). In contrast to the 2,6-disubstituted system cis-85 (see Table 2.2), the cleavage of the 
O-acyl this time proceeded without removal of the amide even though the reaction was left 
for 16 h.  
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Scheme 2.64 
Within this section the synthesis of disubstituted piperidines cis-86, cis-87, cis-84, cis-85, 
trans-95 and trans-95 were all discussed. We were able to access the cis-diastereoisomers 
via pyridine hydrogenation and subsequent protection to aid separation of the major cis-
piperidine. Access to the 2,3-disubstituted trans-piperidine was achievable using base-
mediated epimerisation to afford the more thermodynamically favoured 
trans-diastereoisomer. Finally, derivatisation of the nitrogen gave the six fragments in 3-6 
steps. 
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2.3 Conclusions and Overview 
We were able to synthesise three disubstituted pyrrolidine and six disubstituted piperidine 
fragments using the approaches outlined within the chapter. The three pyrrolidine fragments 
were synthesised via nucleophilic ring opening and condensation to afford the 
dihydropyrrole. Stereoselective reduction of the dihydropyrrole afforded the 
cis-diastereoisomer stereoselectively, with access to the trans-diastereoisomer possible via 
base-mediated epimerisation with neat DBU at reflux for 24 h. 
The six piperidine fragments were all synthesised starting from the hydrogenation of the 
corresponding disubstituted pyridine, which afforded the cis-diastereoisomers as the major 
products. Protection of the 2,5-disubstituted cis-piperidine aided the separation of the 
diastereoisomers, with hydrogenation of the 2,6-disubstituted piperidine selectively 
affording the cis-piperidine. The 2,3-disubstituted trans-piperidine was synthesised via base 
mediated epimerisation of the cis-piperidine using either NaOEt or NaOMe at reflux, which 
afforded the trans-diastereoisomer selectively. 
Along with the other O’Brien group members, 32 fragments were synthesised. Full analysis 
of the physicochemical properties and 3-D shape of the 32 fragments is described in Chapter 
5. 
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Chapter 3 Synthesis of Disubstituted Piperidines 
with Methyl and Methyl Ester Substituents 
In order to carry out the synthesis of the six piperidine 3-D fragments described in Chapter 
2, we had developed ways of carrying out the diastereoselective synthesis of 2,3-trans-, 2,3-
cis-, 2,5-cis- and 2,6-cis-disubstituted piperidines. Other members of the group had also 
developed approaches to some of the other regio- and diastereoisomers during the synthesis 
of some of the other 19 piperidine 3-D fragments. Hence, it was decided to try to develop 
general methodology that would allow the synthesis of all possible regio- and 
diastereoisomers of disubstituted piperidines with methyl and methyl ester substituents.  
If geminal disubstituted isomers are excluded, there are 20 regio- and diastereoisomers of 
disubstituted piperidines. The aim was to identify the fewest number of different pieces of 
synthetic methodology that could be used to access all 20 isomers. This Chapter describes 
our efforts towards that goal and demonstrates that using three main strategies, 
diastereoselective access to each of the 20 piperidines was possible.    
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3.1 Overview of the Three Planned Strategies to Disubstituted Piperidines 
The work in Chapter 2 focused on the synthesis of disubstituted piperidine fragments with a 
methyl substituent and a primary alcohol group (accessed viα reduction of a methyl ester). 
In the work described in Chapter 2 and work by other members of the group, two main 
strategies were used to control the relative stereochemistry in the fragments: pyridine 
hydrogenation gave disubstituted cis-piperidines with good levels of diastereoselectivity and 
epimerisation (via an enolate formation and protonation) gave access to disubstituted trans-
piperidines. As a result of these studies, we had accessed several regioisomers of the 
disubstituted cis- and trans-piperidines containing methyl and methyl ester substituents. 
Therefore, we considered developing a general approach that would allow access to all of 
the 20 possible regio- and diastereoisomers of such disubstituted piperidines, either as the 
free amines or protected versions (e.g. with Bn or Boc protecting groups). As shown in 
Figure 3.1, there are ten different regioisomeric disubstituted cis-piperidines. The plan was 
to access the disubstituted cis-piperidines using the pyridine hydrogenation method 
developed within Chapter 2, which had already led to the synthesis of piperidines cis-176 (R 
= H), cis-179 (R = Bn) and cis-180 (R = Boc). Furthermore, other members of the group had 
also synthesised piperidines cis-182 (R = Boc), cis-183 (R = Bn) and cis-185 (R = Boc) 
starting from pyridines using the same approach.108,109 We would thus focus on synthesising 
piperidines cis-177, cis-178, cis-181 and cis-184.  
 
Figure 3.1 – Structures of the ten disubstituted cis-piperidines accessible by pyridine hydrogenation. 
To access eight of the ten possible trans-piperidines, epimerisation using enolate formation 
was envisaged. Depending on the substitution pattern and substituent on the nitrogen, two 
different variants of epimerisation would be used. For example, base-mediated epimerisation 
of 2,3-. 2,5- and 3,4-cis-disubstituted piperidines with a free amine or N-benzyl group should 
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give diastereoselective access to the corresponding disubstituted piperidines trans-177, 
trans-179, trans-180, trans-182, trans-183 and trans-185 where R = H or Bn (Figure 3.2). 
As explained in Section 2.2.4, due to the substitution pattern around the piperidine ring, the 
thermodynamic driving force for both substituents to be equatorial should give access to the 
trans diastereoisomers stereoselectively. As the synthesise of piperidine trans-179 had 
already been achieved in Chapter 2 and with another member of the group synthesising 
piperidine trans-183 using base-mediated epimerisation focus would be placed on 
piperidines trans-177, trans-180, trans-182 and trans-185. 
 
Figure 3.2 – Structures of six disubstituted trans-piperidines accessible by epimerisation. 
A different type of base-mediated epimerisation could be used to synthesise the 2,4-
disubstituted trans-piperidines trans-186 and trans-187 which have a Boc-protected amine 
(Figure 3.3). With 2,4-disubstituted cis-piperidines having a NH or N-benzyl group, both 
substituents can be in the more favoured equatorial positions. However, installation of a Boc 
group on the nitrogen forces the substituent at the C-2 position to adopt an axial position to 
minimise the steric interaction between the Boc group and the substituent (A1,3-type strain). 
The C-4 substituent would then be forced into an axial position in a chair conformation as it 
is a cis-piperidine or, more likely, it would adopt an equatorial position in a boat 
conformation. Upon epimerisation, the formation of a thermodynamic chair-conformation 
with an equatorial C-4 substituent provides the driving force to afford piperidine trans-186 
(Figure 3.4). The same situation applies to the other 2,4-disubstituted N-Boc piperidine 
trans-187.  
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Figure 3.3 – Structures of two 2,4-disubstituted trans-piperidines. 
 
Figure 3.4 – Base-mediated epimerisation to access N-Boc piperidine trans-186.  
Finally, a lithiation-trapping strategy could be used to access some of the disubstituted N-
Boc piperidines. Indeed, a diastereoselective lithiation-trapping approach to 2,6-trans 
disubstituted N-Boc piperidines has been reported102 (Scheme 2.42) and use of this approach 
for the synthesis of N-Boc piperidine trans-188 was developed by another member of the 
group. Selective lithiation of an equatorial proton  to the N-Boc group occurs from a 
conformation in which the already-present substituent at the 3- and 4-positions is in an 
equatorial position. As a result, this lithiation-trapping strategy could also give access to 
disubstituted piperidines trans-189 and cis-187 (Figure 3.5). However, we anticipated that 
lithiation-trapping would only be explored if the initial epimerisation and hydrogenation 
routes to these piperidines failed to afford the trans and cis-diastereoisomers 
stereoselectively. It should be noted that the lithiation of N-Boc 3-methylpiperidine 190 
could occur at the C-2 or C-6 position. However, the steric hindrance of the methyl 
substituent hinders the C-2 position resulting in lithiation occurring at the C-6 position, 
which leads to high regioselectivity being observed for the formation of organolithium and 
hence trans-189 after trapping with methyl chloroformate (Figure 3.6).101  
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Figure 3.5 – Structures of piperidines trans-188, trans-189 and cis-187 accessible by lithiation-trapping.  
 
Figure 3.6 – Lithiation-trapping to give piperidine trans-189. 
Thus, using only three strategies, namely pyridine hydrogenation, base-mediated 
epimerisation and lithiation-trapping, we believed that it should be possible to synthesise 19 
out of the possible 20 disubstituted cis-/trans-piperidines containing methyl/methyl ester 
substituents, with some of the piperidines potentially accessible via more than one approach. 
At the outset, it appeared that the synthesis of the 3,5-disubstituted piperidine trans-181 
would be challenging to synthesise due its substitution pattern and the inability to access it 
via base-mediated epimerisation. This will be discussed in more detail in Section 3.2.   
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3.2 Strategy One: Pyridine Hydrogenation Route to cis-Disubstituted Piperidines 
The stereoselective synthesis of 2,5- and 2,3-disubstituted piperidines cis-157 and cis-123 
using hydrogenation of the corresponding disubstituted pyridines was described in Chapter 
2 along with proof of stereochemistry (see Scheme 2.45 and Figure 2.18). In that work, the 
hydrogenation conditions were optimised and involved the use of H2 and 10 mol% PtO2 in 
AcOH for 16 h at rt. Using these conditions, 2,5- and 2,3-disubstituted piperidines cis-157 
and cis-123 were synthesised (Figure 3.7).  
 
Figure 3.7 – Piperidines cis-157 and cis-123 accessed using pyridine hydrogenation.  
a) Yield of cis-piperidine over the two steps of hydrogenation and amine protection. 
In Chapter 2, the synthesis of the 2,6-disubstituted piperidine fragments were described. As 
part of that approach, the corresponding 2,6-disubstituted piperidine cis-142 had been 
synthesised diastereoselectively using pyridine hydrogenation (see Scheme 2.49). To isolate 
the cis-piperidine, the 95:5 mixture of crude piperidines cis-142 and trans-142 was directly 
benzylated, which gave N-benzyl piperidine cis-191 in 88% yield (Scheme 3.1).  
 
Scheme 3.1 
The next system to be investigated was 2,3-disubstituted pyridine 192 which, using our 
standard hydrogenation conditions (10 mol% PtO2), afforded a 90:10 mixture of piperidines 
cis-193 and trans-193 in 93% yield. N-Benzylation, using alkylation, enabled the 
diastereoisomers to be separated, with N-benzyl piperidine cis-194 isolated in 64% yield 
(Scheme 3.2). 
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Scheme 3.2 
The relative stereochemistry of piperidine cis-194 was assigned by comparing the 3JHH 
values between the protons at the C-2 and C-3 positions. There are two potential 
conformations for cis-194 (Figure 3.8), but whichever conformation is adopted, the 3JHH 
value of 5.0 Hz for the coupling between the protons on C-2 and C-3 was consistent with an 
axial-equatorial coupling.  
 
Figure 3.8 – Diagnostic 3JHH coupling constants for 2,3-disubstituted piperidine cis-194. 
A system which had not been studied previously during the group’s 3-D fragment synthesis 
efforts was the 3,4-disubstituted piperidines. Hydrogenation of 4-methylpyridine-3-methyl 
ester 195 using our standard hydrogenation conditions (10 mol%, PtO2) failed to afford 
complete reduction. 1H NMR spectroscopic analysis of the crude reaction mixture after a 
136 h reaction time showed a 50:35:15 mixture of piperidines cis-196, trans-196 and 
pyridine 195 (Table 3.1, entry 1). The PtO2 catalyst loading was increased to 20 mol% and 
reacted for 16 h. The 1H NMR spectrum of the crude reaction mixture showed a 40:20:40 
mixture of piperidines cis-196, trans-196 and pyridine 195 (entry 2). Therefore, the catalyst 
loading was finally increased to 30 mol% PtO2, which gave full reduction of pyridine 195 
and afforded a 65:35 mixture of piperidines cis-196 and trans-196 in 97% crude yield (entry 
3). 
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Table 3.1 – Hydrogenation of pyridine 195 using different catalyst loadings of PtO2. 
a) Ratio determined by 1H NMR spectroscopic analysis; (b) Yield of crude product. 
In contrast, the hydrogenation of pyridine 197, which has the methyl and methyl ester groups 
swapped over, gave no problems with full reduction achieved within 16 h using the standard 
conditions (10 mol% PtO2). In this case, an 85:15 mixture of piperidines cis-198 and trans-
198 was isolated in 89% crude yield (Scheme 3.3).  
 
Scheme 3.3 
The two 3,4-disubstituted piperidine mixtures were then converted into their N-Boc 
analogues to enable separation of the diastereoisomers. Starting from a 65:35 mixture of 
piperidines cis-196 and trans-196, purification by chromatography afforded N-Boc 
piperidines cis-199 in 47% yield, trans-199 (22% yield) and a 65:35 mixture of cis-199 and 
trans-199 (14% yield). Similarly, from piperidines cis-198 and trans-198, purification gave 
N-Boc piperidine cis-200 in 49% yield and an 80:20 mixture of N-Boc piperidines cis-200 
and trans-200 (14% yield) (Scheme 3.4).  
Entry PtO2 mol % Time (h) cis-196 : trans-196 : 
195a 
Yield cis-196 and 
trans-196 (%)b  
1 10 136 35:15:50 N/A 
2 20 16 40:20:40 N/A 
3 30 16 65:35:0 97 
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Scheme 3.4 
To aid with assigning the stereochemistry, the Boc protecting group in each of cis piperidine 
was converted into their N-tosyl analogues. N-Tosyl piperidine cis-201 was synthesised in 
84% yield (Scheme 3.5). The relative stereochemistry was assigned as cis-201 by X-ray 
crystallography (Figure 3.9). As shown in Figure 3.9, the methyl substituent occupied an 
axial position and the methyl ester was equatorial, confirming their cis-relationship.  
 
Scheme 3.5 
 
Figure 3.9 - X-ray crystal structure of N-tosyl piperidine cis-201 
N-Boc piperidine cis-200 was converted into N-tosyl piperidine cis-202 in 77% yield 
(Scheme 3.6). On this occasion, the stereochemistry was determined based on 3JHH values 
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(Figure 3.10). The two protons on C-1 showed a 2JHH value of 11.0 Hz and 
3JHH values of 
5.0 and 3.5 Hz to the proton on C-2. These 3JHH values suggested that the proton at the C-2 
position was in an equatorial position (with the methyl group in an axial position). The axial 
proton at the C-4 position showed a 2JHH value of 14.0 Hz and 
3JHH values of 10.0, 10.0 and 
4.0 Hz, which indicated that the C-3 proton was in an axial position (with the methyl ester 
in an equatorial position). All this analysis confirmed the cis-stereochemistry in piperidine 
cis-202. 
 
Scheme 3.6 
 
Figure 3.10 - Confirmation of stereochemistry of cis-202 via 3JHH values. 
Next, we planned to investigate the hydrogenation of 3-methylpyridine-5-methyl ester 203. 
Kappe et al. had in fact studied the hydrogenation of pyridine ester 203 under flow 
hydrogenation conditions and were able to selectively obtain the cis and trans-piperidines 
by varying the catalyst, pressure and temperature of the hydrogenation reactions. The 
selective hydrogenation to afford the cis-piperidine used 10% w/w PtO2 at 80 bar and 80 °C 
and gave a 63:37 mixture of piperidines cis-204 and trans-204. In contrast, hydrogenation 
using 10% w/w Pd/C at 30 bar and 50 °C gave a 65:35 mixture of the piperidines trans-204 
and cis-204 (Scheme 3.7). No explanation was put forward to explain the diastereoselectivity 
of these hydrogenation reactions.  
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Scheme 3.7 
For comparison with Kappe’s results, we explored the use of our standard hydrogenation 
conditions (10 mol% PtO2) with pyridine methyl ester 203. This gave a 60:40 mixture of 
piperidines trans-204 and cis-204 in 93% crude yield. The reaction mixture was treated with 
Boc2O and the diastereoisomeric N-Boc compounds were separated to give N-Boc 
piperidines cis-205 in 43% yield and N-Boc piperidine trans-205 in 29% yield (Figure 3.8). 
The stereochemistry of N-Boc piperidines trans-205 and cis-205 was assigned as follows. 
Kappe had used NOE NMR experiments to assign the stereochemistry of N-tosyl piperidines 
trans-206 and cis-206.110 Therefore, the minor diastereomeric N-Boc piperidine was 
converted into the N-tosyl analogue and, by comparing the 1H NMR spectroscopic data with 
those reported by Kappe, it was established that this was N-tosyl piperidine cis-206 (Figure 
3.8). In contrast to all other substitution patterns, this pyridine hydrogenation reaction gave 
the trans-piperidine as the major product, contrasting with Kappe’s results using PtO2 under 
pressure (see Figure 3.7).  
 
Scheme 3.8 
Since Kappe et al. had obtained the highest trans-diastereoselectivity using Pd/C as the 
calalyst (see Figure 3.8), we wondered whether this would also lead to an even more 
selective approach to N-Boc piperidine trans-205. Thus, using 10 mol% Pd/C under 
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otherwise identical conditions to the PtO2 reactions, hydrogenation of pyridine ester 203 
gave a 70:30 mixture of piperidines trans-204 and cis-204 in 91% crude yield, which was a 
slight improvement on the ratio obtained by Kappe et al. The 70:30 mixture of piperidines 
trans-204 and cis-204 was subsequently reacted with Boc2O to enable separation of the 
diastereoisomers. Purification afforded N-Boc piperidine trans-205 in 56% yield and cis-
205 in 25% yield (Scheme 3.9). Hence, this pyridine hydrogenation strategy afforded a 
stereoselective route to 3,5-disubstituted piperidine trans-205. This was in fact the 
diastereoisomer that we anticipated would be difficult to access since neither base-mediated 
epimerisation nor lithiation-trapping could offer a stereoselective route. 
 
Scheme 3.9 
The remaining three substitution patterns, the 2,5- and both 2,4-disubstituted cis-piperidines 
were studied by another member of the group, with the cis-piperidine being the major 
diastereoisomer after hydrogenation. These three results are summarised in Figure 3.10 and 
the cis-piperidines, cis-207, cis-186 and cis-187, were isolated as either the N-Boc or N-Bn 
derivatives in good yields (Scheme 3.10). 
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Scheme 3.10 – a) The isolated cis-yields are reported over two steps (hydrogenation and amine protection). 
Hydrogenation using the use of H2 and either 10 mol% PtO2, or 30 mol% PtO2 for pyridine 
195, in AcOH for 16 h at rt afforded nine out of ten cis-piperidines selectively. The 
hydrogenation strategy afforded a route to the 3,5-disubstituted trans-piperidine 204, with 
10 mol% Pd/C giving the highest diastereoselectivity after hydrogenation.  
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3.3 Strategy Two: Base-Mediated Epimerisation 
Base-mediated epimerisation using enolate formation could offer a stereoselective route to 
six of the ten disubstituted trans-piperidines with the free amine or N-benzyl group. The 
synthesis of 2,3-disubstituted piperidine trans-116 had already been established using 
epimerisation (NaOMe in MeOH at reflux for 24 h) followed by benzylation to separate out 
the diastereoisomers (see Scheme 2.63). A similar epimerisation approach was envisaged 
for the selective synthesis of piperidine trans-180. To start, an 85:15 mixture of piperidines 
cis-126 and trans-126 was reacted with NaOMe in MeOH at rt. After 92 h, 1H NMR 
spectroscopic analysis of the crude reaction mixture obtained after evaporation of the MeOH 
solvent showed a 70:30 mixture of piperidines cis-126 and trans-126. After a subsequent 
work-up with water and saturated NaHCO3(aq), an 85:15 mixture of piperidines cis-126 and 
trans-126 was isolated in 22% crude yield (Scheme 3.11).  
 
Scheme 3.11 
The outcome of this reaction highlighted two issues. First, there was limited epimerisation 
observed from performing the reaction at rt. Second, the isolated yield after the work-up was 
low. We considered that this could be due to the piperidines 126 undergoing ester hydrolysis 
to the carboxylic acid to generate a water-soluble amino acid. Thus, the aqueous layer was 
analysed by mass spectrometry and a peak corresponding to the m/z value of the carboxylic 
acid was observed, supporting our theory. To try and increase the rate of epimerisation, 
reactions at higher temperatures were explored. In addition, we decided to remove the 
aqueous work-up by evaporating the reaction mixture after treatment with NaOMe in MeOH 
and took the crude product directly on for Boc protection. Table 3.2 summarises the results 
of these reactions; entry 1 shows the result at rt.  
An 85:15 mixture of piperidines cis-126 and trans-126 was reacted with NaOMe in MeOH 
at reflux (80 °C). After 24 h, 1H NMR spectroscopic analysis of the crude reaction mixture 
(no aqueous work-up) showed a 70:30 mixture of piperidines trans-126 and cis-126 (entry 
2), clearly indicating that a significant amount of epimerisation had occurred. The crude 
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reaction mixture was Boc protected and purified by chromatography. This afforded N-Boc 
piperidine trans-157 in 27% yield, cis-157 (10% yield) and a 70:30 mixture of N-Boc 
piperidines trans-157 and cis-157 (4% yield). A similar reaction using K2CO3 in MeOH at 
80 °C for 24 h gave an 80:20 mixture of piperidines trans-126 and cis-126. After Boc 
protection and purification, N-Boc piperidine trans-157 was isolated in 18% yield, with no 
other products isolated (entry 3). Even though an aqueous work-up was avoided, the mass 
recovery from these two experiments was very low and we suspected that ester hydrolysis 
was occurring due to traces of water in the reactions. Epimerisation with DBU was then 
trialled at 50 and 80 °C. In both cases, 1H NMR spectroscopic analysis of the crude reaction 
mixture obtained after evaporation of the toluene solvent showed that no epimerisation of 
the piperidine reaction mixture had occurred (entries 4-5). Thus, using NaOMe at 25 °C and 
DBU at 50 or 80 °C, little epimerisation was observed. In contrast, with NaOMe or K2CO3 
in MeOH at 80 °C for 24 h, epimerisation occurred readily to give piperidine trans-157 as 
the major product, but mass recovery was poor.  
 
Entry Base Temp (°C) Time 
(h) 
cis-126 : trans-126a Yield of trans-157 
(%) 
1 NaOMe 25 96 70:30 N/A 
2 NaOMe  80 24 30:70 27b 
3 K2CO3 80 24 20:80 18
b 
4 DBU 50 96 85:15 N/A 
5 DBU 80 24 80:20 N/A 
Table 3.2 – Epimerisation of an 85:15 mixture of piperidines cis-126 and trans-126. 
 a) Ratio determined by 1H NMR spectroscopy of the crude NH piperidines, b) No aqueous work-up was 
performed after base-mediated epimerisation. 
Given the poor mass recovery, alternative epimerisation conditions were explored and an 
example with a 3,4-disubstituted piperidine system was found. In 2010, work from a patent 
reported that reaction of a 90:10 mixture of N-Boc piperidines cis-199 and trans-199 with 
KOtBu in THF at ‒78 °C gave a 39% yield of N-Boc piperidine trans-199 (Scheme 3.12).81 
Despite the very low ‒78 °C reaction temperature, a yield of N-Boc piperidine trans-199 
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above the 10% that was present to start with showed that some epimerisation had been 
achieved.  
 
Scheme 3.12 
Therefore, these conditions were explored. A 1 M solution of KOtBu in THF was added to 
an 85:15 mixture of piperidine cis-126 and trans-126 in THF at ‒78 °C and reacted for 2 h. 
The reaction mixture was quenched with water at ‒78 °C and it was allowed to warm 
gradually to rt. After an aqueous work-up, the 1H NMR spectrum of the crude product 
showed an 80:20 mixture of piperidines trans-126 and cis-126 together with some 
unidentified impurities (Scheme 3.13). However, the mass recovery was low, and in this 
case, we suspected that the amino esters 126 may be water soluble. An aqueous work-up was 
necessary with the KOtBu epimerisation conditions since the reaction was quenched with 
water. Therefore, the corresponding benzylated piperidine was investigated. Benzylation of 
an 85:15 mixture of piperidines cis-126 and trans-126 with BnBr afforded, after purification, 
N-benzyl piperidine cis-208 in 79% yield and N-benzyl piperidine trans-208 (11% yield) 
(Scheme 3.13). N-Benzyl piperidine cis-208 was treated with KOtBu at ‒78 °C for 2 h and 
the 1H NMR spectrum after an aqueous work-up showed a 70:30 mixture of piperidines 
trans-208 and cis-208. Purification afforded N-benzyl piperidines trans-208 in 20% yield 
along with cis-208 (10% yield); a single unknown diastereoisomer of hydroxy ester 209 was 
also isolated in 8% yield (Scheme 3.13).  
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Scheme 3.13 
The structure of hydroxyl ester 209 was established by MS, IR, 1H and 13C NMR 
spectroscopic data. The IR spectrum confirmed the presence of the hydroxy group, with a 
broad peak at 3456 cm‒1. The 
1H NMR spectrum showed two doublets at 2.93 and 2.38 ppm 
which correspond to the NCH2 protons. The peaks only showed geminal coupling (
2J = 11.5 
Hz). Mass spectrometry showed a m/z peak corresponding to hydroxy ester 209. The 1H 
NMR spectrum after work-up was re-analysed and showed a 50:25:25 mixture of trans-208, 
cis-208 and hydroxy ester 209. Enolate hydroxylation is precedented in the work of 
Gnanaprakasam et al. who explored a series of hydroxylations α to carbonyl groups using 
only KOtBu in air with no other additives or oxidants.111  Their proposed reaction 
mechanism proceeds via deprotonation of 210 to form enolate 211, followed by trapping 
with O2 to give the superoxide anion 212. Deprotonation of 210 forms peroxide 213 which 
is then cleaved by 211 to give hydroxy ketone 214 (Scheme 3.14).  
 
Scheme 3.14 
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In an attempt to avoid the formation of hydroxy ester 209, the reaction of N-benzyl piperidine 
cis-208 with KOtBu was repeated with the rigorous exclusion of O2. The reaction vessel was 
purged and back-filled with Ar three times to remove any O2 within the system before the 
addition of KOtBu. Pleasingly, reaction of N-benzyl piperidine cis-208 with KOtBu at –78 
°C gave a 70:30 mixture of piperidines trans-208 and cis-208 with no evidence of the 
formation of hydroxyl ester 209. After purification, N-benzyl piperidine trans-208 was 
isolated in 53% yield along with N-benzyl piperidine cis-208 in 28% yield (Scheme 3.15). 
Of note, this was our best result so far in terms of mass recovery (81%) from an epimerisation 
reaction. Thus, starting from amino esters 126, we accessed N-benzyl piperidine trans-208 
in 41% yield over the two steps (benzylation and epimerisation). This is higher than the 27% 
yield of N-Boc piperidine trans-157 obtained using NaOMe in MeOH at 80 °C for 24 h 
followed by Boc protection (see Table 3.2, entry 2). 
 
Scheme 3.15 
Next, the KOtBu epimerisation conditions were explored with five other disubstituted 
piperidines and the results are shown in Table 3.3. Therefore, for future epimerisations the 
KOtBu conditions were used (Table 3.3). N-Benzyl piperidine cis-207 (prepared by another 
member of the group via pyridine hydrogenation and benzylation) was reacted with KOtBu 
at ‒78 °C for 2 h to give a 50:50 mixture of N-benzyl piperidine cis-207 and trans-207. 
Purification afforded N-benzyl piperidine cis-207 in 48% yield and N-benzyl piperidine 
trans-207 in 40% yield (entry 1). The stereochemistry for piperidine trans-207 was 
confirmed by 3JHH coupling constants. The lowest energy trans-conformation will have both 
substituents equatorial (Figure 3.11). Therefore, 3JHH coupling constants of 11.0 and 3.0 Hz, 
between the C-2 and C-3 positions and also between the C-5 and C-6 positions allowed for 
the trans-stereochemistry to be assigned. 
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Figure 3.11 - Diagnostic 3JHH coupling constants for 2,3-disubstituted piperidine cis-207. 
Unfortunately, this is the worst diastereoselectivity of all the base-mediated epimerisations 
that we have studied. For comparison, a reaction using NaOMe in MeOH at 80 °C for 24 h 
gave a 90:10 mixture of piperidines cis-207 and trans-207, an even worse result.  
Next, the synthesis of 2,3-trans-piperidines was explored. Treatment of N-benzyl piperidine 
cis-194 with KOtBu at ‒78 °C for 2 h afforded a 65:35 mixture of N-benzyl piperidines 
trans-194 and cis-194. Purification then gave N-benzyl piperidine trans-194 in 56% yield 
and an 80:20 mixture of N-benzyl piperidines cis-194 and trans-194 in 41% yield (entry 2). 
This is a 97% total recovery of piperidines cis-194 and trans-194 after purification. The 
relative stereochemistry was assigned based on the 3JHH coupling between the C-2 and C-3 
positions from trans-piperidine 193. The lowest energy conformation of piperidine trans-
193 (Figure 3.12) will have both substituents equatorial and identification of a 3JHH value of 
10.0 Hz between the protons on C-2 and C-3 allowed the stereochemistry to be assigned. 
 
Figure 3.12 - Diagnostic 3JHH coupling constants for 2,3-disubstituted piperidine cis-193. 
 The 2,3-trans-piperidine with the methyl and methyl ester groups transposed was then 
studied. Epimerisation to afford piperidine trans-123 had been achieved during the synthesis 
of piperidine 3-D fragments trans-95 and trans-96 (see Scheme 2.63). Use of the KOtBu 
conditions with N-benzyl piperidine cis-123 afforded a 70:30 mixture of piperidine trans-
123 and cis-123 from which piperidines trans-123 (60% yield) and cis-123 (23% yield) were 
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isolated (entry 3). Thus, piperidine trans-123 was synthesised in 48% yield over two steps 
from pyridine 115, which is a 10% improvement over the approach using the NaOMe 
epimerisation conditions (see Scheme 2.63). 
 
Entry Piperidine trans : cisb Yield of trans (%) 
1 
(207) 
50 : 50 40c, 207 
2 
 
(194) 
65 : 35 56d, 194 
3 
 
(123) 
70 : 30 60e, 123 
4 
 
(200) 
90 : 10 90f, 200 
5a 
 
(199) 
90 : 10 68g, 199 
Table 3.3 – Base-mediated epimerisation with KtOBu. 
a) 65:35 mixture of piperidine cis-199 and trans-199; b) Ratio determined by 1H NMR spectroscopy of the 
crude product; c) Isolated cis-207 in 48% yield; d) Isolated an 80:20 mixture of N-benzyl piperidines cis-194 
and trans-194 in 41% yield; e) Isolated cis-123 in 23% yield; f) Isolated a 90:10 mixture of piperidines cis-
200 and trans-200; g) Isolated a 75:25 mixture of peroxy ester 215 in 7% yield. 
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Similarly, successful results were obtained with the 3,4-disubstituted piperidines. Thus, 
reaction of N-Boc piperidine cis-200 with KOtBu at  ̶ 78 °C for 2 h gave a 90:10 mixture of 
N-Boc piperidines trans-200 and cis-200 in 90% crude yield, which was not purified further 
as the diastereomers were not separable (entry 4). As shown in Scheme 3.12, epimerisation 
of the regioisomeric 3,4-disubstituted piperidines 199 with KOtBu had already been 
reported.81 In our hands, a 65:35 mixture of N-Boc piperidines cis-199 and trans-199 was 
treated with KOtBu at ‒78 °C for 2 h to give a 90:10 mixture of N-Boc piperidines trans-
199 and cis-199. Purification by chromatography afforded N-Boc piperidine trans-199 in 
68% yield (entry 6). A second product was also isolated and the 1H NMR spectrum had 
features that suggested that α-substitution of the enolate had occurred. For example, there 
were two doublets at 4.33 and 3.23 ppm corresponding to NCH2 protons, which showed 
geminal coupling (2JHH = 15.0 Hz) only. However, α-hydroxylation was ruled out as the 
mass spectrometry showed a m/z peak corresponding to α-peroxy ester 215, which was 
isolated as a 75:25 mixture of diastereoisomers in 7% yield (Scheme 3.16). This further 
supported the mechanism proposed by Gnanaprakasam et al. with peroxide 213 being 
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Scheme 3.16 
As described in Section 3.2, hydrogenation of 3,5-disubstituted pyridine 203 had provided a 
stereoselective route to the 3,5-disubstituted piperidine trans-205. This opened up the 
opportunity to attempt to access the cis-piperidine stereoselectively using base-mediated 
epimerisation. Therefore, a 70:30 mixture of N-Boc piperidines trans-205 and cis-205 was 
subjected to the standard KOtBu conditions. After work-up, a 75:25 mixture of N-Boc 
piperidines cis-205 and trans-205 was formed but in only 30% yield (Scheme 3.17). This 
was surprising as the KOtBu epimerisation conditions had generally given high mass 
recovery (75-97%).  
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Scheme 3.17 
Hence, the corresponding 3,5-disubstituted N-benzyl piperidines 216 were explored. N-
Benzyl piperidine trans-216 was synthesised from a 70:30 mixture of piperidines trans-204 
and cis-204 using BnBr in a 1:1 mixture of saturated Na2CO3(aq) and CH2Cl2 at rt for 72 h. 
Purification afforded N-benzyl piperidine trans-216 in only 25% yield along with the doubly 
benzylated ring-opened amino acrylate 217 in 8% yield (Scheme 3.18). Presumably, the long 
reaction time had resulted in a second benzylation and elimination from enolate 218 would 
account for the formation of amino acrylate 217. With a view to reducing the amount of 
formation of amino acrylate 217, the reaction time was reduced to 16 h. In this way, N-
benzyl piperidine trans-216 was generated in an improved 60% yield with no formation of 
amino acrylate 217 (Scheme 3.18). 
 
Scheme 3.18 
With N-benzyl piperidine trans-216 in hand, epimerisation to cis-216 was then attempted 
with KOtBu at ‒78 °C for 2 h. Pleasingly, this afforded N-benzyl piperidine cis-216 in 62% 
yield, along with a small amount of a mixture of N-benzyl piperidine trans-216 and other 
undetermined impurities (Scheme 3.19). Thus, a higher mass recovery than with the Boc 
protected piperidine was possible using the N-benzyl group.  
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Scheme 3.19 
The remaining two 2,4-disubstituted piperidines trans-186 and trans-187 were synthesised 
by another member of the group. In both cases, it was necessary to use a N-Boc group as the 
epimerisation is driven by placing the 2-substituent in an axial position (as discussed in 
section 3.1, see Figure 3.4). The best result in each case was obtained using a different base 
and the results are briefly summarised in Figure 3.13. Using LDA in THF at –78 °C, 
piperidine trans-186 was selectively prepared in 65% yield. In contrast, the standard KOtBu 
conditions were applied to synthesise N-Boc piperidine trans-187 selectively in 53% yield 
with > 95% purity  
 
Figure 3.13 – Epimerisation to access piperidine trans-186 and 187. 
Optimisation of the epimerisation approach led to the stereoselective synthesise of seven 
disubstituted trans-piperidines, along with the 3,5-disubstituted cis-piperidines. The only 
epimerisation which failed to afford the trans-piperidine as the major diastereoisomer, was 
the 2,5-disubstituted piperidine, which gave a 50:50 mixture of diastereoisomers.  
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3.4 Strategy Three: Lithiation-Trapping of N-Boc Methyl piperidines 
The final strategy that we proposed to use to stereoselectively access disubstituted 
piperidines was Beak’s lithiation of N-Boc methyl piperidines and subsequent trapping with 
CO2 or methyl chloroformate. The 2,6-disubstituted trans-piperidine was one of the systems 
that could be synthesised using this lithiation-trapping approach. This example was 
performed by another member of the group and, as outlined in Scheme 3.20, N-Boc 2-
methylpiperidine 219 was converted into N-Boc piperidine ester trans-188 in 79% yield over 
the two steps, via N-Boc acid trans-220 (Scheme 3.20). 
 
Scheme 3.20 
This lithiation-trapping approach was investigated for the synthesis of the 2,5-trans-
piperidine system since this substitution pattern had given the worst diastereoselectivity in 
the KOtBu-mediated epimerisation reactions: a 50:50 mixture of N-benzyl piperidines trans-
207 and cis-207 had been obtained (see Table 3.3, entry 1). Lithiation-trapping of N-Boc 3-
methylpiperidine 221 with CO2 had been reported in 2013 by Brewer et al. with acid trans-
222 isolated in 78% yield.112  In our reaction, lithiation of N-Boc methyl piperidine 221 was 
carried out using sBuLi and TMEDA in Et2O at ‒78 °C for 3 h. Then, dry CO2(g) was bubbled 
into the solution for 10 min to give, after work-up, a 60:40 mixture of starting N-Boc 2-
methylpiperidine 221 and acids trans-/cis-222. Purification afforded a 29% yield of a 90:10 
mixture of piperidines trans-222 and cis-222 and a 42% yield of recovered starting material 
221 (Scheme 3.21). Analysis of the 1H NMR spectrum after purification, showed the 
presence of two doublets at 1.10 and 0.97 ppm, corresponding to the minor and major acid 
products respectively. Piperidine trans-222 had been fully characterised in the literature112 
and therefore the doublet at 0.97 ppm was assigned to the methyl substituent of piperidine 
trans-222. The doublet at 1.10 ppm was assumed to be the methyl group in piperidine cis-
222, as minor downfield signals at 3.97, 2.94 and 2.51 ppm were identified for the NCH 
signals. Confirmation that the minor product was piperidine cis-222 was obtained by its 
conversion into N-benzyl piperidine cis-207 of known stereochemistry (see Scheme 3.22).  
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Scheme 3.21 
Despite isolating a 90:10 mixture of piperidines trans-222 and cis-222 in only 29% yield, 
the ratio was an improvement over the 50:50 mixture obtained after epimerisation of N-
benzyl piperidines cis-207 and trans-207 (see Table 3.3, entry 1). The hope was that, after 
methylation of the carboxylic acid, separation of the diastereoisomers may be possible. 
Therefore, attempts were made to improve the conversion to products in the lithiation-
trapping reaction. Table 3.4 summarises our results, including the initial reaction shown in 
Scheme 3.21 (entry 1). Initially, the temperature was raised from ‒78 to ‒60 °C which gave 
an improved 81:9:10 mixture of piperidines trans-222, cis-222 and 221, with a 90:10 mixture 
of piperidine trans-222 and cis-222 isolated in 57% yield (entry 2). Extending the lithiation 
time at –60 °C to 6 h in an attempt to fully consume the starting material was not successful 
and a 56% yield of a 90:10 mixture of piperidines trans-222 and cis-222 was obtained (entry 
3). At ‒40 °C, a worse result was obtained with a 36:4:60 ratio of piperidines trans-222, cis-
222 and 221 and a 90:10 mixture of piperidine trans-222 and cis-222 isolated in 29% yield 
(entry 4). Thus, in our hands, the best result involved carrying out the lithiation at –60 °C 
for 3 h to give a 90:10 mixture of piperidines trans-222 and cis-222 in 57% yield.  
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Entry Temp (°C) Time (h) trans-222 : cis-222 
: 221a 
Yield of trans-222 and 
cis-222 (%)b 
1  ‒ 78 3 36 : 4 : 60 29 
2 ‒ 60 3 81 : 9 : 10 57 
3 ‒ 60 6 81 : 9 : 10 56 
4 ‒ 40 3 36 : 4 : 60 29 
Table 3.4 – Lithiation-trapping of 221 with CO2; a) Ratio determined by 1H NMR spectroscopic analysis of 
the crude product; b) trans-222 and cis-222 were isolated as a 90:10 mixture as determined by 1H NMR 
spectroscopic analysis. 
Finally, the 90:10 mixture of piperidines trans-222 and cis-222 was methylated with MeI 
and K2CO3 in DMF at rt for 16 h. Upon purification by chromatography, it was not possible 
to separate the two methyl ester diastereoisomers. Since we knew that the corresponding N-
benzyl piperidines trans-207 and cis-207 were separable, we converted the Boc group into 
the benzyl group. Thus, removal of the Boc protecting group using TFA and installation of 
the benzyl group using BnBr and sat Na2CO3(aq) gave N-benzyl piperidines trans-207 (74% 
yield) and cis-207 (6% yield) over three steps (Scheme 3.22).  
 
Scheme 3.22 
Comparison of the base-mediated epimerisation route (see Table 3.3, entry 1) with the 
lithiation-trapping route to access N-benzyl piperidine trans-207 reveal that the latter gave 
N-benzyl piperidine trans-207 in 42% yield over four steps. The initial route of 
hydrogenation, protection and subsequent epimerisation afforded piperidine trans-207 in a 
slightly lower 36% yield over four steps. However, the ability to access both 
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diastereoisomers in good yields is clearly an advantage of the hydrogenation/epimerisation 
approach.  
3.7 Conclusions and Overview 
We have developed simple and general approaches for the synthesis of all of the possible 20 
disubstituted regio- and diastereoisomeric piperidines using the four strategies outlined in 
Section 3.1. Hydrogenation using 10 or 30 mol% PtO2/Pd/C in AcOH under H2 afforded 
nine of the ten disubstituted cis-piperidines, with hydrogenation of the 3,5-disubstituted 
pyridine affording the trans-piperidine as the major product. We were unable to determine 
an overall trend for predicting the diastereoselectivity for the hydrogenations. However, the 
highest diastereoselectivity was achieved for the three systems with a substituent at the 2- or 
6-positions and where the two substituents were able occupy the more favourable equatorial 
positions, i.e 2,6- and 2,4-disubstituted piperidines.  
Epimerisation using KOtBu at ‒78 °C for 2 h gave a selective route to piperidines trans-208, 
trans-207, trans-194, trans-123, trans-200, trans-199 and cis-216 in good yields (Table 3.3). 
The final approach we outlined was lithiation-trapping to afford piperidine trans-188, which 
had been performed by another member of the group. The approach also offered an 
alternative route to the 2,5-trans piperidine, affording a higher overall yield compared to 
base-mediated epimerisation approach. Therefore, with the use of four simple and general 
approaches, access to all 20 disubstituted regio- and diastereoisomeric piperidines was 
possible. The work complements our piperidine fragment library with access possible to all 
the disubstituted piperidines, which would allow for the rapid elaboration of the piperidine 
core. 
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Chapter 4 Design and Synthesis of 3-D Fragments 
via α-Arylation and α-Alkylation of Cyclic Esters 
In this Chapter, we present a strategy for synthesising 3-D fragments that is different to that 
described in Chapter 2. Our plan was to develop an approach that would allow the more 
rapid synthesis of a wide range of 3-D fragments. PMI plots would still be a key part of the 
design process so that new areas of fragment chemical space were accessed. It was also 
decided to synthesise 3-D fragments based on different cyclic scaffolds that contained at 
least one aromatic substituent. This is because aromatic groups can help in fragment 
screening using 1H NMR spectroscopy.  The final design aspect was to focus on key pieces 
of synthetic methodology which could be easily extended to other scaffolds.   
We planned to use two different synthetic methodologies, namely ester enolate α-arylation 
and α-alkylation, as the key steps in our 3-D fragment syntheses (Scheme 4.1). After setting 
out the challenges and limitations with the first-generation fragments (Chapter 4.1), we go 
on to describe the design and synthesis of 3-D fragments using α-arylation (Chapter 4.2) and 
α-alkylation (Chapter 4.3) methodology. In total, 42 novel 3-D fragments were synthesised 
using this approach. 
 
Scheme 4.1 
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4.1 Challenges and Limitations with First-Generation 3-D Fragments and 
Development of a New Approach for the Synthesis of 3-D Fragments  
The main challenge with the synthesis of the first-generation pyrrolidine and piperidine 3-D 
fragments arose from the range of regioisomers that were selected. The pyrrolidine 
regioisomers required bespoke methodology to access the various substitution patterns, with 
six different routes utilised to synthesise the 14 selected pyrrolidine fragments. The 
piperidines were easier to synthesise, although extensive optimisation was required to access 
some of the trans-diastereoisomers. The need for stereoselective routes to access either the 
cis or trans-diastereoisomers resulted in issues with both synthesis and purification. Finally, 
there were inherent limitations with the first-generation 3-D fragments when it came to 
screening using NMR spectroscopy. The absence of aromatic groups within the fragments 
made analysis of the 1H NMR spectroscopic data difficult, since the signals due to the 
fragments overlapped with those of the target proteins. In this context, aromatic groups are 
ideal for fragment screening by 1H NMR spectroscopy due to the occurrence of signals in 
the 6-8 ppm region. 
As a result of these challenges and limitations, we decided to modify the fragment design 
and selection process. For fragment design, we wanted to avoid the presence of two 
stereogenic centres within the molecules and this in turn removed the need for the 
development of diastereoselective routes. For the new design approach, 3-D fragments 
would either be achiral or contain only one stereogenic centre. The incorporation of an 
aromatic group was also an important design aspect as this would help future fragment 
screening attempts using 1H NMR spectroscopy. Finally, the design of the new 3-D 
fragments would be led by the identification of synthesis methodology that would allow 
aromatic substituents to be readily introduced onto cyclic and heterocyclic saturated nitrogen 
and oxygen scaffolds. Two pieces of synthetic methodology were identified for this purpose. 
These were the α-arylation of cyclic esters using palladium catalysis and more classical α-
alkylation of cyclic esters via the reaction of enolates with benzylic halides. Using these two 
approaches, together with modification of the ester functional group and where applicable 
the N-substituent, 3-D fragments would be designed. Before synthesis, their 3-D shape 
would be analysed using our standard PMI protocol and only fragments in unexplored areas 
of 3-D fragment space would be targeted for synthesis. Crucially, design of 3-D fragments 
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would be based on the capability of the chemistry, which should streamline the synthesis of 
the 3-D fragments.  
An overview of this approach is summarised in Scheme 4.2. Starting from cyclic and 
heterocyclic esters, palladium-catalysed ester enolate α-arylation and classical α-alkylation 
chemistry would be explored. The successful scaffolds would then be derivatised and their 
3-D shape would be analysed using the PMI protocol. Finally, fragments with shapes 
occupying unexplored regions of chemical space would be selected and synthesised.   
 
Scheme 4.2 
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4.2 Synthesis of 3-D Fragments via α-Arylation of Cyclic Esters 
4.2.1 Overview of Palladium-Catalysed α-Arylation of Ketones, Amides and Esters 
Palladium-catalysed α-arylation was first reported with ketones in 1984 by Migita et al.113 
In their work, tributyltin enolates were utilised to access a variety of arylated ketones. One 
of the main drawbacks was the need to pre-form the tributyltin enolates by reacting enol 
acetates with tributyltin methoxide. In 1997, Hartwig et al. reported arylation α to ketones 
to form secondary, tertiary and quaternary carbon centres without the need to pre-form the 
enolates.114 Utilising Pd(dba)2 with 1,1’-bis(di-o-tolylphosphino)ferrocene (DTPF) and 
either KHMDS or NaOtBu it was possible to couple electron rich and poor aryl 
bromides/iodides. Selected examples are shown in Scheme 4.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
 
Scheme 4.3 
The mechanism proposed for this α-arylation reaction, starts with the oxidative addition of 
the aryl halide and is followed by transmetallation to give enolate intermediate 223. The 
final step consists of C-C bond formation via reductive elimination to afford the desired α-
arylated compound 224 (Scheme 4.4).115 It has been shown that the reductive elimination 
step is in competition with a β-hydride elimination process which forms an enone. 
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Scheme 4.4 
Numerous groups have since investigated the α-arylation of esters using different palladium 
sources and ligands. Buchwald et al. used either Pd(OAc)2 or Pd(dba)2 in combination with 
o-biphenyl phosphine ligands.116 The electron richness and bulky size of the o-biphenyl 
phosphine ligands reduced the amount of β-hydride elimination. In an initial example, α-
arylation of 1-bromo-4-t-butyl benzene 225 with t-butyl acetate 226 in the presence of 
NaHMDS, Pd(OAc)2, and o-biphenyl phosphine 227 was studied. This gave both 
monoarylated product 228 and diarylated product 229 in a combined 46% yield. The Claisen 
self-condensation product 230 was also isolated but a yield was not reported (Scheme 4.5). 
 
Scheme 4.5  
Buchwald et al. found that LiHMDS was the most effective base, with only trace amounts 
of diarylated product observed. The rationale behind the finding was connected to the 
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increase in covalency of the Li+ versus Na+ cation. The Li+ cations are able form more 
covalent Li-O bonds, which reduced the formation of the diarylated product. Finally, with 
their optimised conditions in hand, the scope was expanded to include the formation of 
tertiary and quaternary carbon centres with ortho-, meta- and para-substituted aryl groups 
(Scheme 4.6). 
 
Scheme 4.6  
The ester α-arylation reaction was extended by Hartwig et al. to the synthesis of α-aryl amino 
acids via the α-arylation of protected amino acids.117 Mechanistic studies revealed that the 
rate limiting step was the formation of the palladium enolate complex which depended on 
the stability of the alkali metal enolate. The α-arylation of N-(diphenylmethylene)-glycinate 
232 with electron rich and poor aryl bromides in the presence of Pd2(dba)3, P(t-Bu)3 and 
K3PO4, gave the arylated products in high yields (Scheme 4.7). 
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Scheme 4.7  
In 2002, Hartwig et al. described the α-arylation of cyclohexane-derived esters (Scheme 
4.8).118 The installation of electron rich and poor aromatics was possible, although no studies 
were carried out with sterically hindered ortho-substituted aromatics. In these reactions, the 
lithium enolate was pre-formed and the choice of solvent was found to be a key factor for 
successful α-arylation reactions. The best yields were obtained in aromatic solvents, whereas 
none of the α-arylated product was observed in reactions in ether solvents such as Et2O and 
THF.  
 
Scheme 4.8 
In related work, Bercot et al. investigated the diastereoselective α-arylation of 1,4-
disubstituted cyclohexanes 233. Using LDA in toluene, with [(t-Bu3P)PdBr]2 as catalyst, a 
wide range of cis-α-arylated esters were generated (Scheme 4.9). 
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High cis-diastereoselectivity was generally observed for different 4-substituents and 
different aryl and vinyl halides. Reduced diastereoselectivity was found with sterically 
hindered ortho-substituted aryl bromides.  
 
Scheme 4.9 
Bercot et al. proposed the following explanation to explain the highly diastereoselective 
formation of cis-α-arylated esters. Initially, Pd enolate 234 would form, which could be 
transformed into α-palladyl esters cis-235 and trans-235 (Scheme 4.10). Due to both the 
sterically bulky 4-substituent and PdLnAr groups being equatorial, it was proposed that cis-
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235 would preferentially form. Subsequent reductive elimination from cis-235 would 
generate the cis-α-aryl esters. 
 
Scheme 4.10 
A more recent publication by Zhou et al. investigated the palladium-catalysed α-arylation of 
a 4-ketal-substituted cyclohexanone 236.119 α-Arylation was accomplished using LiHMDS, 
[(cinnamyl)PdCl]2, and t-Bu3P·HBF4 and different heteroaromatic groups were introduced, 
including pyridyl, 3-substituted pyridyl, quinolinyl, iso-quinolinyl and isoxazolyl (Scheme 
4.11). 
 
Scheme 4.11  
To the best of our knowledge, there are only two examples of the α-arylation of cyclic esters 
on saturated nitrogen and oxygen heterocycles (Scheme 4.12). Risatti et al. reported the α-
arylation of N-Boc 4-ethyl ester piperidine 237 during the development of a scalable route 
to a duel NK-1/serotonin receptor antagonist.120 Pre-formation of the enolate was followed 
by addition of Pd2(dba)3 and P(t-Bu3)·HBF4 to afford α-arylated ester 238 but unfortunately 
the yield was not reported. The only other example of the palladium-catalysed α-arylation 
of a heterocyclic ester was for 4-methyl ester THP 239, reported within a patent from Indalo 
Therapeutics.121 4-Methyl ester THP 239 was added to a solution of LDA and stirred for 10 
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min to pre-form the enolate prior to the addition of the catalyst/aryl bromide solution. This 
gave α-aryl THP ester 240 in 43% yield.  
 
Scheme 4.12 
This brief overview reveals that a range of catalysts and ligands have been reported for the 
palladium-catalysed α-arylation of ketones, amides and esters. The most common bases used 
were either LiHMDS or LDA, with the reactions being conducted in aromatic solvents. Of 
note, examples with cyclohexane, a piperidine and a THP were described, including the use 
of heteroaromatic bromides as the coupling partner. 
4.2.2 Investigation of the Scope and Limitations of the α-Arylation of Cyclic Esters 
In order to explore the potential for 3-D fragment synthesis, the scope of the α-arylation of 
cyclic esters needed to be established. As outlined in the previous section, there are a few 
known examples of ester α-arylation of cyclic substrates, in particular the work of Zhou and 
Bercot on cyclohexyl esters (see Scheme 4.9 and Scheme 4.11). Therefore, their reaction 
conditions were used as a starting point for our optimisation studies. The main differences 
between the conditions reported by Bercot and Zhou was the formation of the enolate. In 
Bercot’s work, the ester had been added to the base to pre-from the enolate prior to the 
addition of the catalyst/aryl bromide mixture. In contrast, Zhou et al. had added the base to 
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a mixture of the ester and heteroaryl bromide and subsequently added the catalyst solution. 
To start with, we attempted to carry out the reaction between cyclohexyl ketal 236 and 2-
bromopyridine to give α-arylated ester 241 (Table 4.1), a reaction that Zhou et al. had 
reported on the corresponding ethyl ester. Using [(cinnamyl)PdCl]2 (0.5 mol%) and t-
Bu3P.HBF4 (2 mol%) with LiHMDS (1 M in THF), none of the desired α-arylated product 
241 was formed (entry 1). The reaction was repeated with a higher catalyst and ligand 
loading of 2 and 4 mol% respectively. On this occasion, some 2-pyridyl ester 241 was 
identified in the 1H NMR spectrum of the crude product but, after purification, none was 
isolated (entry 2). Disappointingly, under apparent identical reaction conditions, 2-pyridyl 
ester 241 could not be synthesised.  
On closer inspection of the reaction conditions reported by Zhou et al., we realised that they 
did not specify the solvent for the LiHMDS solution. Both THF and toluene solutions of 
LiHMDS are commercially available. Therefore, considering the observation made by 
Hartwig et al. about the importance of conducting the α-arylation reactions in aromatic 
solvents (see Scheme 4.8), the base was switched to a toluene solution of LiHMDS. 
Pleasingly, using LiHMDS (1 M in toluene), 2-pyridyl ester 241 was isolated in 74% yield 
(entry 3), slightly lower than the 91% yield reported by Zhou et al. for the corresponding 
ethyl ester. 
 
Entry Catalyst  Ligand  Base Yield of 241 (%)a 
1 [(cinnamyl)PdCl]2 
(0.5 mol%) 
t-Bu3P.HBF4  
(2 mol%) 
LiHMDS  
(1 M THF) 
- 
2 [(cinnamyl)PdCl]2 
(2 mol%) 
t-Bu3P.HBF4  
(4 mol%) 
LiHMDS  
(1 M THF) 
-  
3 [(cinnamyl)PdCl]2 
(2 mol%) 
t-Bu3P.HBF4  
(4 mol%) 
LiHMDS  
(1 M toluene) 
74 
Table 4.1 – Investigation of the synthesis of 241. 
 a) % yield after chromatography. 
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Encouraged by this result, attention was turned to other cyclic esters and aryl bromides. 
Initially, the α-arylation of cyclopentane ester 242 with 4-bromotoluene was investigated 
(Table 4.2). LiHMDS (1 M in THF) and NaHMDS (2 M in THF) both failed to yield any of 
the desired α-arylated product 243 (Table 4.2, entries 1 and 2) which is in line with our 
previous findings. However, even with the toluene solution of LiHMDS, α-arylated ester 
243 was isolated in only 5% yield (entry 3). We had better success with LDA (prepared in 
toluene) which gave 243 in 20% yield (entry 4). 
 
Entry Base Yield of 243 (%)a 
1 LiHMDS (1 M THF) - 
2 NaHMDS (2 M THF) - 
3 LiHMDS (1 M toluene) 5 
4 LDA (toluene)b 20 
Table 4.2 – Investigation of the α-arylation of cyclopentane ester with 4-bromotoluene. 
 a) % yield after chromatography; b) LDA solution was formed at 0 °C for 30 min in toluene followed by 
addition of ester 242. 
The low yielding reaction for the α-arylation of cyclopentane ester 242 was a cause for 
concern. In the procedure, the base was added to the ester and aryl bromide solution and we 
considered that this could lead to some Claisen self-condensation. To reduce the chance of 
this occurring, the order of addition of the ester and the base was altered, in line with the 
procedure reported by Bercot et al.122 Thus, ester 242 would be added to a solution of the 
base to pre-form the enolate. Then, this enolate solution would be added to a suspension of 
[(cinnamyl)PdCl]2, t-Bu3P·HBF4 and 4-bromotoluene in toluene and stirred at rt for 16 h. 
The results with three different bases are shown in Table 4.3. 
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Entry Base Yield of 243 (%)a 
1 LDAb 58  
2 LiNCy2
b 59 
3 LiHMDS (1 M THF) No product detected  
4 LiHMDS (1 M toluene) 34 
Table 4.3 – Pre-formation of the cyclopentane enolate prior to α-arylation with 4-bromotoluene. 
a) % yield after chromatography; b) The lithium amide solution was formed a at 0 °C for 30 min in toluene 
followed by addition of ester 242. 
Using LDA, α-aryl ester 243 was obtained in 58% yield (entry 1), a significant improvement 
on our previous result (20%, see Table 4.2 entry 4). LiNCy2 was also explored since Hartwig 
et al.118 had found that pre-formation of the enolate with LiNCy2 represented their optimised 
conditions (see Scheme 4.8). This gave a 59% yield of 243 (entry 2). Changing the base to 
the THF solution of LiHMDS failed to afford any of the α-aryl ester (entry 3), whereas the 
toluene solution of LiHMDS gave α-aryl ester 243 in 34% yield (entry 4), which  similar to 
LDA, was an improvement over our previous result using LiHMDS (1 M in toluene) (see 
Table 4.2 entry 3). At this point, pre-formation of the enolate using LDA was identified as 
the best conditions with cyclopentane ester 242. Thus, using these conditions (LDA, 
[(cinnamyl)PdCl]2 (2 mol%), t-Bu3P·HBF4 (4 mol%)), the aryl bromide was varied (Table 
4.4). Electron rich and poor aryl bromides worked well although yields were variable (244-
247, 38-72%) (entries 1-4). An ortho-methyl substituent was reasonably well tolerated and 
gave α-aryl ester 247 in 36% yield (entry 4). Unfortunately, we had less success with 
heteroaryl bromides. Bromides containing pyrimidine and imidazole groups both failed to 
afford any of the desired α-arylated products based on analysis of the crude reaction mixtures 
by 1H NMR spectroscopy and mass spectrometry (entries 5 and 6). However, ester enolate 
α-arylation with 2-bromopyridine gave α-aryl ester product 248, albeit in 6% yield (entry 7). 
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Entry Ar-Br Product Yield (%)a 
1 
 
244 34 
2 
 
245 72 
3 
 
246 68 
4 
 
247 36 
5 
 
- No product 
formation 
6 
 
- No product 
formation 
7 
 
248 6 
Table 4.4 – Investigation of the α-arylation of cyclopentane ester with aryl bromides; a) % yield after 
chromatography. 
The yields for the para-fluorophenyl and ortho-methylphenyl derivatives 244 and 247 were 
relatively low (Table 4.4, entries 1 and 4). This led us to investigate the α-arylations with 
LiHMDS (1 M in toluene) via pre-formation of the enolate prior to addition of the catalyst 
and aryl bromide. For this study, five aryl bromides were used, and the results are shown in  
Table 4.5. Using these conditions, a 27% yield of para-fluorophenyl ester 244 was isolated, 
with none of ortho-methylphenyl ester 247 observed (entries 1 and 2). In contrast, and to our 
surprise, the α-arylation with 2-bromopyridine led to a 72% yield of 2-pyridyl ester 248, 
which was not affected upon scale-up (entry 3). Unfortunately, α-arylation with the 
pyrimidinyl and imidazolyl bromides still failed to yield any of the desired α-arylated 
products (entries 4 and 5) 
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Entry Ar-Br Product Yield (%)a 
1 
 
244 27 
2 
 
247 No product 
formation 
3 
 
248 72 (71b) 
4 
 
- No product 
formation 
5 
 
- No product 
formation 
Table 4.5 – Investigation of the α-arylation of cyclopentane ester with aryl bromides using LiHMDS (1 M in 
toluene); a) % yield after chromatography; b) 7.8 mmol scale. 
With a preliminary study of the scope of the aryl bromides and with two sets of promising 
conditions, either LDA or LiHMDS (1 M in toluene), different heterocyclic esters were 
explored. To determine the best set of conditions, we attempted some using LDA (conditions 
A) and some using LiHMDS (conditions B) with a pre-formed enolate in toluene. The results 
with N-Boc esters are shown in Scheme 4.13.  
LiHMDS (1 M in toluene) and LDA were initially trialled on 4-methyl ester piperidine 249 
with the former giving 4-α-tolyl piperidine 253 in 70% yield. The use of LDA was found to 
only give 253 in a 10% yield. Therefore, conditions B using LiHMDS (1 M in toluene) were 
applied to the 3-methyl ester piperidine which afforded 3-α-tolyl piperidine 254 in a 79% 
yield. However, using the same conditions, none of the desired 2-α-tolyl piperidine 255 was 
observed. Next, the N-Boc pyrrolidines were explored, with both sets of conditions applied 
to the 3-methyl ester pyrrolidine. On this occasion, both sets of conditions afforded similar 
yields, with 3-α-tolyl pyrrolidine 256 isolated in 34% and 37% yields respectively using 
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conditions A and B. However, the lower yields could be attributed to the poor solubility 
observed of the ester enolate, which had not been seen with the piperidine ester enolates.  
 
Scheme 4.13 – a) Conditions not carried out. 
Conditions B (LiHMDS (1 M in toluene)) were applied to the 2-methyl ester pyrrolidine 257 
and, surprisingly, gave 2-methyl ester pyrrolidine alcohol 258 in 64% yield, with none of 
the desired α-aryl pyrrolidine observed (Scheme 4.14). We presume that the formation of 
the α-hydroxy ester was due to the presence of oxygen within the reaction flask which led to 
an α-hydroxylation process.  
 
Scheme 4.14 
The poor solubility of the 3-methyl ester pyrrolidine enolate potentially contributed to the 
low yields observed. Therefore, to try and improve the enolate solubility and hinder the 
formation of the Claisen self-condensation product, the more sterically hindered t-butyl 
enolate was investigated. 3-t-Butyl ester pyrrolidine 259 was prepared by another member 
of the group starting from the corresponding carboxylic acid.123 α-Arylation of 3-t-butyl ester 
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pyrrolidine 259 afforded 3-α-tolyl pyrrolidine 260 in 71% yield with the t-butyl enolate 
showing improved solubility; none of the Claisen self-condensation product was observed 
(Scheme 4.15).  
 
Scheme 4.15  
The final area we wanted to explore was the installation of different aryl bromides. 
Therefore, the α-arylation of 3-methyl ester piperidine 250 using LiHMDS (1 M in toluene) 
with 4-fluorobromobenzene was attempted and gave α-aryl piperidine 261 in 59% yield, 
along with dihydropyridine ester 262 in 7% yield. Presumably, formation of dihydropyridine 
262 proceeded through β-hydride elimination, which is an alternative catalytic pathway to 
reductive elimination (Scheme 4.16).  
 
Scheme 4.16  
Next, the α-arylation of THF and THP esters was investigated, with some attempted using 
LDA (conditions A) and some with LiHMDS (conditions B) with a pre-formed enolate in 
toluene. However, neither set of conditions yielded any of the desired α-arylated products, 
with the only exception being the 4-methyl ester THP 263. In this case, α-tolyl THP 268 was 
isolated in 19% yield along with 4-methyl ester THP 263 in 28% yield (Scheme 4.17).   
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Scheme 4.17 – a) Conditions were not attempted. 
Due to the low yield of α-tolyl THP 268 and the recovery of starting material, we decided to 
extend the reaction time to 24 h. This gave the desired product 268 in 48% yield along with 
Claisen self-condensation product 269 in 20% yield (Scheme 4.18).  
 
Scheme 4.18  
However, similar to the 3-methyl ester pyrrolidine 252 (see Scheme 4.15), we were 
observing poor solubility of the ester enolate. Therefore, the α-arylation of the t-butyl ester 
THP 271 was explored to see whether an improvement in solubility and overall yield could 
be achieved. The t-butyl ester was synthesised by reacting THP acid 270 with t-butyl-2,2,2-
trichloroacetimidate at rt for 4 days. Purification afforded 3-t-butyl ester THP 271 in 30% 
yield. However, despite the improved solubility of the ester enolate, only starting material 
along with some minor undetermined impurities were detected (Scheme 4.19). 
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Scheme 4.19 
Therefore, we returned to the 4-methyl ester THP 265 and decided to explore α-arylation 
with 4-bromoanisole and 2-bromopyridine using LiHMDS (1 M in toluene). Reaction with 
4-bromoanisole at rt for 24 h gave α-aryl THP 272 in 18% yield (Table 4.6, entry 1). Unlike 
α-arylation with 4-bromotoluene, analysis of the 1H NMR spectrum for the α-arylation with 
4-bromoanisole showed unreacted starting material. As a result, the reaction time was 
increased to 64 h, which gave 4-methyl ester THP 272 in an improved 57% yield (entry 2). 
The reaction temperature was also increased to 50 °C, allowing for a shorter reaction time, 
affording 4-methyl ester THP 272 in a higher 63% yield (entry 3). Next, the α-arylation of 
4-methyl ester THP 265 with 2-bromopyridine was explored. Using the optimised reaction 
conditions from Table 4.6 of 50 °C for 16 h, α-aryl THP 273 was isolated in 53% yield along 
with Claisen self-condensation 269 (20%) (Scheme 4.20). 
 
Entry Temperature (° C) Time (h) Yield 272 (%)a Yield 269 (%)a 
1 25 24 18 - 
2 25 64 57 9 
3 50 16  63 21 
Table 4.6 – Optimisation of the synthesis of THP 272. 
 a) % yield after chromatography. 
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Scheme 4.20 
Investigation into the α-arylation of cyclic and heterocyclic esters had revealed the 
limitations of the chemistry, with only the cyclopentane, 3-pyrrolidine, 3- and 4-piperidine 
and the 4-THP esters successfully arylated. The aryl group could be interchanged to 
incorporate electron rich and poor aryls, along with the coupling of 2-pyridyl. Therefore, a 
series of potential fragments were designed which we anticipated would be accessible using 
the ester enolate α-arylation chemistry.  
4.2.3 Design and Analysis of 3-D Fragments from α-Arylated Cyclic Esters 
With knowledge of the scope and limitations of the α-arylation of cyclic esters, both in terms 
of the cyclic esters and the aryl bromides, we could design 3-D fragments that should be 
synthetically accessible. Then, 3-D shape analysis using PMI plots, together with ensuring 
that the fragments were ‘Rule of three’ compliant, would be used to identify the 3-D 
fragments that would be synthesised. Therefore, a series of fragments were designed based 
on the five cyclic scaffolds shown in Figure 4.1. They included cyclopentane, 3-substituted 
pyrrolidine, 3- and 4-substituted piperidines and THP. As well as the ester group, other 
substituents were incorporated such as carboxylic acid, primary alcohol and amine, 
secondary amine and amide since these groups should be accessible using simple 
transformations from the ester. The third point of diversification was the aryl group and the 
seven aromatic groups which had been successfully introduced by ester α-arylation (see 
Section 4.2.2). As a result of these three points of diversification, 210 3-D fragments were 
designed. 
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Figure 4.1 – Structures of 210 3-D fragments. 
The PMI plot of the conformations with a relative energy of ≤ 1.5 kcal mol‒1 of the 210 3-D 
fragments are shown in Figure 4.2. Pleasingly, these 3-D fragments showed good levels of 
shape diversity, with only 18 out of the 1176 conformations occupying the ƩNPR region 
between 1.0-1.1. For all five scaffolds, the 3-D fragments had almost all conformations in 
the most interesting regions of chemical space, normally ƩNPR ≥ 1.1. Hence, any of the 210 
3-D fragments were of interest for synthesis. A sub-set of these were selected based on their 
anticipated ease of synthesis. 
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a)                                                                     b) 
 
 
 
 
 
c)                                                                     d)    
 
 
 
 
 
                                       e) 
 
 
 
 
 
Colour       
Conformation energy 
difference (kcal mol‒1) 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
Figure 4.2 –PMI analysis of (a) cyclopentane, (b) 3-substituted pyrrolidine, (c) 4-substituted piperidine, (d) 3-
substituted piperidine and (e) 4-substituted THP showing all conformations which have a relative energy ≤ 
1.5 kcal mol‒1. The Ar- and R- groups are shown in Figure 4.1. 
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4.2.4 Synthesis of Ester Enolate α-Arylated 3-D Fragments 
The α-arylation of cyclic esters set out in Section 4.2.2 provided several 3-D fragments 
directly. The structures of these eight 3-D fragments are shown in Figure 4.3 and they were 
directly added to the 3-D fragment library. 
 
Figure 4.3 – Structures of eight 3-D fragments synthesised directly using α-arylation. 
The α-arylation chemistry also afforded three N-Boc piperidine and one N-Boc pyrrolidine 
scaffolds, which required deprotection before inclusion within the library. The N-Boc 
protected scaffolds were treated with 4 M HCl in dioxane and stirred for 16 h, which gave 
the desired final fragments, all in quantitative yields (Scheme 4.21). 
 
Scheme 4.21 
We also imagined a range of reactions that could be carried out on the α-arylated ester 
fragments to generate other 3-D fragments. Our planned reactions are summarised in  
Scheme 4.22. For example, ester hydrolysis would give the corresponding carboxylic acid 
which could be converted into an amide via coupling with an amine or into a secondary 
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amine via Curtius rearrangement. Alternatively, reduction of the ester would give a primary 
alcohol. Subsequently, activation and nucleophilic substitution should give a primary amine 
functionality. 
 
Scheme 4.22 
The 4-fluorophenyl piperidine 261 was derivatised by ester hydrolysis and subsequent amide 
coupling followed by Boc removal to give amide piperidine 279 in 36% yield over the three 
steps (Scheme 4.23). Ester hydrolysis was also performed on the 4-methoxy THP 272 to 
afford carboxylic acid 280 in 88% yield (Scheme 4.24). 
 
Scheme 4.23 
 
Scheme 4.24 
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As well as ester hydrolysis, the ester in 4-fluorophenyl piperidine 261 was also reduced to 
the primary alcohol with LiAlH4 at 0 °C for 2 h. After purification, this afforded N-Boc 
piperidine 281 in 98% yield. The Boc group was then removed to afford 3-D fragment 282 
(Scheme 4.25). 
 
Scheme 4.25 
The primary alcohol could also be converted into a primary amine over three steps via 
mesylation, azide insertion and Staudinger reduction. After reduction of ester 248 using our 
standard conditions (LiAlH4, 0°C, 2 h), cyclopentane alcohol 283 was reacted with MsCl 
and Et3N at rt for 16 h to afford cyclopentane mesylate 284 in 91% yield. Nucleophilic 
substitution with NaN3 at 60 °C for 16 h gave azide 285 in 86% yield, which was reduced to 
the amine using a Staudinger reaction to afford amine 286 in 95% yield (Scheme 4.26). In 
the same way, THP ester 273 underwent the same reaction sequence. THP alcohol 287 was 
converted into THP mesylate 288 and then in two steps to afford THP amine 289 in 42% 
over four steps from methyl ester 273 (Scheme 4.27). 
 
Scheme 4.26 
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Scheme 4.27 
As well as synthesising some of the designed 3-D fragments from Section 4.2.3, we also 
decided to carry out the synthesis of a few other 3-D fragments. The shape of the fragments 
was initially analysed using PMI plots, and their synthesis is described in the remainder of 
this section. For example, the conversion of the primary alcohol into a fluoroalkyl group was 
considered since fluorine is a common feature in potential drug molecules and is also used 
as an NMR handle in NMR screening of fragments.  
A convenient method for deoxyfluorination using PyFluor had been developed by Doyle et 
al.124 Hence, cyclopentane alcohol 283 was treated with PyFluor and DBU at rt for two days. 
1H NMR spectroscopic analysis of the reaction mixture revealed the formation of the 
pyridine sulfonate 291, which was subsequently isolated in 99% yield. We reasoned that the 
lack of reactivity could be due to the neopentyl alcohol resulting in a slow rate of 
nucleophilic substitution. Therefore, the reaction temperature was increased to 80 °C, which 
gave the desired fluorinated product 292 in 70% yield (Scheme 4.28). Deoxyfluorination 
was also applied to THP alcohol 287 to afford fluorinated product 293 in 85% yield (Scheme 
4.29). 
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Scheme 4.28 
 
Scheme 4.29 
Fluorination was then attempted on 4-fluorophenyl N-Boc piperidine 281 using the 
conditions outlined above. However, on this occasion, we failed to form the fluorinated 
product and instead isolated the piperidine sulfonate intermediate 294 in 76% yield. We 
decided to take the intermediate and displace the sulfonate to from the primary amine using 
azide insertion and the Staudinger reaction. The Boc protecting group was then removed to 
afford piperidine 295 in a 51% yield over three steps from sulfonate 294 (Scheme 4.30). 
 
Scheme 4.30  
4-Methylphenyl pyrrolidine ester 256 was converted into the acetamide using 4 M HCl in 
dioxane to remove the Boc group, followed by acylation with acetyl chloride and Et3N. This 
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gave acetyl pyrrolidine 297 in 99% yield (Scheme 4.31). We were also able to 
simultaneously reduce the tert-butyl ester and the Boc group in pyrrolidine 260 to afford N-
methyl pyrrolidine alcohol 298 in 31% yield (Scheme 4.32). 
 
 
Scheme 4.31 
 
Scheme 4.32 
The final α-arylated fragment synthesised was piperidine acetamide 300. This was 
synthesised starting from piperidine 275 in two steps via acylation and then subsequent base 
hydrolysis to give 300 in 88% yield over two steps (Scheme 4.33).  
 
Scheme 4.33 
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In total, 26 α-arylated 3-D fragments were synthesised and included within the fragment 
library. The structures of the synthesised 3-D fragments are shown in Figure 4.4. 
 
Figure 4.4 – Structures of 26 α-arylated 3-D fragments. 
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4.3 Synthesis of 3-D Fragments via α-Alkylation of Cyclic Esters 
4.3.1 Overview of α-Alkylation of Cyclic Esters 
The α-alkylation of cyclic esters is a classical reaction that has been widely used in synthesis, 
with typical reaction conditions using LiHMDS at ‒78 °C and trapping with either alkyl 
chlorides or bromides. Numerous examples have been reported within patents, with both 3-
piperidine ethyl ester and dihydrobenzofuran methyl esters alkylated with benzyl bromide 
(Scheme 4.34).125–130  
 
Scheme 4.34 
Substituted benzyl derivatives have also been introduced by alkylation. For example, Dodd 
et al. alkylated 2-methyl ester pyrrolidine 257 with both 4-bromo and 4-nitrile benzyl 
chlorides to give α-alkylated products 301 and 302 in 85% and 30% yields respectively 
(Scheme 4.35).131  
 
Scheme 4.35 
The previous literature revealed that a range of heterocyclic esters have been α-alkylated 
with different benzyl bromides/chlorides. A range of substituents on the benzyl halide have 
been used.  
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4.3.2 Investigation of the Scope of the α-Alkylation of Cyclic Esters 
In order to explore the potential for 3-D fragment synthesis, the scope of the α-alkylation 
chemistry was briefly investigated. We decided to start with the cyclic esters which were 
less successful in the α-arylation chemistry. Thus, 2-methyl ester THF 267, 2-methyl ester 
THP 263, 2-methyl ester pyrrolidine 257 and 3-methyl ester pyrrolidine 252 were all 
explored (Scheme 4.36). Using the conditions outlined by Dodd et al., 2-methyl ester THF 
267 was reacted with LiHMDS (1 M in toluene) in THF at ‒78 °C for 1.5 h to generate the 
enolate. 4-Fluorobenzyl bromide was then added and the reaction mixture was warmed to rt 
and stirred for 16 h. This gave α-alkylated THF 303 in 49% yield. Similarly, 2-methyl THP 
ester 263 was alkylated to afford 304 in 77% yield. The final two heterocycles explored were 
the 2- and 3-pyrrolidine methyl esters 257 and 252 and the alkylated products 305 and 306 
were isolated in 86% and 67% yields respectively.  
 
Scheme 4.36 
Different benzyl bromides were then used, focusing on the 2-methyl ester pyrrolidine 257. 
The meta- and ortho-fluorobenzyl bromides gave alkylated products 307 and 308 in 90% 
and 92% yields respectively (Table 4.7, entries 1 and 2). The benzyl group was varied to 
incorporate the para- and meta-methoxybenzyl bromides giving 309 and 310 in 68% and 
91% yields (entries 3 and 4). The ortho-bromobenzyl bromide was also successfully installed 
to afford 311 in 89% yield (entry 5). As with α-arylation, we were less successful with the 
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installation of a pyridinyl substituent. Alkylation with 2-(bromomethyl) pyridine (generated 
by treating 2-(bromomethyl) pyridine·HBr with base) gave alkylated pyrrolidine 312 in only 
33% yield (entry 6).  
 
Entry Hetero/Ar-Br Yielda (%) 
1 
 
307, 92 
2 
 
308, 90 
3 
 
309, 91 
4 
 
310, 68 
5 
 
311, 89 
6 
 
312, 33 
Table 4.7 – Investigation of the α-alkylation of pyrrolidine ester with aryl bromides using LiHMDS (1 M in 
toluene); a) % yield after chromatography. 
4.3.3 Design and Analysis of 3-D Fragments from α-Alkylated Cyclic Esters 
As with the α-arylated fragments, once the scope of the α-alkylation of cyclic esters had been 
explored, we designed 3-D fragments that should be synthetically accessible. Then, 3-D 
shape analysis using PMI plots, together with the ‘Rule of three’ guidelines, the 3-D 
fragments would be selected and synthesised. Therefore, a series of fragments were designed 
based on the four cyclic scaffolds shown in Figure 4.5. They included 2-substituted THF, 
THP and pyrrolidine and 3-substituted pyrrolidine. The ester group was derivatised to 
include, carboxylic acid, primary alcohol/amine, amide and secondary amine. The third point 
of diversification was the aryl group and the seven aromatic groups which had been 
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successfully introduced by ester α-alkylation were included. As a result of these three points 
of diversification, 140 3-D fragments were designed. 
 
Figure 4.5  - Structures 140 3-D fragments. 
The PMI plots of the conformations with a relative energy of ≤ 1.5 kcal mol‒1 of the 140 3-
D fragments are shown in Figure 4.5. The α-alkylated fragments, showed less diversity 
compared to the α-arylated fragments, with the conformations clustering around the top left-
hand corner of the PMI plot. However, for all four scaffolds, the 3-D fragments had almost 
all conformations in the more interesting region of chemical space, ƩNPR ≥ 1.1. Therefore, 
a sub-set of these fragments were selected based on their proposed ease of synthesis. 
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a)                                                                       b) 
 
 
 
 
 
c)                                                                       d) 
 
 
 
 
 
Colour       
Conformation energy 
difference (kcal mol‒1) 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
Figure 4.6 – PMI analysis of a) 2-substituted THF, b) 2-substituted THP, c) 2-substituted pyrrolidine and d) 
3-substituted pyrrolidine showing all conformations which have a relative energy ≤ 1.5 kcal mol‒1. The Ar- 
and R- groups are shown in Figure 4.5. 
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4.3.4 Synthesis of Ester Enolate α-Alkylated 3-D Fragments  
The α-alkylation of cyclic esters in Section 4.3.2 provided the THP and THF fragments 303 
and 304, which were directly added to the 3-D fragment library (Figure 4.7). 
 
Figure 4.7 - Structures of two 3-D fragments synthesised directly using α-alkylation. 
The α-alkylation chemistry also afforded eight N-Boc pyrrolidines, which required 
deprotection before inclusion within the library. The N-Boc pyrrolidines 309 and 306 were 
treated with 4 M HCl in dioxane and stirred for 16 h, which gave the desired final fragments, 
both in quantitative yields (Scheme 4.37). The remaining six N-Boc pyrrolidine scaffolds 
were deprotected by another member of the group, using the same conditions (Figure 4.8). 
 
Scheme 4.37 
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Figure 4.8 – Six deprotected pyrrolidine fragments. 
We briefly explored some derivatisation chemistry with two of the α-alkylated esters. For 
example, 4-fluorobenzyl pyrrolidine 305 was hydrolysed using KOH to access carboxylic 
acid 321. Then, acid 321 was converted into the amide to afford 322 in 44% yield over the 
two sets (Scheme 4.38). The Boc group was subsequently removed by another member of 
the group to give the final fragment. 
 
Scheme 4.38  
Similarly, the regioisomeric 4-fluorobenzyl pyrrolidine 306 was treated with KOH at 100 
°C to afford carboxylic acid 323 in quantitative yield. Next, a Curtius rearrangement was 
explored. Acid 323 was reacted with DPPA in the presence of Et3N to give amine 324 in 
51% yield (Scheme 4.39). The two Boc groups were subsequently removed by another 
member of the group to afford the final fragment.  
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Scheme 4.39 
In total, 14 α-alkylated 3-D fragments were synthesised and included within the fragment 
library. The structures of the synthesised 3-D fragments are shown in Figure 4.9.  
 
Figure 4.9 – Structures of 14 α-alkylated 3-D fragments. 
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4.3.5 Synthesis of Ester Enolate α-Alkylated 3-D Fragments via Spirocyclisation 
Spirocyclic scaffolds have become popular within drug molecules due to their ability to 
introduce conformational restriction within the molecule, which can modulate a drug’s 
binding potency.59 Numerous examples of the use of spirocycles in drug discovery have been 
reported, including aza-oxetane spirocycles.132–134 As a result, we were interested in 
synthesising spirocyclic scaffolds and envisaged that α-alkylation could offer a potential 
route. Indeed, a patent by Kemp et al.135 had reported the synthesis of spirocycles using the 
alkylation of N-Boc pyrolidine 3-ester 252 with 2-nitrobenzyl bromide. The nitro group in 
325 was reduced to afford the aniline, which subsequently cyclised to give pyrrolidine 
spirocycle 326 in 25% yield over the two steps (Scheme 4.40).  
 
Scheme 4.40 
Based on Kemp et al.’s precedent, two potential routes towards a range of spirocyclic 
scaffolds were proposed. In the first route, we planned to use α-alkylation to install the 
nitrobenzyl group with a variety of cyclic esters. Subsequent reduction would give the 
spirocycles. Alternatively, α-alkylation would be used to introduce a 2-bromobenzyl group 
from which Buchwald amination and lactamisation would then generate the same 
spirocycles (Scheme 4.41).    
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Scheme 4.41 
To start, the alkylation of 2-methyl ester pyrrolidine 257 and 4-methyl ester THP 265 with 
2-nitrobenzyl bromide were attempted using our standard conditions. However, after 
analysing the crude reaction mixtures using 1H NMR spectroscopy, the α-alkylated products 
could not be identified (Scheme 4.42). 
 
Scheme 4.42 
The lack of success with α-alkylation using 2-nitrobenzyl bromide led us to investigate the 
second proposed route. We had already synthesised 2-bromobenzyl N-Boc pyrrolidine 311 
(see Table 4.7). Buchwald coupling of 2-bromobenzyl N-Boc pyrrolidine 311 with 
benzophenone imine was performed using a procedure reported by Winkler et al.136 with 
Pd(OAc)2, Xantphos and Cs2CO3
 in dioxane at 95 °C for 16 h. Pyrrolidine 311 was reacted 
under these conditions, followed by subsequent imine hydrolysis which, after purification, 
afforded aniline 327 in an excellent 87% yield (Scheme 4.43). Following the successful 
installation of the aniline, cyclisation was attempted by heating aniline 327 at 50 °C in 
MeOH. However, 1H NMR spectroscopic analysis of the crude reaction mixture showed that 
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no cyclisation had occurred. The solvent was switched to EtOH allowing for the reaction to 
be heated to 80 °C for 16 h, but this also failed to yield any of the cyclised product. Finally, 
the cyclisation was attempted in the presence of p-TsOH, to promote acid catalysed 
cyclisation, which successfully afforded spirocycle 328 in 74% yield (Scheme 4.43). 
 
Scheme 4.43 
Next, 4-methyl ester THP 265 was subjected to the spirocyclisation sequence. Reaction of 
4-methyl ester THP 265 with 2-bromobenzyl bromide gave α-alkylated THP 329 in 76% 
yield (Scheme 4.44). Buchwald coupling using benzophenone imine gave good conversion 
to aniline 330 as determined by 1H NMR spectroscopic analysis of the crude reaction 
mixture. However, upon purification by chromatography, some spirocyclisation occurred to 
give a 35:65 mixture of aniline 330 and spirocycle 331 based on the 1H NMR spectrum. We 
propose that the acidic nature of the silica had promoted some spirocyclisation. The 35:65 
mixture of aniline 330 and spirocycle 331 was then heated in MeOH at 50 °C for 16 h. This 
gave spirocycle 331 in 91% yield over the two steps (Scheme 4.44). 
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Scheme 4.44 
Thus, after removal of the Boc group, which was conducted by another member of the group, 
we had successfully synthesised two spirocyclic 3-D fragments 332 and 331 via α-alkylation, 
amination and cyclisation. The PMI plot of the conformations with a relative energy of ≤ 1.5 
kcal mol‒1 for these two 3-D fragments is shown in Figure 4.10. The conformations avoided 
the ƩNPR 1.0-1.1 region of the plot. These two fragments were also added to the fragment 
library. 
 
Colour       
Conformation energy 
difference (kcal mol‒1) 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
Figure 4.10 - PMI analysis of spirocycle fragemnts 332 and 331, showing all conformations which have a 
relative energy ≤ 1.5 kcal mol‒1. 
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4.4 Conclusions and Overview 
We were able to adopt two approaches to synthesise novel 3-D fragments using ester enolate 
α-arylation and α-alkylation. Due to the limitations we had identified with the design process 
of our initial fragments, we wanted to initially investigate the chemistry prior to designing 
potential fragments. We were also keen to include aromatic groups which can help fragment 
screening using 1H NMR spectroscopy. 
Investigation into ester enolate α-arylation revealed that we could couple electron rich/poor 
and sterically hindered aromatics. However, out of the 11 cyclic esters we investigated, only 
the cyclopentane, 3-pyrrolidine, 3-piperidine, 4-piperidine and 4-THP methyl esters afforded 
the desired products. The other issue we encountered was with the installation of 
heteroaromatics and only the 2-bromopyridine was successfully introduced. Despite the 
difficulties, we were able to synthesise 26 fragments using the α-arylation chemistry. 
We had been unable to α-arylate at the 2-position on the heterocyclic esters and this led to 
the investigation of α-alkylation with benzyl bromides. The 2-methyl ester pyrrolidine, THF 
and THP scaffolds were all successfully alkylated. The benzyl bromide could be changed to 
include electron rich and poor aromatics, including alkylation with the 2-pyridyl group albeit 
in a low yield. The ester was also derivatised successfully, showing that further elaboration 
of the fragments could be carried out. Finally, we were interested in the formation of 
spirocycles via alkylation and subsequent cyclisation. Buchwald-Hartwig amination of the 
aryl bromide gave access to the corresponding aniline, which was subsequently cyclised, via 
acid-catalysis, to afford the 5,6- and 6,6-spirocycles in excellent yields. In total, our two 
approaches gave 42 novel 3-D fragments which were included within our fragment library. 
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Chapter 5 Properties and PMI Analysis of the 
York 3-D Fragment Library 
During the course of the work described in this thesis, researchers in the O’Brien group have 
carried out the synthesis of numerous 3-D fragments. In this chapter, the 123 York 3-D 
fragments are compared with a set of commercial fragment libraries. This includes a 
comparison of MW, HAC and ClogP together with 3-D shape analysis using PMI plots. This 
has allowed us to evaluate the usefulness of the York 3-D fragments for use in drug 
discovery.  Some example York 3-D fragments in the library are shown in Figure 5.1.  
 
Figure 5.1 
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5.1 Properties and PMI Analysis of the First-Generation Fragment Library  
In Chapter 2, we outlined the design and selection of 33 pyrrolidine and piperidine 3-D 
fragments, with the synthesis of three pyrolidine and six piperidine fragments discussed in 
detail. The remaining fragments were synthesised by other members of the O’Brien group. 
However, due to difficulties encountered with the synthesis of the 2,4-disubstituted cis-
pyrrolidines this fragment was removed from the library to give a total of 32 fragments. 
Another member of the O’Brien group was able to further derivatise the methyl ester 
substituent on some of the selected pyrrolidine and piperidines to introduce carboxylic acids, 
amides, ethers and nitriles (Figure 5.2).  
 
Figure 5.2 – Structures of 24 disubstituted pyrrolidines and piperidines accessible by ester derivatisation. 
These 24 fragments were combined with the initial 32 fragments to create a first-generation 
fragment library containing 56 pyrrolidine/piperidine 3-D fragments. The PMI plot of these 
56 3-D fragments is shown in Figure 5.3. The ground state conformations are coloured in 
red and all other conformations ≤ 1.5 kcal mol‒1 in energy are in blue. Due to our design 
criteria, these fragments provided a good spread of conformations across the PMI plot with 
few conformations in the rod-disc area. The physicochemical properties of the 3-D fragments  
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were assessed against Astex’s ‘Rule of three’ guidelines (Table 5.1) The properties were all 
within the limits set out by Astex.  
 
Figure 5.3 – PMI plot of the 56 first-generation pyrrolidines and piperidines with all conformations that have 
relative energy ≤ 1.5 kcal mol‒1. 
Parameters First-Generation Fragments ‘Rule of 3’ 
MW 173.4  38.5 < 300 
HAC 11.8  2.3 - 
ClogP 0.52  0.66 0-3 
HBA 2.7  0.73 < 3 
HBD 0.9  0.70 < 3 
Table 5.1 – Average physicochemical properties of the 56 first-generation fragments. 
These 56 3-D fragments were also subjected to a quality control (QC) study. Another 
member of the O’Brien group performed purity, stability and solubility studies using NMR 
spectroscopy. The purity of each fragment was assessed by 1H NMR spectroscopic analysis 
of a 2 mM solution in DMSO. Two fragments failed the purity test (Figure 5.4) and were 
removed from the library  
 
Figure 5.4 – Failed due to purity 
The stability and solubility of the remaining 54 fragments were then assessed. The stability 
was assessed in 20 mM phosphate buffer (pH 7.48) (1 mM concentration of fragment) and 
DMSO (2 mM concentration of fragment) solutions. In 20 mM phosphate buffer, fragments 
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74 and 75 (Figure 5.5) were unstable due to hydrolysis of the ester to the carboxylic acid, 
which is not unexpected since hydrolysis was seen during fragment synthesis (see Figure 
2.7) A further two fragments, 69 and 77 (Figure 5.5), were also unstable in solution. The 
remaining 49 fragments had showed no signs of decomposition after 6 weeks in DMSO 
solution. 
 
Figure 5.5 – Fragments removed due to stability in solution 
Finally, the solubility of the 3-D fragments was determined, since precipitation due to poor 
solubility can interfere with fragment screening. The solubility was determined in 20 mM 
phosphate buffer solution (pH 7.48) using a 1 mM concentration of the fragment and a 
calibration compound. From this, four of the fragments (Figure 5.6) had poor solubility, < 
0.5 mM, and were not included in the final library. 
 
Figure 5.6 – Failed due to poor solubility 
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5.2 Properties and PMI Analysis of the Second-Generation Fragment  
In Chapter 4, we described the synthesis of 42 3-D fragments using enolate α-arylation and 
α-alkylation. A similar strategy, focusing on one piece of synthetic methodology, was 
developed by another member of the O’Brien group. This approach produced the 25 3-D 
fragments shown in Figure 5.7.   
 
Figure 5.7 – Structures of 25 fragments synthesised using Suzuki-Miyaura cross-coupling. 
The PMI plot of the 67 3-D second-generation fragments is shown in Figure 5.8. These 
fragments gave 553 conformations with a relative energy ≤ 1.5 kcal mol‒1. Analysis of the 
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PMI plot revealed that only 1.5% of the conformations lay within the initial ƩNPR region of 
1.0-1.1, with the conformations ranging from a ƩNPR value of 1.07 to 1.54. The average 
physicochemical properties of the second-generation 3-D fragments were compared against 
Astex’s guidelines (Table 5.2).  
 
Figure 5.8 – PMI plot of the 67 second-generation fragment conformations with a relative energy ≤ 1.5 kcal 
mol‒1 (blue) and ground state energy conformations (red). 
Table 5.2 – Physicochemical properties of the 67 second-generation fragments. 
The second-generation 3-D fragments were all within the guidelines set out by Astex. A 
comparison of the first-generation 3-D fragments (Table 5.1) with the second-generation 3-
D fragments (Table 5.2) shows that MW and ClogP are higher for the second-generation 
fragments. This is not unexpected since our design criteria for the second-generation 
included the additions of a heavier and more lipophilic aryl substituent. 
  
Parameters Second-Generation Fragments ‘Rule of three’ 
MW 218.3  26 < 300 
HAC 15.7  1.7 N/A 
ClogP 1.64  1.0 0-3 
HBA 2.4  0.86 < 3 
HBD 0.6  0.65 < 3 
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5.3 Analysis of 123 York 3-D fragments 
An analysis of the combined first- and second-generation 3-D fragments has been carried 
out. For this analysis, all 123 3-D fragments were included (even though some of the first-
generation fragments had failed the QC analysis). From the PMI analysis, the 123 3-D 
fragments (Figure 5.9), had a total of 940 conformations with a relative energy ≤ 1.5 kcal 
mol‒1 above the ground state. Only 2.4% of the conformations occupied the initial ƩNPR 
region of 1.0-1.1, with the fragments occupying ƩNPR regions from 1.07 to 1.68. This set 
of 123 3-D fragments provided a broad coverage of 3-D chemical space.    
 
Figure 5.9 – PMI plot of all 123 fragments within the York 3-D fragment library, with all conformations with 
a relative energy ≤ 1.5 kcal mol‒1 (blue) and ground state energy conformations (red). 
The average physicochemical properties for the 123 3-D fragments were within Astex’s 
‘Rule of three’ guidelines (Table 5.3). Analysis of the individual fragments revealed that 84 
(68%) of the 123 fragments fully complied with the ‘Rule of three’ with the remaining 39 
(32%) of the fragments failing either one or multiple criteria. The decision to include the 39 
fragments was supported by Mortenson et al.’s study where data from 85 lead campaigns 
undertaken between 2015-2017 had been collated.137 The results revealed that ~5% of the 
fragments taken through had ClogP values > 3, which lies outside the criteria set out by 
Astex. 
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Table 5.3 – Average physicochemical properties of the 123 3-D fragments. 
The physicochemical properties of the 123 York 3-D fragments were compared with four 
commercial fragment libraries: Maybridge ‘Rule of three’ (RO3), Chembridge, Enamine 
RO3 and Enamine sp3. A plot of % of the library versus MW is shown in Figure 5.10. The 
York 3-D fragments showed a similar trend in MW to the Maybridge fragments, but a lower 
MW compared to the two Enamine and Chembridge fragment libraries. 
 
Figure 5.10 – MW analysis comparing the York 3-D (green), Maybridge (purple) and Chembridge (pink), 
Enamine RO3 (red) and Enamine sp3 (orange) fragments libraries. 
A similar set of trends was observed from the plots of % of library versus HAC (Figure 
5.11). For the York 3-D fragments, 80% had a HAC < 16, which is the recommended upper 
limit put forward by Astex using updated guidelines.138 In contrast, all four commercial 
libraries contained a number of fragments with HAC > 16, with 39% of the fragments within 
the two Enamine libraries having a HAC > 16. 
Parameters First-Generation 
Fragments 
Second-Generation 
Fragments 
Combined 
Library 
‘Rule of 3’ 
MW 173.4 220.7 199.2  40.4 < 300 
HAC 11.8 15.7 13.9  2.8 N/A 
ClogP 0.52 1.64 1.0  1.0 0-3 
HBA 2.7 2.4 2.6  0.82 < 3 
HBD 0.9 0.6 0.76  0.70 < 3 
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Figure 5.11 - HAC analysis comparing the York 3-D (green), Maybridge (purple) and Chembridge (pink), 
Enamine RO3 (red) and Enamine sp3 (orange) fragment libraries. 
The plot of % of library versus Fsp3 is shown in Figure 5.12. The Maybridge RO3, 
Chembridge and Enamine RO3 libraries had relatively low Fsp3 values, with over half of the 
fragments having an Fsp3 value < 0.5. Unsurprisingly, the Enamine sp3 library contained 
fragments with Fsp3 values ranging from 0.5-1.0. This trend is mirrored by the York 3-D 
fragments, with 99.2% of the fragments having Fsp3 values > 0.5. On closer inspection, 45% 
of the York 3-D fragments had an Fsp3 values of 0.8-1.0, with the next best library being the 
Enamine sp3, with 28% of their fragments within the same region. Despite Fsp3 not 
correlating with 3-D shape, the analysis does show that the York 3-D fragments have 
increased complexity and saturation compared to three of the four commercial libraries and 
that they are similar to Enamine sp3 fragments. 
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Figure 5.12 - Fsp3 analysis comparing the York 3-D (green), Maybridge (purple) and Chembridge (pink), 
Enamine RO3 (red) and Enamine sp3 (orange) fragments libraries.  
We have also compared ClogP with the Maybridge and Chembridge libraries (Figure 5.13). 
On average, the York fragments had lower ClogP values, with 58% of the fragments having 
a ClogP < 1.0. In contrast, only 24% of the Maybridge and 35% of the Chembridge fragments 
had values < 1.0. Lower values of ClogP can indicate improved aqueous solubility of the 
fragments, allowing them to be screened at higher concentrations and avoiding any issues 
with precipitation of the fragments that can affect fragment screening. 
 
Figure 5.13 - ClogP analysis comparing the York 3-D (green), Maybridge (purple) and Chembridge (pink) 
fragments libraries.  
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Finally, since the overall aim of the project was to design and synthesise fragments with 
shapes in under-represented areas of 3-D space, we compared the PMI plot of the York 3-D 
fragments with those that we generated from current commercial libraries. In order to obtain 
direct comparisons, a cumulative % of fragments with conformations up to 1.5 kcal mol‒1 
above the ground state for the commercial fragment libraries with a defined distance from 
the rod-disc axis (ƩNPR) was carried out. Along with the commercial libraries already 
discussed, we have carried out a comparison with other 3-D fragment libraries from both 
industry and academia, which are accessible from the Diamond light source webpages.139 
The first was a commercial 3-D fragment library from Life Chemicals, containing 1,500 
fragments which had been evaluated for 3-D shape using PMI plots.140 The remaining three 
libraries included the 3-D Fragment Consortium141 which was discussed in Section 1.4, a 
Leeds 3-D library (Nelson/Marsden groups) which contained diverse natural-product like 
fragments with high levels of Fsp3/3-D shapes142,143 and a library from the Spring group at 
Cambridge University who had designed a DOS library containing fragments with high 
levels of Fsp3. The eight libraries were directly compared with the 123 York 3-D fragments 
and the cumulative PMI plot is shown in Figure 5.14. 
 
Figure 5.14 – Cumulative PMI plot of the York 3-D fragment library and eight fragment libraries. 
Analysis revealed that for seven out of the eight libraries, roughly 50% of the conformations 
were within the initial ƩNPR 1.0-1.1 region. The Leeds 3-D fragments had the best 
conformational distribution out of the eight libraries, with 50% of their fragment 
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conformations lying between the ƩNPR region 1.0-1.17. In contrast, the York 3-D fragments 
had greater conformational distribution, with 50% of the library having a ƩNPR value > 
1.23. Therefore, the main conclusion drawn from the PMI analysis was that the York 3-D 
fragments were able to offer a greater coverage of chemical space. The fragments were able 
to access regions of the PMI plot that are less-densely occupied by the other fragment 
libraries, potentially offering the opportunity to access different protein targets. 
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5.4 Conclusions and Overview 
The work described in this thesis, together with other O’Brien group members, has 
contributed 117 fragments to the York 3-D fragment library, with 84 of the 3-D fragments 
complying with the Astex ‘Rule of three’ guidelines. Comparison of the physicochemical 
properties of the York 3-D fragments against four commercial libraries showed that our 
fragments followed similar trends. However, the average ClogP value was lower for our 
fragments compared to the commercial libraries. This can be explained by the low number 
of aromatic rings and the increase in the number of sp3 carbon centres within our molecules 
compared to the commercial libraries. The lower ClogP often can be considered beneficial 
allowing for greater control of the ClogP during a hit-lead optimisation.  
The aim of our work was to create a library containing molecules with a high degree of 3-D 
shape. Therefore, we compared the PMI plots of eight fragment libraries, of which four were 
described as 3-D fragment libraries, with our 3-D fragments. The data showed that using our 
approach of assessing the shapes of fragments prior to synthesis, we were able to produce a 
more focused 3-D fragment library, with fewer fragments lying within the region of chemical 
space most commonly occupied by current commercial fragment libraries. We look forward 
to the results of protein screening campaigns using the 3-D fragments described in this thesis. 
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Chapter 6 Conclusions and Future Work 
We have created a new approach towards the design and synthesis of a 3-D fragment library   
by generating conformations of potential fragments and then using PMI analysis to assess 
and select the most 3-D fragments to synthesise and include within the 3-D fragment library. 
The fragments were designed based on pyrrolidine and piperidine cores, with the inclusion 
of two substituents to increase the shape and functional group diversity, with four differing 
substituents on the nitrogen, affording 56 pyrrolidine and 92 piperidine fragments. 
The chemical space coverage of the 56 pyrrolidine and 92 piperidine fragments was analysed 
using principal moment of inertia (PMI) plots. A protocol developed in Pipeline Pilot by a 
previous member of the O’Brien group used molecular mechanics to generate 
conformations, which were used to create the PMI plots and predict the fragments 
physicochemical properties. Initially, we analysed a Maybridge ‘Rule of three’ compliant 
fragment library containing 1000 fragments, which showed limited coverage of chemical 
space and occupied the region along the rod-disc axis. In contrast, the pyrrolidine and 
piperidine fragments occupied a much wider region of chemical space despite our very 
simple design criteria. Fragment selection was achieved through PMI analysis with the plot 
being divided into ten regions to allow for selection and synthesis of the most 3-D fragments, 
with 14 pyrrolidine and 19 piperidine fragments selected. 
The pyrrolidine and piperidine fragments were grouped and synthesised by members within 
the O’Brien group, with emphasis placed on investigating known synthetic routes to increase 
the ease of synthesis. In Chapter 2, the synthesis of three 2,3-disubstituted pyrrolidine 
fragments was presented. A previous route had been reported by Zhang et al. with the key 
step being the stereoselective reduction of the corresponding dihydropyrrole to afford the 
cis-pyrrolidine which could be epimerised to access the trans-pyrrolidine. After 
investigating the stereoselective reduction of N-benzyl dihydropyrrole 108, the two 
cis-fragments were accessed. The epimerisation of N-benzyl pyrrolidine cis-109 failed to 
afford the trans-pyrrolidine selectively, and therefore we reverted to the procedure reported 
by Zhang et al. with the epimerisation conditions optimised (DBU, 100 °C, 24 h) to afford 
the trans-pyrrolidine, which was acylated to afford pyrrolidine trans-109. 
The synthesis of 2,5-, 2,6- and 2,3-disubstituted piperidines was also successfully completed, 
with access to the cis-piperidines achieved through hydrogenation of the corresponding 
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pyridine. The trans-diastereoisomer was required for the 2,3-disubstituted piperidine, which 
was accessed via epimerisation of the cis diastereoisomer. The 1,2-relationship of the 
substituents resulted in the cis-piperidine adopting conformations with one group axial and 
one group equatorial. Therefore, we were able to use base-mediated epimerisation to obtain 
the trans-diastereoisomer as the major product. Derivatisation of the nitrogen proceeded 
smoothly, with only the installation of the sulfonyl group onto the cis-2,6-piperidine proving 
problematic. The steric hindrance around the nitrogen potentially reduced the rate of 
mesylation and resulted in the formation of a bismethanesulfonate product. However, 
altering the base and reaction time led to an improvement in the reaction with the 2,6-
piperidine sulfonamide isolated in good yield with no formation of the bismethanesulfonate 
161. 
In Chapter 3, we outlined that, along with lithiation-trapping, we could apply our simple 
hydrogenation and epimerisation conditions to access all 20 disubstituted piperidine regio- 
and diastereoisomers. Hydrogenation, under our mild conditions, contrasted with the 
literature conditions which often employed a higher catalyst loading, elevated reaction 
temperatures and higher pressures. We were able to access nine cis-piperidines and the trans-
3,5-piperidine using 10-30 mol% PtO2 in AcOH at rt under a H2 balloon. Optimisation of 
epimerisation conditions and manipulation of the protecting group on the nitrogen gave eight 
trans-piperidines and the cis-3,5-piperidine. The trans-2,6-disubstituted piperidine had been 
synthesised previously within the O’Brien group via lithiation-trapping and meant we were 
able to selectively access all 20 disubstituted piperidines in 2-3 steps.  
The second-generation fragments (Chapter 4) were designed to incorporate a single 
stereogenic centre to avoid the issues we had encountered with diastereoselectivity and 
separation of diastereoisomers with the first-generation fragments. Two pieces of synthetic 
methodology were identified: α-arylation of cyclic esters using palladium catalysis and α-
alkylation of cyclic esters via the reaction of enolates with benzylic halides. The design of 
3-D fragments was based on the capability of the synthetic chemistry, which streamlined the 
synthesis of the 3-D fragments. With α-arylation, we could couple electron rich/poor and 
sterically hindered aromatics. However, out of the 11 cyclic esters investigated, only the 
cyclopentane, 3-pyrrolidine, 3-piperidine, 4-piperidine and 4-THP methyl esters afforded 
the desired products. The other issue we encountered was with the installation of 
heteroaromatics with only 2-bromopyridine being successfully introduced. Despite the 
difficulties, 26 fragments were efficiently synthesised using the α-arylation chemistry.  
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We had been unable to α-arylate at the 2-position on the heterocyclic esters, which led to us 
investigating α-alkylation with benzyl bromides. The 2-methyl ester pyrrolidine, THF and 
THP were all successfully alkylated. Electron rich and poor benzyl bromides were used as 
well as installation of a 2-pyridyl. Finally, we were interested in the formation of spirocycles 
via alkylation and subsequent cyclisation. Buchwald-Hartwig amination of the aryl bromide 
gave access to the corresponding aniline, which afforded the 5,6- and 6,6-spirocycles. This 
approach gave 16 novel 3-D fragments which were included within our fragment library. 
Combination of the first- and second-generation 3-D fragments gave a total of 123 York 3-
D fragments, which all largely obeyed the ‘Rule of three’. The York 3-D fragments were 
compared against four commercial libraries, which showed that they followed similar trends. 
The main difference between our 3-D fragments and the commercial libraries was the lower 
ClogP, which can often be considered beneficial allowing for greater control of ClogP during 
a hit-lead optimisation. 
Finally, we conducted a % cumulative PMI analysis of the York 3-D fragments against the 
four commercial libraries, as well as four 3-D focused fragment collections from both 
industry and academia. The analysis revealed that the York 3-D fragments contained fewer 
conformations within the initial regions of the PMI plot along the rod-disc axis (ƩNPR 1.0-
1.1), which showed we were able to produce a more 3-D focused fragment library. We hope 
that the design of fragments which access areas of chemical space currently under-
represented within fragment libraries will offer an alternative starting point for the 
pharmaceutical industry and support the drug discovery process.  
The future work within the project will involve making the library available for screening 
campaigns both in-house and externally, and we look forward to seeing the screening results 
with the York 3-D fragments. 
The initial approach towards the synthesis of 3-D fragments was limited by the bespoke 
nature of the designed disubstituted pyrrolidine and piperidine fragments. The need for 
stereoselective routes to access either the cis or trans-diastereoisomers resulted in issues with 
synthesis and purification. The second-generation 3-D fragments were prepared by initially 
investigating the scope and limitations of the synthetic methodology. Fragments were then 
designed based on the capabilities of the chemistry, which streamlined their synthesis. 
Therefore, future work would look to identify suitable pieces of methodology that could 
install aryl groups and incorporate differing scaffolds. One potential route has recently been 
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reported by Baran et al.,144 where they synthesised a series of sp3 rich scaffolds via 
cycloaddition and subsequent C-C cross coupling. Cycloaddition with maleic anhydride was 
followed by desymmetrisation and radical decarboxylative cross-coupling (Suzuki, Negishi 
or Kumada). Hydrolysis of the ester allowed for a second radical decarboxylative cross 
coupling, which gave the trans-stereoisomers in high ee (> 92%) (Scheme 6.1). We envisage 
that this chemistry could offer the potential to access bridged fragments with the installation 
of heteroaryl substituents, which we had previously found difficult to install via α-arylation 
(Figure 6.1).   
 
Scheme 6.1 
 
Figure 6.1 – Four proposed fragments 
Another piece of methodology that had been identified during investigation into the 
synthesis of 2,3-disubstituted pyrrolidines was the stereoselective cyclisation of γ-imino 
esters using TiCl4/Et3N to afford cis 2,3-disubstituted pyrrolidines.
71 The plan would be to 
expand the methodology to synthesise disubstituted piperidines and vary the aldehyde to 
incorporate differing aryl groups, along with derivatisation of the ester (Scheme 6.1). A 
selection of potential 3-D fragments that could be accessed are also shown in Scheme 6.1.  
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Scheme 6.2 
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Chapter 7 Experimental 
7.1 Computational Methods 
7.1.1 Shape Analysis Protocol 
Prior to conformer generation a wash step was performed, which involved stripping salts 
and ionising the molecule at pH 7.4. Any stereocentre created here was left with undefined 
stereochemistry. SMILES strings were converted to their canonical representation. A list of 
allowed chirality at each centre is generated and a SMILES file with all possible 
stereoisomers was written. Conformers were generated using the BEST method in Catalyst 
using the rel option, run directly on the server and not through the built-in Conformation 
Generator component with a chosen maximum relative energy threshold of 20 kcal mol-1, 
maximum of 255 conformers for each compound. Conformations were read, ones that cannot 
be represented by the canonical SMILES are discarded, with the remaining ones standardised 
to a single enantiomer. Duplicates were filtered with a RMSD threshold of 0.1. Minimisation 
with 200 steps of Conjugate Gradient minimisation with an RMS gradient tolerance of 0.1 
was performed using the CHARMm forcefield with Momany-Rone partial charge estimation 
and a Generalised Born implicit solvent model. Duplicates were filtered again with a RMSD 
threshold of 0.1.    
 
7.1.2 Physical Properties 
The physical properties were calculated using Pipeline Pilots built in generator. 
 
7.1.3 ClogP Calculations 
The ClogP data reported for the fragments was generated using Astra Zeneca’s protocol. 
 
7.2 Synthetic Methods 
7.2.1 General Methods 
Non-aqueous reactions were purged and back filled with Ar three times in flame dried 
glassware. Et2O and THF were distilled over sodium and benzophenone respectively. 
Alkyllithiums were titrated using N-benzylbenzamide prior to use.145 CO2 was dried over 
CaCl2 before use in lithiation reactions. Flash column chromatography was carried out using 
Fluka Chemie GmbH silica (220-440 mesh). Thin layer chromatography was carried out 
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using commercially available Merk F254 aluminium backed silica plates. Proton (400 MHz) 
and carbon (100.6 MHz) NMR spectra were recorded on a Jeol ECX-400 instrument using 
an internal deuterium lock. For samples recorded in CDCl3, chemical shifts are quoted in 
parts per million relative to CHCl3 (δH 7.26) and CDCl3 (δC 77.0, central line of triplet). For 
samples recorded in d6-DMSO, chemical shifts are quoted on parts per million relative to d6-
DMSO (δH 2.50, central line of quintet) and d6-DMSO (δC 39.52, central line of septet). For 
samples recorded in d4-MeOH, chemical shifts are quoted on parts per million relative to d4-
MeOH (δH 3.31, central line of quintet) and d4-MeOH (δC 50-41, central line of septet). 
Carbon NMR spectra were recorded with broad band decoupling and assigned using DEPT 
experiments. Coupling constants (J) are quoted in Hertz. Melting points were carried out on 
a Gallenkamp melting point apparatus. Infrared spectra were recorded on an ATI Mattson 
Genesis FT-IR spectrometer. Electrospray high and low resonance mass spectra were 
recorded at room temperature on a Bruker Daltronics micrOTOF spectrometer. 
Some experimental procedures were adapted from methods reported by other group 
members (Mary Wheldon, Masakazu Atobe, Thomas Downes, James Firth and Hanna 
Klein). 
 
7.2.2 General Procedures 
General procedure A: Pyridine Hydrogenation without MeOH wash 
PtO2 (5-10 mol%) was added to a stirred solution of pyridine ester (100 mg, 0.66 mmol) in 
AcOH (1.0 mL) at rt under Ar. The reaction flask was evacuated under reduced pressure and 
back-filled with Ar three times. After the final evacuation, H2 was charged and the reaction 
mixture was stirred vigorously under a balloon of H2 for 24 h. The solids were removed by 
filtration through Celite and washed with CH2Cl2 (30 mL). NH4OH(aq) (20 mL) was added 
to the filtrate and the two layers were separated. The organic layer was dried (MgSO4) and 
evaporated under reduced pressure to give the crude product. 
 
General procedure B: Pyridine Hydrogenation with MeOH wash 
PtO2 (5-33 mol%) was added to a stirred solution of pyridine ester (100 mg, 0.66 mmol) in 
AcOH (1.0 mL) at rt under Ar. The reaction flask was evacuated under reduced pressure and 
back-filled with Ar three times. After the final evacuation, H2 was charged and the reaction 
mixture was stirred vigorously under a balloon of H2 for 24 h. The solids were removed by 
filtration through Celite and washed with MeOH (30 mL). The filtrate was evaporated under 
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reduced pressure to give the crude product. The crude product was dissolved in CH2Cl2 (5 
mL) and NH4OH(aq) (2 mL) was added. The two layers were separated, and the aqueous layer 
was extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were dried (Na2SO4) 
and evaporated under reduced pressure to give the crude product. 
 
General procedure C: Mesylation with Pyridine in CH2Cl2 
MsCl (0.06 mL, 0.77 mmol, 1.2 eq) was added dropwise to a stirred solution of piperidine 
(100 mg, 0.64 mmol, 1.0 eq) and pyridine (0.05 mL, 0.64 mmol, 1.0 eq or 0.27 mL, 1.91 
mmol, 3.0 eq) in CH2Cl2 (8.5 mL)
 at 0 °C under Ar. The resulting solution was stirred at 0 
°C for 1 h or rt for 24 h. The reaction mixture was evaporated under reduced pressure to give 
the crude product. 
 
General procedure D: Mesylation with Pyridine 
MsCl (0.03 mL, 0.38 mmol, 1.2 eq) was added dropwise to a stirred solution of piperidine 
(50 mg, 0.32 mmol, 1.0 eq) in pyridine (3.2 mL) at 0 °C under Ar. The resulting solution 
was stirred at rt or 60 °C for 16-72 h. The reaction mixture was evaporated under reduced 
pressure to give the crude product. 
 
General Procedure E: Piperidine epimerisation via KOtBu 
N-Benzyl/N-Boc piperidine (50 mg, 0.20 mmol, 1.0 eq) was added to a flask containing dry 
THF (3 mL) at rt under Ar. The reaction flask was evacuated under reduced pressure and 
back-filled with Ar three times and the solution was cooled to ‒78 °C. KOtBu (0.24 mL of 
a 1 M solution in THF, 0.24 mmol, 1.2 eq) was added dropwise. The resulting solution was 
stirred at ‒78 °C for 2 h. Then, water (1 mL) was added at ‒78 °C and the reaction mixture 
was allowed to warm to rt. The mixture was extracted with EtOAc (3 x 5 mL) and the 
combined organics were dried (MgSO4) and evaporated under reduced pressure to give the 
crude product. 
 
General procedure F: Enolate arylation using LiHMDS (1 M THF or toluene)  
A solution of cyclic ester (0.2 mL, 1.56 mmol, 1.2 eq) in toluene (1 mL) was added dropwise 
to a stirred solution of LiHMDS (2.6 mL of a 1.0 M solution in THF or toluene, 2.6 mmol, 
2.0 eq) in toluene (2 mL) at rt under Ar. The resulting solution was stirred at rt for 40 min. 
In a separate reaction flask, [(cinnamyl)PdCl2] (13 mg, 0.026 mmol, 0.02 eq), t-Bu3P·HBF4 
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(15 mg, 0.052 mmol, 0.04 eq) and aryl bromide (1.30 mmol, 1.0 eq) were added, followed 
by dry toluene (5 mL). The reaction flask was then evacuated under reduced pressure and 
back-filled with Ar three times. The LiHMDS/ester solution was then added dropwise to the 
reaction flask and the resulting solution was stirred at rt for 16 h. The solution was poured 
into 1 M AcOH(aq) (10 mL) and the aqueous layer was extracted with EtOAc (3 x 10 mL). 
The combined organics were washed with brine (20 mL) and sat NaHCO3(aq) (20 mL), dried 
(MgSO4) and evaporated under reduced pressure to give the crude product. 
 
General procedure G: Enolate arylation using LDA 
n-BuLi (1.0 mL of a 2.3 M solution in hexane, 2.3 mmol, 2.0 eq) was added dropwise to a 
stirred solution of diisopropylamine (0.32 mL, 2.3 mmol, 2.0 eq) in dry toluene (1 mL) at 0 
°C under Ar. The resulting solution was stirred at 0 °C for 30 min. A solution of cyclic ester 
(0.2 mL, 1.56 mmol, 1.2 eq) in toluene (1 mL) was added dropwise to the LDA solution at 
0 °C under Ar. The solution was stirred at 0 °C for 10 min and then allowed to warm to rt 
and stirred at rt for 10 min. In a separate reaction flask, [(cinnamyl)PdCl2] (13 mg, 0.026 
mmol, 0.02 eq), t-Bu3P·HBF4 (15 mg, 0.052 mmol, 0.04 eq) and aryl bromide (1.30 mmol, 
1.0 eq) were added, followed by dry toluene (5 mL). The reaction flask was then evacuated 
under reduced pressure and back-filled with Ar three times. The LDA/ester solution was 
then added dropwise to the reaction flask and the resulting solution was stirred at rt for 16 h. 
The solution was poured into 1 M AcOH(aq) (10 mL) and the aqueous layer was extracted 
with EtOAc (3 x 10 mL). The combined organics were washed with brine (20 mL) and sat 
NaHCO3(aq) (20 mL), dried (MgSO4) and evaporated under reduced pressure to give the 
crude product. 
 
General procedure H: Enolate alkylation using LiHMDS (1 M in toluene) 
LiHMDS (0.61 mL of a 1.0 M solution in toluene, 0.61 mmol, 1.4 eq) was added dropwise 
to a stirred solution of cyclic ester (100 mg, 0.43 mmol, 1.0 eq) in THF (4 mL) at ‒78 °C 
under Ar. The resulting solution was stirred at ‒78 °C for 1.5 h. Then, a solution of benzyl 
bromide (152 mg, 0.61 mmol, 1.4 eq) in THF (1 mL) was added dropiwise ‒78 °C under Ar. 
The resulting solution was stirred at ‒78 °C and slowly warmed up to rt over 16 h. The 
solution was poured into sat NH4Cl(aq) (10 mL) and the two layers were separated. The 
aqueous layer was extracted with EtOAc (3 x 10 mL) and the combined organics were dried 
(MgSO4) and evaporated under reduced pressure to give the crude product. 
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7.2.3 Experimental Procedures and Characterisation Data 
Methyl 1-acetylcyclopropane-1-carboxylate 107 and methyl 2-(2-bromoethyl)-3-
hydroxybut-2-enoate 110 
 
Methyl acetoacetate (3.0 mL, 27.8 mmol, 1.0 eq) was added dropwise to a stirred suspension 
of 1,2-dibromoethane (4.7 mL, 55.6 mmol, 2.0 eq) and K2CO3 (9.5 g, 69.5 mmol, 2.5 eq) in 
MeCN (50 mL, 0.55 M) at rt under Ar.  The resulting suspension was stirred and heated at 
reflux for 23 h.  After being allowed to cool to rt, the solids were removed by filtration and 
the filtrate was evaporated under reduced pressure to give an orange oil. The residue was 
dissolved in EtOAc (50 mL) and the solution was washed with brine (2  50 mL), dried 
(MgSO4) and evaporated under reduced pressure to give the crude product as a 
yellow/orange oil. Purification by flash column chromatography on silica with 8:1 hexane-
EtOAc as eluent gave enol-bromide 110 (130 mg, 3%) as a colourless oil, RF (1:1 hexane-
EtOAc) 0.55; IR (ATR) 2949 (OH), 1709 (C=O), 1435, 1269, 1138, 817 cm–1; 1H NMR 
(400 MHz, CDCl3) δ 4.98 (s, 1H, OH), 4.06 (t, 2H, J = 6.0 Hz, BrCH2), 3.66 (s, 3H, OMe), 
3.55 (t, J = 6.0 Hz, CH2CH2Br), 2.31 (s, 3H, Me); 
13C NMR (100.6 MHz, CDCl3) 171.7 
(C=O or =COH), 168.1 (C=O or =COH), 91.7 (=CCH2), 67.7 (CH2Br), 51.0 (OMe), 28.2 
(CH2CH2Br), 18.9 (Me); MS (ESI) m/z 245 (M + Na)
+; HRMS m/z calcd for C7H11
79BrO3 
(M + Na)+ 244.9777, found 244.9784 (+2.6 ppm error) and a 85:15 mixture (by 1H NMR 
spectroscopy) of cyclopropane 107 and enol-bromide 110 (2.37 g, 1.85 g of cyclopropane 
107 (47%); 520 mg of enol-bromide 110 (8%)) as a colourless oil, RF (1:1 hexane-EtOAc) 
0.5; IR (ATR) 2955, 1698 (C=O, CO2Me), 1625 (C=O, C(O)Me), 1436, 1120, 729 cm
–1; 1H 
NMR (400 MHz, CDCl3) of 107: δ 3.69 (s, 3H, OMe), 2.42 (s, 3H, Me), 1.44-1.39 (m, 4H, 
CH); 13C NMR (100.6 MHz, CDCl3) of 107: 203.3 (C=O, C(O)Me), 171.7 (C=O, CO2Me), 
52.4 (OMe), 35.1 (C), 30.0 (Me), 19.5 (CH2); MS (ESI) m/z 165 (M + Na)
+; HRMS m/z 
calcd for C7H10O3 (M + Na)
+ 165.0522, found 165.0524 (–1.2 ppm error). Spectroscopic 
data for 107 consistent with those reported in the literature.146  
Lab Book - PJ-01-35. 
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Methyl acetoacetate (0.25 mL, 2.3 mmol, 1.0 eq) was added dropwise to a stirred suspension 
of 1,2 dibromoethane (0.39 mL, 4.6 mmol, 2.0 eq) and Cs2CO3 (1.89 g, 5.7 mmol, 2.5 eq) in 
MeCN (20 mL, 0.1 M) at rt under Ar.  The resulting suspension was stirred and heated at 
reflux for 23 h.  After being allowed to cool to rt, the solids were removed by filtration and 
the filtrate was evaporated under reduced pressure to give an orange oil.  The residue was 
dissolved in EtOAc (50 mL) and the solution was washed with brine (2  50 mL), dried 
(MgSO4) and evaporated under reduced pressure to give the crude product as a 
yellow/orange oil. Purification by flash column chromatography on silica with 19:1 hexane-
EtOAc as eluent gave an 80:20 mixture (by 1H NMR spectroscopy) of cyclopropane 107 and 
enol-bromide 110 (150 mg, 83 mg of cyclopropane 107 (25%); 67 mg of enol-bromide 110 
(7%)) as a colourless oil. 
Lab Book - PJ-01-56. 
 
Methyl 1-benzyl-2-methyl-4,5-dihydro-1H-pyrrole-3-carboxylate 108 
 
Benzylamine (1.26 mL, 11.6 mmol, 1.6 eq) was added to a stirred solution a 95:5 mixture of 
cyclopropane 107 and enol-bromide 110 (1.10 g i.e. 1.04 g, 7.3 mmol, 1.0 eq of cyclopropane 
110) in toluene (30 mL) at rt under Ar. The resulting solution was stirred and heated at reflux 
for 23 h. After being allowed to cool to rt, the solvent was evaporated under reduced pressure 
to give the crude product as an orange oil. Purification by flash column chromatography on 
silica with 5:1 hexane-EtOAc as eluent gave dihydropyrrole 108 (1.23 g, 72%) as a yellow 
oil, RF (5:1 hexane-EtOAc) 0.24; IR (ATR) 2946, 1668 (C=O), 1421, 1128, 727 cm
–1; 1H 
NMR (400 MHz, CDCl3) δ 7.36-7.30 (m, 2H, Ph), 7.29-7.25 (m, 1H, Ph), 7.19-7.14 (m, 2H, 
Ph), 4.28 (s, 2H, NCH2Ph), 3.65 (s, 3H, OMe), 3.29 (t, J = 9.5, 2H, NCH2), 2.70 (t, J = 9.5, 
2H, NCH2CH2), 2.29 (s, 3H, Me);
 13C NMR (100.6 MHz, CDCl3) δ 167.8 (C=O), 161.7 
(C=CMe), 137.3 (ipso-Ph), 128.8 (Ph), 127.5 (Ph), 127.2 (Ph), 96.4 (C=CCO2Me), 50.7 
(NCH2Ph), 50.5 (NCH2), 50.2 (OMe), 27.0 (CH2), 21.2 (Me); MS (ESI) m/z 232 (M + H)
+; 
HRMS m/z calcd for C14H17NO2 (M + H)
+ 232.1332, found 232.1337 (–1.5 ppm error). 
Spectroscopic data consistent with those reported in the literature.147 
Lab Book - PJ-01-15. 
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Benzylamine (0.03 mL, 0.5 mmol, 1.5 eq) was added to a stirred solution of enol-bromide 
110 (50 mg, 0.2 mmol, 1.0 eq) in toluene (5 mL) at rt under Ar. The resulting solution was 
stirred and heated at reflux for 72 h. After being allowed to cool to rt, the solvent was 
evaporated under reduced pressure to give a brown oil (178 mg, crude). No dihydropyrrole 
108 was detected by 1H NMR spectroscopy. 
Lab Book - PJ-01-38. 
 
Methyl acetoacetate (3.0 mL, 26.0 mmol, 1.0 eq) was added dropwise to a stirred suspension 
of 1,2-dibromoethane (4.7 mL, 53.0 mmol, 2.0 eq) and K2CO3 (9.5 g, 66.0 mmol, 2.5 eq) in 
MeCN (50 mL, 0.55 M) at rt under Ar.  The resulting suspension was stirred and heated at 
reflux for 23 h.  After being allowed to cool to rt, the solids were removed by filtration and 
the filtrate was evaporated under reduced pressure to give the crude product as an orange oil. 
Benzylamine (4.26 mL, 39.0 mmol, 1.5 eq) was added to a stirred solution of the crude 
product in toluene (30 mL) at rt under Ar. The resulting solution was stirred and heated at 
reflux for 48 h. After being allowed to cool to rt, the solvent was evaporated under reduced 
pressure to give the crude product as an orange oil. Purification by flash column 
chromatography on silica with 19:1 hexane-EtOAc as eluent gave dihydropyrrole 108 (2.88 
g, 44% over 2 steps) as a colourless oil.  
Lab Book - PJ-01-71. 
 
Methyl 1-benzyl-2-methylpyrrolidine-3-carboxylate cis-109 
 
NaBH(OAc)3 (2.47 g, 1.17 mmol, 3.0 eq) was added to a stirred solution of dihydropyrrole 
108 (900 mg, 3.9 mmol, 1.0 eq)  in 1:1 AcOH-MeCN (12 mL) at rt under Ar. The resulting 
solution was cooled to 0 °C and stirred at 0 °C for 3 h. Then, the solvent was evaporated 
under reduced pressure to give an orange oil. The residue was dissolved in CH2Cl2 (30 mL) 
and sat NaHCO3(aq) (70 mL) was added. The two layers were separated, and the aqueous 
layer was extracted with CH2Cl2 (3 x 30 mL). The combined organic layers were dried 
(MgSO4) and evaporated under reduced pressure to give the crude product as a 
yellow/orange oil which contained an 85:15 mixture of pyrrolidines cis-109 and trans-109 
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(by 1H NMR spectroscopy). Purification by flash column chromatography on silica with 9:1 
hexane-EtOAc as eluent gave pyrrolidine cis-109 (590 mg, 65%) as a colourless oil, RF (9:1 
hexane-EtOAc) 0.1; IR (ATR) 2970, 1736 (C=O), 1434, 1164, 731 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.31-7.14 (m, 5H, Ph), 3.85 (d, J = 13.5 Hz, 1H, NCHPh), 3.65 (s, 3H, 
OMe), 3.33 (d, J = 13.5 Hz, 1H, NCHPh), 3.02 (ddd, J = 8.0, 8.0, 8.0 Hz, 1H, CHCO2) 2.94-
2.80 (m, 2H, CHMe and NCH) 2.26 (ddd, J = 9.0, 9.0, 7.0 Hz, 1H, NCH), 2.23-2.14 (m, 1H, 
CH), 1.92-1.83 (m, 1H, CH), 0.99 (d, J = 6.5 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) 
δ 174.4 (C=O), 139.2 (ipso-Ph), 128.9 (Ph), 128.3 (Ph), 127.0 (Ph), 60.1 (NCH), 57.4 
(NCH2Ph), 52.3 (NCH2), 51.6 (OMe), 47.4 (CHCO2Me), 25.9 (CH2), 14.7 (Me); MS (ESI) 
m/z 234 (M + H)+; HRMS m/z calcd for C14H19NO2 (M + H)
+ 234.1489, found 234.1498 (–
3.9 ppm error) and a 65:35 mixture (by 1H NMR spectroscopy) of pyrrolidines trans-109 
and cis-109 (162 mg, 17%) as a yellow oil. Diagnostic signal for trans-109: 1H NMR (400 
MHz, CDCl3) δ 1.29 (d, J = 6.0 Hz, 3H, CHMe). 
Lab Book - PJ-01-23.  
 
3-(Methoxycarbonyl)-2-methylpyrrolidin-1-ium chloride cis-74 
 
A suspension of 20% Pd(OH)2/C in MeOH (1 mL) was added to a stirred solution of benzyl 
pyrrolidine cis-109 (50 mg, 0.21 mmol, 1.0 eq) and NH4
+HCO2
- (68 mg, 1.05 mmol, 5.0 eq) 
in MeOH (1 mL). The resulting suspension was stirred and heated at reflux for 2 h. After 
being allowed to cool to rt, the solids were removed by filtration through Celite and washed 
with MeOH (10 mL). The solvent was evaporated under reduced pressure to give the crude 
product as a clear oil. Purification by flash column chromatography on silica with 95:4:1 
CH2Cl2-MeOH-NH4OH as eluent unfortunately did not afford cis-74 due to volatility. 
Lab Book - PJ-01-25 
 
 
 
 
 
199 
 
3-(Methoxycarbonyl)-2-methylpyrrolidin-1-ium chloride cis-74·HCl 
 
10% Pd/C (160 mg, 0.15 mmol, 0.7 eq) was added to a stirred solution of benzyl pyrrolidine 
cis-109 (500 mg, 2.15 mmol, 1.0 eq) in MeOH (10 mL) at rt under Ar. The reaction flask 
was evacuated under reduced pressure and back-filled with Ar three times. After the final 
evacuation, H2 was charged and the reaction mixture was stirred vigorously under a H2 
balloon at rt for 3 h. The solids were removed by filtration through Celite and washed with 
Et2O (30 mL). HCl (5.3 mL of a 2 M solution in Et2O, 5.3 mmol, 5.0 eq) was added dropwise 
to the filtrate. The resulting solution was stirred at rt for 30 min. Then, the solvent was 
evaporated under reduced pressure to give pyrrolidine cis-74·HCl (300 mg, 78%) as a red 
oil,  IR (ATR) 2912, 1730 (C=O), 1437, 1177, 731 cm
-1; 1H NMR (400 MHz, d4-MeOH) δ 
3.96-3.82 (m, 1H, NCHMe), 3.72 (s, 3H, OMe), 3.58-3.46 (m, 1H, NCH), 3.42-3.32 (m, 1H, 
NCH), 3.32-3.24 (m, 1H, CHCO2), 2.38-2.23 (m, 2H, CH2), 1.33 (d, J = 6.0 Hz, 3H, CHMe); 
13C NMR (100.6 MHz, d4-MeOD) δ 173.5 (C=O), 58.7 (NCHMe), 52.8 (OMe), 47.6 
(CHCO2), 45.2 (NCH2), 28.2 (CH2), 13.9 (CHMe); MS (ESI) m/z 144 (M
+); HRMS m/z calcd 
for C7H14NO2 (M
+) 144.1019, found 144.1023 (–2.2 ppm error). Spectroscopic data for 
consistent with those reported in the literature.148   
Lab Book - PJ-02-04. 
 
10% Pd/C (120 mg, 1.13 mmol, 0.7 eq) was added to a stirred solution of an 80:20 mixture 
of α-methyl benzyl pyrrolidine cis,trans-103 and cis,cis-103 (400 mg, 1.62 mmol, 1.0 eq.) 
in MeOH (9 mL) at rt under Ar. The reaction flask was evacuated under reduced pressure 
and back-filled with Ar three times. After the final evacuation, H2 was charged and the 
reaction mixture was stirred vigorously under a H2 balloon at rt for 3 h. The solids were 
removed by filtration through Celite and washed with Et2O (30 mL). HCl (4 mL of a 2 M 
solution in Et2O, 8.27 mmol, 5.0 eq) was added dropwise to the filtrate. The resulting 
solution was stirred at rt for 30 min. Then, the solvent was evaporated under reduced pressure 
to give pyrrolidine cis-74·HCl (280 mg, 97%) as a red oil. 
Lab Book - PJ-02-55. 
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Methyl 2-methyl-1-(methylsulfonyl)pyrrolidine-3-carboxylate cis-112 
 
Et3N (0.23 mL, 1.68 mmol, 3.0 eq) was added dropwise to a stirred solution of cis-74·HCl 
(100 mg, 0.56 mmol, 1.0 eq) in CH2Cl2 (10 mL) at rt under Ar. The resulting mixture was 
stirred at rt for 10 min and MsCl (0.13 mL, 1.68 mmol, 3.0 eq) was added dropwise. The 
resulting mixture was stirred at rt for 18 h. The reaction mixture was poured into water (50 
mL) and extracted with CH2Cl2 (3 x 30 mL). The combined organics were dried (MgSO4) 
and the solvent was evaporated under reduced pressure to give the crude product as an orange 
solid. Purification by flash column chromatography on silica with 1:1 hexane-EtOAc as 
eluent gave N-sulfonamide pyrrolidine cis-112 (90 mg, 73%) as a white solid, mp 83-86 °C; 
RF (1:1 hexane-EtOAc)  0.23; IR (ATR) 2973, 1745 (C=O), 1316, 1147, 1130, 783 cm
-1; 1H 
NMR (400 MHz, CDCl3) δ 4.17 (dq, J = 13.0, 6.5 Hz, 1H, NCHMe), 3.72 (s, 3H, OMe), 
3.60-3.50 (m, 1H, NCH), 3.30 (ddd, J = 10.0, 10.0, 7.0 1H, NCH), 3.15-3.06 (m, 1H, 
CHCO2Me), 2.85 (s, 3H, SO2Me), 2.41-2.30 (m, 1H, CH), 2.18-2.10 (m, 1H, CH), 1.17 (d, 
J = 6.5 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 171.2 (C=O), 56.5 (NCHMe), 
52.2 (OMe), 47.9 (CHCO2Me), 46.9 (NCH2), 36.7 (SO2Me), 26.0 (CH2), 18.2 (CHMe); MS 
(ESI) m/z 244 (M + H)+; HRMS m/z calcd for C8H15NO4S (M + Na)
+ 244.0614, found 
244.0617 (‒3.8 ppm error).   
Lab Book - PJ-02-57. 
 
3-(Methoxycarbonyl)-1,2-dimethylpyrrolidin-1-ium chloride cis-75·HCl 
 
37% aqueous formaldehyde (0.5 mL, 17.6 mmol, 10.0 eq) was added dropwise to a stirred 
suspension of pyrrolidine 74·HCl (300 mg, 1.7 mmol, 1.0 eq), NaBH(OAc)3 (1.06 g, 5.0 
mmol, 3.0 eq) and MgSO4 (500 mg, 4.15 mmol) in 4:1 CH2Cl2-AcOH (16 mL) at rt under 
Ar. The resulting mixture was stirred at rt for 1 h. The reaction mixture was dissolved in 
CH2Cl2 (30 mL) and sat NaHCO3(aq) (70 mL) was added. The two layers were separated, and 
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the aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were 
washed with brine (50 mL) and dried (MgSO4) to give a solution of the crude cis-75. HCl 
(4.25 mL of a 2 M solution in Et2O, 8.5 mmol, 5.0 eq) was added dropwise to the solution 
of crude cis-75. The resulting solution was stirred at rt for 30 min. Then, the solvent was 
evaporated under reduced pressure to give N-methyl pyrrolidine cis-75·HCl (160 mg, 48%) 
as an orange solid, mp 42-45 °C; IR (ATR) 2952, 1736 (C=O), 1436, 1202, 780 cm-1; 1H 
NMR (400 MHz, d4-MeOD) δ 3.89-3.80 (m, 1H, NCHMe), 3.73 (s, 3H, OMe), 3.71-3.63 
(m, 1H, NCH), 3.44-3.36 (m, 1H, NCH), 3.26-3.18 (m, 1H, CHCO2), 2.91 (s, 3H, NMe), 
2.45-2.33 (m, 1H, CH), 2.31-2.19 (m, 1H, CH), 1.36 (d, J = 6.5 Hz, 3H, CHMe); 13C NMR 
(100.6 MHz, d4-MeOH) δ 173.9 (C=O), 67.4 (NCHMe), 56.5 (NCH2), 52.9 (OMe), 47.9 
(CHCO2), 40.6 (NMe), 26.9 (CH2), 12.4 (Me); MS (ESI) m/z 158 (M
+); HRMS m/z calcd 
for C8H16NO2 (M
+) 158.1176, found 158.1171 (+2.9 ppm error).   
Lab Book - PJ-02-05. 
 
Methyl 1-benzyl-2-methylpyrrolidine-3-carboxylate cis-109 and trans-109 
 
A solution of a 90:10 mixture of pyrrolidines cis-109 (50 mg, 0.29 mmol, 1.0 eq) in DBU 
(0.1 mL, 0.64 mmol, 3.0 eq) and xylene (1 mL) was stirred and heated at 100 °C for 48 h 
under Ar. After being allowed to cool to rt, water (50 mL) was added and the mixture was 
extracted with Et2O (3 x 25 mL). The combined organics were dried (MgSO4) and 
evaporated under reduced pressure to give a 50:50 mixture of pyrrolidines cis-109 and trans-
109 (25 mg, 50%) as a colourless oil, RF (75:25 hexane-EtOAc) 0.23. Diagnostic signal for 
cis-109: 1H NMR (400 MHz, CDCl3) δ 1.03 (d, J = 6.5 Hz, 1.5H, CHMe). Diagnostic signal 
for trans-109: 1H NMR (400 MHz, CDCl3) δ 1.29 (d, J = 6.0 Hz, 1.5H, CHMe). 
Lab Book - PJ-01-19. 
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Methyl 2-methyl-1-(1-phenylethyl)-4,5-dihydro-1H-pyrrole-3-carboxylate 102 
 
Methyl acetoacetate (3.0 mL, 27.8 mmol, 1.0 eq) was added dropwise to a stirred suspension 
of 1,2-dibromoethane (4.7 mL, 55.6 mmol, 2.0 eq) and K2CO3 (9.5 g, 69.5 mmol, 2.5 eq) in 
MeCN (50 mL, 0.55 M) at rt under Ar. The resulting suspension was stirred and heated at 
reflux for 23 h. After being allowed to cool to rt, the solids were removed by filtration and 
the filtrate was evaporated under reduced pressure to give the crude product as an orange oil. 
α-Methylbenzylamine (4.45 mL, 39.0 mmol, 1.5 eq) was added to a stirred solution of the 
crude product in toluene (130 mL) at rt under Ar. The resulting solution was stirred and 
heated at reflux for 48 h. After being allowed to cool to rt, the solvent was evaporated under 
reduced pressure to give the crude product as an orange oil. Purification by flash column 
chromatography on silica with 19:1 hexane-EtOAc as eluent gave α-methyl dihydropyrrole 
102 (3.04 g, 44%) as an orange oil, RF (1:1 hexane-EtOAc) 0.29; IR (ATR) 2976, 2942, 1667 
(C=O), 1417, 1130, 1025, 699 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.37-7.31 (m, 2H, Ph), 
7.28-7.20 (m, 3H, Ph), 4.88 (q, J = 7.0 Hz, 1H, NCHMe), 3.66 (s, 3H, OMe), 3.46-3.37 (m, 
1H, NCH), 3.18-3.11 (m, 1H, NCH), 2.71-2.64 (m, 2H, CH), 2.32 (s, 3H, Me), 1.54 (d, J = 
7.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 167.9 (C=O), 160.9 (C=CMe), 141.2 
(ipso-Ph), 128.7 (Ph), 127.4 (Ph), 126.4 (Ph), 95.7 (C=CCO2Me), 52.6 (NCHMe), 50.2 
(OMe), 45.2 (NCH2), 26.6 (CH2), 17.6 (Me), 12.2 (CHMe); MS (ESI) m/z 246 (M + H)
+; 
HRMS m/z calcd for C15H20NO2 (M + H)
+ 246.1489, found 246.1497 (‒3.2 ppm error). 
Spectroscopic data consistent with those reported in the literature.72    
Lab Book - PJ-01-80. 
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Methyl 2-methyl-1-(1-phenylethyl)pyrrolidine-3-carboxylate (R,R,R)-103, (R,R,S)-103 
and (R,S,S)-103 
 
NaBH(OAc)3 (1.3 g, 6.12 mmol, 3.0 eq) was added to a stirred solution of dihydropyrrole 
102 (500 mg, 2.04 mmol, 1.0 eq) in 1:1 AcOH-MeCN (8 mL) at rt under Ar. The resulting 
solution was cooled and stirred at 0 °C for 3 h. Then, the solvent was evaporated under 
reduced pressure to give an orange oil. The residue was dissolved in CH2Cl2 (50 mL) and 
sat NaHCO3(aq) (50 mL) was added. The two layers were separated, and the aqueous layer 
was extracted with CH2Cl2 (3 x 50 mL). The combined organics were dried (MgSO4) and 
evaporated under reduced pressure to give the crude product as a yellow/orange oil which 
contained a 70:20:10 mixture of (R,R,R)-103, (R,R,S)-103 and (R,S,S)-103 (by 1H NMR 
spectroscopy). Purification by flash column chromatography on silica with 7:3 hexane-
EtOAc as eluent gave a 90:10 mixture of  α-methyl benzyl pyrrolidines (R,R,R)-103 and 
(R,R,S)-103 (230 mg, 45%) as a yellow oil, RF (7:3 hexane-EtOAc) 0.22; IR (ATR) 2971, 
1736 (C=O), 1452, 1163, 700 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.37-7.19 (m, 5H, Ph), 
3.67 (s, 2.7H, OMe), 3.63 (s, 0.3H, OMe), 3.58 (q, J = 6.5 Hz, 1H, PhCHMe), 3.53-3.44 (m, 
1H, NCHMe), 3.15-3.06 (m, 1H, CHCO2), 2.70 (ddd, J = 9.0, 9.0, 4.0 Hz, 1H, NCH), 2.53 
(ddd, J = 9.0, 8.0, 8.0 Hz, 1H, NCH), 2.24-2.12 (m, 1H, CH), 1.93-1.82 (m, 1H, CH), 1.36 
(d, J = 6.5, 0.3H, PhCHMe), 1.35 (d, J = 6.5, 2.7H, PhCHMe), 0.81 (d, J = 7.0 Hz, 0.3H, 
NCHMe), 0.75 (d, J = 7.0 Hz, 2.7H, NCHMe); 13C NMR (100.6 MHz, CDCl3) for (R,R,R)-
103 δ 173.8 (C=O), 145.6 (ipso-Ph), 128.3 (Ph), 127.5 (Ph), 127.0 (Ph), 60.9 (PhCHMe), 
57.1 (NCHMe), 51.6 (OMe), 48.9 (NCH2), 47.6 (CHCO2), 25.0 (CH2), 21.1 (PhCHMe), 12.7 
(CHMe); MS (ESI) m/z 248 (M + H)+; HRMS m/z calcd for C15H21NO2 (M + H)
+ 248.1645, 
found 248.1647 (‒0.3 ppm error) and a 60:25:15 mixture of pyrrolidines (R,R,R)-103, 
(R,R,S)-103 and (R,S,S)-103 (162 mg, 18%) as a  yellow oil. Diagnostic signals for 
pyrrolidine (R,R,S)-103: 13C NMR (100.6 MHz, CDCl3) δ 60.2 (PhCHMe), 56.4 (NCHMe), 
48.1 (NCH2), 24.8 (CH2), 23.3 (PhCHMe), 11.9 (CHMe). Diagnostic signal for (R,S,S)-103: 
1H NMR (400 MHz, CDCl3) δ 1.00 (d, J = 6.0 Hz, 3H, NCHMe). Spectroscopic data for 
(R,R,R)-103, (R,R,S)-103 and (R,S,S)-103 consistent with those reported in the literature.74  
Lab Book - PJ-02-02. 
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Methyl 2-methyl-1-(1-phenylethyl)pyrrolidine-3-carboxylate (S,R,R)-103 
 
A solution of a 90:10 mixture of pyrrolidines (R,R,R)-103 and (R,R,S)-103 (1.8 g, 7.3 mmol, 
1.0 eq) in DBU (4.3 mL, 29.1 mmol, 4.0 eq) was stirred and heated at 100 °C for 16 h under 
Ar. After being allowed to cool to rt, water (50 mL) was added and the aqueous layer was 
extracted with Et2O (3 x 50 mL). The combined organics were dried (MgSO4) and 
evaporated under reduced pressure to give the crude product as an orange oil. Purification 
by flash column chromatography on silica with 9:1 hexane-EtOAc as eluent gave a 60:30:10 
mixture (by 1H NMR spectroscopy) of α-methyl benzyl pyrolidines (S,R,R)-103, 
(R,R,R)-103 and (R,R,S)-103 (530 mg, 30%) and a 95:3:2 mixture (by 1H NMR 
spectroscopy) of α-methyl benzyl pyrolidines (S,R,R)-103, (R,R,R)-103 and (R,R,S)-103 
(380 mg, 24%) as an orange oil, RF (9:1 hexane-EtOAc) 0.1; IR (ATR) 2971, 1731 (C=O), 
1452, 1168, 908, 729 cm‒1; 1H NMR (400 MHz, CDCl3) for (S,R,R)-103: δ 7.39-7.35 (m, 
2H, Ph), 7.33-7.27 (m, 2H, Ph), 7.24-7.20 (m, 1H, Ph), 3.81 (q, J = 6.5 Hz, 1H, PhCHMe), 
3.70 (s, 3H, OMe), 3.06-2.99 (m, 1H, NCHMe), 2.79-2.74 (m, 1H, NCH), 2.61 (ddd, J = 
8.0, 8.0, 8.0 Hz, 1H, NCH), 2.56 (ddd, J = 6.0, 6.0, 6.0 Hz, 1H, CHCO2), 2.01-1.94 (m, 2H, 
CH), 1.34 (d, J = 6.5 Hz, 3H, PhCHMe), 1.00 (d, J = 6.0 Hz, 3H, NCHMe); 13C NMR (100.6 
MHz, CDCl3) for (S,R,R)-103: δ 175.9 (C=O), 145.2 (ipso-Ph), 128.2 (Ph), 127.7 (Ph), 126.8 
(Ph), 60.4 (NCHMe), 58.8 (PhCHMe), 51.9 (OMe), 50.8 (CHCO2), 48.0 (NCH2), 26.4 
(CH2), 19.7 (PhCHMe), 16.3 (CHMe); MS (ESI) m/z 248 (M + H)
+; HRMS m/z calcd for 
C15H21NO2 (M + H)
+ 248.1645, found 248.1640 (+2.0 ppm error).  
Lab Book - PJ-02-08.  
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Methyl 1-acetyl-2-methylpyrrolidine-3-carboxylate trans-73 
 
10% Pd/C (106 mg, 1.0 mmol, 0.7 eq) was added to a stirred solution of a 95:3:2 mixture of 
pyrrolidines (S,R,R)-103, (R,R,R)-103 and (R,R,S)-103 (350 mg,  1.3 mmol, 1.0 eq.) in 
MeOH (7 mL) at rt under Ar. The reaction flask was evacuated under reduced pressure and 
back-filled with Ar three times. After the final evacuation, H2 was charged and the reaction 
mixture was stirred vigorously at rt under a H2 balloon for 3 h. The solids were removed by 
filtration through Celite and washed with the MeOH (20 mL). AcCl (0.49 mL, 6.9 mmol, 
5.0 eq) was added to the reaction mixture and the reaction was stirred at rt under Ar for 18 
h. Then, the solvent was evaporated under reduced pressure to give crude pyrrolidine 74·HCl 
(250 mg). Et3N (0.8 mL, 5.8 mmol, 3.0 eq) was added dropwise to a stirred solution of crude 
pyrrolidine 74·HCl (250 mg) in CH2Cl2 (30 mL) and the mixture was stirred at rt for 10 min 
under Ar. Then, AcCl (0.4 mL, 5.8 mmol, 3.0 eq) was added dropwise and the resulting 
mixture was stirred at rt for 18 h. The solution was poured into water (50 mL) and the two 
layers were separated. The organic layer was collected, dried (MgSO4) and evaporated under 
reduced pressure to give the crude product as an orange oil. Purification by flash column 
chromatography on silica with 8:2 hexane-EtOAc as eluent gave N-acyl pyrrolidine trans-
73 (140 mg, 42%) as a yellow oil, RF (8:2 hexane-EtOAc) 0.1; IR (ATR) 2955, 1731 (C=O, 
CO2Me), 1634 (C=O, acetamide), 1412, 1171, 669 cm
‒1; 1H NMR (400 MHz, CDCl3) (65:35 
mixture of rotamers) δ 4.40 (qd, J = 6.5, 2.5 Hz, 0.65H, NCHMe), 4.25 (dq, J = 6.5, 2.5 Hz, 
0.35H, NCHMe), 3.70 (s, 1.05H, OMe), 3.68 (s, 1.95H, OMe), 3.63-3.54 (m, 1H, NCH), 
3.53-3.46 (m, 0.65H, NCH), 3.45-3.38 (m, 0.35H, NCH), 2.77 (ddd, J = 6.0, 6.0, 3.0 Hz, 
0.65H, CHCO2), 2.72-2.65 (m, 0.35H, CHCO2), 2.26-2.14 (m, 2H, CH), 2.09 (s, 1.05H, 
MeCO), 2.01 (s, 1.95H, MeCO), 1.31-1.25 (s, 3H, NCHMe); 13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 173.9 (C=O), 169.1 (C=O), 56.1 (NCHMe), 52.2 (OMe), 49.4 (CHCO2), 46.7 
(NCH2), 26.9 (CH2), 23.0 (MeCO), 20.2 (CHMe); MS (ESI) m/z 208 (M + Na)
+; HRMS m/z 
calcd for C9H15NO3 (M + Na)
+ 208.0944, found 208.0951 (‒3.5 ppm error).   
Lab Book - PJ-02-11/13. 
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3-(Methoxycarbonyl)-2-methylpyrrolidin-1-ium chloride trans-74·HCl 
 
10% Pd/C (30 mg, 0.028 mmol, 0.7 eq) was added to a stirred solution of a 95:3:2 mixture 
of N-α-methyl benzyl pyrrolidine (S,R,R)-103, (R,R,R)-103 and (R,R,S)-103 (100 mg, 0.4 
mmol, 1.0 eq) in MeOH (2 mL) at rt under Ar. The reaction flask was evacuated under 
reduced pressure and back-filled with Ar three times. After the final evacuation, H2 was 
charged and the reaction mixture was stirred vigorously under a H2 balloon at rt for 3 h. The 
solids were removed by filtration through Celite and washed with Et2O (10 mL). HCl (1 mL 
of a 2 M solution in Et2O, 2.0 mmol, 5.0 eq) was added dropwise to the filtrate. The resulting 
solution was stirred at rt for 30 min. Then, the solvent was evaporated under reduced pressure 
to give pyrrolidine trans-74·HCl (70 mg, 99%) as a green oil, IR (ATR) 2921, 1723 (C=O), 
1386, 1196, 1083, 800 cm‒1; 1H NMR (400 MHz, d4-MeOH) δ 3.89-3.80 (m, 1H, NCHMe), 
3.72 (s, 3H, OMe), 3.34-3.29 (m, 2H, NCH2), 2.92 (ddd, J = 8.0, 8.0, 8.0 Hz, 1H, CHCO2), 
2.38 (dddd, J = 14.5, 7.5, 7.5, 7.5 Hz, 1H, CH), 2.22 (dddd, J = 14.5, 7.5, 7.5, 7.5 Hz, 1H, 
CH), 1.42 (d, J = 7.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, d4-MeOH) δ 173.0 (C=O), 
59.3 (NCHMe), 53.9 (OMe), 49.9 (CHCO2), 46.8 (NCH2), 29.3 (CH2), 18.1 (CHMe); MS 
(ESI) m/z 144 (M+); HRMS m/z calcd for C7H14NO2 (M
+) 144.1019, found 14.1019 (‒0.3 
ppm error).  Spectroscopic data consistent with those reported in the literature.74   
Lab Book - PJ-02-01. 
 
3-(Methoxycarbonyl)-2-methylpyrrolidin-1-ium chloride cis-74·AcOH 
 
10% Pd/C (149 mg, 0.14 mmol, 0.07 eq) was added to a stirred solution of an 80:20 mixture 
of pyrrolidines (R,R,R)-103 and (R,R,S)-103 (500 mg, 2.0 mmol, 1.0 eq) in MeOH (20 mL) 
at rt under Ar. The reaction flask was evacuated under reduced pressure and back-filled with 
Ar three times. After the final evacuation, H2 was charged and the reaction mixture was 
stirred vigorously at rt under a H2 balloon for 3 h. The solids were removed by filtration 
through Celite and washed with the Et2O (10 mL). AcOH (0.11 mL, 2.0 mmol, 1.0 eq) was 
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added dropwise to the filtrate and stirred at rt for 30 min. The solvent was evaporated under 
reduced pressure to give pyrrolidine cis-74·AcOH (392 mg, 96%) as a yellow oil, IR (ATR)  
2955, 1733 (C=O), 1553, 1390, 1009, 654 cm‒1; 1H NMR (400 MHz, d4-MeOH) δ 3.82 (dq, 
J = 7.0, 7.0 Hz, 1H, NCHMe), 3.70 (s, 3H, OMe), 3.46 (ddd, J = 8.0, 6.0, 6.0 Hz, 1H, 
CHCO2), 3.35-3.20 (m, 2H, NCH), 2.31-2.18 (m, 2H, CH), 1.91 (s, 3H, MeCO2), 1.29 (d, J 
= 7.0 Hz, 3H, NCHMe); 13C NMR (100.6 MHz, d4-MeOH) δ 178.0 (C=O, MeCO2), 173.6 
(C=O), 58.4 (NCHMe), 52.6 (OMe), 47.7 (CHCO2), 45.0 (NCH2), 28.2 (CH2), 22.5 
(MeCO2), 14.0 (CHMe); MS (ESI) m/z 144 (M)
+; HRMS m/z calcd for C7H14NO2 (M
+) 
144.1019, found 144.1023 (–2.7 ppm error).   
Lab Book - PJ-02-91. 
 
3-(Methoxycarbonyl)-1,2-dimethylpyrrolidin-1-ium chloride cis-75·AcOH 
 
37% aqueous formaldehyde (0.55 mL, 7.4 mmol, 10.0 eq) was added dropwise to a stirred 
suspension of pyrrolidine 74·AcOH (150 mg, 0.74 mmol, 1.0 eq), NaBH(OAc)3 (466 mg, 
2.2 mmol, 3.0 eq) and MgSO4 (550 mg, 4.5 mmol) in 4:1 CH2Cl2-AcOH (7.4 mL) at rt under 
Ar. The resulting mixture was stirred at rt for 1 h. The residue was dissolved in CH2Cl2 (30 
mL) and sat NaHCO3(aq) (80 mL) was added. The two layers were separated, and the aqueous 
layer was extracted with CH2Cl2 (3 x 20 mL). The organic layers were combined and dried 
(MgSO4), AcOH (0.04 mL, 0.74 mmol, 1.0 eq) was added dropwise to the filtrate and stirred 
at rt for 30 min. The solvent was evaporated under reduced pressure to give N-methyl 
pyrrolidine cis-75·AcOH (91mg, 0.42 mmol, 57%) as an orange oil, IR (ATR) 2917, 1734 
(C=O), 1562, 1366, 1256, 2008, 659 cm‒1; 1H NMR (400 MHz, d4-MeOH) δ 3.65-3.53 (m, 
1H, NCH), 3.63 (s, 3H, OMe), 3.47 (dq, J = 7.0, 7.0 Hz, 1H, CHMe), 3.28 (ddd, J = 7.5, 6.0, 
6.0 Hz, 1H, CHCO2), 3.05 (ddd, J =8.0, 6.0, 6.0 Hz, 1H, NCH), 2.72 (s, 3H, NMe), 2.23-
2.15 (m, 2H, CH), 1.84 (s, 3H, MeCO2
‒), 1.21 (d, J = 7.0 Hz, 3H, CHMe); 13C NMR (100.6 
MHz, d4-MeOH) δ 176.8 (C=O, MeCO2‒), 173.8 (C=O), 66.4 (NCHMe), 55.9 (NCH2), 52.7 
(OMe), 47.8 (CHCO2), 40.0 (NMe), 26.6 (CH2), 21.9 (MeCO2
‒), 12.35 (CHMe); MS (ESI) 
m/z 158 M+; HRMS m/z calcd for C8H16NO2 (M)
+ 158.1176, found 158.1179 (‒0.9 ppm 
error).   
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Lab Book - PJ-02-100. 
 
Methyl-6-methylpiperidine-3-carboxylate cis-126 and trans-126 
 
Table 2.1, Entry 1 
Using general procedure A, PtO2 (37 mg, 0.2 mmol, 20 mol%) and methyl-6-
methylnicotinate (100 mg, 0.66 mmol) in AcOH (1.0 mL) gave the crude product which 
contained an 85:18 mixture of piperidines cis-126 and trans-126 (76 mg, 74%) as a 
colourless oil. 
Lab Book - PJ-02-18. 
 
Table 2.1, Entry 2 
Using general procedure A, PtO2 (15 mg, 0.1 mmol, 10 mol%) and methyl-6-
methylnicotinate (100 mg, 0.66 mmol) in AcOH (1.0 mL) gave the crude product which 
contained an 85:18 mixture of piperidines cis-126 and trans-126 (76 mg, 74%) as a 
colourless oil. 
Lab Book - PJ-02-18. 
 
Table 2.1, Entry 3 
Using general procedure A, PtO2 (7.5 mg, 0.05 mmol, 5 mol%) and methyl-6-
methylnicotinate (100 mg, 0.66 mmol) in AcOH (1.0 mL) gave the crude product which 
contained an 85:18 mixture of piperidines cis-126 and trans-126 (68 mg, 65%) as a 
colourless oil. 
Lab Book - PJ-02-21. 
 
Table 2.1, Entry 4 
Using general procedure B, PtO2 (60 mg, 0.26 mmol, 10 mol%) and methyl-6-
methylnicotinate (400 mg, 2.64 mmol, 1.0 eq) in AcOH (4 mL) gave the crude product which 
contained an 85:15 mixture (by 1H NMR spectroscopy) of piperidines cis-126 and trans-126 
(386 mg, 93%) as a colourless oil.  
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Lab Book – PJ-04-56. 
 
Using general procedure A, PtO2 (300 mg, 1.3 mmol, 10 mol%) and methyl-6-
methylnicotinate (2.0 g, 13.2 mmol) in AcOH (20 mL) gave the crude product which 
contained an 85:18 mixture of piperidines cis-126 and trans-126 (1.58 g, 76%) as a 
colourless oil, 1H NMR (400 MHz, CDCl3) δ 3.70 (s, 2.55H, OMe), 3.65 (s, 0.45H, OMe), 
3.41 (ddd, J = 13.0, 2.5, 2.5 Hz, 1H, NCH), 2.81 (dd, J = 13.0, 4.0 Hz, 1H, NCH), 2.64 (dqd, 
J = 13, 6.5, 3.0 Hz, 1H, NCHMe), 2.48-2.44 (m, 1H, CH), 2.20-2.12 (m, 1H, CH), 2.09 (br, 
1H, NH), 1.71-1.61 (m, 1H, CH), 1.54 (ddd, J = 13.5, 7.0, 3.5 Hz, 1H, CH), 1.23-1.12 (m, 
1H, CH), 1.07-1.02 (m, 3H, Me); 13C NMR (100.6 MHz, CDCl3) δ 175.2 (C=O), 51.8 
(OMe), 51.8 (CH), 47.4 (NCH2), 39.1 (CH), 31.5 (CH2), 26.1 (CH2), 22.7 (Me). The crude 
product was sufficiently pure for use in the next step. Spectroscopic data for cis-126 and 
trans-126 consistent with those reported in the literature.84   
Lab Book - PJ-02-29. 
 
1-(tert-Butyl) 3-methyl-6-methylpiperidine-1,3-dicarboxylate cis-157 and trans-157 
 
Et3N (4.15 mL, 29.8 mmol, 3.0 eq) was added dropwise to an 85:15 mixture of piperidines 
cis- 126 and trans-126 (1.5 g, 9.93 mmol, 1.0 eq), Boc2O (2.16 g, 9.93 mmol, 1.0 eq) and 
DMAP (60 mg, 4.97 mmol, 0.05 eq) in CH2Cl2 (100 mL) at rt under Ar. The reaction mixture 
was stirred at rt for 16 h. Then, the solvent was evaporated under reduced pressure to give 
the crude product as a colourless oil. Purification by flash column chromatography on silica 
with 9:1 hexane-EtOAc as eluent gave N-Boc piperidine cis-157 (1.73 g, 68%) as a 
colourless oil, RF  (9:1 hexane-EtOAc) 0.22; IR (ATR) 2973, 1734 (C=O, CO2Me), 1688 
(C=O, Boc), 1408, 1161, 871 cm‒1; 1H NMR (400 MHz, CDCl3) δ 4.52-4.29 (m, 1H, 
NCHMe), 4.29-4.04 (m, 1H, NCH), 3.69 (s, 3H, OMe), 2.97-2.82 (m, 1H, NCH), 2.45-2.33 
(m, 1H, CHCO2), 1.98-1.85 (m, 1H, CH), 1.79-1.65 (m, 2H, CH), 1.59-1.50 (m, 1H, CH), 
1.45 (s, 9H, CMe3), 1.12 (d, J = 7.0 Hz, 3H, CHMe); 
13C NMR (100.6 MHz, CDCl3)
 δ 174.1 
(C=O, CO2Me), 154.7 (C=O, Boc), 79.6 (CMe3), 51.7 (OMe), 45.0 (NCHMe), 41.9 
(CHCO2), 39.7 (NCH2), 29.1 (CH2), 28.4 (CMe3), 22.1 (CH2), 15.5 (Me); MS (ESI) m/z 280 
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(M + Na)+; HRMS m/z calcd for C13H23NO4 (M + Na)
+ 280.1519, found 280.1507 (+4.4 
ppm error), a 65:35 mixture of N-Boc piperidines trans-157 and cis-157 (144 mg, 6%) and 
N-Boc piperidine trans-157 (150 mg, 6%), RF  (9:1 hexane-EtOAc) 0.17; IR (ATR) 2972, 
1735 (C=O, CO2Me), 1686 (C=O, Boc), 1414, 1152, 865 cm
‒1; 1H NMR (400 MHz, CDCl3) 
δ 4.45-4.29 (m, 2H, NCHMe and NCH), 3.67 (s, 3H, OMe), 3.04 (dd, J = 14.0, 4.0 Hz, 1H, 
NCH), 2.58 -2.53 (m, 1H, CHCO2), 2.04-1.96 (m, 1H, CH), 1.92-1.72 (m, 2H, CH), 1.43 (s, 
9H, CMe3), 1.37-1.30 (m, 1H, CH), 1.11 (d, J = 7.0 Hz, 1H, CHMe); 
13C NMR (100.6 MHz, 
CDCl3) δ 173.9 (C=O, CO2Me), 154.9 (C=O, Boc), 77.5 (CMe3), 51.9 (OMe), 45.9 
(NCHMe), 39.4 (NCH2), 39.2 (CHCO2), 28.6 (CMe3), 26.6 (CH2), 20.2 (CH2), 16.0 (Me); 
MS (ESI) m/z 280 (M + Na)+; HRMS m/z calcd for C13H23NO4 (M + Na)
+ 280.1519, found 
280.1519 (‒0.3 ppm error). Spectroscopic data for cis-157 and trans-157 consistent with 
those reported in the literature.149   
Lab Book - PJ-02-32. 
 
1-Benzyl 3-methyl-6-methylpiperidine-1,3-dicarboxylate cis-127 
 
HCl (3.9 mL of a 2 M solution in Et2O, 7.8 mmol, 10.0 eq) was added dropwise to piperidine 
cis-157 (200 mg, 0.78 mmol, 1.0 eq) at rt under Ar. The resulting solution was stirred at rt 
for 112 h. Then, the solvent was evaporated under reduced pressure to give the hydrochloride 
salt (100 mg). Et3N (0.14 mL, 1.04 mmol, 2.0 eq) was added dropwise to a solution of the 
hydrochloride salt (100 mg, 0.52 mmol, 1.0 eq) and DMAP (6 mg, 0.052 mmol, 0.1 eq) in 
CH2Cl2 (5 mL) under Ar. The reaction mixture was cooled to 0 °C and stirred for 1 h. Cbz-
Cl (0.08 mL, 0.57 mmol, 1.1 eq) was then added dropwise to the reaction mixture at 0 °C. 
The reaction mixture was stirred at 0 °C for 30 min, then warmed to rt and stirred at rt for 
16 h. 2 M HCl(aq) (5 mL) was added and the solvent was evaporated under reduced pressure 
to give a colourless oil. The oil was partitioned between toluene (10 mL), Et2O (10 mL) and 
water (20 mL). The two layers were separated, and the organic layer was washed with brine 
(50 mL), dried (MgSO4) and evaporated under reduced pressure to give the crude product as 
a colourless oil. Purification by flash column chromatography on silica with 9:1 hexane-
EtOAc as eluent gave N-Cbz piperidine cis-127 (59 mg, 26%) as a colourless oil, RF  (8:2 
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hexane-EtOAc) 0.2; IR (ATR) 2950, 1732 (C=O, CO2Me), 1688 (C=O, Cbz), 1421, 1171, 
727 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.41-7.28 (m, 5H, Ph), 5.13 (s, 2H, CH2Ph), 4.49 
(br s, 1H, NCH), 4.38-4.13 (br s, 1H, NCHMe), 3.68 (s, 3H, OMe), 3.05-2.91 (m, 1H, NCH), 
2.48-2.35 (m, 1H, CHCO2), 1.99-1.84 (m, 1H, CH), 1.81-1.62 (m, 2H, CH), 1.62-1.54 (m, 
1H, CH), 1.16 (d, J = 7.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 174.0 (C=O, 
CO2Me), 155.2 (C=O, Cbz), 136.9 (ipso-Ph), 128.6 (Ph), 128.1 (Ph), 128.0 (Ph), 67.3 
(NCH2Ph), 51.9 (OMe), 45.9 (CH), 41.9 (CH), 40.0 (NCH2), 29.2 (CH2), 22.2 (CH2), 15.8 
(Me); MS (ESI) m/z 314 (M + Na)+; HRMS m/z calcd for C16H21NO4 (M + Na)
+ 314.1363, 
found 314.1353 (+2.6 ppm error). Spectroscopic data consistent with those reported in the 
literature.84  
Lab Book - PJ-02-44. 
 
1-Benzyl 3-methyl-6-methylpiperidine-1,3-dicarboxylate trans-127 
 
HCl (1.95 mL of a 2 M solution in Et2O, 3.9 mmol, 10.0 eq) was added dropwise to 
piperidine trans-157 (100 mg, 0.39 mmol, 1.0 eq) at rt under Ar. The resulting solution was 
stirred at rt for 16 h. Then, the solvent was evaporated under reduced pressure to give the 
hydrochloride salt (60 mg). Et3N (0.09 mL, 0.62 mmol, 2.0 eq) was added dropwise to a 
solution of the hydrochloride salt (60 mg, 0.31 mmol, 1.0 eq) and DMAP (4 mg, 0.031 mmol, 
0.1 eq) in CH2Cl2 (5 mL) under Ar. The reaction mixture was cooled to 0 °C and stirred for 
1 h. Cbz-Cl (0.05 mL, 0.34 mmol, 1.1 eq) was then added dropwise to the reaction mixture 
at 0 °C. The reaction mixture was stirred at 0 °C for 30 min, then warm to rt and stirred at rt 
for 16 h. 2 M HCl(aq) (2 mL) was added and the solvent was evaporated under reduced 
pressure to give a yellow oil. The oil was partitioned between toluene (10 mL), Et2O (10 
mL) and water (20 mL). The two layers were separated, and the organic layer was washed 
with brine (50 mL), dried (MgSO4) and evaporated under reduced pressure to give the crude 
product as a yellow oil. Purification by flash column chromatography on silica with 9:1 
hexane-EtOAc as eluent gave N-Cbz piperidine trans-127 (55 mg, 48%) as a colourless oil, 
RF  (8:2 hexane-Et2O) 0.2; IR (ATR) 2949, 1732 (C=O, CO2Me), 1690 (C=O, Boc), 1421, 
1155, 697 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.38-7.34 (m, 4H, Ph), 7.34-7.27 (m, 1H, 
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Ph), 5.18 (d, J = 12.5 Hz, 1H, CHPh), 5.08 (d, J = 12.5 Hz, 1H, CHPh), 4.49 (m, 1H, NCH), 
4.46-4.40 (m, 1H, CHMe), 3.61 (s, 3H, OMe), 3.12 (dd, J = 14.0, 4.0 Hz, 1H, NCH), 2.60-
2.58 (m, 1H, CHCO2), 2.09-2.00 (m, 1H, CH), 1.95-1.75 (m, 2H, CH2), 1.42-1.36 (m, 1H, 
CH), 1.16 (d, J = 7.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 173.7 (C=O, 
CO2Me), 155.5 (C=O, Cbz), 137.2 (ipso-Ph), 128.6 (Ph), 128.0 (Ph), 127.8 (Ph), 67.1 
(NCH2Ph), 52.0 (OMe), 46.4 (CH), 39.6 (NCH2), 39.1 (CH), 26.6 (CH2), 20.1 (CH2), 16.0 
(Me); MS (ESI) m/z 314 (M + Na)+; HRMS m/z calcd for C16H21NO4 (M + Na)
+ 314.1363, 
found 314.1364 (‒1.0 ppm error). Spectroscopic data consistent with those reported in the 
literature.84  
Lab Book - PJ-02-54. 
 
tert-Butyl-5-(hydroxymethyl)-2-methylpiperidine-1-carboxylate cis-158 
 
LiAlH4 (0.97 mL of a 1 M solution in THF, 0.97 mmol, 1.0 eq) was added dropwise to a 
stirred solution of N-Boc piperidine cis-157 (250 mg, 0.97 mmol, 1.0 eq) in THF (15 mL) at 
rt under Ar. The reaction mixture was stirred at 0 °C for 2 h. Water (4 mL), 20% NaOH(aq) 
(4 mL) and water (4 mL) were added sequentially (CARE – vigorous reaction). The two 
layers were separated, and the aqueous layer was extracted with EtOAc (3 x 20 mL). The 
combined organics were dried (MgSO4) and evaporated under reduced pressure to give 
alcohol cis-158 (218 mg, 98%) as a colourless oil, IR (ATR) 3415 (OH), 2929, 1687 (C=O), 
1411, 1142, 867 cm‒1; 1H NMR (400 MHz, CDCl3) δ 4.46-4.30 (m, 1H, NCHMe), 4.07-3.96 
(m, 1H, NCH), 3.58-3.41 (m, 2H, CH2OH), 2.56-2.48 (m, 1H, NCH), 1.72-1.48 (m, 4H, 
CH), 1.46-1.40 (m, 9H, CMe3), 1.36-1.20 (m, 1H, CH), 1.08 (d, J = 7.0 Hz, 3H, CHMe); 
13C 
NMR (100.6 MHz, CDCl3) δ 155.2 (C=O), 79.5 (CMe3), 66.0 (CH2OH), 46.2 (NCHMe), 
41.5 (NCH2), 39.3 (CH), 29.7 (CH2), 28.6 (CMe3), 22.0 (CH2), 15.8 (Me); MS (ESI) m/z 252 
(M + Na)+; HRMS m/z calcd for C12H23NO3 (M + Na)
+ 252.1570, found 252.1573 (‒1.0 ppm 
error). The crude piperidine cis-158 was sufficiently pure for the next step. 
Lab Book - PJ-02-33. 
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5-(Hydroxymethyl)-2-methylpiperidin-1-ium cis-86·HCl 
 
HCl (2.1 mL of a 2 M solution in Et2O, 4.37 mmol, 5.0 eq) was added dropwise to piperidine 
cis-158 (200 mg, 0.87 mmol, 1.0 eq) at rt under Ar. The resulting solution was stirred at rt 
for 16 h. Then, the solvent was evaporated under reduced pressure to give piperidine cis-
86·HCl (143 mg, 99%) as a colourless oil, IR (ATR) 3360 (OH), 2940, 1450, 1053 cm‒1; 1H 
NMR (400 MHz, d4-MeOH) δ 3.68-3.54 (m, 2H, CH), 3.46-3.37 (m, 1H, NCHMe), 3.23-
3.12 (m, 2H, NCH), 2.00-1.93 (m, 1H, CHCH2OH), 1.89-1.80 (m, 1H, CH), 1.77-1.65 (m, 
3H, CH), 1.33 (d, J = 7.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, d4-MeOH) δ 63.9 
(CH2OH), 51.9 (CHMe), 44.2 (CH2), 35.5 (CH), 28.0 (CH2), 23.1 (CH2), 17.1 (Me); MS 
(ESI) m/z 130 (M)+; HRMS m/z calcd for C7H16NO (M)
+ 130.1226, found 130.1229 (‒1.7 
ppm error).  
Lab Book - PJ-02-37. 
 
1,6-Dimethylpiperidin-3-yl)methanol cis-87 
 
A solution of N-Boc piperidine cis-158 (400 mg, 1.56 mmol, 1.0 eq) in THF (10 mL) was 
added dropwise to a stirred suspension of LiAlH4 (295 mg, 7.78 mmol, 5.0 eq) in THF (10 
mL) at 0 °C under Ar. The resulting suspension was stirred at 0 °C for 2 h. The reaction 
mixture was then allowed to warm up to rt, stirred and heated at reflux for 16 h. The reaction 
mixture was cooled to 0 °C, water (3 mL), 20% NaOH(aq) (3 mL) and water (3 mL) were 
added sequentially (CARE – vigorous reaction). The two layers were separated, and the 
aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organics were dried 
(MgSO4) and evaporated under reduced pressure to afford the crude product as a green oil. 
Purification by flash column chromatography on silica with 85:14:1 CH2Cl2-MeOH-
NH4OH(aq) as eluent gave N-methyl piperidine cis-87 (93 mg, 42%) as a red oil, RF (85:14:1 
CH2Cl2-MeOH-NH4OH(aq)) 0.15; IR (ATR) 3333 (OH), 2925, 1446, 1046, 597 cm
‒1; 1H 
NMR (400 MHz, CDCl3) δ 3.84 (dd, J = 11.0, 5.0 Hz, 1H, OCH), 3.74 (dd, J = 11.0, 5.0 Hz, 
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1H, OCH), 2.85 (dd, J = 11.0, 3.0 Hz, 1H, NCH), 2.37 (dd, J = 11.0, 3.0 Hz, 1H, NCH), 2.22 
(s, 3H, NMe), 2.13-2.04 (m, 1H, CHMe), 1.81-1.74 (m, 1H, CH), 1.69-1.52 (m, 4H, CH), 
1.05 (d, J = 6.5 Hz, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 67.8 (OCH2), 58.88 (NCH2), 
58.81 (NCHMe), 43.3 (NMe), 35.4 (CH), 31.8 (CH2), 27.4 (CH2), 18.9 (Me); MS (ESI) m/z 
144 (M + H)+; HRMS m/z calcd for C8H17NO (M + H)
+ 144.1383, found 144.1379 (+3.1 
ppm error).  
Lab Book - PJ-02-50. 
 
Methyl 6‐methylpiperidine‐2‐carboxylate cis-142 
 
Using general procedure B, PtO2 (30 mg, 0.13 mmol, 10 mol%) and 6-methyl-pyridine-2-
methyl ester 159 (0.18 mL, 1.32 mmol, 1.0 eq) in AcOH (4.9 mL) gave the crude product 
which contained (by 1H NMR spectroscopy) only piperidine cis-142 (200 mg, 97%) as a 
colourless oil. IR (ATR) 2929, 1737 (C=O), 1436, 1212, 1056, 735 cm‒1; 1H NMR (400 
MHz, CDCl3) δ 3.68 (s, 3H, OMe), 3.34 (dd, J = 11.0, 3.0 Hz, 1H, NCHCO2), 2.62 (dqd, J 
= 12.5, 6.5, 2.5 Hz, 1H, NCHMe), 1.99-1.92 (m, 1H, CH), 1.88-1.80 (m, 1H, CH), 1.62-1.54 
(m, 1H, CH), 1.45-1.26 (m, 2H, CH), 1.08 (d, J = 6.5 Hz, 3H, CHMe), 1.06-0.96 (m, 1H, 
CH); 13C NMR (100.6 MHz, CDCl3) δ 173.8 (C=O), 59.4 (NCH), 52.0 (OMe), 51.9 
(NCHMe), 33.8 (CH2), 29.0 (CH2), 24.6 (CH2), 22.9 (CHMe); MS (ESI) m/z 158 (M + H)
+; 
HRMS m/z calcd for C8H15NO2 (M + H)
+ 158.1176, found 158.1174 (+1.3 ppm error). 
Lab Book - PJ-05-88. 
 
 
 
 
 
 
 
 
215 
 
Methyl 1‐methanesulfonyl‐6‐methylpiperidine‐2‐carboxylate cis-160, trans-160 and 
methyl 1‐methanesulfonylmethanesulfonyl‐6‐methylpiperidine‐2‐carboxylate cis-161 
 
MsCl (0.19 mL, 2.52 mmol, 4.0 eq) was added dropwise to a stirred solution of piperidine 
cis-142 (100 mg, 0.64 mmol, 1.0 eq) and Et3N (0.09 mL, 0.64 mmol, 1.0 eq or 0.27 mL, 1.91 
mmol, 3.0 eq) in CH2Cl2 (6.3 mL)
 at rt or 0 °C under Ar. The resulting solution was stirred 
at 0 °C for 1 h. The solution was poured into water (50 mL) and the two layers were 
separated. The aqueous layer was extracted with CH2Cl2 (3 x 50 mL) and the combined 
organics were dried (MgSO4) and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 80:20 hexane-EtOAc 
as eluent gave sulfonamide piperidine cis-160 (34 mg, 20%)  as a yellow oil , RF (60:40 
hexane-EtOAc) 0.33; IR (ATR) 2944, 1734 (C=O), 1315, 1160, 766 cm‒1; 1H NMR (400 
MHz, CDCl3) δ 4.77-4.71 (m, 1H, NCHCO2), 4.31-4.23 (m, 1H, NCHMe), 3.74 (s, 3H, 
OMe), 3.01 (s, 3H, SO2Me), 2.35-2.28 (m, 1H, CH), 1.74-1.50 (m, 5H, CH), 1.15 (d, J = 7.0 
Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 173.2 (C=O), 52.8 (NCH), 52.5 (OMe), 
48.4 (NCHMe), 41.2 (SO2Me), 30.5 (CH2), 26.4 (CH2), 18.2 (CHMe), 15.3 (CH2); MS (ESI) 
m/z 258 (M + Na)+; HRMS m/z calcd for C9H17NO4S (M + Na)
+ 258.0770, found 258.0769 
(+0.5 ppm error) and impure bismethanesulfonamide piperidine cis-161 (102 mg). 
Purification of the impure bismethanesulfonamide piperidine cis-161 by flash column 
chromatography on silica with 50:50 hexane-EtOAc as eluent gave bismethanesulfonamide 
piperidine cis-161 (66 mg, 30%) as a white solid, mp 100-102 °C; RF (50:50, hexane-EtOAc) 
0.34; IR (ATR) 2980, 1733 (C=O), 1320, 1165, 966, 488 cm‒1; 1H NMR (400 MHz, CDCl3) 
δ 4.75 (d, J = 15.0 Hz, CHSO2), 4.72 (dd, J = 6.0, 1.5 Hz, 1H, NCHCO2), 4.49 (d, J = 15 
Hz, 1H, CHSO2), 4.29-4.19 (m, 1H, NCHMe), 3.79 (s, 3H, OMe), 3.23 (s, 3H, SO2Me), 
2.38-2.31 (m, 1H, CH), 1.86-1.74 (m, 2H, CH), 1.73-1.58 (m, 3H, CH), 1.23 (d, J = 7.0 Hz, 
3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 172.6 (C=O), 71.0 (CH2SO2), 54.2 (NCH), 
52.9 (OMe), 50.6 (NCHMe), 42.5 (SO2Me), 30.4 (CH2), 25.9 (CH2), 21.3 (CHMe), 15.1 
(CH2); MS (ESI) m/z 336 (M + Na)
+; HRMS m/z calcd for C10H19NO6S2 (M + Na)
+ 
336.0546, found 336.0536 (+3.0 ppm error). 
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Lab Book - PJ-04-02. 
 
Methyl 1‐methanesulfonyl‐6‐methylpiperidine‐2‐carboxylate cis-160, trans-160 and 
methyl 6‐methylpiperidine‐2‐carboxylate cis-142·HCl 
  
Table 2.2, Entry 1 
Using general procedure C, MsCl (0.06 mL, 0.77 mmol, 1.2 eq), piperidine cis-142 (100 mg, 
0.64 mmol, 1.0 eq) and pyridine (0.05 mL, 0.64 mmol, 1.0 eq) in CH2Cl2 (8.5 mL)
 at 0 °C 
for 1 h gave a 25:5:70 mixture (by 1H NMR spectroscopy) of sulfonamide piperidine cis-
160, sulfonamide piperidine trans-160 and piperidine cis-142·HCl. Purification by flash 
column chromatography on silica with 80:20 hexane-EtOAc followed by 85:15 CH2Cl2-
MeOH as eluent gave an 80:20 mixture (by 1H NMR spectroscopy) of sulfonamide 
piperidine cis-160 and trans-160 (40 mg, 26%) as a colourless oil, and piperidine cis-
142·HCl (63 mg, 50%) as a cream solid, mp 208-210 °C IR (ATR) 2980, 2698, 1749 (C=O), 
1224, 1047 cm‒1; 1H NMR (400 MHz, CDCl3) δ 3.98 (dd, J = 12.5, 3.0 Hz, 1H, NCHCO2), 
3.82 (s, 3H, OMe), 3.25-3.15 (m, 1H, NCHMe), 2.30-2.23 (m, 1H, CH), 1.97-1.87 (m, 2H, 
CH), 1.72-1.51 (m, 2H, CH), 1.42-1.26 (m, 1H, CH), 1.33 (d, J = 6.5 Hz, 3H, CHMe); 13C 
NMR (100.6 MHz, CDCl3) δ 170.4 (C=O), 58.5 (NCH), 54.4 (NCHMe), 53.7 (OMe), 30.9 
(CH2), 26.9 (CH2), 23.3 (CH2), 19.2 (CHMe); MS (ESI) m/z 158 (M
+); HRMS m/z calcd for 
C8H15NO2 (M
+) 158.1176, found 158.1179 (+0.2 ppm error). 
Lab Book - PJ-04-40. 
 
Table 2.2, Entry 2 
Using general procedure C, MsCl (0.06 mL, 0.77 mmol, 1.2 eq), piperidine cis-142 (100 mg, 
0.64 mmol, 1.0 eq) and pyridine (0.05 mL, 0.64 mmol, 1.0 eq) in CH2Cl2 (6.5 mL)
 at rt for 
24 h gave a 20:5:75 mixture (by 1H NMR spectroscopy) of sulfonamide piperidine cis-160, 
sulfonamide piperidine trans-160 and piperidine cis-142·HCl. Purification by flash column 
chromatography on silica with 80:20 hexane-EtOAc as eluent gave sulfonamide piperidine 
cis-160 (28 mg, 19%) as a colourless oil and a 55:45 mixture (by 1H NMR spectroscopy) of 
sulfonamide piperidines cis-160 and trans-160 (5 mg, 3%) as a colourless oil. 
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Lab Book - PJ-04-41. 
 
Table 2.2, Entry 3 
Using general procedure C, MsCl (0.03 mL, 0.38 mmol, 1.2 eq), piperidine cis-142 (50 mg, 
0.32 mmol, 1.0 eq) and pyridine (0.08 mL, 0.96 mmol, 3.0 eq) in CH2Cl2 (3.2 mL)
 at rt for 
24 h gave a 30:5:65 mixture (by 1H NMR spectroscopy) of sulfonamide piperidine cis-160, 
sulfonamide piperidine trans-160 and piperidine cis-142·HCl. Purification by flash column 
chromatography on silica with 80:20 hexane-EtOAc as eluent gave an 80:20 mixture (by 1H 
NMR spectroscopy) of sulfonamide piperidines cis-160 and trans-160 (28 mg, 37%) as a 
colourless oil. 
Lab Book - PJ-04-53. 
 
Table 2.2, Entry 4 
Using general procedure D, MsCl (0.03 mL, 0.38 mmol, 1.2 eq) and piperidine cis-142 (50 
mg, 0.32 mmol, 1.0 eq) in pyridine (3.2 mL) at rt for 24 h gave a 45:10:45 mixture (by 1H 
NMR spectroscopy) of sulfonamide piperidine cis-160, sulfonamide piperidine trans-160 
and piperidine cis-142·HCl. Purification by flash column chromatography on silica with 
80:20 hexane-EtOAc as eluent gave sulfonamide piperidine cis-160 (32 mg, 43%) as a 
colourless oil and an 80:20 mixture (by 1H NMR spectroscopy) of sulfonamides piperidines 
trans-160 and cis-160 (3 mg, 4%) as a colourless oil. 
Lab Book - PJ-04-54. 
 
Table 2.2, Entry 5 
Using general procedure D, MsCl (0.03 mL, 0.38 mmol, 1.2 eq) and piperidine cis-142 (50 
mg, 0.32 mmol, 1.0 eq) in pyridine (3.2 mL) at rt for 72 h gave a 60:5:35 mixture (by 1H 
NMR spectroscopy) of sulfonamide piperidine cis-160, sulfonamide piperidine trans-160 
and piperidine cis-142·HCl. Purification by flash column chromatography on silica with 
80:20 hexane-EtOAc as eluent gave sulfonamide piperidine cis-160 (45 mg, 60%) as a 
colourless oil and a 90:10 mixture (by 1H NMR spectroscopy) of sulfonamides piperidine 
trans-160 and sulfonamide piperidine cis-160 (3 mg, 4%) as a colourless oil. 
Lab Book - PJ-04-62. 
 
 
218 
 
Table 2.2, Entry 6 
Using general procedure D, MsCl (0.03 mL, 0.38 mmol, 1.2 eq) and piperidine cis-142 (50 
mg, 0.32 mmol, 1.0 eq) in pyridine (3.2 mL) at 60 °C for 16 h gave a 45:5:50 mixture (by 1H 
NMR spectroscopy) of sulfonamide piperidine cis-160, sulfonamide piperidine trans-160 
and piperidine cis-142·HCl. Purification by flash column chromatography on silica with 
80:20 hexane-EtOAc as eluent gave an 80:20 mixture (by 1H NMR spectroscopy) of 
sulfonamides piperidine cis-160 and sulfonamide piperidine trans-160 (28 mg, 38%) as a 
colourless oil. 
Lab Book - PJ-04-73. 
 
Table 2.2, Entry 7 
Using general procedure D, MsCl (0.03 mL, 0.38 mmol, 1.2 eq) and piperidine cis-142 (50 
mg, 0.32 mmol, 1.0 eq) in pyridine (3.2 mL) at 60 °C for 24 h gave a 50:5:45 mixture (by 1H 
NMR spectroscopy) of sulfonamide piperidine cis-160, sulfonamide piperidine trans-160 
and piperidine cis-142·HCl. Purification by flash column chromatography on silica with 
80:20 hexane-EtOAc as eluent gave a 90:10 mixture (by 1H NMR spectroscopy) of 
sulfonamide piperidine cis-160 and sulfonamide piperidine trans-160 (33 mg, 44%) as a 
colourless oil. 
Lab Book - PJ-04-74. 
 
Table 2.2, Entry 8 
Using general procedure D, MsCl (0.15 mL, 1.83 mmol, 1.2 eq) and piperidine cis-142 (240 
mg, 1.53 mmol, 1.0 eq) in pyridine (15 mL) at rt for 72 h gave a 55:5:40 mixture (by 1H 
NMR spectroscopy) of sulfonamide piperidine cis-160, sulfonamide piperidine trans-160 
and piperidine cis-142·HCl. Purification by flash column chromatography on silica with 
80:20 hexane-EtOAc as eluent gave sulfonamide piperidine cis-160 (187 mg, 52%) as a 
colourless oil. 
Lab Book - PJ-04-82. 
 
Table 2.2, Entry 9 
MsCl (0.04 mL, 0.40 mmol, 1.2 eq) was added dropwise to a stirred solution of piperidine 
cis-142 (54 mg, 0.34 mmol, 1.0 eq) and lutidine (0.12 mL, 1.02 mmol, 3.0 eq) in CH2Cl2 
(3.4 mL) at 0 °C under Ar. The resulting solution was stirred at 0 °C for 1 h then warmed to 
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rt and stirred at rt for 24 h. The reaction mixture was evaporated under reduced pressure to 
afford the crude product as a cream solid. Purification by flash column chromatography on 
silica with 80:20 hexane-EtOAc as eluent gave an 80:20 mixture (by 1H NMR spectroscopy) 
of sulfonamide piperidine cis-160 and sulfonamide piperidine trans-160 (23 mg, 28%) as a 
colourless oil. 
Lab Book - PJ-04-60. 
 
(1‐Methanesulfonyl‐6‐methylpiperidin‐2‐yl)methanol cis-84 
 
A solution of sulfonamide piperidine cis-160 (92 mg, 0.39 mmol, 1.0 eq) in THF (4 mL) was 
added dropwise to a stirred suspension of LiAlH4 (30 mg, 0.79 mmol, 2.0 eq) in THF (5 mL) 
at 0 °C under Ar. The resulting mixture was stirred at 0 °C for 2 h. Water (0.1 mL), 20% 
NaOH(aq) (0.2 mL) and water (0.1 mL) were added sequentially (CARE – vigorous reaction). 
Then, MgSO4 was added and the solids were removed by filtration. The filtrate was 
evaporated under reduced pressure to give the crude product as a green oil. Purification by 
flash column chromatography on silica with 95:5 CH2Cl2-acetone as eluent gave 
sulfonamide cis-84  (63 mg, 78%) as a white solid, mp 58-60 °C; RF (95:5 CH2Cl2-acetone) 
0.06; IR (ATR) 3505 (OH), 2941, 1305, 1138, 966, 766 cm‒1;  1H NMR (400 MHz, CDCl3) 
δ 4.21-4.13 (m, 1H, NCHMe), 4.03-3.98 (m, 1H, NCH), 3.79 (ddd, J = 11.0, 8.0, 5.5 Hz, 
1H, OCH), 3.66-3.59 (m, 1H, HOCH), 2.89 (s, 3H, SO2Me), 2.03 (dd, J = 8.0, 8.0 Hz, 1H, 
OH), 1.82-1.76 (m, 1H, CH), 1.73-1.51 (m, 5H, CH), 1.34 (d, J = 7.0 Hz, 3H, CHMe); 13C 
NMR (100.6 MHz, CDCl3) δ 64.6 (OCH2), 53.7 (NCH), 48.1 (NCHMe), 40.0 (SO2Me), 30.3 
(CH2), 25.4 (CH2), 22.2 (CHMe), 14.3 (CH2); MS (ESI) m/z 230 (M + Na)
+; HRMS m/z 
calcd for C8H17NO3S (M + Na)
+ 230.0821, found 230.0814 (+3.7 ppm error). 
Lab Book - PJ-03-60. 
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Methyl-1-acetyl-6-methylpiperidine-2-carboxylate cis-166 
 
AcCl (0.27 mL, 3.82 mmol, 3.0 eq) was added dropwise to a solution of piperidine cis-160 
(200 mg, 1.27 mmol, 1.0 eq) and Et3N (0.54 mL, 3.82 mmol, 3.0 eq) in CH2Cl2 (10 mL)
 at 
rt under Ar. The resulting solution was stirred at rt for 16 h. The solution was poured into 
water (10 mL) and the two layers were separated. The aqueous layer was extracted with 
CH2Cl2 (3 x 10 mL) and the combined organics were dried (MgSO4) and evaporated under 
reduced pressure to give the crude product as a yellow oil. Purification by flash column 
chromatography on silica with 5:5 hexane-EtOAc as eluent gave acetamide piperidine cis-
166 (188 mg, 85%) as a yellow oil, RF (1:1 hexane-EtOAc) 0.17; IR (ATR) 2943, 1732 
(C=O, CO2Me), 1636 (C=O, NCO), 1409, 1210, 1021, 613 cm
‒1; 1H NMR (400 MHz, 
DMSO d-6) (55:45 mixture of rotamers) δ 5.16-5.06 (m, 0.55H, CHCO2), 4.73-4.67 (m, 
0.45H, CHCO2), 4.64-4.56 (m, 0.45H, CHMe), 4.18-4.09 (m, 0.55H, CHMe), 3.64 (s, 1.35H, 
CO2Me), 3.59 (s, 1.65H, CO2Me), 2.21-2.11 (m, 1H, CH), 2.07 (s, 1.65H, COMe), 2.00 (s, 
1.35H, COMe), 1.65-1.42 (m, 5H, CH), 1.07 (d, J = 7.0 Hz, 1.65H, CHMe), 0.87 (d, J = 7.0 
Hz, 1.35H, CHMe); 13C NMR (100.6 MHz, DMSO d-6) (rotamers) δ 172.6 (C=O, CO2Me), 
172.5 (C=O, CO2Me), 170.3 (C=O, NCO), 169.6 (C=O, NCO), 53.5 (CHCO2), 52.2 (OMe), 
51.9 (OMe), 48.8 (CHCO2), 48.1 (CHMe), 43.1 (CHMe), 29.9 (CH2), 29.3 (CH2), 25.7 
(CH2), 25.4 (CH2), 21.9 (COMe), 21.3 (COMe), 18.8 (CHMe), 16.9 (CHMe), 15.2 (CH2); 
MS (ESI) m/z 222 (M + Na)+; HRMS m/z calcd for C10H17NO3 (M + Na)
+ 222.1101, found 
222.1105 (‒2.3 ppm error). 
Lab Book - PJ-05-63. 
 
1-Ethyl-6-methylpiperidin-2-yl)methanol cis-167 and trans-167 
 
A solution of piperidine cis-166 (75 mg, 0.48 mmol, 1.0 eq) in THF (2 mL) was added 
dropwise to a stirred suspension of LiAlH4 (36 mg, 0.95 mmol, 2.0 eq) in THF (2 mL) at 0 
°C under Ar. The resulting mixture was stirred at 0 °C for 2 h. Water (0.1 mL), 20% NaOH(aq) 
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(0.2 mL) and water (0.1 mL) were added sequentially (CARE – vigorous reaction). Then, 
MgSO4 was added and the solids were removed by filtration. The filtrate was evaporated 
under reduced pressure to give the crude product as a green oil. Purification by flash column 
chromatography on silica with 90:9:1 CH2Cl2-MeOH-NH4OH(aq) as eluent gave a 75:25 
mixture of piperidines cis-167 and trans-167 (39 mg, 53%) as a colourless oil, RF (90:9:1 
CH2Cl2-MeOH-NH4OH(aq)) 0.11; IR (ATR) 3302 (OH), 2926, 1454, 1377, 1032, 732 cm
‒1; 
1H NMR (400 MHz, CDCl3) cis-167 δ 3.78 (dd, J = 11.0, 4.0 Hz, 1H, OCH), 3.36 (dd, J = 
11.0, 2.5 Hz, 1H, OCH), 2.87-2.74 (m, 2H, NCH2CH3), 2.57-2.47 (m, 2H, CHMe and NCH), 
1.71-1.64 (m, 1H, CH), 1.63-1.51 (m, 3H, CH), 1.39-1.25 (m, 1H, CH), 1.24-1.14 (m, 1H, 
CH), 1.09 (d, J = 6.0 Hz, 3H, Me), 0.94 (t, J = 7.0 Hz, 3H, NCH2CH3); 
13C NMR (100.6 
MHz, CDCl3) δ 63.5 (OCH2), 59.5 (CHMe or NCH), 54.5 (CHMe or NCH), 41.7 
(NCH2CH3), 34.3 (CH2), 29.0 (CH2), 23.9 (CH2), 21.5 (CHMe), 9.41 (NCH2CH3); MS (ESI) 
m/z 158 (M + Na)+; HRMS m/z calcd for C9H19NO (M + H)
+ 158.1539, found 158.1540 (‒
1.5 ppm error). Diagnostic signal for trans-167: 1H NMR (400 MHz, CDCl3) δ 3.60 (ddd, J 
= 10.5, 4.0, 1.5 Hz, 1H, OCH) and 3.41 (dd, J = 10.5, 8.0 Hz, 1H, OCH). 
Lab Book - PJ-05-64. 
 
(6‐Methylpiperidin‐2‐yl)methanol cis-168 
 
A solution of piperidine cis-142 (800 mg, 5.1 mmol, 1.0 eq) in THF (20 mL) was added 
dropwise to a stirred suspension of LiAlH4 (380 mg, 10.0 mmol, 2.0 eq) in THF (53 mL) at 
0 °C under Ar. The resulting mixture was stirred at 0 °C for 2 h. Water (0.4 mL), 20% 
NaOH(aq) (0.8 mL) and water (0.4 mL) were added sequentially (CARE – vigorous reaction). 
Then, MgSO4 was added and the solids were removed by filtration. The filtrate was 
evaporated under reduced pressure to give the crude product as a green oil. Purification by 
flash column chromatography on silica with 90:9:1 CH2Cl2-MeOH-NH4OH(aq) as eluent 
gave alcohol cis-168 (490 mg, 76%) as a white solid, mp 62-64 °C; RF  (90:9:1 CH2Cl2-
MeOH-NH4OH(aq)) 0.03; IR (ATR) 3117 (OH or NH), 2927, 1488, 1061, 868 cm
‒1; 1H NMR 
(400 MHz, CDCl3) δ 3.62 (dd, J = 10.5, 4.0 Hz, 1H, OCH), 3.43 (dd, J = 10.5, 8.0 Hz, 1H, 
OCH), 2.77-2.62 (m, 2H, NCH), 2.30 (br s, 2H, OH and NH) 1.84-1.76 (m, 2H, CH), 1.67-
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1.59 (m, 1H, CH), 1.56-1.49 (m, 1H, CH), 1.38 (ddddd, J = 13.0, 13.0, 13.0, 4.0, 4.0 Hz, 1H,  
CH), 1.09 (d, J = 6.5 Hz, 3H, CHMe), 1.14-0.98 (m, 1H, CH); 13C NMR (100.6 MHz, CDCl3) 
δ 67.1 (OCH2), 58.3 (NCH), 52.1 (NCHMe), 34.4 (CH2), 28.1 (CH2), 24.5 (CH2), 23.1 
(CHMe); MS (ESI) m/z 130 (M + H)+; HRMS m/z calcd for C7H16NO (M + H)
+ 130.1226, 
found 130.1224 (+2.8 ppm error). Spectroscopic data for piperidines alcohol cis-168 
consistent with those reported in the literature.95 
Lab Book - PJ-03-72. 
 
 (6‐Methylpiperidin‐2‐yl)methanol cis-168 and 1‐[2‐(hydroxymethyl)‐6‐
methylpiperidin‐1‐yl]ethanone cis-85 
 
Table 2.3, Entry 1 
Ac2O (0.12 mL, 1.3 mmol, 6.0 eq) was added dropwise to a stirred solution of alcohol cis-
168 (28 mg, 0.21 mmol, 1.0 eq) in pyridine (2 mL) at rt under Ar. The resulting solution was 
stirred at rt for 16 h. The reaction mixture was evaporated under reduced pressure to give an 
orange oil. CH2Cl2 (20 mL) was added and the solution was washed with 15% CuSO4(aq) (3 
x 20 mL) and saturated EDTA(aq) (3 x 20 mL). The organic layers were dried (MgSO4) and 
evaporated under reduced pressure to give crude piperidine cis-169 (29 mg, 67%) as a 
colourless oil. K2CO3 (57 mg, 0.41 mmol, 3.0 eq) was added to a stirred solution of cis-169 
(29 mg, 0.14 mmol, 1.0 eq) in MeOH (1.4 mL) at rt under Ar. The resulting solution was 
stirred at rt for 2 h. The solution was poured into water (20 mL) and extracted with CH2Cl2 
(3 x 20 mL). The combined organics were dried (MgSO4) and evaporated under reduced 
pressure to give cis-168 (12 mg, 66%) as a white solid. 
Lab Book - PJ-03-19/22.  
 
Table 2.3, Entry 2 
Ac2O (0.08 mL, 0.93 mmol, 6.0 eq) was added dropwise to a stirred solution of piperidine 
cis-168 (20 mg, 0.16 mmol, 1.0 eq) in pyridine (1.6 mL) at rt under Ar. The resulting solution 
was stirred at rt for 16 h. The reaction mixture was evaporated under reduced pressure to 
give an orange oil. CH2Cl2 (20 mL) was added and the solution was washed with 15% 
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CuSO4(aq) (3 x 20 mL) and saturated EDTA(aq) (3 x 20 mL). The organic layer was dried 
(MgSO4) and evaporated under reduced pressure to give crude piperidine cis-169 (31 mg, 
92%) as a colourless oil. K2CO3 (62 mg, 0.45 mmol, 3.0 eq) was added to a stirred solution 
of cis-169 (31 mg, 0.15 mmol, 1.0 eq) in MeOH (1.5 mL) at rt under Ar. The resulting 
solution was stirred at rt for 30 min. The solution was poured into water (20 mL) and 
extracted with CH2Cl2 (3 x 20 mL). The combined organics were dried (MgSO4) and 
evaporated under reduced pressure to give the crude product as an orange oil. Purification 
by flash column chromatography on silica with 90:9:1 CH2Cl2-MeOH-NH4OH(aq) as eluent 
gave cis-169 (7 mg, 28%) as a colourless oil and cis-85 (2 mg, 12%) as a white solid. 
Lab Book - PJ-03-23/28. 
 
Table 2.3, Entry 3 
Ac2O (0.44 mL, 4.65 mmol, 6.0 eq) was added dropwise to a stirred solution of piperidine 
cis-168 (100 mg, 0.78 mmol, 1.0 eq) in pyridine (7.8 mL) at rt under Ar. The resulting 
solution was stirred at rt for 16 h. The reaction mixture was evaporated under reduced 
pressure to give an orange oil. CH2Cl2 (20 mL) was added and the solution was washed with 
15% CuSO4(aq) (3 x 80 mL) and saturated EDTA(aq) (3 x 20 mL). The organic layer was 
combined, dried (MgSO4) and evaporated under reduced pressure to give crude piperidine 
cis-169 (147 mg, 89%) as a colourless oil. K2CO3 (165 mg, 1.2 mmol, 3.0 eq) was added to 
a solution of cis-169 (85 mg, 0.4 mmol, 1.0 eq) in MeOH (4 mL) at rt under Ar. The resulting 
solution was stirred at rt for 30 min. The solution was poured into water (20 mL) and 
extracted with CH2Cl2 (3 x 20 mL). The combined organics were dried (MgSO4) and 
evaporated under reduced pressure to give the crude product as an orange oil. Purification 
by flash column chromatography on silica with 95:5 CH2Cl2-MeOH as eluent gave cis-85 
(39 mg, 60%) as a colourless oil, RF (95:5, CH2Cl2-MeOH) 0.21; IR (ATR) 3368 (OH), 2936, 
1606 (C=O), 1416, 1372, 1049, 1009, 616 cm‒1; 
1H NMR (400 MHz, CDCl3) (75:25 mixture 
of rotamers) δ 4.79-4.66 (m, 1H, NCH), 4.11-3.99 (m, 0.75H, NCHMe), 3.99-3.88 (m, 
0.25H, NCHMe), 3.72-3.59 (m, 2H, OCH), 3.06-2.92 (m, 0.75H, OH), 2.92-2.74 (m, 0.25H, 
OH), 2.13 (s, 3H, NCOMe), 1.84-1.77 (m, 1H, CH), 1.70-1.44 (m, 5H, CH), 1.24 (d, J = 7.0 
Hz, 2.25H, CHMe), 1.17–1.08 (m, 0.75H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 172.8 
(C=O), 66.1 (OCH2), 50.1 (NCH), 48.6 (NCHMe), 30.5 (CH2), 25.0 (CH2), 22.0 (COMe), 
21.2 (CHMe), 14.4 (CH2); MS (ESI) m/z 194 (M + Na)
+; HRMS m/z calcd for C9H17NO2 (M 
+ Na)+ 194.1151, found 194.1146 (+2.5 ppm error). 
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Lab Book - PJ-03-50/68. 
 
Methyl 3‐methylpiperidine‐2‐carboxylate cis-116 and trans-116 
 
Using general procedure B, PtO2 (150 mg, 0.099 mmol, 10 mol%) and methyl-3-
methylpicolinate (0.13 mL, 0.99 mmol, 1.0 eq) in AcOH (1.5 mL) gave the crude product 
which contained an 85:15 mixture (by 1H NMR spectroscopy) of piperidines cis-116 and 
trans-116 (150 mg, 97%) as a colourless oil, IR (ATR) 2929, 1741 (C=O), 1435, 1202 1005, 
758 cm‒1; 1H NMR (400 MHz, CDCl3) δ 3.72 (s, 0.45H, OMe), 3.71 (s, 2.55H, OMe), 3.52 
(d, J = 3.5 Hz, 0.85H, NCHCO2), 3.16-3.08 (m, 1H, NCH), 2.96 (d, J = 10.0 Hz, 0.15H, 
NCHCO2), 2.65-2.57 (m, 1H, NCH), 2.24-2.13 (m, 1H, CHMe), 1.68-1.57 (m, 3H, CH), 
1.39-1.32 (m, 1H, CH), 0.93 (d, J = 7.0 Hz, 2.55H, CHMe), 0.87 (d, J = 7.0 Hz, 0.45H, 
CHMe); 13C NMR (100.6 MHz, CDCl3) for cis-116:
 δ 173.6 (C=O), 62.2 (NCHCO2), 51.8 
(OMe), 46.1 (NCH2), 30.9 (CH2), 30.6 (CHMe), 21.2 (CH2), 13.6 (CHMe); for trans-116: 
66.5 (NCHCO2), 45.9 (CH2), 34.9 (CH), 33.1 (CH2), 26.7 (CH2), 19.0 (CHMe); MS (ESI) 
m/z 158 (M + H)+; HRMS m/z calcd for C8H15NO2 (M + H)
+ 158.1176, found 158.1177 (‒
1.3 ppm error). 
Lab Book - PJ-04-37. 
 
Methyl 1‐benzyl‐3‐methylpiperidine‐2‐carboxylate cis-123 and trans-123 
 
PhCHO (0.36 mL, 3.5 mmol, 1.1 eq) was added dropwise to a stirred solution of an 85:15 
mixture of piperidines cis-116 and trans-116 (500 mg, 3.18 mmol, 1.0 eq), NaBH(OAc)3 
(1.35 g, 6.37 mmol, 2.0 eq) and AcOH (0.03 mL, 0.64 mmol, 0.2 eq) in DCE (30 mL) at rt 
under Ar. The resulting mixture was stirred at rt for 18 h. The reaction mixture was poured 
into sat NaHCO3(aq) (100 mL) and extracted with CH2Cl2 (3 x 50 mL). The combined 
organics were washed with brine (100 mL), dried (MgSO4) and evaporated under reduced 
pressure to give the crude product as a green oil which contained a 90:10 mixture (by 1H 
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NMR spectroscopy) of piperidines cis-123 and trans-123. Purification by flash column 
chromatography on silica with 98:2 hexane-EtOAc as eluent gave N-benzyl piperidine cis-
123 (626 mg, 80%) as a yellow oil, RF (95:5 hexane-EtOAc) 0.23; IR (ATR) 2928, 1728 
(C=O), 1453, 1148, 697 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.32-7.29 (m, 4H, Ph), 7.25-
7.22 (m, 1H, Ph), 3.69 (s, 3H, OMe), 3.61 (d, J = 13.5 Hz, 1H, NCHPh), 3.56 (d, J = 13.5 
Hz, 1H, NCHPh), 3.45 (d, J = 5.0 Hz, 1H, NCHCO2), 3.00-2.92 (m, 1H, NCH), 2.54-2.45 
(m, 1H, NCH), 2.03-1.93 (m, 1H, CHMe), 1.71-1.64 (m, 1H, CH), 1.60-1.46 (m, 3H, CH), 
0.90 (d, J = 7.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3)
 δ 173.0 (C=O), 139.1 (ipso-
Ph), 128.9 (Ph), 128.3 (Ph), 127.1 (Ph), 66.2 (NCHCO2), 60.2 (NCH2Ph), 50.5 (OMe), 47.0 
(NCH2), 33.2 (CHMe), 27.8 (CH2), 25.2 (CH2), 18.2 (CHMe); MS (ESI) m/z 248 (M + H)
+; 
HRMS m/z calcd for C15H21NO2 (M + H)
+ 248.1645, found 248.1643 (‒0.7 ppm error) and 
piperidine trans-123 (82 mg, 10%) as a yellow oil, RF (95:5 hexane-EtOAc) 0.1; IR (ATR) 
2928, 1727 (C=O), 1453, 1147, 734, 697 cm‒1; 
1H NMR (400 MHz, CDCl3) δ 7.32-7.29 (m, 
4H, Ph), 7.26-7.22 (m, 1H, Ph), 3.76 (s, 3H, OMe), 3.71 (d, J = 13.5 Hz, 1H, NCHPh), 3.25 
(d, J = 13.5 Hz, 1H, NCHPh), 2.87 (ddd, J = 11.0, 5.5, 5.5 Hz, 1H, NCH), 2.64 (d, J = 9.0 
Hz, 1H, NCHCO2), 1.95-1.86 (m, 2H, CH), 1.76-1.68 (m, 1H, CH), 1.61-1.53 (m, 2H, CH), 
1.05-0.94 (m, 1H, CH), 0.90 (d, J = 7.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3)
 δ 
174.3 (C=O), 137.7 (ipso-Ph), 129.6 (Ph), 128.3 (Ph), 127.2 (Ph), 73.7 (NCHCO2), 61.2 
(NCH2Ph), 51.8 (OMe), 51.3 (NCH2), 34.4 (CHMe), 32.0 (CH2), 24.6 (CH2), 18.9 (CHMe); 
MS (ESI) m/z 248 (M + H)+; HRMS m/z calcd for C15H21NO2 (M + H)
+ 248.1645, found 
248.1641 (+1.3 ppm error). Spectroscopic data for N-benzyl piperidines cis-123 and trans-
123 consistent with those reported in the literature.79 
Lab Book - PJ-02-45. 
 
n-BuLi (0.75 mL of a 2.15 M solution in hexane, 1.62 mmol, 4.0 eq) was added dropwise to 
a stirred solution of diisopropylamine (0.36 mL, 1.62 mmol, 4.0 eq) in THF (1 mL) at 0 °C 
under Ar. The resulting solution was stirred at 0 °C for 30 min. The LDA solution was added 
dropwise to a stirred solution of cis-123 (100 mg, 0.404 mmol, 1.0 eq) in Et2O (20 mL) at –
20 °C under Ar. The resulting solution was allowed to warm to rt over 20 min and then 
stirred at rt for 20 min. The solution was cooled to 0 °C and a 2:1 solution of sat NH4Cl(aq)-
NH4OH(aq) (10 mL) was added. The resulting mixture was then allowed to warm to rt over 
30 min and stirred at rt for 18 h. The mixture was extracted with Et2O (3 x 20 mL). The 
combined organic extracts were washed with brine (50 mL), dried (MgSO4) and evaporated 
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under reduced pressure to give the crude product, which contained a 50:50 mixture (by 1H 
NMR spectroscopy) of piperidines cis-123 and trans-123. Purification by flash column 
chromatography on silica with 90:10 and then 50:50 hexane-Et2O as eluent gave piperidine 
cis-123 (31 mg, 31%) as a yellow oil and piperidine trans-123 (34 mg, 34%) as a yellow oil. 
Lab Book - PJ-02-48.  
 
Ethyl 1‐benzyl‐3‐methylpiperidine‐2‐carboxylate cis-172 and trans-172 
 
NaOEt (2.5 mL of a 13 M solution in EtOH, 32.5 mmol, 3.0 eq) was added dropwise to an 
85:15 mixture of piperidines cis-116 and trans-116 (1.7 g, 10.8 mmol, 1.0 eq) in EtOH (108 
mL) at rt under Ar.  The resulting solution was stirred and heated at reflux for 24 h. After 
being allowed to cool to rt, the solvent was evaporated under reduced pressure to give an 
orange oil. CH2Cl2 (100 mL) and water (100 mL) were added and the two layers were 
separated. The aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The combined organic 
layers were dried (MgSO4) and evaporated under reduced pressure to give the crude 
piperidines (1.04 g, 6.62 mmol assumed) as an orange oil which contained an 80:20 mixture 
(by 1H NMR spectroscopy) of piperidines trans-171 and cis-171. PhCHO (0.74 mL, 7.28 
mmol, 1.1 eq) was added dropwise to a stirred solution of the crude piperidines, 
NaBH(OAc)3 (2.8 g, 13.2 mmol, 2.0 eq) and AcOH (0.08 mL, 1.32 mmol, 0.2 eq) in DCE 
(66 mL) at rt under Ar. The resulting mixture was stirred at rt for 18 h. The reaction mixture 
was poured into sat NaHCO3(aq) (100 mL) and extracted with CH2Cl2 (3 x 50 mL). The 
combined organics were washed with brine (100 mL), dried (MgSO4) and evaporated under 
reduced pressure to give the crude product as an orange oil which contained a 75:25 mixture 
(by 1H NMR spectroscopy) of N-benzyl piperidines trans-172 and cis-172. Purification by 
flash column chromatography on silica with 9:1 hexane-EtOAc as eluent gave N-benzyl 
piperidine trans-172 (975 mg, 36%) as a yellow oil, RF (9:1 hexane-EtOAc) 0.18; IR (ATR) 
2927, 1730 (C=O), 1453, 1176, 697 cm‒1; 
1H NMR (400 MHz, CDCl3) δ 7.34-7.27 (m, 4H, 
Ph), 7.26-7.21 (m, 1H, Ph), 4.25 (q, J = 7.0 Hz, 2H, OCH), 3.73 (d, J = 13.5 Hz, 1H, NCHPh), 
3.24 (d, J = 13.5 Hz, 1H, NCHPh), 2.89-2.83 (m, 1H, NCH), 2.61 (d, J = 9.0 Hz, 1H, 
NCHCO2), 1.96-1.85 (m, 2H, CH), 1.76-1.68 (m, 1H, CH), 1.60-1.53 (m, 2H, CH), 1.31 (t, 
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J = 7.0 Hz, 3H, OCH2Me), 1.05-0.94 (m, 1H, CH), 0.91 (d, J = 6.5 Hz, 3H, CHMe); 
13C 
NMR (100.6 MHz, CDCl3) δ 173.8 (C=O), 137.9 (ipso-Ph), 129.6 (Ph), 128.2 (Ph), 127.2 
(Ph), 73.8 (NCHCO2), 61.0 (OCH2Me), 60.6 (NCH2Ph), 51.3 (CH2), 34.3 (CHMe), 32.1 
(CH2), 24.6 (CH2), 18.8 (CHMe), 14.5 (OCH2Me); MS (ESI) m/z 262 (M + H)
+; HRMS m/z 
calcd for C16H23NO2 (M + H)
+ 262.1802, found 262.1804 (‒0.5 ppm error) and an 85:15 
mixture of piperidines cis-172 and benzaldehyde (320 mg). This mixture was purified by 
flash column chromatography on silica with 9:1 to 10:0 n-hexane-CH2Cl2 as eluent to give 
N-benzyl piperidine cis-172 (268 mg, 10%) as a yellow oil, RF (9:1 hexane-CH2Cl2) 0.04; 
IR (ATR) 2929, 1725 (C=O), 1146, 1026, 697 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.36-
7.27 (m, 4H, Ph), 7.25-7.20 (m, 1H, Ph), 4.18 (q, J = 7.0 Hz, 2H, OCH), 3.63 (d, J = 13.5 
Hz, 1H, CHPh), 3.58 (d, J = 13.5 Hz, 1H, CHPh), 3.42 (d, J = 5.0 Hz, 1H, NCHCO2), 3.03-
2.93 (m, 1H, NCH), 2.53-2.46 (m, 1H, NCH), 2.05-1.92 (m, 1H, CHMe), 1.73-1.63 (m, 1H, 
CH), 1.61-1.44 (m, 3H, CH), 1.29 (t, J = 7.0 Hz, 3H, OCH2Me), 0.91 (d, J = 7.0 Hz, 3H, 
CHMe); 13C NMR (100.6 MHz, CDCl3) δ 172.5 (C=O), 139.2 (ipso-Ph), 128.9 (Ph), 128.3 
(Ph), 127.0 (Ph), 66.2 (NCHCO2), 60.1 (CH2Ph), 59.5 (OCH2Me), 47.1 (NCH2), 33.2 
(CHMe), 27.9 (CH2), 25.2 (CH2), 18.2 (CHMe), 14.7 (OCH2Me); MS (ESI) m/z 262 (M + 
H)+; HRMS m/z calcd for C16H23NO2 (M + H)
+ 262.1802, found 262.1797 (‒2.7 ppm error). 
Lab Book - PJ-02-83/85. 
 
Ethyl 3‐methylpiperidine‐2‐carboxylate trans-171 
 
A suspension of 20% Pd(OH)2/C (106 mg, 0.12 mmol, 10 mol%) in EtOH (10 mL) was 
added to a stirred solution of N-benzyl piperidine trans-172 (395 mg, 1.51 mmol, 1.0 eq) 
and NH4
+HCO2
‒ (1.91 g, 30.3 mmol, 20.0 eq) in EtOH (13 mL) at rt under Ar. The resulting 
suspension was stirred and heated at reflux for 16 h. After being allowed to cool to rt, the 
solids were removed by filtration through Celite and washed with EtOH (40 mL). The filtrate 
was evaporated under reduced pressure to give piperidine trans-171 (159 mg, 62%) as a 
colourless oil, RF (9:1 CH2Cl2-MeOH) 0.23; IR (ATR) 2926, 1731 (C=O), 1187, 1031, 733 
cm‒1; 1H NMR (400 MHz, CDCl3) δ 4.17 (q, J = 7.0 Hz, 2H, OCH2Me), 3.11-3.04 (m, 1H, 
NCH), 2.93 (d, J = 10.0 Hz, 1H, NCHCO2), 2.55 (ddd, J = 12.0, 12.0, 4.0 Hz, 1H, NCH), 
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1.84-1.77 (m, 1H, CH), 1.66-1.54 (m, 2H, CH), 1.45 (ddddd, J = 12.0, 12.0, 12.0, 4.0, 4.0 
Hz 1H, CH), 1.26 (t, J = 7.0 Hz, 3H, OCH2Me), 1.14 (dddd, J = 12.0, 12.0, 12.0, 4.0 Hz,  
1H, CH), 0.87 (d, J = 6.5 Hz, 1H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 173.5 (C=O), 
66.6 (NCHCO2), 60.7 (OCH2Me), 45.9 (NCH2), 34.9 (CHMe), 33.2 (CH2), 26.8 (CH2), 19.0 
(CHMe), 14.4 (OCH2Me); MS (ESI) m/z 172 (M + H)
+; HRMS m/z calcd for C9H17NO2 (M 
+ H)+ 172.1332, found 172.1336 (+2.3 ppm error). 
Lab Book - PJ-03-09. 
 
Ethyl 1‐methanesulfonyl‐3‐methylpiperidine‐2‐carboxylate trans-173 
  
MsCl (0.07 mL, 0.96 mmol, 3.3 eq) was added dropwise to a stirred solution of piperidine 
trans-171 (50 mg, 0.29 mmol, 1.0 eq) and Et3N (0.13 mL, 0.96 mmol, 3.3 eq) in CH2Cl2 (5 
mL) at rt under Ar. The resulting solution was stirred at rt for 16 h. The solution was poured 
into water (50 mL) and the two layers were separated. The aqueous layer was extracted with 
CH2Cl2 (3 x 20 mL) and the combined organics were dried (MgSO4) and evaporated under 
reduced pressure to give the crude product as a yellow oil. Purification by flash column 
chromatography on silica with 9:1 hexane-EtOAc as eluent gave sulfonamide piperidine 
trans-173 (62 mg, 86%) as a yellow oil, RF (9:1 hexane-EtOAc) 0.2; IR (ATR) 2938, 1731 
(C=O), 1320, 1139, 768 cm‒1; 
1H NMR (400 MHz, CDCl3) δ 4.38 (br s, 1H, NCHCO2), 4.25-
4.17 (m, 2H, OCH2Me), 3.72-3.68 (m, 1H, NCH), 3.19 (ddd, J = 12.0, 12.0, 3.0 Hz, 1H, 
NCH), 2.93 (s, 3H, SO2Me), 2.58-2.50 (m, 1H, CHMe), 1.89-1.77 (m, 1H, CH), 1.53-1.50 
(m, 1H, CH), 1.49-1.46 (m, 1H, CH), 1.46-1.41 (m, 1H, CH), 1.30 (t, J = 7.0 Hz, 3H, 
OCH2Me), 1.20 (d, J = 7.0 Hz, 3H, CHMe); 
13C NMR (100.6 MHz, CDCl3) δ 171.5 (C=O), 
61.6 (OCH2Me), 61.1 (NCHCO2), 42.5 (NCH2), 38.9 (SO2Me), 29.7 (CHMe), 26.3 (CH2), 
19.2 (CH2), 17.2 (OCH2Me), 14.4 (CHMe); MS (ESI) m/z 250 (M + H)
+; HRMS m/z calcd 
for C10H19NO4S (M + H)
+ 250.1108, found 250.1114 (+2.7 ppm error). 
Lab Book - PJ-03-14. 
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(1‐Methanesulfonyl‐3‐methylpiperidin‐2‐yl)methanol trans-95 
 
A solution of sulfonamide piperidine trans-173 (148 mg, 0.59 mmol, 1.0 eq) in THF (5 mL) 
was added dropwise to a stirred suspension of LiAlH4 (45 mg, 1.18 mmol, 2.0 eq) in THF 
(5 mL) at 0 °C under Ar. The resulting mixture was stirred at 0 °C for 2 h. Water (0.1 mL), 
20% NaOH(aq) (0.2 mL) and water (0.1 mL) were added sequentially (CARE – vigorous 
reaction). Then, MgSO4 was added and the solids were removed by filtration. The filtrate 
was evaporated under reduced pressure to give crude product as a yellow oil. Purification by 
flash column chromatography on silica with 95:5 CH2Cl2-MeOH as eluent gave fragment 95 
(100 mg, 82%) as a white solid, mp 40-42 °C; RF (95:5 CH2Cl2-MeOH) 0.2 ; IR (ATR) 3500 
(OH), 2933, 1307, 1133, 766 cm‒1; 1H NMR (400 MHz, CDCl3) δ 3.94 (ddd, J = 11.0, 9.5, 
6.0 Hz, 1H, NCH), 3.78-3.72 (m, 1H, NCH), 3.67-3.59 (m, 2H, OCH), 3.08-2.99 (ddd, J = 
12.0, 12.0, 4.0 Hz, 1H, NCH), 2.97 (s, 3H, SO2Me), 2.00-1.94 (m, 1H, OH), 1.90-1.82 (m, 
1H, CHMe), 1.82-1.72 (m, 1H, CH), 1.69-1.66 (m, 2H, CH), 1.49-1.38 (m, 2H, CH), 1.13 
(d, J = 7.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 61.6 (OCH2), 61.1 (NCH), 
40.7 (NCH2), 40.0 (SO2Me), 28.1 (CHMe), 25.7 (CH2), 20.1 (CH2), 18.5 (CHMe); MS (ESI) 
m/z 230 (M + Na)+; HRMS m/z calcd for C8H17NO3S (M + Na)
+ 230.0821, found 230.0822 
(0.0 ppm error). 
Lab Book - PJ-03-34. 
 
Methyl 1‐benzyl‐3‐methylpiperidine‐2‐carboxylate cis-123 and trans-123 
 
 
A solution of an 85:15 mixture of piperidines cis-116 and trans-116 (442 mg, 2.8 mmol, 1.0 
eq) in MeOH (10 mL) was added dropwise to a stirred solution of NaOMe (152 mg, 2.8 
mmol, 1.2 eq) in MeOH (20 mL) at rt under Ar.  The resulting solution was stirred and heated 
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at reflux for 64 h.  After being allowed to cool to rt, 1 M HCl(aq) was added until pH 7 was 
reached. The solids were removed by filtration through Celite and washed with CH2Cl2 (50 
mL). The filtrate was evaporated under reduced pressure to give the crude product as a white 
solid. MeOH (20 mL) was added and the solids were removed by filtration and washed with 
CH2Cl2 (50 mL). The filtrate was evaporated under reduced pressure to give the crude 
piperidines as a white solid which contained a 75:25 mixture (by 1H NMR spectroscopy) of 
piperidines trans-116 and cis-116. PhCHO (0.31 mL, 3.08 mmol, 1.1 eq) was added 
dropwise to a stirred solution of the crude piperidines, NaBH(OAc)3 (1.19 g, 5.6 mmol, 2.0 
eq) and AcOH (0.03 mL, 0.56 mmol, 0.2 eq) in DCE (21 mL) at rt under Ar. The resulting 
mixture was stirred at rt for 18 h. The reaction mixture was poured into sat NaHCO3(aq) (100 
mL) and extracted with CH2Cl2 (3 x 50 mL). The combined organics were washed with brine 
(100 mL), dried (MgSO4) and evaporated under reduced pressure to give the crude product 
as a green oil which contained a 70:30 mixture (by 1H NMR spectroscopy) of N-benzyl 
piperidines trans-123 and cis-123. Purification by flash column chromatography on silica 
with 95:5 hexane-EtOAc as eluent gave N-benzyl piperidine cis-123 (43 mg, 6%) as a yellow 
oil and N-benzyl piperidine trans-123 (265 mg, 38%) as a yellow oil. 
Lab Book - PJ-02-71/73. 
 
(1‐Benzyl‐3‐methylpiperidin‐2‐yl)methanol trans-170 
 
A solution of N –benzyl piperidine trans-123 (370 mg, 1.5 mmol, 1.0 eq) in THF (5 mL) was 
added dropwise to a suspension of LiAlH4 (114 mg, 3.0 mmol, 2.0 eq) in THF (20 mL) at 0 
°C under Ar. The reaction mixture was stirred at 0 °C for 2 h. Water (0.1 mL), 20% NaOH(aq) 
(0.2 mL) and water (0.1 mL) were added sequentially (CARE – vigorous reaction). Then, 
MgSO4 was added and the solids were removed by filtration. The filtrate was evaporated 
under reduced pressure to give alcohol trans-170 (330 mg, 100%) as a colourless oil, IR 
(ATR) 3401 (OH), 2926, 1452, 1061, 697 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.33-7.21 
(m, 5H, Ph), 4.09 (d, J = 13.5 Hz, 1H, NCHPh), 3.94 (dd, J = 11.5, 3.5 Hz, 1H, OCH), 3.69 
(dd, J = 11.5, 2.0 Hz, 1H, OCH), 3.23 (d, J = 13.5 Hz, 1H, NCHPh), 2.91 (br s, 1H, OH), 
2.86 (dddd, J = 12.0, 4.0, 4.0, 2.0 Hz, 1H, NCH), 2.11 (ddd, J = 11.5, 11.5, 4.0 Hz, 1H, 
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NCH), 2.05 (ddd, J = 9.0, 3.0, 3.0 Hz, 1H, NCH), 1.85-1.70 (m, 2H, CH), 1.52-1.45 (m, 2H, 
CH), 1.11-1.00 (m, 1H, CH), 0.97 (d, J = 6.5 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) 
δ 139.1 (ipso-Ph), 128.9 (Ph), 128.5 (Ph), 127.1 (Ph), 68.2 (NCH), 58.8 (OCH2), 57.1 
(NCH2Ph), 52.0 (NCH2), 33.2 (CH2), 30.5 (CHMe), 24.1 (CH2), 20.0 (CHMe); MS (ESI) 
m/z 220 (M + H)+; HRMS m/z calcd for C14H21NO (M + H)
+ 220.1696, found 220.1691 
(+2.5 ppm error). 
Lab Book - PJ-03-79. 
 
(3‐Methylpiperidin‐2‐yl)methanol trans-174 
 
20% Pd(OH)2/C (124 mg, 0.18 mmol, 10 mol%) was added to a stirred solution of trans-170 
(389 mg, 1.78 mmol, 1.0 eq) and NH4
+HCO2
‒ (2.24 g, 35.6 mmol, 20.0 eq) in EtOH (35.6 
mL) at rt under Ar. The resulting suspension was stirred and heated at reflux for 16 h. After 
being allowed to cool to rt, the solids were removed by filtration through Celite. The filtrate 
was evaporated under reduced pressure to give alcohol trans-174 (172 mg, 73%) as an 
orange oil, IR (ATR) 3314 (OH), 2924, 1455, 1055, 829, 578 cm‒1; 1H NMR (400 MHz, 
CDCl3) δ 3.75 (dd, J = 11.0, 3.0 Hz, 1H, OCH), 3.44 (dd, J = 11.0, 8.0 Hz, 1H, OCH), 3.07 
(dddd, J = 12.0, 4.0, 2.0, 2.0 Hz, 1H, NCH), 2.87 (br s, 2H, OH and NH), 2.56 (ddd, J = 
12.0, 12.0, 3.0 Hz, 1H, NCH), 2.25 (ddd, J = 10.0, 8.0, 3.0 Hz, 1H, NHCH), 1.77-1.68 (m, 
1H, CH), 1.66-1.58 (m, 1H, CH), 1.52-1.37 (m, 1H, CH), 1.37-1.25 (m, 1H, CHMe), 1.12-
1.00 (m, 1H, CH), 0.85 (d, J = 7.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 64.1 
(NCH), 63.9 (OCH2), 46.5 (NCH2), 33.9 (CH2), 33.2 (CHMe), 26.7 (CH2), 18.6 (CHMe); 
MS (ESI) m/z 130 (M + H)+; HRMS m/z calcd for C7H15NO (M + H)
+ 130.1226, found 
130.1233 (‒4.9 ppm error). 
Lab Book - PJ-03-06. 
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1‐[2‐(Hydroxymethyl)‐3‐methylpiperidin‐1‐yl]ethanone trans-96 
 
Ac2O (0.48 mL, 5.12 mmol, 6.0 eq) was added dropwise to a stirred solution of alcohol 
trans-174 (100 mg, 0.85 mmol, 1.0 eq) and DMAP (95 mg, 0.85 mmol, 1.0 eq) in pyridine 
(8.5 mL) at rt under Ar. The resulting solution was stirred at rt for 16 h. The reaction mixture 
was evaporated under reduced pressure to give an orange oil. The crude product was 
dissolved in CH2Cl2 (50 mL) and washed with 15% CuSO4(aq) (3 x 40 mL). The combined 
organics were washed with sat EDTA(aq) (2 x 50 mL), dried (MgSO4) and evaporated under 
reduced pressure to give the crude product as a yellow oil. K2CO3 (352 mg, 2.60 mmol, 3.0 
eq) was added to the crude product in MeOH (8.5 mL). The resulting solution was stirred at 
rt for 16 h. The solution was poured into water (100 mL) and the two layers were separated. 
The aqueous layer was extracted with CH2Cl2 (7 x 30 mL) and the combined organics were 
dried (MgSO4) and evaporated under reduced pressure to give 96 (106 mg, 71%) as a yellow 
oil, IR (ATR) 3256 (OH), 2918, 1624 (C=O), 1440, 1076, 522 cm‒1; 1H NMR (400 MHz, 
CDCl3) (55:45 mixture of rotamers) δ 4.57-4.48 (m, 0.45H, CH), 4.33 (ddd, J = 9.0, 4.5, 4.5 
Hz, 0.55H, CH), 4.02 (dd, J = 11.5, 10.0 Hz, 0.45H, CH), 3.80-3.66 (m, 1.55H, CH), 3.61-
3.55 (m, 0.45H, CH), 3.56-3.52 (m, 0.45H, CH), 3.27-3.17 (m, 0.55H, CH), 2.66-2.56 (m, 
0.55H, NH), 2.13 (s, 1.55H, NCOMe), 2.13 (s, 1.45H, NCOMe), 1.91-1.81 (m, 1H, CHMe), 
1.76-1.61 (m, 2H, CH), 1.54-1.46 (m, 0.55H, CH), 1.45-1.33 (m, 1.45H, CH), 1.07 (d, J = 
7.0 Hz, 1.35H, CHMe), 1.02 (d, J = 7.0 Hz, 1.65H, CHMe); 13C NMR (100.6 MHz, CDCl3) 
δ 172.3 (C=O, COMe), 171.7 (C=O, COMe), 62.6 (OCH2), 61.9 (NCH), 61.5 (OCH), 58.3 
(NCH), 42.8 (NCH2), 36.5 (NCH2), 28.5 (CHMe), 28.2 (CHMe), 26.7 (CH2), 25.9 (CH2), 
22.2 (NCOMe), 22.0 (NCOMe), 21.1 (CH2), 19.6 (CH2), 18.8 (CHMe), 18.3 (CHMe); MS 
(ESI) m/z 194 (M + Na)+; HRMS m/z calcd for C9H17NO2 (M + Na)
+ 194.1151, found 
194.1146 (+2.7 ppm error). 
Lab Book - PJ-03-81/86. 
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Methyl-1-benzyl-6-methylpiperidine-2-carboxylate cis-191 
 
BnBr (0.23 mL, 1.91 mmol, 3.0 eq) was added dropwise to a stirred solution of a 95:5 
mixture of piperidines cis-142 and trans-142 (100 mg, 0.64 mmol, 1.0 eq) in sat Na2CO3(aq) 
(2 mL) and CH2Cl2 (2 mL) at rt under Ar. The resulting solution was stirred at rt for 16 h. 
The two layers were separated, and the aqueous layer was extracted with CH2Cl2 (3 x 10 
mL). The combined organics were dried (MgSO4) and evaporated under reduced pressure to 
give the crude product as a colourless oil. Purification by flash column chromatography on 
silica with 80:20 hexane-EtOAc as eluent gave N-benzyl piperidine cis-191 (139 mg, 88%) 
as a yellow oil, RF (95:5 hexane-EtOAc) 0.04; IR (ATR) 2932, 1747 (C=O), 1453, 1163, 
729, 696 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.36-7.27 (m, 4H, Ph), 7.24-7.19 (m, 1H, Ph), 
3.84 (d, J = 15.5 Hz, 1H, CHPh), 3.73 (d, J = 15.5 Hz, 1H, CHPh), 3.60 (s, 3H, OMe), 3.17 
(dd, J = 10.5, 3.5 Hz, 1H, CHCO2), 2.41 (dqd, J = 13.0, 6.0, 3.0 Hz, 1H, CHMe), 1.85-1.78 
(m, 1H, CH), 1.76-1.66 (m, 2H, CH), 1.64-1.56 (m, 1H, CH), 1.46-1.35 (m, 1H, CH), 1.29 
(dddd, J = 13.0, 8.0, 2.0, 2.0 Hz, 1H, CH), 1.14 (d, J = 6.0 Hz, 3H, CHMe); 13C NMR (100.6 
MHz, CDCl3) δ 174.9 (CO2Me), 138.5 (ipso-Ph), 129.2 (Ph), 128.1 (Ph), 126.9 (Ph), 66.0 
(NCHCO2), 56.4 (CH2Ph), 55.7 (NCHMe), 51.8 (OMe), 34.2 (CH2), 30.3 (CH2), 23.2 (CH2), 
21.4 (CHMe); MS (ESI) m/z 248 (M + H)+; HRMS m/z calcd for C15H21NO2 (M + H)
+ 
248.1645, found 248.1648 (‒1.5 ppm error). 
Lab Book - PJ-05-91. 
 
Methyl 2‐methylpyridine‐3‐carboxylate 192 
 
 
SOCl2 (0.77 mL, 10.60 mmol, 3.0 eq) was added dropwise to a stirred solution of 2-methyl-
nicotinic acid (485 mg, 3.54 mmol, 1.0 eq) in MeOH (20 mL) at 0 °C under Ar. The reaction 
mixture was warmed to rt, stirred and heat at reflux for 16 h. Then, the solvent was 
evaporated under reduced pressure to give the crude product as an orange oil. The reaction 
mixture was poured into sat NaHCO3(aq) (10 mL) and extracted with CH2Cl2 (5 x 10 mL). 
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The combined organic layers were, dried (Na2SO4) and evaporated under reduced pressure 
to give pyridine 192 (443 mg, 82%) as an orange oil, IR (ATR) 1722 (C=O), 1571, 1433, 
1278, 1084, 754 cm‒1; 1H NMR (400 MHz, CDCl3) δ 8.61 (dd, J = 5.0, 2.0 Hz, 1H, Ar), 8.19 
(dd, J = 8.0, 2.0 Hz, 1H, Ar), 7.21 (dd, J = 8.0, 5.0 Hz, 1H, Ar), 3.92 (s, 3H, OMe), 2.83 (s, 
3H, Me); 13C NMR (100.6 MHz, CDCl3) δ 167.1 (C=O), 160.1 (ipso-Ar), 152.0 (Ar), 138.6 
(Ar), 125.5 (ipso-Ar), 121.0 (Ar), 52.4 (OMe), 25.0 (Me); MS (ESI) m/z 152 (M + H)+; 
HRMS m/z calcd for C8H10NO2 (M + H)
+ 152.0706, found 152.0703 (+1.8 ppm error). 
Spectroscopic data for piperidines 192 consistent with those reported in the literature.150 
Lab Book - PJ-05-50. 
 
Methyl 2‐methylpiperidine‐3‐carboxylate cis-193 and trans-193 
 
 
 
Using general procedure B, PtO2 (10 mg, 0.05 mmol, 10 mol%) and pyridine 192 (70 mg, 
0.45 mmol, 1.0 eq) in AcOH (5 mL) gave the crude product which contained a 90:10 mixture 
of piperidines cis-193 and trans-193 (65 mg, 93%) as a yellow oil, 1H NMR (400 MHz, 
CDCl3) δ 3.68 (s, 3H, OMe), 3.10-3.03 (m, 1H, NCH), 2.96 (qd, J = 7.0, 3.5 Hz, 1H, CHMe), 
2.66 (ddd, J = 13.5, 10.0, 3.5 Hz, 1H, NCH), 2.56-2.51 (m, 1H, CHCO2), 2.02-1.94 (m, 1H, 
CH), 1.80-1.71 (m, 1H, CH), 1.71-1.60 (m, 2H, CH and NH), 1.42-1.33 (m, 1H, CH), 1.11 
(d, J = 7.0 Hz, 2.7H, CHMe), 1.06 (d, J = 6.0 Hz, 0.3H); 13C NMR (100.6 MHz, CDCl3) cis 
δ 174.8 (C=O), 52.4 (CHMe), 51.3 (OMe), 45.3 (NCH2), 44.1 (CHCO2), 26.4 (CH2), 22.8 
(CH2), 19.2 (CHMe). Spectroscopic data for piperidines cis-193 and trans-193 consistent 
with those reported in the literature.151  
Lab Book - PJ-05-51. 
 
Methyl 1‐benzyl‐2‐methylpiperidine‐3‐carboxylate cis-194 
 
 
 
BnBr (0.14 mL, 1.20 mmol, 3 eq) was added dropwise to a 90:10 solution of piperidine cis-
193 and trans-193 (63 mg, 0.40 mmol, 1.0 eq) in 1:1 CH2Cl2-sat Na2CO3(aq) (4 mL)
 at rt 
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under Ar. The resulting solution was stirred at rt for 16 h. The two layers were separated, 
and the aqueous layer was extracted with CH2Cl2 (4 x 10 mL). The combined organics were 
dried (MgSO4) and evaporated under reduced pressure to give the crude product as a 
colourless oil. Purification by flash column chromatography on silica with 80:20 hexane-
EtOAc as eluent gave N-benzyl piperidine cis-194 (63 mg, 64%) as a colourless oil, RF (80:20 
hexane-EtOAc) 0.13; IR (ATR) 2943, 1732, 1138, 732, 697 cm‒1; 1H NMR (400 MHz, 
CDCl3) δ 7.36-7.28 (m, 4H, Ph), 7.26-7.21 (m, 1H, Ph), 3.66 (d, J = 13.5 Hz, 1H, NCHPh), 
3.65 (s, 3H, OMe), 3.54 (d, J = 13.5 Hz, 1H, NCHPh), 3.42 (qd, J = 6.5, 5.0 Hz, 1H, 
NCHMe), 2.84 (ddd, J = 12.5, 5.0, 5.0 Hz, 1H, CHCO2), 2.48-2.37 (m, 2H, NCH), 1.82-1.73 
(m, 1H, CH), 1.73-1.58 (m, 2H, CH), 1.56-1.45 (m, 1H, CH), 0.91 (d, J = 6.5 Hz, 3H, 
CHMe); 13C NMR (100.6 MHz, CDCl3) δ 174.7 (C=O), 139.8 (ipso-Ph), 128.6 (Ph), 128.4 
(Ph), 126.9 (Ph), 59.3 (NCH2Ph), 54.1 (NCHMe), 51.6 (OMe), 46.1 (CHCO2), 44.6 (NCH2), 
24.5 (CH2), 20.7 (CH2), 6.2 (CHMe); MS (ESI) m/z 248 (M + H)
+; HRMS m/z calcd for 
C15H21NO2 (M + H)
+ 248.1645, found 248.1652 (˗2.0 ppm error). 
Lab Book - PJ-05-53.  
 
Methyl 4‐methylpiperidine‐3‐carboxylate cis-196 and trans-196 
 
 
 
Table 3.1, Entry 3 
Using general procedure B, PtO2 (45 mg, 0.20 mmol, 30 mol%) and methyl-4-
methylnicotinate (100 mg, 0.66 mmol, 1.0 eq) in AcOH (1 mL) gave the crude product which 
contained a 65:35 mixture (by 1H NMR spectroscopy) of piperidines cis-196 and trans-196 
(93 mg, 90%) as a yellow oil, IR (ATR) 3314 (NH), 2952, 1726 (C=O), 1435, 1197, 1139, 
754 cm‒1; 1H NMR (400 MHz, CDCl3) δ 3.66 (s, 3H, OMe), 3.20-3.10 (m, 1H, NCH), 3.07-
2.96 (m, 1H, NCH), 2.86-2.79 (m, 0.65H, NCH), 2.69-2.57 (m, 1.65H, CH), 2.55-2.50 (m, 
0.65H, CH), 2.15 (br m, 1H, NH), 2.12-2.04 (m, 0.35H, CH), 2.04-1.93 (m, 0.65H, CH), 
1.83-1.72 (m, 0.35H, CH), 1.66 (dddd, J = 7.0, 7.0, 5.0, 2.0, Hz, 0.35H, CH), 1.59-1.46 (m, 
1H, CH), 1.16-1.03 (m, 0.35H, CH), 0.94 (d, J = 7.0 Hz, 1.95H, CHMe), 0.90 (d, J = 6.5 Hz, 
1.05H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 174.9 (C=O), 174.7 (C=O), 51.6 (OMe), 
51.3 (OMe), 49.1 (NCH2), 46.6 (NCH2), 46.3 (NCH2), 45.4 (NCH2), 44.7 (CHCO2), 34.4 
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(CH2), 33.4 (CHMe), 31.5 (CHMe), 31.2 (CH2), 20.6 (CHMe), 18.2 (CHMe); MS (ESI) m/z 
158 (M + H)+; HRMS m/z calcd for C8H16NO2 (M + H)
+ 158.11776, found 158.1173 (+1.9 
ppm error). Spectroscopic data for piperidines cis-196 and trans-196 consistent with those 
reported in the literature.152  
Lab Book - PJ-04-43. 
 
Table 3.1, Entry 1 
Using general procedure B, PtO2 (30 mg, 0.13 mmol, 10 mol%) and methyl-4-
methylnicotinate (200 mg, 1.32 mmol, 1.0 eq) in AcOH (2 mL) after 136 h, gave the crude 
product which contained a 30:50:20 mixture (by 1H NMR spectroscopy) of methyl-4-
methylnicotinate, piperidine cis-196 and trans-196 as an orange oil.  
Lab Book - PJ-05-07. 
 
Table 3.1, Entry 2 
Using general procedure B, PtO2 (30 mg, 0.13 mmol, 20 mol%) and methyl-4-
methylnicotinate (100 mg, 0.66 mmol, 1.0 eq) in AcOH (5 mL) gave the crude product which 
contained a 40:40:20 mixture (by 1H NMR spectroscopy) of methyl-4-methylnicotinate 
piperidine cis-196 and trans-196 as a yellow oil.  
Lab Book - PJ-05-29. 
 
Methyl 3‐methylpyridine‐4‐carboxylate 197 
 
 
 
SOCl2 (0.23 mL, 3.16 mmol, 1.1 eq) was added dropwise to a solution of 3-methyl-
isonicotinic acid (393 mg, 2.87 mmol, 1.0 eq) in MeOH (20 mL) at 0 °C under Ar. The 
reaction mixture was warmed to rt and stirred and heated at reflux for 16 h. Then, the solvent 
was evaporated under reduced pressure to give the crude product as an orange oil. The 
reaction mixture was poured into sat NaHCO3(aq) (10 mL) and extracted with CH2Cl2 (5 x 10 
mL). The combined organic were dried (Na2SO4) and evaporated under reduced pressure to 
give pyridine 197 (345 mg, 80%) as an orange oil, 1H NMR (400 MHz, d4-MeOH) δ 8.66-
8.51 (m, 2H, Ar), 7.77 (d, J = 5.0 Hz, 1H, Ar), 3.94 (s, 3H, OMe), 2.56 (s, 3H, Me); 13C 
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NMR (100.6 MHz, d4-MeOH) δ 167.6 (C=O), 153.2 (Ar), 148.3 (Ar), 138.9 (ipso-Ar), 135.3 
(ipso-Ar), 124.7 (Ar), 53.0 (OMe), 18.1 (Me). Spectroscopic data consistent with those 
reported in the literature.153 
Lab Book - PJ-04-79. 
 
Methyl 3‐methylpiperidine‐4‐carboxylate cis-198 and trans-198 
 
 
 
Using general procedure B, PtO2 (24 mg, 0.11 mmol, 10 mol%) and pyridine 197 (163 mg, 
1.1 mmol, 1.0 eq) in AcOH (2 mL) gave the crude product which contained an 85:15 mixture 
(by 1H NMR spectroscopy) of piperidines cis-198 and trans-198 (147 mg, 89%) as a 
colourless oil, IR (ATR) 3319 (NH), 2951, 1726 (C=O), 1434, 1269, 1171 cm‒1; 1H NMR 
(400 MHz, CDCl3) cis-198 δ 3.66 (s, 3H, OMe), 3.07 (ddd, J = 12.5, 4.5, 4.5 Hz, 1H, NCH), 
2.89-2.76 (m, 2H, NCH, CHCO2), 2.64-2.56 (m, 2H, NCH), 2.26-2.19 (m, 0.15H, CHMe), 
2.14-2.06 (m, 0.85H, CHMe), 1.79 (dddd, J = 14.5, 10.5, 10.5, 4.0 Hz, 1H, CH), 1.65-1.58 
(m, 1H, CH), 1.53 (br s, 1H, NH), 0.94 (d, J = 7.0 Hz, 2.55H, CHMe), 0.82 (d, J = 7.5 Hz, 
0.45H, CHMe).; 13C NMR (100.6 MHz, CDCl3) δ 175.1 (C=O), 52.0 (NCH2), 51.5 (OMe), 
45.4 (NCH2), 44.7 (CHCO2), 31.3 (CHMe), 24.5 (CH2), 13.8 (CHMe); MS (ESI) m/z 158 
(M + H)+; HRMS m/z calcd for C8H16NO2 (M + H)
+ 158.1176, found 158.1178 (‒1.3 ppm 
error).  
Lab Book - PJ-05-09. 
 
1‐tert‐Butyl 3‐methyl 4‐methylpiperidine‐1,3‐dicarboxylate cis-199 and trans-199 
 
 
 
Et3N (0.14 mL, 0.98 mmol, 2.0 eq) was added dropwise to a stirred solution of a 65:35 
mixture of piperidines cis-196 and trans-196 (77 mg, 0.49 mmol, 1.0 eq) and Boc2O (214 
mg, 0.98 mmol, 2.0 eq) in CH2Cl2 (5 mL) at rt under Ar. The reaction mixture was stirred at 
rt for 16 h. Then, the solvent was evaporated under reduced pressure to give the crude 
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product as an orange oil. Purification by flash column chromatography on silica with 9:1 
hexane-EtOAc as eluent gave N-Boc piperidine trans-199 (28 mg, 22%) as a colourless oil, 
a 65:35 mixture of N-Boc piperidines cis-199 and trans-199 (22 mg, 18%) and a 90:10 
mixture of N-Boc piperidines cis-199 and trans-199 (67 mg, 54%). The 65:35 and 90:10 
mixtures of N-Boc piperidines cis-199 and trans-199 were combined and purified by flash 
column chromatography on silica with 98:2 CH2Cl2-acetone as eluent to give a 65:35 
mixture (by 1H NMR spectroscopy) of N-Boc piperidines cis-199 and trans-199 (18 mg, 
14%) as a colourless oil and N-Boc piperidine cis-199 (59 mg, 47%) as a colourless oil, RF  
(99:1 CH2Cl2-acetone) 0.18; IR (ATR) 2971, 1734 (C=O, CO2Me), 1689 (C=O, Boc), 1422, 
1365, 1163, 1138, 866 cm‒1; 1H NMR (400 MHz, CDCl3) δ 3.67 (br s, 3H, OMe), 3.61-3.55 
(m, 2H, NCH), 3.47-3.40 (m, 1H, NCH), 3.40-3.32 (m, 1H, NCH), 2.60-2.53 (m, 1H, 
CHCO2), 2.19-2.10 (m, 1H, CHMe), 1.72-1.64 (m, 1H, CH), 1.61-1.54 (m, 1H, CH), 1.45 
(s, 9H, CMe3), 0.97 (d, J = 7.0 Hz, 3H, CHMe); 
13C NMR (100.6 MHz, CDCl3) δ 173.2 
(C=O, CO2Me), 154.5 (C=O, Boc), 79.6 (CMe3), 51.6 (OMe), 44.7 (CHCO2), 42.9 (CH2), 
40.5 (CH2), 30.5 (CHMe), 30.3 (CH2), 28.5 (CMe3), 15.6 (CHMe); MS (ESI) m/z 280 (M + 
Na)+; HRMS m/z calcd for C13H23NO4 (M + Na)
+ 280.1519, found 280.1523 (‒1.5 ppm 
error). Spectroscopic data for N-Boc piperidines cis-199 consistent with those reported in 
the literature.152 
Lab Book - PJ-05-15. 
 
1‐tert‐Butyl 4‐methyl 3‐methylpiperidine‐1,4‐dicarboxylate cis-200 and trans-200 
 
 
 
Et3N (0.16 mL, 1.16 mmol, 2.0 eq) was added dropwise to a stirred solution of an 85:15 
mixture of piperidines cis-198 and trans-198 (91 mg, 0.58 mmol, 1.0 eq) and Boc2O (252 
mg, 1.16 mmol, 2.0 eq) in CH2Cl2 (5 mL) at rt under Ar. The resulting solution was stirred 
at rt for 16 h. Then, the solvent was evaporated under reduced pressure to give the crude 
product as a green oil. Purification by flash column chromatography on silica with 99:1 
CH2Cl2-acetone as eluent gave an 65:35 mixture (by 
1H NMR spectroscopy) of N-Boc 
piperidines cis-200 and trans-200 (20 mg, 14%) as a colourless oil and N-Boc piperidine cis-
200 (73 mg, 49%) as a colourless oil, RF (99:1 CH2Cl2-acetone) 0.14; IR (ATR) 2970, 1733 
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(C=O, CO2Me), 1687 (C=O, Boc), 1425, 1161, 880 cm
‒1; 1H NMR (400 MHz, CDCl3) 
(60:40 mixture of rotamers) δ 4.12-3.97 (m, 0.6H, NCH), 3.97-3.83 (m, 0.4H, NCH), 3.81-
3.72 (m, 1H, NCH), 3.67 (s, 1.8H, OMe), 3.67 (s, 1.2H, OMe), 3.09-3.01 (m, 1H, NCH), 
3.00-2.88 (m, 0.4H, NCH), 2.88-2.77 (m, 0.6H, NCH), 2.59 (ddd, J = 10.5, 6.5, 3.0 Hz, 1H, 
CHCO2), 2.18 (br m, 1H, CHMe), 1.89-1.76 (m, 1H, CH), 1.75-1.59 (m, 1H, CH), 1.44 (s, 
5.4H, CMe3), 1.43 (s, 3.6H, CMe3), 0.88 (d, J = 7.0 Hz, 1.8H, CHMe), 0.87 (d, J = 7.0 Hz, 
1.2H, CHMe); 13C NMR (100.6 MHz, CDCl3) (rotamers) δ 174.4 (C=O, CO2Me), 155.3 
(C=O, Boc), 79.6 (CMe3), 51.7 (OMe), 49.6 (NCH2), 48.3 (NCH2), 44.7 (CHCO2), 43.0 
(NCH2), 42.3 (NCH2), 31.3 (CHMe), 28.5 (CMe3), 23.4 (CH2), 22.9 (CH2), 13.2 (CHMe); 
MS (ESI) m/z 280 (M + Na)+; HRMS m/z calcd for C13H23NO4 (M + Na)
+ 280.1519, found 
280.1517 (+0.6 ppm error). 
Lab Book - PJ-05-21. 
 
Methyl-4-methyl-1-tosyl piperidine-3-carboxylate 201 
 
 
 
HCl (0.78 mL of a 2 M solution in Et2O, 1.56 mmol, 10.0 eq) was added dropwise to N-Boc 
piperidine cis-199 (40 mg, 0.15 mmol, 1.0 eq) at rt under Ar. The resulting solution was 
stirred at rt for 16 h. Then, the solvent was evaporated under reduced pressure to give the 
hydrochloride salt (33 mg). Et3N (0.065 mL, 0.47 mmol, 3.0 eq) was added dropwise to a 
solution of the hydrochloride salt (33 mg, 0.95 mmol, 1.0 eq) and TsCl (6 mg, 0.052 mmol, 
0.1 eq) in CH2Cl2 (5 mL) under Ar. The reaction mixture was stirred at rt for 16 h. The 
reaction mixture was poured into water (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The 
combined organics were dried (Na2SO4) and evaporated under reduced pressure to give the 
crude product as a yellow oil. Purification by flash column chromatography on silica with 
8:2 hexane-EtOAc as eluent gave N-tosyl piperidine cis-201 (41 mg, 84%) as a white solid, 
mp 65-67 °C; RF (0.12, 8:2 hexane-EtOAc); IR (ATR) 2929, 1726 (C=O),1340, 1161, 920 
cm˗1; 1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 8.0 Hz, 2H, Ph), 7.32 (d, J = 8.0 Hz, 1H, 
Ph), 3.66 (s, 3H, OMe), 3.50 (ddd, J = 11.5, 3.0, 1.0 Hz, 1H, NCH), 3.31 (dddd, J = 11.5, 
4.5, 4.5, 1.5 Hz, 1H, NCH), 2.86-2.73 (m, 2H, NCH and CHCO2), 2.66 (ddd, J = 11.5, 11.5, 
3.0 Hz, 1H, NCH), 2.43 (s, 3H, ArMe), 2.26-2.17 (m, 1H, CHMe), 1.88-1.78 (m, 1H, CH), 
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1.70-1.62 (m, 1H, CH), 0.78 (d, J = 7.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 
172.6 (C=O), 143.7 (ispo-Ph), 132.3 (ipso-Ph), 129.9 (Ph), 127.8 (Ph), 51.8 (OMe), 44.6 
(CHCO2), 43.3 (NCH2), 42.0 (NCH2), 30.7 (NCH2), 28.7 (CHMe), 21.7 (PhMe), 13.9 
(CHMe); MS (ESI) m/z 334 (M + Na)+; HRMS m/z calcd for C15H21NO4S (M + Na)
+ 
334.1083, found 334.1089 (‒1.4 ppm error). 
Lab Book - PJ-05-55. 
 
Methyl-3-methyl-1-tosylpiperidine-4-carboxylate 202 
 
 
 
HCl (1.25 mL of a 2 M solution in Et2O, 2.50 mmol, 10.0 eq) was added dropwise to N-Boc 
piperidine cis-200 (64 mg, 0.25 mmol, 1.0 eq) at rt under Ar. The resulting solution was 
stirred at rt for 32 h. Then, the solvent was evaporated under reduced pressure to give the 
hydrochloride salt. Et3N (0.1 mL, 0.75 mmol, 3.0 eq) was added dropwise to a solution of 
the hydrochloride salt and TsCl (143 mg, 0.75 mmol, 3.0 eq) in CH2Cl2 (5 mL) under Ar. 
The reaction mixture was stirred at rt for 16 h. The reaction mixture was poured into water 
(10 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined organics were dried 
(Na2SO4) and evaporated under reduced pressure to give the crude product as a yellow oil. 
Purification by flash column chromatography on silica with 8:2 hexane-EtOAc as eluent 
gave N-tosyl piperidine cis-200 (60 mg, 77%) as a white solid, mp 76-80 °C; RF (8:2 hexane-
EtOAc) 0.17; IR (ATR) 2976, 1722 (C=O), 1288, 1158, 921, 545 cm˗1; 1H NMR (400 MHz, 
CDCl3) δ 7.61 (d, J = 8.5 Hz, 2H, Ph), 7.30 (d, J = 8.0 Hz, 2H, Ph), 3.63 (s, 3H, OMe), 3.55-
3.48 (m, 1H, NCH), 3.31 (dd, J = 11.5, 5.0 Hz, 1H, NCH), 2.68 (dd, J = 11.5, 3.5 Hz, 1H, 
NCH), 2.56 (ddd, J = 11.5, 10.0, 3.5 Hz, 1H, NCH), 2.44-2.38 (m, 4H, PhMe and CHCO2), 
2.31-2.21 (m, 1H, CHMe), 1.97 (dddd, J = 14.0, 10.0, 10.0, 4.0 Hz, 1H, CH), 1.78 (dddd, J 
= 14.0, 5.0, 5.0, 3.5 Hz, 1H, CH), 0.98 (d, J = 7.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, 
CDCl3) δ 173.9 (C=O), 143.6 (ipso-Ph), 133.4 (ipso-Ph), 129.8 (Ph), 127.7 (Ph), 51.8 
(CO2Me), 51.1 (NCH2), 44.9 (NCH2), 43.5 (CHCO2), 31.0 (CHMe), 23.5 (CH2), 21.7 
(PhMe), 13.9 (CHMe); MS (ESI) m/z 334 (M + Na)+; HRMS m/z calcd for 334.1083 
C15H21NO4S (M + Na)
+, found 334.1087 (+0.1 ppm error).  
Lab Book - PJ-05-70. 
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Methyl 3‐methylpyridine‐5‐carboxylate 203 
 
 
SOCl2 (0.06 mL, 0.80 mmol, 1.1 eq) was added dropwise to a stirred solution of methyl 3‐
methylpyridine‐5‐carboxylate (100 mg, 0.73 mmol, 1.0 eq) in MeOH (5 mL) at 0 °C under 
Ar. The reaction mixture was warmed to rt and stirred and heated at reflux for 16 h. Then, 
the solvent was evaporated under reduced pressure to give the crude product as an orange 
oil. The reaction mixture was poured into saturated NaHCO3(aq) (10 mL) and extracted with 
CH2Cl2 (5 x 10 mL). The combined organic layers were dried (Na2SO4) and evaporated 
under reduced pressure to give pyridine 203 (106 mg, 96%) as a white solid, mp 37-39 °C; 
IR (ATR) 2960, 1712 (C=O), 1574, 1293, 1108, 766 cm‒1; 1H NMR (400 MHz, CDCl3) δ 
9.03 (d, J = 2.0 Hz, 1H, Ph), 8.61 (d, J = 2.0 Hz, 1H, Ph), 8.13-8.09 (m, 1H, Ph), 3.95 (s, 
3H, OMe), 2.40 (s, 3H, Me); 13C NMR (100.6 MHz, d4-MeOH) δ 166.9 (C=O), 154.3 (Ar), 
148.2 (Ar), 139.1 (Ar), 135.7 (Ar), 127.5 (Ar), 52.9 (OMe), 18.2 (Me); MS (ESI) m/z 151 
(M + H)+; HRMS m/z calcd for C8H9NO2 (M + H)
+ 152.0706, found 152.0702 (+2.7 ppm 
error). Spectroscopic data consistent with those reported in the literature.154 
Lab Book - PJ-04-81. 
 
Methyl 5‐methylpiperidine‐3‐carboxylate cis-204 and trans-204 
 
 
Using general procedure B, 10% Pd/C (70 mg, 0.07 mmol, 10 mol%) and pyridine 203 (100 
mg, 0.66 mmol, 1.0 eq) in AcOH (5 mL), gave the crude product which contained a 70:30 
mixture (by 1H NMR spectroscopy) of piperidines trans-204 and cis-204 (94 mg, 91%) as a 
colourless oil, IR (ATR) 2951, 1725 (C=O), 1435, 1198, 1177, 860 cm-1; 1H NMR (400 
MHz, CDCl3) δ 3.69 (s, 2.1H, OMe), 3.65 (s, 0.9H, Ome), 3.30-3.23 (m, 1H, NCH), 2.97-
2.90 (m, 1H, NCH), 2.73 (dd, J = 13.0, 3.5 Hz, 0.70H, NCH), 2.59-2.54 (m, 1H, CHCO2), 
2.51-2.43 (m, 0.3H, NCH), 2.24 (dd, J = 13.0, 10.0 Hz, 0.7H, NCH), 2.15-2.04 (m, 1.3H, 
NCH, CH), 1.69-1.57 (m, 0.7H, CHMe), 1.57-1.47 (m, 0.3H, CHMe), 1.39-1.30 (m, 0.7H, 
NCH), 1.17 (m, 0.3H, CH), 0.86 (d, J = 6.6 Hz, 0.9H, CHMe), 0.84 (d, J = 6.7 Hz, 2.1H, 
CHMe); 13C NMR (100.6 MHz, CDCl3) δ 175.4 (C=O), 174.7 (C=O), 53.8 (NCH2), 53.7 
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(NCH2), 51.8 (Ome), 51.7 (Ome), 48.3 (CH2), 47.4 (CH2), 43.4 (CHCO2), 39.7 (CHCO2), 
36.2 (CH2), 34.5 (CH2),  31.8 (CHMe), 28.8 (CHMe), 19.5 (CHMe), 19.1 (CHMe); MS (ESI) 
m/z 158 (M + H)+; HRMS m/z calcd for C8H16NO2 (M + H)
+ 158.1176, found 158.1171 (‒
1.5 ppm error). 
Lab Book - PJ-05-25. 
 
Using general procedure B, PtO2 (15 mg, 0.066 mmol, 10 mol%) and pyridine 203 (100 mg, 
0.66 mmol, 1.0 eq) in AcOH (5 mL), gave the crude product which contained a 60:40 mixture 
(by 1H NMR spectroscopy) of piperidines trans-204 and cis-204 (96 mg, 93%) as a 
colourless oil. 
Lab Book - PJ-05-28. 
 
1‐tert‐Butyl 3‐methyl 5‐methylpiperidine‐1,3‐dicarboxylate cis-205 and trans-205 
 
 
 
 
A solution of Boc2O (225 mg, 1.03 mmol, 3.0 eq) in CH2Cl2 (2 mL) was added dropwise to 
a stirred solution of a 70:30 mixture of piperidines trans-204 and cis-204 (54 mg, 0.34 mmol, 
1.0 eq), DMAP (4 mg, 0.034 mmol, 0.1 eq) and Et3N (0.15 mL, 1.03 mmol, 3.0 eq) in CH2Cl2 
(3 mL) at rt under Ar. The reaction mixture was stirred at rt for 16 h. Then, the reaction 
mixture was evaporated under reduced pressure to give the crude product as a yellow oil. 
Purification by flash column chromatography on silica with 90:10 hexane-EtOAc as eluent 
gave N-Boc piperidine cis-205 (22 mg, 25%) as a colourless oil and N-Boc piperidine trans-
205 (49 mg, 56%) as a colourless oil, RF (90:10 hexane-EtOAc) 0.16; IR (ATR) 2954, 1735 
(C=O, CO2Me), 1688 (C=O, Boc), 1422, 1160, 1136, 867 cm
‒1; 1H NMR (400 MHz, CDCl3) 
(60:40 mixture of rotamers) δ 4.02-3.88 (br s, 0.4H, NCH), 3.66 (br, s, 3H, OMe), 3.73-3.55 
(m, 1H, NCH), 3.43-3.33 (m, 0.6H, NCH), 3.33-3.22 (m, 0.6H, NCH), 3.13-2.99 (m, 0.4H, 
NCH), 2.78-2.68 (m, 1H, NCH), 2.68-2.58 (m, 1H, CHCO2), 2.08-1.98 (m, 0.6H, CH), 1.98-
1.84 (m, 1.4H, CHMe and CH), 1.43 (s, 10H, CH and CMe3), 0.90 (d, J = 6.5 Hz, 3H, 
CHMe); 13C NMR (100.6 MHz, CDCl3) (rotamers) δ 174.1 (C=O, CO2Me), 154.8 (C=O, 
Boc), 79.6 (CMe3), 51.8 (OMe), 50.5 (NCH2), 49.7 (NCH2), 45.4 (NCH2), 45.1 (NCH2), 
38.8 (CHCO2), 38.0 (CHCO2), 33.9 (CH2), 28.5 (CMe3), 27.5 (CHMe), 18.2 (CHMe), 17.8 
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(CHMe); MS (ESI) m/z 258 (M + H)+; HRMS m/z calcd for C13H23NO4 (M + H)
+ 258.1700, 
found 258.1704 (‒1.2 ppm error). 
Lab Book - PJ-05-27. 
 
Methyl 5‐methyl‐1‐(4‐methylbenzenesulfonyl)piperidine‐3‐carboxylate cis-206 
 
 
HCl (0.88 mL of a 2 M solution in Et2O, 1.75 mmol, 10.0 eq) was added dropwise to N-Boc 
piperidine cis-205 (45 mg, 0.18 mmol, 1.0 eq) at rt under Ar. The resulting solution was 
stirred at rt for 32 h. Then, the solvent was evaporated under reduced pressure to give the 
hydrochloride salt (32 mg). Et3N (0.07 mL, 0.52 mmol, 3.0 eq) was added dropwise to a 
solution of the hydrochloride salt (32 mg) in CH2Cl2 (5 mL) at rt under Ar. The reaction 
mixture was stirred at rt for 30 min. TsCl (99 mg, 0.52 mmol, 3.0 eq) was then added 
dropwise to the reaction mixture which was stirred at rt for 16 h. The solution was poured 
into water (10 mL) and the two layers separated. The aqueous layer was extracted with 
CH2Cl2 (4 x 5 mL) and the combined organics were dried (Na2SO4) and evaporated under 
reduced pressure to give the crude product as a colourless oil. Purification by flash column 
chromatography on silica with 9:1 hexane-EtOAc as eluent gave N-tosyl piperidine cis-206 
(37 mg, 68%) as a white solid, mp  84-86 °C; RF (9:1 hexane-EtOAc) 0.08; IR (ATR) 2914, 
1736 (C=O), 1335, 1150, 810, 548 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 8.0 Hz, 
2H, Ph), 7.33 (d, J = 8.0 Hz, 2H, Ph), 4.06-4.00 (m, 1H, NCH), 3.77-3.71 (m, 1H, NCH), 
3.67 (s, 3H, OMe), 2.68 (dddd, J = 11.5, 11.5, 4.0, 4.0 Hz, 1H, CHCO2), 2.43 (s, 3H, PhMe), 
2.17 (dd, J = 11.5, 11.5 Hz, 1H, NCH), 2.00-2.07 (m, 1H, CH), 1.85-1.75 (m, 1H, CHMe), 
1.72 (dd, J = 11.0, 11.0 Hz, 1H, NCH), 0.99-0.86 (m, 1H, CH), 0.89 (d, J = 6.0 Hz, 3H, 
CHMe); 13C NMR (100.6 MHz, CDCl3) δ 173.4 (C=O), 143.8 (ipso-Ph), 133.2 (ispo-Ph), 
129.9 (Ph), 127.8 (Ph), 52.8 (NCH2), 52.1 (OMe), 47.4 (NCH2), 41.5 (CHCO2), 35.3 (CH2), 
30.5 (CHMe), 21.7 (PhMe), 18.9 (CHMe); MS (ESI) m/z 334 (M + Na)+; HRMS m/z calcd 
for C15H21NO4S (M + Na)
+ 334.1083, found 334.1079 (‒0.8 ppm error). Spectroscopic data 
consistent with those reported in the literature.110 
Lab Book - PJ-05-46. 
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Methyl 2‐methylpiperidine‐5‐carboxylate cis-126 and trans-126 
 
 
 
 
Table 3.2, Entry 1 
NaOMe (21 mg, 0.38 mmol, 1.2 eq) was added to a stirred solution of an 85:15 mixture of 
piperidines cis-126 and trans-126 (50 mg, 0.32 mmol, 1.0 eq) in MeOH (5 mL) at rt under 
Ar. The resulting solution was stirred at rt for 96 h. The reaction mixture was evaporated 
under reduced pressure and water (2 mL) and sat NaHCO3(aq) (2 mL) were added. The 
mixture was extracted with CH2Cl2 (5 x 5 mL) and the combined extracts were dried 
(Na2SO4) and evaporated under reduced pressure to give an 85:15 mixture (by 
1H NMR 
spectroscopy) of piperidines cis-126 and trans-126 (11 mg, 22%) as a colourless oil. 
Lab Book - PJ-04-92. 
 
Table 3.2, Entry 4 
DBU (0.14 mL, 0.96 mmol, 3.0 eq) was added dropwise to a stirred solution of an 85:15 
mixture of piperidines cis-126 and trans-126 (50 mg, 0.32 mmol, 1.0 eq) in toluene (5 mL) 
at rt under Ar.  The resulting solution was stirred at 50 °C for 96 h. The reaction mixture was 
cooled to rt and evaporated under reduced pressure to give a colourless oil. Water (5 mL) 
was added and the mixture was extracted with CH2Cl2 (3 x 10 mL). The combined organics 
were dried (Na2SO4) and evaporated under reduced pressure to give an 85:15 mixture (by 
1H NMR spectroscopy) of piperidines cis-126 and trans-126 (169 mg, impure) as an orange 
oil. 
Lab Book - PJ-05-10. 
 
Table 3.2, Entry 5 
DBU (0.14 mL, 0.96 mmol, 3.0 eq) was added dropwise to a stirred solution of an 85:15 
mixture of piperidines cis-126 and trans-126 (50 mg, 0.32 mmol, 1.0 eq) in toluene (5 mL) 
at rt under Ar.  The resulting solution was stirred at 85 °C for 24 h. The reaction mixture was 
cooled to rt and evaporated under reduced pressure to give an 80:20 mixture (by 1H NMR 
spectroscopy) of piperidines cis-126 and trans-126 (150 mg, impure) as a colourless oil.  
Lab Book - PJ-05-18. 
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KOtBu (0.38 mL of a 1 M solution in THF, 0.38 mmol, 1.2 eq) was added dropwise to a 
stirred solution of an 85:15 mixture of piperidines cis-126 and trans-126 (50 mg, 0.32 mmol, 
1.0 eq) in THF (3 mL) at ‒78 °C under Ar. The resulting solution was stirred at ‒78 °C for 
2 h. Then, water (1 mL) was added at ‒78 °C and the reaction mixture was allowed to warm 
to rt. The mixture was extracted with EtOAc (3 x 10 mL) and the combined organics were 
dried (Na2SO4) and evaporated under reduced pressure to give an 80:20 mixture (by 
1H NMR 
spectroscopy) of piperidines trans-126 and cis-126 (16 mg, impure) as a colourless oil. 
Lab Book - PJ-04-80. 
 
1‐tert‐Butyl 3‐methyl 6‐methylpiperidine‐1,3‐dicarboxylate trans-157 and cis-157 
 
 
 
 
Table 3.2, Entry 2 
NaOMe (62 mg, 1.15 mmol, 1.2 eq) was added to a stirred solution of an 85:15 mixture of 
piperidines cis-126 and trans-126 (150 mg, 0.96 mmol, 1.0 eq) in MeOH (9 mL) at rt under 
Ar.  The resulting solution was stirred and heated at reflux for 24 h. The reaction mixture 
was cooled to rt and evaporated under reduced pressure to give the crude product as a white 
solid which contained a 70:30 mixture (by 1H NMR spectroscopy) of piperidines trans-126 
and cis-126. The crude product was dissolved in CH2Cl2 (10 mL) and added to DMAP (59 
mg, 0.48 mmol, 0.5 eq), Et3N (0.4 mL, 2.87 mmol, 3.0 eq) and Boc2O (627 mg, 2.88 mmol, 
3.2 eq) at rt under Ar. The resulting solution was stirred at rt for 16 h. The reaction mixture 
was evaporated under reduced pressure to give the crude product as a yellow oil/solid. 
Purification by flash column chromatography on silica with 9:1 hexane-EtOAc as eluent 
gave N-Boc piperidines cis-157 (24 mg, 10%) as a colourless oil, a 70:30 mixture of N-Boc 
piperidine trans-157 and cis-157 (11 mg, 4%) as a colourless oil and N-Boc piperidine trans-
157 (66 mg, 27%) as a colourless oil. 
Lab Book - PJ-04-57/58. 
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Table 3.2, Entry 3 
K2CO3 (53 mg, 0.38 mmol, 1.2 eq) was added to a stirred solution of an 85:15 mixture of 
piperidines cis-126 and trans-126 (50 mg, 0.32 mmol, 1.0 eq) in MeOH (5 mL) at rt under 
Ar.  The resulting solution was stirred and heated at reflux for 24 h. The reaction mixture 
was cooled to rt and evaporated under reduced pressure to give the crude product as a 
colourless oil which contained an 80:20 mixture (by 1H NMR spectroscopy) of piperidines 
trans-126 and cis-126. The crude product was dissolved in CH2Cl2 (5 mL) and added to a 
solution of DMAP (20 mg, 0.16 mmol, 0.5 eq), Et3N (0.13 mL, 0.96 mmol, 3.0 eq) and 
Boc2O (222 mg, 1.02 mmol, 3.2 eq) at rt under Ar. The resulting solution was stirred at rt 
for 16 h. The reaction mixture was evaporated under reduced pressure to give a yellow 
oil/solid. Purification by flash column chromatography on silica with 9:1 hexane-EtOAc as 
eluent gave N-Boc piperidine trans-157 (15 mg, 18%) as a colourless oil. 
Lab Book - PJ-04-93/97.  
 
Methyl 1‐benzyl‐6‐methylpiperidine‐3‐carboxylate cis-208 
 
 
 
BnBr (0.24 mL, 1.99 mmol, 1.2 eq) was added dropwise to a stirred solution of an 85:15 
mixture of piperidines cis-126 and trans-126 (260 mg, 1.66 mmol, 1.0 eq) in saturated 
Na2CO3(aq) (2 mL) and CH2Cl2 (2 mL) at rt under Ar. The resulting solution was stirred at rt 
for 16 h. The two layers were separated, and the aqueous layer was extracted with CH2Cl2 
(3 x 10 mL). The combined organics were dried (MgSO4) and evaporated under reduced 
pressure to give the crude product as a colourless oil. Purification by flash column 
chromatography on silica with 90:10 hexane-EtOAc as eluent gave N-benzyl piperidine cis-
208 (325 mg, 79%) as a colourless oil, RF (90:10 hexane-EtOAc) 0.1; IR (ATR) 2947, 1732 
(C=O), 1434, 1192, 1149, 697 cm‒1;
 1H NMR (400 MHz, CDCl3) δ 7.34-7.27 (m, 4H, Ph), 
7.22 (m, 1H, Ph), 3.78 (d, J = 13.5 Hz, 1H, NCHPh), 3.62 (s, 3H, OMe), 3.37 (d, J = 13.5 
Hz, 1H, NCHPh), 2.83 (dd, J = 11.5, 7.5 Hz, 1H, NCH), 2.74-2.65 (m, 1H, NCHMe), 2.57-
2.49 (m, 1H, CHCO2), 2.44 (dd, J = 11.5, 4.0 Hz, 1H, NCH), 1.92-1.82 (m, 1H, CH), 1.74-
1.63 (m, 2H, CH), 1.57 (m, 1H, CH), 1.06 (d, J = 6.5 Hz, 3H, CHMe); 13C NMR (100.6 
MHz, CDCl3) δ 174.9 (C=O), 139.8 (ipso-Ph), 128.8 (Ph), 128.2 (Ph), 126.9 (Ph), 58.7 
247 
 
(NCH2Ph), 53.9 (NCHMe), 51.5 (OMe), 50.1 (NCH2), 41.3 (CHCO2), 31.1 (CH2), 23.4 (CH-
2), 14.2 (CHMe); MS (ESI) m/z 248 (M + H)
+; HRMS m/z calcd for C15H22NO2 (M + H)
+ 
248.1645, found 248.1636 (+4.1 ppm error) and N-benzyl piperidine trans-208 (48 mg, 
11%) as a colourless oil. 
Lab Book - PJ-06-23. 
 
Methyl 1‐benzyl‐6‐methylpiperidine‐3‐carboxylate cis-208, trans-208 and methyl 1‐
benzyl‐3‐hydroxy‐6‐methylpiperidine‐3‐carboxylate 209 
 
 
 
 
KOtBu (0.24 mL of a 1 M solution in THF, 0.24 mmol, 1.2 eq) was added dropwise to a 
stirred solution of N-benzyl piperidine cis-208 (50 mg, 0.20 mmol, 1.0 eq) in THF (3 mL) at 
‒78 °C under Ar. The resulting solution was stirred at ‒78 °C for 2 h. Then, water (1 mL) 
was added at ‒78 °C and the reaction mixture was allowed to warm to rt. The reaction 
mixture was then concentrated under reduced pressure to give an orange oil. The solution 
was taken up into water (2 mL) and extracted with EtOAc (3 x 5 mL) and the combined 
organics were dried (MgSO4) and evaporated under reduced pressure to give the crude 
product as a pale yellow oil which contained a 50:25:25 mixture (by 1H NMR spectroscopy) 
of piperidines trans-208, cis-208 and hydroxy ester 209. Purification by flash column 
chromatography on silica with 80:20 hexane-EtOAc as eluent gave N-benzyl piperidine cis-
208 (5 mg, 10%) as a colourless oil, N-benzyl piperidine trans-208 (10 mg, 20%) as a 
colourless oil and a single unknown diastereoisomer of hydroxy ester 209 (5 mg, 8%) as a 
colourless oil, RF (80:20 hexane-EtOAc) 0.04; IR (ATR) 3456 (OH), 2949, 1733 (C=O), 
1451, 1373, 1223, 1027, 737, 697 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.33-7.27 (m, 4H, 
Ph), 7.27-7.22 (m, 1H, Ph), 3.73 (s, 3H, OMe), 3.64 (d, J = 13.5 Hz, 1H, NCHPh), 3.56 (d, 
J = 13.5 Hz, 1H, NCHPh), 3.41 (br s, 1H, OH), 2.98-2.92 (m, 1H, NCHMe), 2.93 (d, J = 
11.5 Hz, 1H, NCH), 2.38 (dd, J = 11.5, 2.0 Hz, 1H, NCH), 2.07-1.96 (m, 2H, CH), 1.69-
1.62 (m, 1H, CH), 1.52-1.45 (m, 1H, CH), 1.07 (d, J = 6.5 Hz, 3H, CHMe); 13C NMR (100.6 
MHz, CDCl3) δ 174.3 (C=O), 138.9 (ipso-Ph), 128.9 (Ph), 128.5 (Ph), 127.3 (Ph), 72.9 
(HOC), 58.7 (NCH2Ph), 54.0 (NCH2), 52.4 (OMe), 52.1 (NCHMe), 29.2 (CH2), 27.6 (CH2), 
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10.4 (CHMe); MS (ESI) m/z 264 (M + H)+; HRMS m/z calcd for C15H22NO3 (M + H)
+ 
264.1594, found 264.1584 (+3.3 ppm error). 
Lab Book - PJ-04-91. 
 
Using general procedure E, N-benzyl piperidine cis-208 (150 mg, 0.61 mmol, 1.0 eq) and. 
KOtBu (0.73 mL of a 1 M solution in THF, 0.73 mmol, 1.2 eq) in THF (5 mL) gave a 75:25 
mixture (by 1H NMR spectroscopy) of N-benzyl piperidines trans-208 and cis-208. 
Purification by flash column chromatography on silica with 90:10 hexane-EtOAc as eluent 
gave an 85:15 mixture of N-benzyl piperidine cis-208 and trans-208 (43 mg, 28%) as a 
colourless oil and N-benzyl piperidine trans-208 (80 mg, 53%) as a colourless oil, RF (80:20 
hexane-EtOAc) 0.18; IR (ATR) 2947, 1732 (C=O), 1329, 1144, 697 cm-1; 
1H NMR (400 
MHz, CDCl3) δ 4.05 (d, J = 13.5 Hz, 1H, NCHPh), 3.58 (s, 3H, OMe), 3.16 (d, J = 13.5 Hz, 
1H, NCHPh), 2.98 (dd, J = 11.5, 3.5 Hz, 1H, NCH), 2.49 (dddd, J = 11.5, 11.5, 3.5, 3.5 Hz, 
1H, CHCO2), 2.28-2.19 (m, 1H, NCHMe), 2.04 (dd, J = 11.5, 11.5 Hz, 1H, NCH), 1.99-1.92 
(m, 1H, CH), 1.74-1.68 (m, 1H, CH), 1.50 1.31 (m, 2H, CH), 1.18 (d, J = 6.0 Hz, 3H, CHMe); 
13C NMR (100.6 MHz, CDCl3) δ 175.0 (C=O), 139.2 (ipso-Ph), 129.1 (Ph), 128.3 (Ph), 
126.9 (Ph), 57.9 (NCH2Ph), 56.4 (NCHMe), 54.1 (NCH2), 51.6 (CHCO2), 42.2 (OMe), 34.0 
(CH2), 27.7 (CH2), 20.7 (CHMe); MS (ESI) m/z 248 (M + H)
+; HRMS m/z calcd for 
C15H21NO2 (M + H)
+ 248.1645, found 248.1638 (+2.3 ppm error). 
Lab Book - PJ-06-25. 
 
Methyl 1‐benzyl‐5‐methylpiperidine‐2‐carboxylate cis-207 and trans-207 
 
Using general procedure E, N-benzyl piperidine cis-207 (50 mg, 0.20 mmol, 1.0 eq) and 
KOtBu (0.24 mL of a 1 M solution in THF, 0.24 mmol, 1.2 eq) in THF (3 mL) gave a 50:50 
mixture (by 1H NMR spectroscopy) of N-benzyl piperidines trans-207 and cis-207. 
Purification by flash column chromatography on silica with 90:10 hexane-Et2O as eluent 
gave N-benzyl piperidine cis-207 (23 mg, 48%) as a colourless oil, RF (90:10 hexane-Et2O) 
0.25; IR (ATR) 2950, 1734 (C=O), 1453, 1155, 1136, 735, 698 cm‒1; 1H NMR (400 MHz, 
CDCl3) δ 7.34-7.27 (m, 4H, Ph), 7.26-7.21 (m, 1H, Ph), 3.82 (d, J = 13.5 Hz, 1H, NCHPh), 
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3.76 (d, J = 13.5 Hz, 1H, NCHPh), 3.69 (s, 3H, OMe), 3.49 (dd, J = 5.5, 3.0 Hz, 1H, 
NCHCO2), 2.65 (dd, J = 11.0, 11.0 Hz, 1H, NCH), 2.56 (dd, J = 11.0, 4.0 Hz, 1H, NCH), 
2.00 (m, 1H, CH), 1.83 (dddd, J = 13.5, 13.5, 5.5, 4.0 Hz, 1H, CH), 1.71-1.62 (m, 1H, 
CHMe), 1.62-1.54 (m, 1H, CH), 1.10-0.98 (m, 1H, CH), 0.84 (d, J = 6.5 Hz, 3H, CHMe); 
13C NMR (100.6 MHz, CDCl3) δ 174.0 (C=O), 139.5 (ipso-Ph), 128.7 (Ph), 128.4 (Ph), 
127.0 (Ph), 60.1 (NCHCO2), 59.8 (NCH2Ph), 54.9 (NCH2), 51.1 (OMe), 30.9 (CHMe), 29.8 
(CH2), 28.3 (CH2), 19.5 (CHMe); MS (ESI) m/z 248 (M + H)
+; HRMS m/z calcd for 
C15H21NO2 (M + H)
+ 248.1645, found 248.1648 (‒0.9 ppm error) and N-benzyl piperidine 
trans-207 (20 mg, 40%) as a colourless oil, RF (90:10 hexane-Et2O) 0.07; IR (ATR) 2927, 
1746 (C=O), 1436, 1161, 698 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.32-7.29 (m, 4H, Ph), 
7.29-7.23 (m, 1H, Ph). 3.76 (d, J = 13.0 Hz, 1H, NCHPh), 3.75 (s, 3H, OMe), 3.21 (d, J = 
13.0 Hz, 1H, NCHPh), 2.91 (dd, J = 11.0, 3.0 Hz, 1H, NCHCO2), 2.83 (ddd, J = 11.0, 3.0, 
1.5 Hz, 1H, NCH), 1.94-1.87 (m, 1H, CH), 1.81-1.70 (m, 2H, CH), 1.69-1.58 (m, 1H, 
CHMe), 1.55 (dd, J = 11.0, 11.0  Hz, 1H, NCH), 0.96-0.84 (m, 1H, CH), 0.79 (d, J = 6.5 Hz, 
1H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 174.9 (C=O), 137.4 (ipso-Ph), 129.7 (Ph), 
128.2 (Ph), 127.2 (Ph), 66.3 (NCHCO2), 61.0 (NCH2Ph), 59.3 (NCH2), 52.1 (OMe), 32.1 
(CH2), 30.5 (CHMe), 30.1 (CH2), 19.6 (CHMe); MS (ESI) m/z 248 (M + H)
+; HRMS m/z 
calcd for C15H21NO2 (M + H)
+ 248.1645, found 248.1647 (‒0.6 ppm error). 
Lab Book - PJ-05-32. 
 
Methyl 1‐benzyl‐2‐methylpiperidine‐3‐carboxylate cis-194 and trans-194 
 
 
 
 
Using general procedure E, a 90:10 mixture of N-Benzyl piperidine cis-194 and trans-194 
(150 mg, 0.61 mmol, 1.0 eq) and KOtBu (0.73 mL of a 1 M solution in THF, 0.73 mmol, 
1.2 eq) in THF (5 mL) gave the crude product as an orange oil. Purification by flash column 
chromatography on silica with 90:10 hexane-EtOAc as eluent gave an 80:20 mixture of N-
benzyl piperidine cis-194 and trans-194 (61 mg, 41%) and N-benzyl piperidine trans-194 
(84 mg, 56%) as a colourless oil, RF  (80:20 hexane-Et2O) 0.19; IR (ATR) 2943, 2795, 1732 
(C=O), 1434, 1138, 732, 697 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.32-7.27 (m, 4H, Ph), 
7.24-7.20 (m, 1H, Ph), 3.95 (d, J = 13.5 Hz, 1H, NCHPh), 3.67 (s, 3H, OMe), 3.25 (d, J = 
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13.5 Hz, 1H, NCHPh), 2.76-2.68 (m, 2H, NCHMe and NCH), 2.35 (ddd, J = 10.0, 9.0, 4.0 
Hz, 1H, CHCO2), 2.12-2.04 (m, 1H, NCH), 1.88-1.81 (m, 1H, CH), 1.65-1.56 (m, 2H, CH), 
1.51-1.44 (m, 1H, CH), 1.15 (d, J = 6.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 
175.7 (C=O), 139.5 (ipso-Ph), 129.0 (Ph), 128.3 (Ph), 126.9 (Ph), 57.6 (NCH2Ph), 57.2 
(CHMe), 51.7 (OMe), 51.2 (NCH2), 49.5 (CHCO2), 27.3 (CH2), 24.0 (CH2), 17.3 (CHMe); 
MS (ESI) m/z 248 (M + H)+; HRMS m/z calcd for C15H21NO2 (M + H)
+ 248.1645, found 
248.1646 (˗2.9 ppm error).  
Lab Book - PJ-06-22. 
 
Methyl 1‐benzyl‐3‐methylpiperidine‐2‐carboxylate cis-123 and trans-123 
 
PhCHO (0.36 mL, 3.5 mmol, 1.1 eq) was added dropwise to a stirred solution of an 85:15 
mixture of piperidines cis-116 and trans-116 (500 mg, 3.18 mmol, 1.0 eq), NaBH(OAc)3 
(1.35 g, 6.37 mmol, 2 eq) and AcOH (0.03 mL, 0.64 mmol, 0.2 eq) in DCE (30 mL) at rt 
under Ar. The resulting mixture was stirred at rt for 18 h. The reaction mixture was poured 
into sat NaHCO3(aq) (100 mL) and extracted with CH2Cl2 (3 x 50 mL). The combined 
organics were washed with brine (100 mL), dried (MgSO4) and evaporated under reduced 
pressure to give the crude product as a green oil which contained a 90:10 mixture (by 1H 
NMR spectroscopy) of piperidines cis-123 and trans-123. Purification by flash column 
chromatography on silica with 98:2 hexane-EtOAc as eluent gave N-benzyl piperidine cis-
123 (626 mg, 80%) as a yellow oil, RF (95:5 hexane-EtOAc) 0.23; IR (ATR) 2928, 1728 
(C=O), 1453, 1148, 697 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.32-7.29 (m, 4H, Ph), 7.25-
7.22 (m, 1H, Ph), 3.69 (s, 3H, OMe), 3.61 (d, J = 13.5 Hz, 1H, NCHPh), 3.56 (d, J = 13.5 
Hz, 1H, NCHPh), 3.45 (d, J = 5.0 Hz, 1H, NCHCO2), 3.00-2.92 (m, 1H, NCH), 2.54-2.45 
(m, 1H, NCH), 2.03-1.93 (m, 1H, CHMe), 1.71-1.64 (m, 1H, CH), 1.60-1.46 (m, 3H, CH), 
0.90 (d, J = 7.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3)
 δ 173.0 (C=O), 139.1 (ipso-
Ph), 128.9 (Ph), 128.3 (Ph), 127.1 (Ph), 66.2 (NCHCO2), 60.2 (NCH2Ph), 50.5 (OMe), 47.0 
(NCH2), 33.2 (CHMe), 27.8 (CH2), 25.2 (CH2), 18.2 (CHMe); MS (ESI) m/z 248 (M + H)
+; 
HRMS m/z calcd for C15H21NO2 (M + H)
+ 248.1645, found 248.1643 (‒0.7 ppm error) and 
piperidine trans-123 (82 mg, 10%) as a yellow oil, RF (95:5 hexane-EtOAc) 0.1; IR (ATR) 
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2928, 1727 (C=O), 1453, 1147, 734, 697 cm‒1; 
1H NMR (400 MHz, CDCl3) δ 7.32-7.29 (m, 
4H, Ph), 7.26-7.22 (m, 1H, Ph), 3.76 (s, 3H, OMe), 3.71 (d, J = 13.5 Hz, 1H, NCHPh), 3.25 
(d, J = 13.5 Hz, 1H, NCHPh), 2.87 (ddd, J = 11.0, 5.5, 5.5 Hz, 1H, NCH), 2.64 (d, J = 9.0 
Hz, 1H, NCHCO2), 1.95-1.86 (m, 2H, CH), 1.76-1.68 (m, 1H, CH), 1.61-1.53 (m, 2H, CH), 
1.05-0.94 (m, 1H, CH), 0.90 (d, J = 7.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3)
 δ 
174.3 (C=O), 137.7 (ipso-Ph), 129.6 (Ph), 128.3 (Ph), 127.2 (Ph), 73.7 (NCHCO2), 61.2 
(NCH2Ph), 51.8 (OMe), 51.3 (NCH2), 34.4 (CHMe), 32.0 (CH2), 24.6 (CH2), 18.9 (CHMe); 
MS (ESI) m/z 248 (M + H)+; HRMS m/z calcd for C15H21NO2 (M + H)
+ 248.1645, found 
248.1641 (+1.3 ppm error).Spectroscopic data for N-benzyl piperidines cis-123 and trans-
123 consistent with those reported in the literature.79 
Lab Book - PJ-02-45. 
 
Using general procedure E, N-benzyl piperidine cis-123 (173 mg, 0.70 mmol, 1.0 eq) and 
KOtBu (0.84 mL of a 1 M solution in THF, 0.84 mmol, 1.2 eq) in THF (5 mL) gave a 70:30 
mixture (by 1H NMR spectroscopy) of N-benzyl piperidines trans-123 and cis-123. 
Purification by flash column chromatography on silica with 95:5 hexane-EtOAc as eluent 
gave N-benzyl piperidine cis-123 (40 mg, 23%) as a colourless oil and N-benzyl piperidine 
trans-123 (104 mg, 60%) as a colourless oil. 
Lab Book - PJ-06-08. 
 
1‐tert‐Butyl 4‐methyl 3‐methylpiperidine‐1,4‐dicarboxylate cis-200 and trans-200 
 
 
 
 
Et3N (0.16 mL, 1.16 mmol, 2.0 eq) was added dropwise to a stirred solution of an 85:15 
mixture of piperidines cis-198 and trans-198 (91 mg, 0.58 mmol, 1.0 eq) and Boc2O (253 
mg, 1.16 mmol, 2.0 eq) in CH2Cl2 (5 mL) at rt under Ar. The reaction mixture was stirred at 
rt for 16 h. Then, the solvent was evaporated under reduced pressure to give the crude 
product as a green oil. Purification by flash column chromatography on silica with 90:10 
hexane-Et2O as eluent gave a 90:10 mixture (by 
1H NMR spectroscopy) of N-Boc 
piperidines cis-200 and trans-200 (117 mg, 78%) as a colourless oil. 
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Lab Book - PJ-04-100. 
 
Using general procedure E, a 90:10 mixture of N-Boc piperidines cis-200 and trans-200 (50 
mg, 0.19 mmol, 1.0 eq) and KOtBu (0.23 mL of a 1 M solution in THF, 0.23 mmol, 1.2 eq) 
in THF (5 mL) gave  a 90:10 mixture (by 1H NMR spectroscopy) of N-Boc piperidine trans-
200 and cis-200 (45 mg, 0.17 mmol, 90%) as a colourless oil, RF (90:10 hexane-EtOAc) 
0.14; IR (ATR) 2931, 1735 (C=O, CO2Me), 1689 (C=O, Boc), 1420, 1158, 767 cm
‒1; 1H 
NMR (400 MHz, CDCl3) trans-200; δ 4.17-3.92 (m, 2H, NCH), 3.68 (s, 3H, OMe), 2.73-
2.63 (m, 1H, NCH), 2.41-2.24 (m, 1H, NCH), 2.08 (ddd, J = 12.0, 11.0, 4.0 Hz, 1H, CHCO2), 
1.87-1.75 (m, 2H, CH and CHMe), 1.69-1.57 (dddd, J = 12.5, 12.5, 12.5, 4.5 Hz, 1H, CH), 
1.45 (s, 9H, CMe3), 0.87 (d, J = 6.5 Hz, 3H, CHMe); 
13C NMR (100.6 MHz, CDCl3) trans-
200; δ 175.3 (C=O, CO2Me), 154.7 (C=O, Boc), 79.8 (CMe3), 51.8 (OMe), 50.0 (NCH2), 
49.5 (CHCO2), 43.2 (NCH2), 33.1 (CHMe), 28.8 (CH2), 28.6 (CMe3), 17.1 (CHMe); MS 
(ESI) m/z 280 (M + Na)+; HRMS m/z calcd for C13H23NO4 (M + Na)
+ 280.1519, found 
280.1523 (‒1.7 ppm error). 
Lab Book - PJ-05-17. 
 
1‐tert‐Butyl 3‐methyl 4‐methylpiperidine‐1,3‐dicarboxylate trans-199, cis-199 and 3‐
methyl 3‐hydroperoxy‐4‐methylpiperidine‐1,3‐dicarboxylate 215 
 
Et3N (0.94 mL, 6.78 mmol, 2.0 eq) was added dropwise to a stirred solution of a 65:35 
mixture of piperidines cis-196 and trans-196 (533 mg, 3.39 mmol, 1.0 eq) and Boc2O (1.5 
g, 6.78 mmol, 2.0 eq) in CH2Cl2 (10 mL) at rt under Ar. The reaction mixture was stirred at 
rt for 16 h. Then, the solvent was evaporated under reduced pressure to give the crude 
product as an orange oil. Purification by flash column chromatography on silica with 9:1 
hexane-EtOAc as eluent gave a 65:35 mixture of Boc piperidines cis-199 and trans-199 (740 
mg, 84%) as a colourless oil.  
Lab Book - PJ-04-71. 
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Using general procedure E, a 65:35 mixture of N-Boc piperidines cis-199 and trans-199 (150 
mg, 0.58 mmol, 1.0 eq) and KOtBu (0.47 mL of a 1 M solution in THF, 0.47 mmol, 1.2 eq) 
in THF (9 mL) gave the crude product as an orange oil. Purification by flash column 
chromatography on silica with 80:20 hexane-EtOAc as eluent gave Boc piperidine trans-
199 (68 mg, 68%) as a colourless oil, RF (90:10 hexane-Et2O) 0.19; IR (ATR) 2930, 1733 
(C=O, CO2Me), 1692 (C=O, Boc), 1419, 1241, 1145, 963 cm
‒1; 1H NMR (400 MHz, CDCl3) 
δ 4.32-3.98 (m, 2H, NCH), 3.68 (s, 3H, OMe), 2.86-2.61 (m, 2H, NCH and CHCO2), 2.14-
2.05 (m, 1H, NCH), 1.86-1.73 (m, 1H, CHMe), 1.71-1.58 (m, 1H, CH), 1.44 (s, 9H, CMe3), 
1.20-1.05 (m, 1H, CH), 0.92 (d, J = 6.5 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 
174.1 (C=O, CO2Me), 154.6 (C=O, Boc), 79.9 (CMe3), 51.7 (OMe), 49.8 (CHCO2), 46.2 
(NCH2), 44.0 (CH2), 33.7 (CHMe), 33.0 (CH2), 28.5 (CMe3), 20.1 (CHMe); MS (ESI) m/z 
280 (M + H)+; HRMS m/z calcd for C8H15NO2 (M + H)
+ 280.1519, found 280.1519 (+0.3 
ppm error) and a 70:30 mixture of diastereotopic peroxides 215 (8 mg, 7%) as a colourless 
oil, RF  (90:10 hexane-Et2O) 0.14; IR (ATR) 2975, 1740 (C=O, CO2Me), 1654 (C=O, Boc), 
1428, 1274, 1147, 763 cm‒1; 1H NMR (400 MHz, CDCl3) 215 δ 10.81 (s, 1H, OOH), 10.68 
(s, 0.3H), 4.44 (dd, J = 15.0, 2.0 Hz, 0.3H, NCH), 4.33 (d, J = 15.0 Hz, 1H, NCH), 3.83-
3.76 (m, 1H, NCH), 3.81 (s, 0.9H, CO2Me), 3.79 (s, 3H, OMe), 3.23 (d, J = 15.0 Hz, 1H, 
NCH), 3.17 (d, J = 15.0 Hz, 0.3H, NCH), 2.96 (ddd, J = 13.5, 13.5, 3.0 Hz, 1H, NCH), 2.87 
(ddd, J = 13.5, 13.5, 3.0 Hz, 0.3H, NCH), 2.22-2.11 (m, 1H, CHMe), 2.07-2.00 (m, 0.3H, 
CH), 1.89 (dddd, J = 13.5, 13.5, 5.0, 5.0 Hz, 1H, CH), 1.48 (s, 9H, CMe3) 1.19-1.13 (m, 1H, 
CH), 0.98 (d, J = 7.5 Hz, 3H, CHMe), 0.94 (d, J = 7.0 Hz, 0.9H, CHMe); 13C NMR (100.6 
MHz, CDCl3) δ 171.5 (C=O, CO2Me), 158.5 (C=O, Boc), 86.0 (HOOC), 81.4 (CMe3), 52.4 
(OMe), 41.9 (NCH2), 41.2 (NCH2), 32.2 (CHMe), 28.5 (CMe3), 27.3 (CH2), 15.0 (CHMe); 
MS (ESI) m/z 290 (M + H)+; HRMS m/z calcd for C13H24NO6 (M + H)
+ 290.1598, found 
290.1598 (‒1.2 ppm error).  
Lab Book - PJ-05-26. 
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1‐tert‐Butyl 3‐methyl 5‐methylpiperidine‐1,3‐dicarboxylate cis-205 and trans-205 
 
 
 
 
A 70:30 mixture of piperidines trans-205 and cis-205 (100 mg, 0.38 mmol, 1.0 eq) was 
added to a flask containing dry THF (5 mL) at rt under Ar. The reaction flask was evacuated 
under reduced pressure and back-filled with Ar three times and the solution was cooled to ‒
78 °C. KOtBu (0.47 mL of a 1 M solution in THF, 0.47 mmol, 1.2 eq) was added dropwise. 
The resulting solution was stirred at ‒78 °C for 2 h. Then, water (1 mL) was added at ‒78 
°C and the reaction mixture was allowed to warm to rt. The mixture was extracted with 
EtOAc (3 x 5 mL) and the combined organics were dried (MgSO4) and evaporated under 
reduced pressure to give a 75:25 mixture (by 1H NMR spectroscopy) of N-Boc piperidines 
cis-205 and trans-205 (30 mg, 30%). 
Lab Book - PJ-05-74. 
 
Methyl 1-benzyl-5-methylpiperidine-3-carboxylate cis-216, trans-216 and 217 
 
 
 
BnBr (0.16 mL, 1.35 mmol, 3.0 eq) was added dropwise to a 70:30 solution of piperidine 
trans-204 and cis-204 (70 mg, 0.45 mmol, 1.0 eq) in CH2Cl2:Na2CO3(aq) (1:1, 4 mL)
 at rt 
under Ar. The resulting solution was stirred at rt for 72 h. The two layers were separated, 
and the aqueous layer was extracted with CH2Cl2 (4 x 10 mL). The combined organics were 
dried (MgSO4) and evaporated under reduced pressure to give a colourless oil. Purification 
by flash column chromatography on silica with 90:10 hexane-EtOAc as eluent gave N-
benzyl 217 (12 mg, 8%) as a yellow oil, RF (90:10 hexane-EtOAc) 0.34; IR (ATR) 3027, 
295, 1719 (C=O), 1214, 697 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.38-7.34 (m, 4H, Ph), 
7.32-7.26 (m, 4H, Ph), 7.23-7.18 (m, 2H, Ph), 6.13 (d, J = 1.5 Hz, 1H, CH), 5.40 (s, 1H, 
CH), 3.68 (s, 3H, CO2Me), 3.56 (d, J = 13.5 Hz, 2H, CHPh), 3.46 (d, J = 13.5 Hz, 2H, 
CHPh), 2.72 (dd, J = 13.0, 4.0 Hz, 1H, NCH), 2.20 (m, 2H, CH2), 2.01-1.91 (m, 1H, CHMe), 
1.71 (dd, J = 13.0, 9.5 Hz, 1H, NCH), 0.79 (d, J = 6.5 Hz, 3H, CHMe); 13C NMR (100.6 
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MHz, CDCl3) δ 168.0 (C=O), 139.9 (ipso-Ph) 139.6 (C=CH2), 129.0 (Ph), 128.2 (Ph), 126.9 
(Ph), 126.4 (CH2) 60.6 (CH2Ph), 58.8 (NCH2), 51.8 (OMe), 37.8 (CH2), 30.2 (CHMe), 17.8 
(CHMe); MS (ESI) m/z 338 (M + H)+; HRMS m/z calcd for C22H28NO2 (M + H)
+ 338.2115, 
found 338.2115 (0.2 ppm error) and N-benzyl piperidine trans-216 (28 mg, 25%) as a 
colourless oil, RF (90:10 hexane-EtOAc) 0.14; IR (ATR) 2949, 1732 (C=O), 1453, 1199, 
1150, 697 cm‒1; 1H NMR (400 MHz, ) δ 7.31-7.28 (m, 4H, Ph), 7.25-7.22 (m, 1H, Ph), 3.67 
(s, 3H, CO2Me), 3.56 (d, J = 13.5 Hz, 1H, CHPh), 3.39 (d, J = 13.5 Hz, 1H, CHPh), 2.96-
2.88 (m, 1H, NCH), 2.69-2.63 (m, 1H, CHCO2), 2.63-2.57 (m, 1H, NCH), 2.31-2.23 (m, 1H, 
NCH), 2.06-1.94 (m, 2H, CHMe and CH), 1.91-1.83 (m, 1H, NCH), 1.24-1.14 (m, 1H, CH), 
0.92 (d, J = 6.5 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 174.9 (C=O), 138.8 (ipso-
Ph), 128.9 (Ph), 128.2 (Ph), 127.0 (Ph), 63.1 (CH2Ph), 61.3 (NCH2), 54.9 (NCH2), 51.6 
(OMe), 39.7 (CHCO2), 33.4 (CH2), 28.1 (CHMe), 19.2 (CHMe); MS (ESI) m/z 248 (M + 
H)+; HRMS m/z calcd for C15H22NO2 (M + H)
+ 248.1645, found 248.1646 (‒0.9 ppm error). 
Lab Book - PJ-06-04. 
 
Pd/C (450 mg, 10 mol%) was added to a stirred solution of pyridine ester (600 mg, 4.0 mmol, 
1.0 eq) in AcOH (30 mL) at rt under Ar. The reaction flask was evacuated under reduced 
pressure and back-filled with Ar three times. After the final evacuation, H2 was charged and 
the reaction mixture was stirred vigorously under a balloon of H2 for 16 h. The solids were 
removed by filtration through Celite and washed with MeOH (30 mL). The filtrate was 
evaporated under reduced pressure to give the crude product. The crude product was 
dissolved in 1:1 CH2Cl2-sat Na2CO3(aq) (12 mL) and BnBr (1.4 mL, 12.0 mmol, 3.0 eq) was 
added dropwise at rt under Ar. The resulting solution was stirred at rt for 16 h. The two 
layers were separated, and the aqueous layer was extracted with CH2Cl2 (4 x 15 mL). The 
combined organics were dried (MgSO4) and evaporated under reduced pressure to give the 
crude product as a colourless oil. Purification by flash column chromatography on silica with 
90:10 hexane-EtOAc as eluent gave N-benzyl piperidine trans-216 (590 mg, 60%) as a 
colourless oil and N-benzyl piperidine cis-216 (88 mg, 9%) as a yellow oil, RF (90:10 
hexane-EtOAc) 0.05; IR (ATR) 2951, 1732 (C=O), 1434, 1136, 1154, 697 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.34-7.29 (m, 4H, Ph), 7.280-7.24 (m, 1H, Ph), 3.64 (s, 3H, OMe), 3.52 
(s, 2H, CHPh), 3.12-3.06 (m, 1H, NCH), 2.84-2.79 (m, 1H, NCH), 2.64 (dddd, J = 12.0, 
12.0, 4.0, 4.0 Hz, 1H, CHCO2), 2.04-1.98 (m, 1H, CH), 1.95 (dd, J = 12.0, 12.0 Hz, 1H, 
NCH), 1.78-1.66 (m, 1H, CHMe), 1.55 (d, J = 12.0, 4.0 Hz, 1H, NCH), 1.02 (ddd, J = 12.0, 
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12.0, 12.0 Hz, 1H, CH), 0.87 (d, J = 6.5 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 
174.9 (C=O), 140.1 (ipso-Ph), 129.2 (Ph), 128.4 (Ph), 127.1 (Ph), 63.2 (CH2Ph), 61.2 
(NCH2), 55.1 (NCH2), 51.7 (OMe), 42.3 (CHCO2), 35.9 (CH2), 30.6 (CHMe), 19.5 (CHMe); 
MS (ESI) m/z 248 (M + H)+; HRMS m/z calcd for C15H21NO2 (M + H)
+ 248.1645, found 
248.1647 (‒1.1 ppm error). 
Lab Book - PJ-06-10. 
 
Using general procedure E, N-benzyl piperidine trans-216 (150 mg, 0.61 mmol, 1.0 eq) and 
KOtBu (0.73 mL of a 1 M solution in THF, 0.73 mmol, 1.2 eq) in THF (5 mL) gave a crude 
85:15 mixture (by 1H NMR spectroscopy) of N-benzyl piperidines cis-216 and trans-216 
(149 mg). Purification by flash column chromatography on silica with 90:10 hexane-EtOAc 
as eluent gave N-benzyl piperidine cis-216 (93 mg, 62%) as a yellow oil.  
Lab Book - PJ-06-16. 
 
tert-Butyl 3-methylpiperidine-1-carboxylate 221                        
 
A solution of Boc2O (1.3 g, 6.0 mmol, 1.2 eq) in CH2Cl2 (5 mL) was added dropwise to a 
stirred solution of piperidines (0.59 mL, 5.0 mmol, 1.0 eq), and Et3N (2.1 mL, 15.0 mmol, 
3.0 eq) in CH2Cl2 (15 mL) at rt under Ar. The resulting solution was stirred at rt for 16 h. 
Then, the reaction mixture was evaporated under reduced pressure to give the crude product 
as a colourless oil. Purification by flash column chromatography on silica with 99:1 hexane-
EtOAc as eluent gave N-Boc piperidine 221 (975 mg, 98%) as a colourless oil, RF (99:1 
hexane-EtOAc) 0.1; IR (ATR) 2959, 1690 (C=O), 1416, 1149, 1075, 969 cm‒1; 
1H NMR 
(400 MHz, CDCl3) δ 4.07-3.74 (m, 2H, NCH), 2.68 (ddd, J = 13.0, 11.5, 3.0 Hz, 1H, NCH), 
2.49-2.21 (m, 1H, CH), 1.80-1.71 (m, 1H, CH), 1.68-1.50 (m, 2H, NCH and CHMe), 1.45 
(s, 9H, CMe3), 1.43-1.35 (m, 1H, CH), 1.09-0.97 (m, 1H, CH), 0.86 (d, J = 6.5 Hz, 3H, 
CHMe); 13C NMR (100.6 MHz, CDCl3) δ 155.1 (C=O), 79.3 (CMe3), 51.5 (NCH2), 50.8 
(NCH2), 44.5 (NCH2), 43.8 (NCH2), 33.1 (CH2), 31.1 (CHMe), 28.6 (CMe3), 25.3 (CH2), 
19.1 (CHMe); MS (ESI) m/z 222 (M + Na)+; HRMS m/z calcd for C11H21NO2 (M + Na)
+ 
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222.1464, found 222.1471 (‒3.8 ppm error). Spectroscopic data consistent with those 
reported in the literature.155 
Lab Book - PJ-05-79. 
 
1-(tert-butoxycarbonyl)-5-Methylpiperidine-2-carboxylic acid trans-222 and cis-222 
 
Table 3.4, Entry 1 
s-BuLi (1.0 mL of a 1.3 M solution in hexane, 1.3 mmol, 1.3 eq) was added drop wise to a 
stirred solution of N-Boc piperidine 221 (199 mg, 1.0 mmol, 1.0 eq) and TMEDA (0.19 mL, 
1.3 mmol, 1.3 eq) in Et2O (4 mL) at ‒78 °C under Ar. The resulting solution was stirred at ‒
78 °C for 3 h. Then, CO2 (excess) was bubbled through the reaction mixture at ‒78 °C for 
10 min. 1 M HCl(aq) (10 mL) was added and the mixture extracted with EtOAc (3 x 10 mL). 
The combined organic extracts were dried (MgSO4) and evaporated under reduced pressure 
to give the crude product. Purification by flash chromatography on silica with 98:2 CH2Cl2-
acetic acid as eluent gave a 90:10 mixture of piperidine carboxylic acid trans-222 and cis-
222 (71 mg, 29%) as a white solid and N-Boc piperidine (85 mg, 42%) as a colourless oil. 
Lab Book - PJ-05-85. 
 
Table 3.4, Entry 2 
s-BuLi (1.0 mL of a 1.3 M solution in hexane, 1.3 mmol, 1.3 eq) was added drop wise to a 
stirred solution of N-Boc piperidine 221 (199 mg, 1.0 mmol, 1.0 eq) and TMEDA (0.19 mL, 
1.3 mmol, 1.3 eq) in Et2O (4 mL) at ‒60 °C under Ar. The resulting solution was stirred at ‒
60 °C for 3 h. Then, CO2 (excess) was bubbled through the reaction mixture at ‒60 °C for 
10 min. 1 M HCl(aq) (10 mL) was added and the mixture extracted with EtOAc (3 x 10 mL). 
The combined organic extracts were dried (MgSO4) and evaporated under reduced pressure 
to give the crude product. Purification by flash chromatography on silica with 99:1 to 99:2 
CH2Cl2-acetic acid as eluent gave a 90:10 mixture of piperidine carboxylic acid trans-222 
and cis-222 (140 mg, 57 %) as a white solid, m.p 99-101 °C; RF (95:5 CH2Cl2-AcOH) 0.22; 
IR (ATR) 2936, 1725 (C=O, CO2H), 1622 (C=O, Boc), 1438, 1365, 1151, 850 cm
‒1; 1H 
NMR (400 MHz, CDCl3) trans-222: δ 11.56-10.82 (m, 1H, CO2H), 4.97-4.51 (m, 1H, 
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NCHCO2), 3.69-3.45 (m, 1H, NCH), 3.18 (dd, J = 13.0, 3.0 Hz, 1H, NCH), 1.97-1.93 (m, 
2H, CH2), 1.92-1.82 (m, 1H, CHMe), 1.68-1.54 (m, 1H, CH), 1.53-1.34 (m, 10H, CMe3 and 
CH), 0.97 (d, J = 7.0 Hz, 2.7H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 178.0 (C=O, 
CO2H), 156.5 (C=O, Boc), 80.5 (CMe3), 53.9 (NCHCO2), 47.5 (NCH2), 28.4 (CMe3), 27.1 
(CHMe), 27.0 (CH2), 21.6 (CH2), 16.7 (CHMe); MS (ESI) m/z 266 (M + Na)+; HRMS m/z 
calcd for C12H21NO4 (M + Na)
+ 266.1363, found 266.1367 (‒3.8 ppm error). Spectroscopic 
data consistent with those reported in the literature.112 
Lab Book - PJ-05-90. 
 
Table 3.4, Entry 3 
s-BuLi (1.0 mL of a 1.3 M solution in hexane, 1.3 mmol, 1.3 eq) was added drop wise to a 
stirred solution of N-Boc piperidine 221 (199 mg, 1.0 mmol, 1.0 eq) and TMEDA (0.19 mL, 
1.3 mmol, 1.3 eq) in Et2O (4 mL) at ‒40 °C under Ar. The resulting solution was stirred at ‒
40 °C for 3 h. Then, CO2 (excess) was bubbled through the reaction mixture at ‒40 °C for 
10 min. 1 M HCl(aq) (10 mL) was added and the mixture extracted with EtOAc (3 x 10 mL). 
The combined organic extracts were dried (MgSO4) and evaporated under reduced pressure 
to give the crude product. Purification by flash chromatography on silica with 99:1 to 99:2 
CH2Cl2-acetic acid as eluent gave 3-methyl piperidine (69 mg, 35%) as a yellow oil and a 
90:10 mixture of piperidine carboxylic acid trans-222 and cis-222 (70 mg, 29%) as a white 
solid. 
Lab Book - PJ-05-93. 
 
Table 3.4, Entry 4 
s-BuLi (1.0 mL of a 1.3 M solution in hexane, 1.3 mmol, 1.3 eq) was added drop wise to a 
stirred solution of N-Boc piperidine 221 (199 mg, 1.0 mmol, 1.0 eq) and TMEDA (0.19 mL, 
1.3 mmol, 1.3 eq) in Et2O (4 mL) at ‒60 °C under Ar. The resulting solution was stirred at ‒
60 °C for 6 h. Then, CO2 (excess) was bubbled through the reaction mixture at ‒60 °C for 
10 min. 1 M HCl(aq) (10 mL) was added and the mixture extracted with EtOAc (3 x 10 mL). 
The combined organic extracts were dried (MgSO4) and evaporated under reduced pressure 
to give the crude product. Purification by flash chromatography on silica with 99:1 to 99:2 
CH2Cl2-acetic acid as eluent gave a 90:10 mixture of piperidine carboxylic acid trans-222 
and cis-222 (140 mg, 56 %) as a white solid. 
Lab Book - PJ-05-97. 
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1-(tert-butyl) 2-Methyl-5-methylpiperidine-1,2-dicarboxylate trans-189 and cis-189 
 
Potassium carbonate (86 mg, 0.62 mmol, 3.0 eq) was added to a stirred solution of N-Boc 
piperidine carboxylic acid 222 (50 mg, 0.21 mmol, 1.0 eq) in dimethylformamide (3 mL) at 
rt. The resulting suspension was stirred at rt for 30 min before the addition of methyl iodide 
(0.038 mL, 0.62 mmol, 3.0 eq). The mixture was then stirred at rt for 18 h. The reaction 
mixture was taken up into water (3 mL) and extracted with EtOAc (4 x 10 mL). The 
combined organic extracts were washed with brine (4 x 5 mL), dried (MgSO4) and 
evaporated under reduced pressure to give the crude product. Purification by flash 
chromatography on silica with 90:10 hexane-EtOH as eluent gave a 90:10 mixture of 
piperidine ester trans-189 and cis-189 (47 mg, 87%) as a yellow oil, RF (90:10, hexane-
EtOH) 0.17; IR (ATR) 2940, 1743 (C=O, CO2Me), 1690 (C=O, Boc), 1363, 1147, 864 cm
‒
1; 1H NMR (400 MHz, CDCl3) δ 4.86-4.59 (m, 1H, NCHCO2), 3.72 (s, 3H, OMe), 3.64-3.55 
(m, 1H, NCH), 3.20-3.11 (m, 1H, NCH), 1.97-1.90 (m, 2H, CH), 1.90-1.83 (m, 1H, CHMe), 
1.59-1.50 (m, 1H, CH), 1.44 (s, 9H, CMe3), 1.41-1.32 (m, 1H), 0.98 (d, J = 7.0 Hz, 3H, 
CHMe); 13C NMR (100.6 MHz, CDCl3) δ 172.7 (C=O, CO2Me), 156.3 (C=O, Boc), 80.1 
(CMe3), 54.5 (NCHCO2), 52.2 (OMe), 47.3 (NCH2), 28.4 (CMe3), 27.2 (CHMe), 27.1 (CH2), 
21.8 (CH2), 16.7 (CHMe); MS (ESI) m/z 280 (M + Na)
+; HRMS m/z calcd for C13H23NO4 
(M + Na)+ 280.1519, found 280.1525 (‒2.0 ppm error). 
Lab Book - PJ-05-95. 
 
Methyl-1-benzyl-5-methylpiperidine-2-carboxylate trans-207 
 
TFA (1 mL) was added to a stirred solution of a 90:10 mixture of piperidine ester trans-189 
and cis-189 (47 mg, 0.18 mmol, 1.0 eq) in CH2Cl2 (5 mL) at 0 °C under Ar. The resulting 
solution was warmed to rt and stirred for 3 h at rt, then evaporated under reduced pressure. 
The residue was dissolved in CH2Cl2 (2 mL) and sat Na2CO3(aq) (2 mL) and benzyl bromide 
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(0.06 mL, 0.54 mmol, 3.0 eq) were added. The resulting mixture was stirred at rt for 16 h. 
The two layers were separated, and the aqueous layer was extracted with CH2Cl2 (3 x 5 mL). 
The combined organics were dried (MgSO4) and evaporated under reduced pressure to give 
the crude product as a colourless oil. Purification by flash column chromatography on silica 
with 90:10 hexane-EtOAc as eluent gave N-benzyl piperidine cis-207 (4 mg, 7%) as a 
colourless oil and N-benzyl piperidine trans-207 (38 mg, 85%) as a colourless oil. 
Lab Book - PJ-05-98. 
 
Methyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 236 
 
 
 
Ethylene glycol (1.14 mL, 20.4 mmol, 3.5 eq) was added dropwise to a stirred solution of 
methyl 4-oxocyclohexanecarboxylate (910 mg, 5.83 mmol, 1.0 eq) and p-TsOH (111 mg, 
0.53 mmol, 0.1 eq) in dry toluene (30 mL) at rt under Ar. The resulting solution was stirred 
at rt for 16 h. Et2O (30 mL) was added and the combined organics were washed with water 
(20 mL) and sat NaHCO3(aq) (20 mL), dried (Na2CO3) and evaporated under reduced pressure 
to give the crude product as a colourless oil. Purification by flash column chromatography 
on silica with 80:20 hexane-EtOAc as eluent gave ketal 236 (954 mg, 81%) as a colourless 
oil, RF (80:20 hexane-Et2O) 0.21; IR (ATR) 2950, 1730 (C=O), 1098, 923 cm
‒1; 1H NMR 
(400 MHz, CDCl3) δ 3.93 (s, 4H, OCH2), 3.66 (s, 3H, OMe), 2.34 (tt, J = 10.5, 4.0 Hz, 1H, 
CH), 1.97-1.87 (m, 2H, CH), 1.85-1.72 (m, 4H, CH), 1.54 (ddd, J = 13.0, 13.0, 4.5 Hz, 2H, 
CH); 13C NMR (100.6 MHz, CDCl3) δ 175.8 (C=O), 108.2 (OCO), 64.4 (OCH2), 51.7 
(OMe), 41.6 (CH), 33.8 (CH2), 26.4 (CH2); MS (ESI) m/z 223 (M + Na)
+; HRMS m/z calcd 
for C10H16O4 (M + Na)
+ 223.0941, found 223.0935 (+0.9 ppm error). Spectroscopic data 
consistent with those reported in the literature.156 
Lab Book - PJ-06-47 
 
 
 
 
 
261 
 
Methyl 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carboxylate 241 
 
 
 
 
 
Table 4.1, entry 1 
LiHMDS (0.83 mL of a 1.0 M solution in THF, 0.83 mmol, 2.0 eq) was added dropwise to 
a solution of ketal 236 (100 mg, 1.56 mmol, 1.2 eq) and 2-bromopyridine (0.04 mL, 0.42 
mmol, 1.0 eq) in dry toluene (5 mL) at rt under Ar. The reaction mixture was then added 
dropwise to a solution of [(cinnamyl)PdCl]2 (1.1 mg, 0.002 mmol, 0.005 eq) and t-
Bu3P·HBF4 (2.4 mg, 0.008 mmol, 0.02 eq) in dry toluene (1 mL). The reaction flask was 
then evacuated under reduced pressure and back-filled with Ar three times. The resulting 
solution was stirred at rt for 16 h. The solution was poured into 1 M AcOH(aq) (10 mL) and 
the aqueous layer was extracted with EtOAc (3 x 5 mL). The combined organics were 
washed with brine (10 mL), sat NaHCO3(aq) (10 mL), dried (MgSO4) and evaporated under 
reduced pressure to give crude product as an orange oil which contained no product by 1H 
NMR spectroscopic analysis.  
Lab Book - PJ-06-35. 
 
Table 4.1, entry 2 
LiHMDS (3.74 mL of a 1.0 M solution in THF, 3.74 mmol, 2.0 eq) was added dropwise to 
a solution of ketal 236 (450 mg, 2.25 mmol, 1.2 eq) and 2-bromopyridine (0.18 mL, 1.9 
mmol, 1.0 eq) in dry toluene (5 mL) at rt under Ar. The reaction mixture was then added 
dropwise to a solution of [(cinnamyl)PdCl]2 (19 mg, 0.037 mmol, 0.02 eq) and t-Bu3P·HBF4 
(21.7 mg, 0.075 mmol, 0.04 eq) in dry toluene (1 mL). The reaction flask was then evacuated 
under reduced pressure and back-filled with Ar three times. The resulting solution was 
stirred at rt for 16 h. The solution was poured into 1 M AcOH(aq) (10 mL) and the aqueous 
layer was extracted with EtOAc (3 x 5 mL). The combined organics were washed with brine 
(10 mL) and sat NaHCO3(aq) (10 mL), dried (MgSO4) and evaporated under reduced pressure 
to give the crude product as an orange oil which contained an 80:20 mixture of 2-
bromopyridine and aryl ketal 241 by 1H NMR spectroscopy. 
Lab Book - PJ-06-37. 
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Table 4.1, entry 3 
LiHMDS (1.7 mL of a 1.0 M solution in toluene, 1.7 mmol, 2.0 eq) was added dropwise to 
a solution of ketal 236 (200 mg, 1.0 mmol, 1.2 eq) and 2-bromopyridine (0.08 mL, 0.83 
mmol, 1.0 eq) in dry toluene (6 mL) at rt under Ar. The reaction mixture was then added 
dropwise to a solution of [(cinnamyl)PdCl]2 (8.8 mg, 0.017 mmol, 0.02 eq) and t-Bu3P·HBF4 
(9.9 mg, 0.034 mmol, 0.04 eq) in dry toluene (1 mL). The reaction flask was then evacuated 
under reduced pressure and back-filled with Ar three times. The resulting solution was 
stirred at rt for 16 h. The solution was poured into 1 M AcOH(aq) (10 mL) and the aqueous 
layer was extracted with EtOAc (3 x 5 mL). The combined organics were washed with brine 
(10 mL) and sat NaHCO3(aq) (10 mL), dried (MgSO4) and evaporated under reduced pressure 
to give an orange oil. Purification by flash column chromatography on silica with 80:20-
70:30 hexane-EtOAc as eluent gave aryl ketal 241 (171 mg, 74%) as a colourless oil, RF 
(70:30 hexane-EtOAc) 0.17; IR (ATR) 2950, 1726 (C=O), 1220, 1194, 1100 cm‒1; 1H NMR 
(400 MHz, CDCl3) δ 8.56 (ddd, J = 5.0, 2.0, 1.0 Hz, 1H, 6-py), 7.65 (ddd, J = 8.0, 8.0, 2.0 
Hz, 1H, 4-py), 7.36 (ddd, J = 8.0, 1.0, 1.0 Hz, 1H, 3-py), 7.15 (ddd, J = 8.0, 5.0, 1.0 Hz, 1H, 
5-py), 3.99-3.91 (m, 4H, OCH2), 3.69 (s, 3H, OMe), 2.53-2.45 (m, 2H, CH), 2.28-2.19 (m, 
2H, CH), 1.78-1.71 (m, 4H, CH); 13C NMR (100.6 MHz, CDCl3) δ 174.8 (C=O), 161.7 
(ipso-Ar), 149.2 9 (Ar), 136.7 (Ar), 122.0 (Ar), 120.6 (Ar), 108.3 (C), 64.4 (OCH2), 53.4 
(C), 52.4 (OMe), 32.2 (CH2), 31.4 (CH2); MS (ESI) m/z 278 (M + H)
+; HRMS m/z calcd for 
C15H19NO4 (M + H)
+ 278.1387, found 278.1383 (+1.5 ppm error). Spectroscopic data 
consistent with those reported in the literature.119 
Lab Book - PJ-07-55. 
 
Methyl 1-phenylcyclopentane-1-carboxylate 243 
 
 
 
Table 4.2, entry 1 
LiHMDS (2.6 mL of a 1.0 M solution in THF, 2.6 mmol, 2.0 eq) was added dropwise to a 
solution of cyclopentane ester 242 (0.2 mL, 1.56 mmol, 1.2 eq) and 4-bromotoluene (222 
mg, 1.30 mmol, 1.0 eq) in dry toluene (5 mL) at rt under Ar. The reaction mixture was then 
added dropwise to a solution of [(cinnamyl)PdCl2] (13 mg, 0.026 mmol, 0.02 eq) and t-
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Bu3P·HBF4 (15 mg, 0.052 mmol, 0.04 eq) in dry toluene (1 mL). The reaction flask was then 
evacuated under reduced pressure and back-filled with Ar three times. The resulting solution 
was stirred at rt for 16 h. The solution was poured into 1 M AcOH(aq) (10 mL) and the 
aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organics were washed 
with brine (20 mL) and sat NaHCO3(aq) (20 mL), dried (MgSO4) and evaporated under 
reduced pressure to give the crude product as an orange oil which contained no product by 
1H NMR spectroscopy.  
Lab Book - PJ-06-39. 
 
Table 4.2, entry 2 
NaHMDS (1.3 mL of a 2.0 M solution in THF, 2.6 mmol, 2.0 eq) was added dropwise to a 
solution of cyclopentane ester 242 (0.2 mL, 1.56 mmol, 1.2 eq) and 4-bromotoluene (222 
mg, 1.30 mmol, 1.0 eq) in dry toluene (5 mL) at rt under Ar. The solution was then added 
dropwise to a solution of [(cinnamyl)PdCl2] (13 mg, 0.026 mmol, 0.02 eq) and t-Bu3P·HBF4 
(15 mg, 0.052 mmol, 0.04 eq) in dry toluene (1 mL). The reaction flask was then evacuated 
under reduced pressure and back-filled with Ar three times. The resulting solution was 
stirred at rt for 16 h. The solution was poured into 1 M AcOH(aq) (10 mL) and the aqueous 
layer was extracted with EtOAc (3 x 10 mL). The combined organics were washed with 
brine (20 mL) and sat NaHCO3(aq) (20 mL), dried (MgSO4) and evaporated under reduced 
pressure to give the crude product as an orange oil which contained no product by 1H NMR 
spectroscopy. 
Lab Book - PJ-06-43. 
 
Table 4.2, entry 3 
LiHMDS (2.6 mL of a 1.0 M solution in toluene, 2.6 mmol, 2.0 eq) was added dropwise to 
a solution of cyclopentane ester 242 (0.2 mL, 1.56 mmol, 1.2 eq) and 4-bromotoluene (222 
mg, 1.30 mmol, 1.0 eq) in dry toluene (5 mL) at rt under Ar. The reaction mixture was then 
added dropwise to a solution of [(cinnamyl)PdCl2] (13 mg, 0.026 mmol, 0.02 eq) and t-
Bu3P·HBF4 (15 mg, 0.052 mmol, 0.04 eq) in dry toluene (1 mL). The reaction flask was then 
evacuated under reduced pressure and back-filled with Ar three times. The resulting solution 
was stirred at rt for 16 h. The solution was poured into 1 M AcOH(aq) (10 mL) and the 
aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organics were washed 
with brine (20 mL) and sat NaHCO3(aq) (20 mL), dried (MgSO4) and evaporated under 
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reduced pressure to give the crude product as an orange oil. Purification by flash column 
chromatography on silica with 90:10 hexane-Et2O as eluent gave aryl cyclopentane ester 243 
(15 mg, 5%) as a white solid and cyclopentane ester 242 (138 mg). 
Lab Book - PJ-06-41. 
 
Table 4.2, entry 4 
n-BuLi (1.0 mL of a 2.3 M solution in hexane, 2.3 mmol, 2.0 eq) was added dropwise to a 
stirred solution of diisopropylamine (0.32 mL, 2.3 mmol, 2.0 eq) in dry toluene (1 mL) at 0 
°C under Ar. The resulting solution was stirred at 0 °C for 30 min. A solution of cyclopentane 
ester 242 (0.2 mL, 1.56 mmol, 1.2 eq) and 4-bromotoluene (222 mg, 1.30 mmol, 1.0 eq) in 
toluene (5 mL) was added dropwise to the LDA solution under Ar. The solution was stirred 
at 0 °C for 10 min and then allowed to warm to rt and stirred at rt for 10 min. The solution 
was then added dropwise to a solution of [(cinnamyl)PdCl2] (13 mg, 0.026 mmol, 0.02 eq) 
and t-Bu3P·HBF4 (15 mg, 0.052 mmol, 0.04 eq) in dry toluene (1 mL). The reaction flask 
was then evacuated under reduced pressure and back-filled with Ar three times. The resulting 
solution was stirred at rt for 16 h. The solution was poured into 1 M AcOH(aq) (10 mL) and 
the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organics were 
washed with brine (20 mL) and sat NaHCO3(aq) (20 mL), dried (MgSO4) and evaporated 
under reduced pressure to give the crude product as an orange oil. Purification by flash 
column chromatography on silica with 98:2-90:10 hexane-Et2O as eluent gave aryl 
cyclopentane ester 243 (58 mg, 20%) as a white solid, mp 46-48 °C; RF (90:10 hexane-Et2O) 
0.37; IR (ATR) 2947, 1720 (C=O), 1193, 1157, 742 cm‒1; 1H NMR (400 MHz, CDCl3) δ 
7.27 (d, J = 8.0 Hz, 2H, Ar), 7.13 (d, J = 8.0 Hz, 2H, Ar), 3.62 (s, 3H, OMe), 2.68-2.60 (m, 
2H, CH2), 2.34 (s, 3H, C6H4Me), 1.96-1.87 (m, 2H, CH2), 1.78-1.68 (m, 4H, CH2); 
13C NMR 
(100.6 MHz, CDCl3) δ 176.8 (C=O), 140.5 (ipso-Ar), 136.4 (ipso-Ar), 129.1 (Ar), 126.8 
(Ar), 58.8 (OMe), 52.5 (C), 36.3 (CH2), 23.7 (CH2), 21.1 (C6H4Me); MS (ESI) m/z 241 (M 
+ Na)+; HRMS m/z calcd for C14H18O2 (M + Na)
+ 241.1199, found 241.1191 (+0.8 ppm 
error). Spectroscopic data consistent with those reported in the literature.157 
Lab Book - PJ-07-54. 
 
Table 4.3, entry 1 
Using general procedure G, n-BuLi (1.0 mL of a 2.3 M solution in hexane, 2.3 mmol, 2.0 
eq), diisopropylamine (0.32 mL, 2.3 mmol, 2.0 eq), cyclopentane ester 242 (0.2 mL, 1.56 
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mmol, 1.2 eq), [(cinnamyl)PdCl2] (13 mg, 0.026 mmol, 0.02 eq), t-Bu3P·HBF4 (15 mg, 0.052 
mmol, 0.04 eq) and 4-bromotoluene (222 mg, 1.30 mmol, 1.0 eq) in dry toluene (7 mL) at rt 
for 16 h gave the crude product as an orange oil. Purification by flash column 
chromatography on silica with 98:2-90:10 hexane-Et2O as eluent gave aryl cyclopentane 
ester 243 (58 mg, 58%) as a white solid. 
Lab Book - PJ-06-44. 
 
Table 4.3, entry 2 
n-BuLi (1.0 mL of a 2.3 M solution in hexane, 2.3 mmol, 2.0 eq) was added dropwise to a 
stirred solution of dicyclohexylamine (0.46 mL, 2.3 mmol, 2.0 eq) in dry toluene (1 mL) at 
0 °C under Ar. The resulting solution was stirred at 0 °C for 30 min. A solution of 
cyclopentane ester 242 (0.2 mL, 1.56 mmol, 1.2 eq) in toluene (1 mL) was added dropwise 
to the LiNCy2 solution at 0 °C under Ar. The solution was stirred at 0 °C for 10 min and then 
allowed to warm to rt and stirred at rt for 10 min. The solution was then added dropwise to 
a solution of [(cinnamyl)PdCl2] (13 mg, 0.026 mmol, 0.02 eq), t-Bu3P·HBF4 (15 mg, 0.052 
mmol, 0.04 eq) and 4-bromotoluene (222 mg, 1.30 mmol, 1.0 eq) in dry toluene (5 mL). The 
reaction flask was then evacuated under reduced pressure and back-filled with Ar three 
times. The resulting solution was stirred at rt for 16 h. The solution was poured into 1 M 
AcOH(aq) (10 mL) and the aqueous layer was extracted with EtOAc (3 x 10 mL). The 
combined organics were washed with brine (20 mL) and sat NaHCO3(aq) (20 mL), dried 
(MgSO4) and evaporated under reduced pressure to give the crude product as a green oil. 
Purification by flash column chromatography on silica with 98:2-90:10 hexane-Et2O as 
eluent gave aryl cyclopentane ester 243 (58 mg, 59%) as a white solid. 
Lab Book - PJ-06-46. 
 
Table 4.3, entry 3 
Using general procedure F, cyclopentane ester 242 (0.2 mL, 1.56 mmol, 1.2 eq), LiHMDS 
(2.6 mL of a 1.0 M solution in THF, 2.6 mmol, 2.0 eq), [(cinnamyl)PdCl2] (13 mg, 0.026 
mmol, 0.02 eq), t-Bu3P·HBF4 (15 mg, 0.052 mmol, 0.04 eq) and 4-bromotoluene (222 mg, 
1.30 mmol, 1.0 eq) in toluene (7 mL) at rt for 16 h gave the crude product as an orange oil 
which contained no product by 1H NMR spectroscopy. 
Lab Book - PJ-06-48. 
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Table 4.3, entry 4 
Using general procedure F, cyclopentane ester 242 (0.2 mL, 1.56 mmol, 1.2 eq), LiHMDS 
(2.6 mL of a 1.0 M solution in toluene, 2.6 mmol, 2.0 eq), [(cinnamyl)PdCl2] (13 mg, 0.026 
mmol, 0.02 eq), t-Bu3P·HBF4 (15 mg, 0.052 mmol, 0.04 eq) and 4-bromotoluene (222 mg, 
1.30 mmol, 1.0 eq) in toluene (7 mL) at rt for 16 h gave the crude product as an orange oil. 
Purification by flash column chromatography on silica with 98:2-90:10 hexane-Et2O as 
eluent gave aryl cyclopentane ester 243 (98 mg, 34%) as a white solid. 
Lab Book - PJ-06-55. 
 
Methyl 1-(4-fluorophenyl)cyclopentane-1-carboxylate 244 
 
 
 
Table 4.4, entry 1 
Using general procedure G, n-BuLi (0.57 mL of a 2.3 M solution in hexane, 1.32 mmol, 2.0 
eq), diisopropylamine (0.19 mL, 1.32 mmol, 2.0 eq), cyclopentane ester 242 (0.1 mL, 0.79 
mmol, 1.2 eq), [(cinnamyl)PdCl2] (6.8 mg, 0.013 mmol, 0.02 eq), t-Bu3P·HBF4 (7.5 mg, 
0.026 mmol, 0.04 eq) and 4-bromofluorobenzene (0.07 mL, 0.66 mmol, 1.0 eq) in dry 
toluene (6 mL) at rt for 16 h gave the crude product as a black oil. Purification by flash 
column chromatography on silica with 80:20 CH2Cl2-hexane as eluent gave aryl 
cyclopentane ester 244 (50 mg, 34%) as a colourless oil, RF (CH2Cl2) 0.19, IR (ATR) 2952, 
1726 (C=O), 1508, 1228, 1154, 834 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.33 (dd, J = 9.0, 
5.5 Hz, 2H, Ar), 7.02-6.95 (dd, J = 9.0, 9.0 Hz, 2H, Ar), 3.61 (s, 3H, OMe), 2.69-2.58 (m, 
2H, CH), 1.93-1.81 (m, 2H, CH), 1.77-1.66 (m, 4H, CH); 13C NMR (100.6 MHz, CDCl3) δ 
176.4 (C=O), 161.7 (d, J = 245.0 Hz, ipso-Ar), 139.2 (d, J = 3.0 Hz, ipso-Ar), 128.6 (d, J = 
8.0 Hz, Ar), 115.1 (d, J = 21.0 Hz, Ar), 58.6 (C), 52.5 (OMe), 36.4 (CH2), 23.6 (CH2); MS 
(ESI) m/z 223 (M + H)+; HRMS m/z calcd for C13H15FO2 (M + H)
+ 223.1129 found 223.1125 
(+1.9 ppm error). Spectroscopic data consistent with those reported in the literature.158 
Lab Book - PJ-06-67. 
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Methyl 1-(4-(trifluoromethyl)phenyl)cyclopentane-1-carboxylate 245 
 
 
 
Table 4.4, entry 2 
Using general procedure G, n-BuLi (0.57 mL of a 2.3 M solution in hexane, 1.32 mmol, 2.6 
eq), diisopropylamine (0.19 mL, 1.32 mmol, 2.6 eq), cyclopentane ester 242 (0.1 mL, 0.79 
mmol, 1.6 eq), [(cinnamyl)PdCl2] (6.8 mg, 0.013 mmol, 0.026 eq), t-Bu3P·HBF4 (7.5 mg, 
0.026 mmol, 0.052 eq) and 4-bromobenzotrifluoride (0.07 mL, 0.66 mmol, 1.0 eq) in dry 
toluene (6 mL) at rt for 16 h gave the crude product as a black oil. Purification by flash 
column chromatography on silica with 98:2 hexane-Et2O as eluent gave aryl cyclopentane 
ester 245 (97 mg, 72%) as a white solid, mp 52-54 °C; RF (90:10 hexane-Et2O) 0.3, IR (ATR) 
2967, 1730 (C=O), 1320, 1158, 1122, 1101, 1067 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.57 
(d, J = 8.0 Hz, 2H, Ar), 7.47 (d, J = 8.0 Hz, 2H, Ar), 3.62 (s, 3H, OMe), 2.71-2.63 (m, 2H, 
CH), 1.96-1.87 (m, 2H, CH), 1.79-1.70 (m, 4H, CH); 13C NMR (100.6 MHz, CDCl3) δ 175.8 
(C=O), 147.4 (ipso-Ar), 129.6 (q, J = 32.5 Hz, ipso-Ar), 127.4 (Ar), 125.3 (q, J = 4.0 Hz, 
Ar), 124.3 (q, J = 272.0 Hz, CF3), 59.2 (C), 52.6 (OMe), 36.3 (CH2), 23.6 (CH2); MS (ESI) 
m/z 273 (M + H)+; HRMS m/z calcd for C14H16F3O2 (M + H)
+ 273.1097 found 273.1098 (‒
2.2 ppm error). 
Lab Book - PJ-06-62. 
 
Methyl 1-(4-methoxyphenyl)cyclopentane-1-carboxylate 246 
 
 
 
Table 4.4, entry 3 
Using general procedure G, n-BuLi (0.57 mL of a 2.3 M solution in hexane, 1.32 mmol, 2.0 
eq), diisopropylamine (0.19 mL, 1.32 mmol, 2.0 eq), cyclopentane ester 242 (0.1 mL, 0.79 
mmol, 1.2 eq), [(cinnamyl)PdCl2] (6.8 mg, 0.013 mmol, 0.02 eq), t-Bu3P·HBF4 (7.5 mg, 
0.026 mmol, 0.04 eq) and 4-bromoanisole (0.08 mL, 0.66 mmol, 1.0 eq) in dry toluene (6 
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mL) at rt for 16 h gave the crude product as a black oil. Purification by flash column 
chromatography on silica with 98:2 hexane-Et2O as eluent gave aryl cyclopentane ester 246 
(106 mg, 68%) as a yellow oil, RF (95:5 hexane-EtOAc) 0.08, IR (ATR) 2950, 1725 (C=O), 
1511, 1247, 1181, 1034, 830 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.29 (d, J = 9.0 Hz, 2H, 
Ar), 6.84 (d, J = 9.0 Hz, 2H, Ar), 3.79 (s, 3H, OMe), 3.60 (s, 3H, OMe), 2.71-2.55 (m, 2H, 
CH), 2.07-1.80 (m, 2H, CH), 1.79-1.61 (m, 4H, CH); 13C NMR (100.6 MHz, CDCl3) δ 176.8 
(C=O), 158.4 (ipso-Ar), 135.5 (ipso-Ar), 128.0 (Ar), 113.7 (Ar), 58.4 (C), 55.3 (OMe), 52.4 
(OMe), 36.3 (CH2), 23.6 (CH2); MS (ESI) m/z 257 (M + Na)
+; HRMS m/z calcd for C14H18O3 
(M + Na)+ 257.1148 found 257.1146 (+0.8 ppm error). 
Lab Book - PJ-06-68. 
 
Methyl 1-(o-tolyl)cyclopentane-1-carboxylate 247 
 
 
 
Table 4.4, entry 4 
Using general procedure G, n-BuLi (0.57 mL of a 2.3 M solution in hexane, 1.32 mmol, 2.0 
eq), diisopropylamine (0.19 mL, 1.32 mmol, 2.0 eq), cyclopentane ester 242 (0.1 mL, 0.79 
mmol, 1.2 eq), [(cinnamyl)PdCl2] (6.8 mg, 0.013 mmol, 0.02 eq), t-Bu3P·HBF4 (7.5 mg, 
0.026 mmol, 0.04 eq) and 2-bromotoluene (0.08 mL, 0.66 mmol, 1.0 eq) in dry toluene (6 
mL) at rt for 16 h gave the crude product as a black oil. Purification by flash column 
chromatography on silica with 98:2 hexane-Et2O as eluent gave aryl cyclopentane ester 247 
(52 mg, 36%) as a yellow oil, RF (90:10 hexane-Et2O) 0.27, IR (ATR) 2949, 1725 (C=O), 
1231, 1152, 741 cm‒1; 
1H NMR (400 MHz, CDCl3) δ 7.35-7.32 (m, 1H, Ar), 7.20-7.11 (m, 
3H, Ar), 3.61 (s, 3H, OMe), 2.55-2.47 (m, 2H, CH), 2.23 (s, 3H, C6H4Me), 2.08-1.98 (m, 
2H, CH), 1.83-1.66 (m, 4H, CH); 13C NMR (100.6 MHz, CDCl3) δ 177.8 (C=O), 142.2 
(ipso-Ar), 136.7 (ipso-Ar), 131.7 (Ar), 126.8 (Ar), 125.9 (Ar), 125.8 (Ar), 58.1 (C), 52.5 
(OMe), 36.9 (CH2), 24.7 (CH2), 20.9 (C6H4Me); MS (ESI) m/z 241 (M + Na)
+; HRMS m/z 
calcd for C14H18O2 (M + Na)
+ 241.1199 found 241.1198 (+0.3 ppm error). 
Lab Book - PJ-06-63. 
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Methyl 1-(pyridin-2-yl)cyclopentane-1-carboxylate 248 
 
 
 
 
 
Table 4.4, entry 7 
Using general procedure G, n-BuLi (1.0 mL of a 2.3 M solution in hexane, 2.3 mmol, 2.0 
eq), diisopropylamine (0.32 mL, 2.3 mmol, 2.0 eq), cyclopentane ester 242 (0.2 mL, 1.56 
mmol, 1.2 eq), [(cinnamyl)PdCl2] (13 mg, 0.026 mmol, 0.02 eq), t-Bu3P·HBF4 (15 mg, 0.052 
mmol, 0.04 eq) and 4-bromotoluene (222 mg, 1.30 mmol, 1.0 eq) in dry toluene (7 mL) at rt 
for 16 h gave give the crude product as a black oil. Purification by flash column 
chromatography on silica with 90:10 to 70:30 hexane-Et2O, followed by 98:2 CH2Cl2-Et2O 
as eluent gave aryl cyclopentane ester 248 (15 mg, 6%) as a yellow oil, RF (80:20 hexane-
Et2O) 0.12, IR (ATR) 2950, 1727 (C=O), 1429, 1153, 750 cm
‒1; 1H NMR (400 MHz, CDCl3) 
δ 8.55 (ddd, J = 5.0, 2.0, 1.0 Hz, 1H, 6-py), 7.64 (ddd, J = 8.0, 8.0, 2.0 Hz, 1H, 4-py), 7.29 
(ddd, J = 8.0, 1.0, 1.0 Hz, 1H, 3-py), 7.14 (ddd, J = 8.0, 5.0, 1.0 Hz, 1H, 5-py), 3.66 (s, 3H, 
OMe), 2.57-2.48 (m, 2H, CH), 2.24-2.16 (m, 2H, CH), 1.79-1.70 (m, 4H, CH); 13C NMR 
(100.6 MHz, CDCl3) δ 176.3 (C=O), 162.6 (ipso-Ar), 148.9 (Ar), 136.5 (Ar), 121.7 (Ar), 
121.1 (Ar), 61.7 (C), 52.4 (OMe), 36.2 (CH2), 24.6 (CH2); MS (ESI) m/z 206 (M + H)
+; 
HRMS m/z calcd for C12H15NO (M + Na)
+ 206.1170, found 206.0964 (+3.7 ppm error).   
Lab Book - PJ-06-52. 
 
Methyl 1-(4-fluorophenyl)cyclopentane-1-carboxylate 244 
 
 
 
 
Table 4.5, entry 1 
Using general procedure F, cyclopentane ester 242 (0.1 mL, 0.79 mmol, 1.2 eq), LiHMDS 
(1.32 mL of a 1.0 M solution in toluene, 1.32 mmol, 2.0 eq), [(cinnamyl)PdCl2] (6.8 mg, 
0.013 mmol, 0.02 eq), t-Bu3P·HBF4 (7.5 mg, 0.026 mmol, 0.04 eq) and 4-
bromofluorobenzene (0.07 mL, 0.66 mmol, 1.0 eq) in toluene (6 mL) at rt for 16 h gave the 
270 
 
crude product as a yellow oil. Purification by flash column chromatography on silica with 
95:5-80:20 hexane-Et2O as eluent gave aryl cyclopentane ester 244 (40 mg, 27%) as a yellow 
oil. 
Lab Book - PJ-06-58. 
 
Methyl 1-(pyridin-2-yl)cyclopentane-1-carboxylate 248 
 
 
 
 
 
Table 4.5, entry 3 
Using general procedure F, cyclopentane ester 242 (0.2 mL, 1.56 mmol, 1.2 eq), LiHMDS 
(2.6 mL of a 1.0 M solution in toluene, 2.6 mmol, 2.0 eq), [(cinnamyl)PdCl2] (13 mg, 0.026 
mmol, 0.02 eq), t-Bu3P·HBF4 (15 mg, 0.052 mmol, 0.04 eq) and 2-bromopyridine (0.12 mL, 
1.30 mmol, 1.0 eq) in toluene (7 mL) at rt for 16 h gave the crude product as an orange oil. 
Purification by flash column chromatography on silica with 90:10-80:20 hexane-Et2O as 
eluent gave aryl cyclopentane ester 248 (193 mg, 72%) as a yellow oil, RF (80:20 hexane-
Et2O) 0.12, IR (ATR) 2950, 1727 (C=O), 1429, 1153, 750 cm
‒1; 1H NMR (400 MHz, CDCl3) 
δ 8.55 (ddd, J = 5.0, 2.0, 1.0 Hz, 1H, 6-py), 7.64 (ddd, J = 8.0, 8.0, 2.0 Hz, 1H, 4-py), 7.29 
(ddd, J = 8.0, 1.0, 1.0 Hz, 1H, 3-py), 7.14 (ddd, J = 8.0, 5.0, 1.0 Hz, 1H, 5-py), 3.66 (s, 3H, 
OMe), 2.57-2.48 (m, 2H, CH), 2.24-2.16 (m, 2H, CH), 1.79-1.70 (m, 4H, CH); 13C NMR 
(100.6 MHz, CDCl3) δ 176.3 (C=O), 162.6 (ipso-Ar), 148.9 (Ar), 136.5 (Ar), 121.7 (Ar), 
121.1 (Ar), 61.7 (C), 52.4 (OMe), 36.2 (CH2), 24.6 (CH2); MS (ESI) m/z 206 (M + H)
+; 
HRMS m/z calcd for C12H15NO (M + Na)
+ 206.1170, found 206.0964 (+3.7 ppm error). 
Lab Book - PJ-06-56. 
 
Using general procedure F, cyclopentane ester 242 (1.18 mL, 9.36 mmol, 1.2 eq), LiHMDS 
(15.6 mL of a 1.0 M solution in toluene, 15.6 mmol, 2.0 eq), [(cinnamyl)PdCl2] (80 mg, 
0.156 mmol, 0.02 eq), t-Bu3P·HBF4 (90 mg, 0.312 mmol, 0.04 eq) and 2-bromopyridine 
(0.74 mL, 7.8 mmol, 1.0 eq) in toluene (36 mL) at rt for 16 h gave the crude product as an 
orange oil. Purification by flash column chromatography on silica with 90:10-80:20 hexane-
Et2O as eluent gave aryl cyclopentane ester 248 (1.13 g, 71%) as a yellow oil. 
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Lab Book - PJ-07-15. 
 
1-(tert-Butyl) 4-methyl piperidine-1,4-dicarboxylate 249 
 
 
 
 
Potassium carbonate (724 mg, 5.24 mmol, 3.0 eq) was added to a stirred solution of 
piperidine-4-carboxylic acid (400 mg, 1.75 mmol, 1.0 eq) in DMF (10 mL) at rt. The 
resulting suspension was stirred at rt for 30 min and methyl iodide (0.33 mL, 5.24 mmol, 3.0 
eq) was added. The mixture was then stirred at rt for 18 h. Water (3 mL) was added and the 
mixture was extracted with EtOAc (4 x 10 mL). The combined organic were washed with 
brine (4 x 80 mL), dried (MgSO4) and evaporated under reduced pressure to give N-Boc 
piperidine-4-methyl ester 249 (399 mg, 94%) as a colourless oil, IR (ATR) 2953, 1734 
(C=O, CO2Me), 1689 (C=O, Boc), 1419, 1158, 1038 cm
‒1; 1H NMR (400 MHz, CDCl3) δ 
4.08-3.92 (m, 2H, NCH), 3.67 (s, 3H, OMe), 2.87-2.75 (m, 2H, NCH), 2.43 (tt, J = 11.0, 4.0 
Hz, 1H, CH), 1.90-1.81 (m, 2H, CH), 1.60 (dddd, J = 13.5, 11.0, 11.0, 4.0 Hz, 2H, CH), 1.43 
(s, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) δ 175.2 (C=O, CO2Me), 154.8 (C=O, Boc), 
79.7 (CMe3), 51.9 (OMe), 43.2 (NCH2), 41.1 (CH), 28.5 (CH2), 28.1 (CMe3); MS (ESI) m/z 
266 (M + Na)+; HRMS m/z calcd for C12H21NO4 (M + Na)
+ 266.1363, found 266.1359 (+1.3 
ppm error). Spectroscopic data consistent with those reported in the literature.159 
Lab Book - PJ-06-86. 
 
1-(tert-Butyl) 4-methyl 4-(p-tolyl)piperidine-1,4-dicarboxylate 253 
 
 
 
 
 
Using general procedure G, n-BuLi (0.57 mL of a 2.3 M solution in hexane, 1.32 mmol, 2.0 
eq), diisopropylamine (0.19 mL, 1.32 mmol, 2.0 eq), N-Boc piperidine-4-methyl ester 249 
(191 mg, 0.79 mmol, 1.2 eq), [(cinnamyl)PdCl2] (6.8 mg, 0.013 mmol, 0.02 eq), t-
Bu3P·HBF4 (7.5 mg, 0.026 mmol, 0.04 eq) and 4-bromotoluene (113 mg, 0.66 mmol, 1.0 
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eq) in dry toluene (6 mL) at rt for 16 h gave the crude product as an orange oil. Purification 
by flash column chromatography on silica with 90:10 hexane-EtOAc as eluent gave N-Boc 
aryl piperidine-4-methyl ester 253 (22 mg, 10%) as a colourless oil, RF (80:20 hexane-
EtOAc) 0.27, IR (ATR) 2973, 1727 (C=O, CO2Me), 1690 (C=O, Boc), 1421, 1161 cm
‒1; 1H 
NMR (400 MHz, CDCl3) δ 7.24 (d, J = 8.0 Hz, 2H, Ar), 7.15 (d, J = 8.0 Hz, 2H, Ar), 4.04-
3.85 (m, 2H, NCH), 3.65 (s, 3H, OMe), 3.11-2.91 (m, 2H, NCH), 2.55-2.44 (m, 2H, CH), 
2.32 (s, 3H, C6H4Me), 1.93-1.76 (m, 2H, CH), 1.49-1.39 (m, 9H, CMe3); 
13C NMR (100.6 
MHz, CDCl3) (rotamers) δ 174.8 (C=O, CO2Me), 155.0 (C=O, Boc), 139.3 (ipso-Ar), 137.1 
(ipso-Ar), 129.5 (Ar), 125.8 (Ar), 79.6 (CMe3), 52.4 (OMe), 49.2 (C), 42.0 (NCH2), 41.3 
(NCH2), 34.1 (CH2), 33.5 (CH2), 28.5 (CMe3), 21.1 (C6H4Me); MS (ESI) m/z 356 (M + Na)
+; 
HRMS m/z calcd for C19H27NO4 (M + Na)
+ 356.1832, found 356.1832 (+0.1 ppm error) and 
N-Boc piperidine-4-methyl ester 249 (108 mg, 0.33 mmol) as a colourless oil. 
Lab Book - PJ-06-87. 
 
Using general procedure F, N-Boc piperidine-4-methyl ester 249 (150 mg, 0.62 mmol, 1.2 
eq), LiHMDS (1.02 mL of a 1.0 M solution in toluene, 1.02 mmol, 2.0 eq), 
[(cinnamyl)PdCl2] (5.2 mg, 0.010 mmol, 0.02 eq), t-Bu3P·HBF4 (5.8 mg, 0.020 mmol, 0.04 
eq) and 4-bromotoluene (87 mg, 0.51 mmol, 1.0 eq) in toluene (6 mL) at rt for 16 h gave the 
crude product as an orange oil. Purification by flash column chromatography on silica with 
85:15 hexane-EtOAc as eluent gave N-Boc aryl piperidine-4-methyl ester 253 (120 mg, 
70%) as a colourless oil. 
Lab Book - PJ-06-89. 
 
1-(tert-Butyl) 3-methyl piperidine-1,3-dicarboxylate 250 
 
 
 
Potassium carbonate (724 mg, 5.24 mmol, 3.0 eq) was added to a stirred solution of N-Boc 
piperidine-3-carboxylic acid (400 mg, 1.75 mmol, 1.0 eq) in DMF (10 mL) at rt. The 
resulting suspension was stirred at rt for 30 min and methyl iodide (0.33 mL, 5.24 mmol, 3.0 
eq) was added. The mixture was then stirred at rt for 18 h. Water (3 mL) was added and the 
mixture was extracted with EtOAc (4 x 10 mL). The combined organic were washed with 
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brine (4 x 80 mL), dried (MgSO4) and evaporated under reduced pressure to give N-Boc 
piperidine-3-methyl ester 250 (383 mg, 90%) as a white solid, mp 38-40 °C; IR (ATR) 2952, 
1734 (C=O, CO2Me), 1690 (C=O, Boc), 1421, 1142 cm
‒1; 1H NMR (400 MHz, CDCl3) δ 
4.24-3.97 (m, 1H, NCH), 3.95-3.83 (m, 1H, NCH), 3.67 (s, 3H, OMe), 3.08-2.85 (m, 1H, 
NCH), 2.79 (ddd, J = 13.5, 11.0, 3.0 Hz, 1H, NCH), 2.49-2.38 (m, 1H, CH), 2.06-1.97 (m, 
1H, CH), 1.74-1.65 (m, 1H, CH), 1.64-1.54 (m, 1H, CH), 1.50-1.37 (m, 10H, CMe3 and 
CH); 13C NMR (100.6 MHz, CDCl3) δ 174.1 (C=O, CO2Me), 154.8 (C=O, Boc), 79.8 
(CMe3), 51.9 (OMe), 45.8 (NCH2), 43.9 (NCH2), 41.5 (CH), 28.5 (CMe3), 27.5 (CH2), 24.4 
(CH2); MS (ESI) m/z 266 (M + Na)
+; HRMS m/z calcd for C12H21NO4 (M + Na)
+ 266.1363, 
found 266.1360 (0.8 ppm error). Spectroscopic data consistent with those reported in the 
literature.160 
Lab Book - PJ-06-90. 
 
1-(tert-Butyl) 3-methyl 3-(p-tolyl)piperidine-1,3-dicarboxylate 254 
 
 
 
Using general procedure F, N-Boc piperidine-3-methyl ester 250 (191 mg, 0.76 mmol, 1.2 
eq), LiHMDS (1.32 mL of a 1.0 M solution in toluene, 1.32 mmol, 2.0 eq), 
[(cinnamyl)PdCl2] (6.8 mg, 0.013 mmol, 0.02 eq), t-Bu3P·HBF4 (7.5 mg, 0.026 mmol, 0.04 
eq) and 4-bromotoluene (113 mg, 0.66 mmol, 1.0 eq) in toluene (6 mL) at rt for 16 h gave 
the crude product as a yellow oil. Purification by flash column chromatography on silica 
with 95:5-90:10 hexane-EtOAc as eluent gave N-Boc aryl piperidine-3-methyl ester 254 
(174 mg, 79%) as a yellow oil, RF (90:10 hexane-EtOAc) 0.13, IR (ATR) 2950, 1730 (C=O, 
CO2Me), 1688 (C=O, Boc), 1424, 1147, 731 cm
‒1; 1H NMR (400 MHz, CDCl3) δ 7.32-7.23 
(m, 2H, Ar), 7.13 (d, J = 8.0 Hz, 2H, Ar), 4.38 (d, J = 13.5 Hz, 1H, NCH), 3.76-3.65 (m, 1H, 
NCH), 3.62 (s, 3H, OMe), 3.47 (d, J = 13.5 Hz, 1H, NCH), 3.04 (ddd, J = 13.0, 6.5, 6.5 Hz, 
1H, NCH), 2.49-2.40 (m, 1H, CH), 2.31 (s, 3H, C6H4Me), 1.99-1.88 (m, 1H, CH), 1.68-1.56 
(m, 2H, CH), 1.51-1.41 (m, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) δ 174.2 (C=O, 
CO2Me), 154.7 (C=O, Boc), 137.3 (ipso-Ar), 137.1 (ipso-Ar), 129.4 (Ar), 126.2 (Ar), 79.7 
(CMe3), 52.3 (OMe), 50.6 (C), 50.1 (NCH2), 43.1 (NCH2), 33.1 (CH2), 28.5 (CMe3), 22.5 
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(CH2), 21.0 (C6H4Me); MS (ESI) m/z 356 (M + Na)
+; HRMS m/z calcd for C19H27NO4 (M + 
Na)+ 356.1838, found 356.1837 (‒0.3 ppm error). 
Lab Book - PJ-06-92. 
 
1-(tert-Butyl) 2-methyl piperidine-1,2-dicarboxylate 251 
 
 
A solution of Boc2O (1.22 g, 5.59 mmol, 2.0 eq) in CH2Cl2 (7.5 mL) was added dropwise to 
a stirred solution of piperidine-2-methyl ester (400 mg, 2.79 mmol, 1.0 eq) and Et3N (1.16 
mL, 8.37 mmol, 3.0 eq) in CH2Cl2 (7.5 mL) at rt under Ar. The resulting solution was stirred 
at rt for 16 h. Then, the reaction mixture was evaporated under reduced pressure to give the 
crude product as a white solid. Purification by flash column chromatography on silica with 
90:10 hexane-EtOAc as eluent gave N-Boc piperidine-2-methyl ester 251 (650 mg, 95%) as 
a colourless oil, RF (90:10 hexane-EtOAc) 0.11, IR (ATR) 2938, 1742 (C=O, CO2Me), 1693 
(C=O, Boc) 1364, 1155 cm‒1; 1H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 
4.90-4.79 (m, 0.5H, NCH), 4.71-4.63 (m, 0.5H, NCH), 4.06-3.83 (m, 1H, NCH), 3.69 (s, 
3H, OMe), 3.00-2.74 (m, 1H, NCH), 2.23-2.08 (m, 1H, CH), 1.70-1.52 (m, 3H, CH), 1.50-
1.29 (m, 10H, CH and CMe3), 1.28-1.10 (m, 1H, CH); 
13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 172.7 (C=O, CO2Me), 172.5 (C=O, CO2Me), 156.0 (C=O, Boc), 155.6 (C=O, 
Boc), 80.0 (CMe3), 55.0 (NCH), 53.8 (NCH), 52.1 (OMe), 42.1 (NCH2), 41.2 (NCH2), 28.4 
(CMe3), 26.8 (CH2), 24.9 (CH2), 24.6 (CH2), 20.9 (CH2); MS (ESI) m/z 266 (M + Na)
+; 
HRMS m/z calcd for C12H21NO4 (M + Na)
+ 266.1363, found 266.1361 (+0.5 ppm error). 
Spectroscopic data consistent with those reported in the literature.161 
Lab Book - PJ-06-98. 
 
1-(tert-Butyl) 3-methyl pyrrolidine-1,3-dicarboxylate 252 
 
 
 
A solution of Boc2O (1.04 g, 4.8 mmol, 2.0 eq) in CH2Cl2 (7.5 mL) was added dropwise to 
a stirred solution of pyrrolidine-3-methyl ester (400 mg, 2.4 mmol, 1.0 eq), and Et3N (1.0 
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mL, 4.8 mmol, 3.0 eq) in CH2Cl2 (7.5 mL) at rt under Ar. The resulting solution was stirred 
at rt for 16 h. Then, the reaction mixture was evaporated under reduced pressure to give the 
crude product as a white solid. Purification by flash column chromatography on silica with 
80:20 hexane-EtOAc as eluent gave N-Boc pyrrolidine-3-methyl ester 252 (445 mg, 81%) 
as a colourless oil, RF (80:20 hexane-Et2O) 0.14, IR (ATR) 2976, 1736 (C=O, CO2Me), 1691 
(C=O, Boc) 1400, 1163 cm‒1; 
1H NMR (400 MHz, CDCl3) δ 3.71 (s, 3H, OMe), 3.65-3.41 
(m, 3H, CH), 3.39 -3.29 (m, 1H, CH), 3.09-2.98 (m, 1H, CH), 2.19-2.05 (m, 2H, CH), 1.45 
(s, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) δ 173.7 (C=O, CO2Me), 154.4 (C=O, Boc), 
79.6 (CMe3), 52.2 (OMe), 48.2 (CH2), 45.2 (CH2), 43.3 (CH), 42.4 (CH2), 28.6 (CMe3); MS 
(ESI) m/z 252 (M + Na)+; HRMS m/z calcd for C11H19NO4 (M + Na)
+ 252.1206, found 
252.1208 (‒0.9 ppm error). Spectroscopic data consistent with those reported in the 
literature.162 
Lab Book - PJ-06-82. 
 
 1-(tert-Butyl) 3-methyl 3-(p-tolyl)pyrrolidine-1,3-dicarboxylate 256 
 
 
 
 
 
 
Using general procedure G, n-BuLi (0.57 mL of a 2.3 M solution in hexane, 1.32 mmol, 2.0 
eq), diisopropylamine (0.19 mL, 1.32 mmol, 2.0 eq), N-Boc pyrrolidine-3-methyl ester 252 
(180 mg, 0.79 mmol, 1.2 eq), [(cinnamyl)PdCl2] (6.8 mg, 0.013 mmol, 0.02 eq), t-
Bu3P·HBF4 (7.5 mg, 0.026 mmol, 0.04 eq) and 4-bromotoluene (113 mg, 0.66 mmol, 1.0 
eq) in dry toluene (6 mL) at rt for 16 h gave the crude product as an orange oil. Purification 
by flash column chromatography on silica with 90:10 hexane-EtOAc as eluent gave N-Boc 
aryl pyrrolidine-3-methyl ester 256 (72 mg, 34%) as a white solid, mp 102-104 °C; RF (80:20 
hexane-EtOAc) 0.20, IR (ATR) 2971, 1721 (C=O, CO2Me), 1686 (C=O, Boc), 1406, 1170, 
1151, 1123, 1097 cm‒1; 1H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 7.20 (d, 
J = 8.0 Hz, 2H, Ar), 7.14 (d, J = 8.0 Hz, 2H, Ar), 4.36 (d, J = 11.0 Hz, 0.5H, NCH), 4.32 (d, 
J = 11.0 Hz, 0.5H, NCH), 3.67-3.58 (m, 3.5H, OMe and NCH), 3.53-3.46 (m, 1H, NCH), 
3.45-3.31 (m, 1.5H, NCH), 2.91-2.80 (m, 1H, CH), 2.33 (s, 3H, C6H4Me), 2.21-2.08 (m, 1H, 
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CH), 1.48 (s, 4.5H, CMe3), 1.46 (s, 4.5H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) 
δ 174.2 (C=O, CO2Me), 154.5 (C=O, Boc), 137.5 (ipso-Ar), 137.4 (ipso-Ar), 136.8 (ipso-
Ar), 136.7 (ipso-Ar), 129.5 (Ar), 126.5 (Ar), 126.4 (Ar), 79.7 (CMe3), 79.6 (CMe3), 57.1 
(C), 56.2 (NCH2), 53.9 (OMe), 53.3 (OMe), 52.9 (NCH2), 44.9 (NCH2), 44.5 (NCH2), 34.9 
(CH2), 33.9 (CH2), 28.6 (CMe3), 21.2 (C6H4Me); MS (ESI) m/z 342 (M + Na)
+; HRMS m/z 
calcd for C18H25NO4 (M + Na)
+ 342.1676, found 342.1167 (‒0.1 ppm error). 
Using general procedure F, N-Boc pyrolidine-3-methyl ester 252 (180 mg, 0.76 mmol, 1.2 
eq), LiHMDS (1.32 mL of a 1.0 M solution in toluene, 1.32 mmol, 2.0 eq), 
[(cinnamyl)PdCl2] (6.8 mg, 0.013 mmol, 0.02 eq), t-Bu3P·HBF4 (7.5 mg, 0.026 mmol, 0.04 
eq) and 4-bromotoluene (113 mg, 0.66 mmol, 1.0 eq) in toluene (6 mL) at rt for 16 h gave 
the crude product as an orange oil. Purification by flash column chromatography on silica 
with 90:10 hexane-EtOAc as eluent gave N-Boc aryl pyrolidine-3-methyl ester 256 (78 mg, 
37%) as a white solid. 
Lab Book - PJ-06-85. 
 
1-(tert-Butyl) 2-methyl pyrrolidine-1,2-dicarboxylate 257 
 
 
 
Potassium carbonate (579 mg, 4.2 mmol, 3.0 eq) was added to a stirred solution of N-Boc 
pyrrolidine-2-carboxylic acid (300 mg, 1.4 mmol, 1.0 eq) in DMF (6 mL) at rt. The resulting 
suspension was stirred at rt for 30 min and methyl iodide (0.26 mL, 4.2 mmol, 3.0 eq) was 
added. The mixture was then stirred at rt for 18 h. Water (3 mL) was added and the mixture 
was extracted with EtOAc (4 x 10 mL). The combined organics were washed with brine (4 
x 5 mL), dried (MgSO4) and evaporated under reduced pressure to give the crude product as 
an orange oil. Purification by flash chromatography on silica with 80:20 hexane-EtOAc as 
eluent gave N-Boc pyrrolidine-2-methyl ester 257 (270 mg, 84%) as a colourless oil, RF 
(80:20 hexane-EtOAc) 0.15, IR (ATR) 2975, 1746 (C=O, CO2Me), 1695 (C=O, Boc) 1391, 
1157 cm‒1; 1H NMR (400 MHz, CDCl3) 60:40 mixture of rotamers δ 4.32 (dd, J = 8.5, 3.5 
Hz, 0.4H, CH), 4.22 (dd, J = 8.5, 4.0 Hz, 0.6H, CH), 3.72 (s, 3H, OMe), 3.59-3.33 (m, 2H, 
CH), 2.28-2.11 (m, 1H, CH), 2.02-1.91 (m, 2H, CH), 1.91-1.81 (m, 1H, CH), 1.46 (s, 3.6H, 
CMe3), 1.41 (s, 5.4H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 173.9 (C=O, 
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CO2Me), 153.9 (C=O, Boc), 80.0 (CMe3), 79.9 (CMe3), 59.2 (OMe), 58.8 (OMe), 52.3 
(CHCO2), 52.1 (CHCO2), 46.7 (CH2), 46.5 (CH2), 31.0 (CH2), 30.1 (CH2), 28.6 (CMe3), 28.4 
(CMe3), 24.5 (CH2), 23.8 (CH2); MS (ESI) m/z 252 (M + Na)
+; HRMS m/z calcd for 
C11H19NO4 (M + Na)
+ 252.1206, found 252.1207 (‒0.7 ppm error). Spectroscopic data 
consistent with those reported in the literature.163 
Lab Book - PJ-06-79. 
 
1-(tert-Butyl) 2-methyl 2-hydroxypyrrolidine-1,2-dicarboxylate 258 
 
 
 
 
Using general procedure G, n-BuLi (0.57 mL of a 2.3 M solution in hexane, 1.32 mmol, 2.0 
eq), diisopropylamine (0.19 mL, 1.32 mmol, 2.0 eq), N-Boc pyrrolidine-2-methyl ester 257 
(180 mg, 0.79 mmol, 1.2 eq), [(cinnamyl)PdCl2] (6.8 mg, 0.013 mmol, 0.02 eq), t-
Bu3P·HBF4 (7.5 mg, 0.026 mmol, 0.04 eq) and 4-bromotoluene (113 mg, 0.66 mmol, 1.0 
eq) in dry toluene (6 mL) at rt for 16 h gave the crude product as an orange oil. Purification 
by flash column chromatography on silica with 80:20 hexane-EtOAc as eluent gave N-Boc 
pyrrolidine hydroxy ester 258 (104 mg, 64%) as a yellow oil, RF (70:30 hexane-EtOAc) 0.15, 
IR (ATR) 3483 (OH), 2977, 1747 (C=O, CO2Me), 1701 (C=O, Boc), 1394, 1367, 1163 cm
‒
1; 1H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 4.45 (s, 0.5H, OH), 4.02 (s, 
0.5H, OH), 3.80 (s, 1.5H, OMe), 3.80 (s, 1.5H, OMe), 3.67 (ddd, J = 11.0, 7.5, 4.0 Hz, 0.5H, 
NCH), 3.59 (ddd, J = 10.5, 7.5, 5.0 Hz, 0.5H, NCH), 3.52-3.41 (m, 1H, NCH), 2.28-2.15 (m, 
1H, CH), 2.15-2.01 (m, 2H, CH), 1.99-1.89 (m, 1H, CH), 1.44 (s, 4.5H, CMe3), 1.41 (s, 
4.5H, CMe3), 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 173.7 (C=O, CO2Me), 173.3 
(C=O, CO2Me), 152.6 (C=O, Boc), 88.9 (C), 88.0 (C), 81.4 (CMe3), 80.9 (CMe3), 53.3 
(OMe), 47.2 (NCH2), 39.8 (CH2), 38.3 (CH2), 28.4 (CMe3), 23.0 (CH2), 22.4 (CH2); MS 
(ESI) m/z 268 (M + Na)+; HRMS m/z calcd for C11H19NO5 (M + Na)
+ 268.1161, found 
268.1157 (‒1.49 ppm error). 
Lab Book - PJ-06-72. 
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tert-Butyl 3-(p-tolyl)pyrrolidine-1,3-dicarboxylate 260 
 
 
 
 
Using general procedure F, N-Boc pyrolidine-3-t-butyl ester 259 (205 mg, 0.76 mmol, 1.2 
eq), LiHMDS (1.32 mL of a 1.0 M solution in toluene, 1.32 mmol, 2.0 eq), 
[(cinnamyl)PdCl2] (6.8 mg, 0.013 mmol, 0.02 eq), t-Bu3P·HBF4 (7.5 mg, 0.026 mmol, 0.04 
eq) and 4-bromotoluene (113 mg, 0.66 mmol, 1.0 eq) in toluene (6 mL) at rt for 16 h gave 
the crude product as an orange oil. Purification by flash column chromatography on silica 
with 90:10 hexane-EtOAc as eluent gave N-Boc aryl pyrolidine-3-t-butyl ester 260 (170 mg, 
71%) as a white solid, mp 84-86 °C; RF (70:30 hexane-EtOAc) 0.38, IR (ATR) 2974, 1714 
(C=O, CO2tBu), 1687 (C=O, Boc), 1410, 1147 cm
‒1; 1H NMR (400 MHz, CDCl3) (50:50 
mixture of rotamers) δ 7.17 (d, J = 8.0 Hz, 2H, Ar), 7.12 (d, J = 8.0 Hz, 2H, Ar), 4.30 (d, J 
= 11.0 Hz, 1H, NCH), 3.54 (d, J = 11.0 Hz, 0.5H, NCH), 3.52-3.43 (m, 0.5H, NCH), 3.43-
3.30 (m, 2H, NCH), 2.83-2.72 (m, 1H, CH), 2.31 (s, 3H, C6H4Me), 2.19-2.01 (m, 1H, CH), 
1.47 (s, 4.5H, CMe3), 1.44 (s, 4.5H, CMe3), 1.34 (s, 4.5H, CMe3), 1.33 (s, 4.5H, CMe3); 
13C 
NMR (100.6 MHz, CDCl3) (rotamers) δ 178.1 (C=O, CO2tBu), 172.8 (C=O, Boc), 154.5 
(ipso-Ar), 137.1 (ipso-Ar), 129.6 (Ar), 126.2 (Ar), 81.9 (CMe3), 79.6 (CMe3), 57.9 (C), 57.0 
(C), 53.8 (NCH2), 53.3 (NCH2), 44.9 (NCH2), 44.5 (NCH2), 34.9 (CH2), 33.9 (CH2), 28.6 
(CMe3), 27.8 (CMe3), 21.1 (C6H4Me); MS (ESI) m/z 284 (M + Na)
+; HRMS m/z calcd for 
C21H31NO4 (M + Na)
+ 384.2145, found 384.2138 (+0.9 ppm error). 
Lab Book - PJ-07-45. 
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1-(tert-Butyl) 3-methyl 3-(4-fluorophenyl)piperidine-1,3-dicarboxylate 261 and 1-(tert-
butyl) 3-methyl 5,6-dihydropyridine-1,3(4H)-dicarboxylate 262 
 
Using general procedure F, N-Boc piperidine-3-methyl ester 250 (192 mg, 0.76 mmol, 1.2 
eq), LiHMDS (1.32 mL of a 1.0 M solution in toluene, 1.32 mmol, 2.0 eq), 
[(cinnamyl)PdCl2] (6.8 mg, 0.013 mmol, 0.02 eq), t-Bu3P·HBF4 (7.5 mg, 0.026 mmol, 0.04 
eq) and 4-fluorobromobenzene (0.07 mL, 0.66 mmol, 1.0 eq) in toluene (6 mL) at rt for 16 
h gave the crude product as a yellow oil. Purification by flash column chromatography on 
silica with 90:10-80:20 hexane-EtOAc as eluent gave dihydropyridine 262 (15 mg, 7%) as 
a colourless oil, RF (70:30 hexane-EtOAc) 0.32; IR (ATR) 2950, 1717 (C=O, CO2Me), 1631 
(C=O, Boc), 1366, 1241, 1146 cm‒1; 1H NMR (400 MHz, CDCl3) δ 8.21-7.82 (m, 1H, =CH), 
3.72 (s, 3H, OMe), 3.58-3.51 (m, 2H, NCH), 2.29 (ddd, J = 6.0, 6.0, 1.5 Hz, 2H, CH), 1.93-
1.76 (m, 2H, CH), 1.51 (s, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) δ 168.3 (C=O, 
CO2Me), 152.0 (C=O, Boc), 136.2 (=CH), 107.4 (=C), 82.4 (CMe3), 51.5 (OMe), 41.8 
(NCH2), 28.3 (CMe3), 21.0 (CH2), 20.8 (CH2); MS (ESI) m/z 264 (M + Na)
+; HRMS m/z 
calcd for C12H19NO4 (M + Na)
+ 264.1212, found 264.1209 (‒1.1 ppm error) and N-Boc aryl 
piperidine-3-methyl ester 261 (132 mg, 59%) as an orange oil, RF (70:30 hexane-EtOAc) 
0.24; IR (ATR) 2951, 1731 (C=O, CO2Me), 1688 (C=O, Boc), 1511, 1423, 1147 cm
‒1; 1H 
NMR (400 MHz, CDCl3) δ 7.41-7.31 (s, 2H, Ar), 7.01 (dd, J = 9.0, 9.0 Hz, 2H, Ar), 4.34-
4.16 (m, 1H, NCH), 3.62 (s, 3H, OMe), 3.75-3.45 (m, 2H, NCH) , 3.30-2.94 (s, 1H, NCH), 
2.47-2.33 (m, 1H, CH), 1.99 (ddd, J = 13.5, 7.0, 7.0 Hz, 1H, CH), 1.75-1.54 (m, 2H, CH), 
1.49-1.37 (m, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) δ 173.9 (C=O, CO2Me), 162.0 (d, 
J = 246.5 Hz, ipso-Ar), 154.6 (C=O, Boc), 135.7 (d, J = 3.5 Hz, ipso-Ar), 128.3 (d, J = 8.0 
Hz, Ar), 115.6 (d, J = 21.0 Hz, Ar), 79.9 (CMe3), 52.4 (OMe), 50.6 (C), 49.8 (NCH2), 43.1 
(NCH2), 33.1 (CH2), 28.5 (CMe3), 22.3 (CH2); MS (ESI) m/z 360 (M + Na)
+; HRMS m/z 
calcd for C18H24NO4 (M + Na)
+ 360.1582, found 360.1589 (‒2.5 ppm error). 
Lab book - PJ-07-11. 
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Methyl 4-(p-tolyl)tetrahydro-2H-pyran-4-carboxylate 268 
 
 
 
 
Using general procedure F, THP-4-methyl ester 263 (0.1 mL, 0.76 mmol, 1.2 eq), LiHMDS 
(1.32 mL of a 1.0 M solution in toluene, 1.32 mmol, 2.0 eq), [(cinnamyl)PdCl2] (6.8 mg, 
0.013 mmol, 0.02 eq), t-Bu3P·HBF4 (7.5 mg, 0.026 mmol, 0.04 eq) and 4-bromotoluene (113 
mg, 0.66 mmol, 1.0 eq) in toluene (6 mL) at rt for 16 h gave the crude product as a yellow 
oil. Purification by flash column chromatography on silica with 75:25 hexane-EtOAc as 
eluent gave aryl THP-4-methyl ester 268 (29 mg, 19%) as a yellow solid, mp 58-60 °C; RF 
(75:25 hexane-EtOAc) 0.31; IR (ATR) 2949, 1719 (C=O), 1445, 1125, 739 cm‒1; 1H NMR 
(400 MHz, CDCl3) δ 7.26 (d, J = 8.0 Hz, 2H, Ar), 7.16 (d, J = 8.0 Hz, 2H, Ar), 3.92 (ddd, J 
= 11.5, 4.0, 4.0 Hz, 2H, OCH), 3.66 (s, 3H, OMe), 3.55 (ddd, J = 11.5, 11.0, 2.0 Hz, 2H, 
OCH), 2.56-2.45 (m, 2H, CH), 2.33 (s, 3H, Ar Me), 1.97 (ddd, J = 13.5, 11.0, 4.0 Hz, 2H, 
CH); 13C NMR (100.6 MHz, CDCl3) δ 175.1 (C=O), 139.6 (ipso-Ar), 137.1 (ipso-Ar), 129.5 
(Ar), 125.7 (Ar), 65.8 (OCH2), 52.4 (OMe), 48.4 (C), 34.6 (CH2), 21.1 (C6H4Me); MS (ESI) 
m/z 257 (M + Na)+; HRMS m/z calcd for C14H18O3 (M + Na)
+ 257.1148, found 257.1146 
(+1.3 ppm error). 
Lab Book - PJ-06-93. 
 
Methyl 4-(p-tolyl)tetrahydro-2H-pyran-4-carboxylate 268 and methyl 4-(tetrahydro-
2H-pyran-4-carbonyl)tetrahydro-2H-pyran-4-carboxylate 269 
 
 
 
 
 
Using general procedure F, THP-4-methyl ester 263 (0.1 mL, 0.76 mmol, 1.2 eq), LiHMDS 
(1.32 mL of a 1.0 M solution in toluene, 1.32 mmol, 2.0 eq), [(cinnamyl)PdCl2] (6.8 mg, 
0.013 mmol, 0.02 eq), t-Bu3P·HBF4 (7.5 mg, 0.026 mmol, 0.04 eq) and 4-bromotoluene (113 
mg, 0.66 mmol, 1.0 eq) in toluene (6 mL) at rt for 24 h gave the crude product as a yellow 
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oil. Purification by flash column chromatography on silica with 75:25 hexane-EtOAc as 
eluent gave aryl THP-4-methyl ester 268 (75 mg, 48%) as a yellow solid and THP-keto-ester 
269 (40 mg, 20%) as a colourless oil, RF (70:30 hexane-EtOAc) 0.08; IR (ATR) 2954, 2848, 
1731 (C=O, ketone), 1707 (C=O CO2Me), 1119, 1106 cm
‒1; 1H NMR (400 MHz, CDCl3) δ 
4.00-3.92 (m, 2H, OCH), 3.82-3.72 (m, 2H, OCH), 3.76 (s, 3H, OMe), 3.59 (ddd, J = 12.0, 
9.0, 3.0 Hz, 2H, OCH), 3.38 (ddd, J = 12.0, 12.0, 2.0 Hz, 2H, OCH), 2.91 (tt, J = 12.0, 4.0 
Hz, 1H, CH), 2.19-2.11 (m, 2H, CH), 1.99 (ddd, J = 13.5, 9.0, 4.0 Hz, 2H, CH), 1.80 (dddd, 
J = 12.0, 12.0, 12.0, 4.5 Hz, 2H, CH), 1.45 (ddd, J = 12.0, 4.0, 2.0 Hz, 2H, CH); 13C NMR 
(100.6 MHz, CDCl3) δ 207.5 (C=O, ketone), 171.9 (C=O, CO2Me), 67.1 (NCH2), 64.8 
(NCH2), 58.8 (C), 52.8 (OMe), 43.6 (CH), 30.2 (CH2), 29.7 (CH2); MS (ESI) m/z 279 (M + 
Na)+; HRMS m/z calcd for C13H20O5 (M + Na)
+ 279.1208, found 279.1202 (‒2.1 ppm error). 
Lab Book - PJ-06-94. 
 
tert-Butyl tetrahydro-2H-pyran-4-carboxylate 271 
 
 
 
Trichloroacetimidate (2.2 mL, 12.3 mmol, 2.0 eq) was added dropwise to a stirred solution 
of THP-4-carboxylic acid 270 (800 mg, 6.15 mmol, 1.0 eq) in 1:1 CH2Cl2-Et2O (8 mL) at rt 
under Ar. The resulting solution was stirred at rt for 16 h. Then, the reaction mixture was 
evaporated under reduced pressure to give a white solid. Sat NaHCO3(aq) (20 mL) was added 
and the mixture was extracted with CH2Cl2 (3 x 10 mL). The combined organics were dried 
(MgSO4) and evaporated under reduced pressure to give the crude product as a white solid. 
Purification by flash column chromatography on silica with 90:10 hexane-EtOAc as eluent 
gave THP-4-tbutyl ester 271 (340 mg, 30%) as a colourless oil, RF (70:30 hexane-EtOAc) 
0.53, IR (ATR) 2957, 1724 (C=O), 1366, 1154, 1135 cm‒1; 1H NMR (400 MHz, CDCl3) δ 
4.00-3.89 (m, 2H, OCH), 3.41 (ddd, J = 11.5, 10.5, 3.0 Hz, 2H, OCH), 2.42 (tt, J = 10.5, 4.5 
Hz, 1H, CH), 1.97-1.65 (m, 4H, CH), 1.44 (s, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) δ 
174.1 (C=O), 80.4 (CMe3), 67.3 (OCH2), 41.2 (CH), 28.9 (CH2), 28.2 (CMe3); MS (ESI) m/z 
209 (M + Na)+; HRMS m/z calcd for C10H18O3 (M + Na)
+ 209.1148, found 209.1148 (+0.4 
ppm error). 
Lab Book - PJ-07-60. 
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Methyl 4-(4-methoxyphenyl)tetrahydro-2H-pyran-4-carboxylate 272 
 
Table 4.6, entry 1 
Using general procedure F, THP-4-methyl ester 263 (0.1 mL, 0.76 mmol, 1.2 eq), LiHMDS 
(1.32 mL of a 1.0 M solution in toluene, 1.32 mmol, 2.0 eq), [(cinnamyl)PdCl2] (6.8 mg, 
0.013 mmol, 0.02 eq), t-Bu3P·HBF4 (7.5 mg, 0.026 mmol, 0.04 eq) and 4-bromoanisole 
(0.083 mL, 0.66 mmol, 1.0 eq) in toluene (6 mL) at rt for 24 h gave the crude product as a 
yellow oil. Purification by flash column chromatography on silica with 70:30 hexane-EtOAc 
as eluent gave aryl THP-4-methyl ester 272 (31 mg, 18%) as a yellow solid.  
Lab Book - PJ-07-07. 
 
Table 4.6, entry 2 
Using general procedure F, THP-4-methyl ester 263 (0.1 mL, 0.76 mmol, 1.2 eq), LiHMDS 
(1.32 mL of a 1.0 M solution in toluene, 1.32 mmol, 2.0 eq), [(cinnamyl)PdCl2] (6.8 mg, 
0.013 mmol, 0.02 eq), t-Bu3P·HBF4 (7.5 mg, 0.026 mmol, 0.04 eq) and 4-bromoanisole 
(0.083 mL, 0.66 mmol, 1.0 eq) in toluene (6 mL) at rt for 64 h gave the crude product as a 
yellow oil. Purification by flash column chromatography on silica with 70:30 hexane-EtOAc 
as eluent gave aryl THP-4-methyl ester 272 (98 mg, 57%) as a yellow solid and Claisen 
THP-keto-ester 269 (18 mg, 9%) as a colourless oil. 
Lab Book - PJ-07-17. 
 
Table 4.6, entry 3 
A solution of 4-methyl THP ester 263 (0.1 mL, 0.76 mmol, 1.2 eq), in toluene (1 mL) was 
added dropwise to a stirred solution of LiHMDS (1.32 mL of a 1.0 M solution in toluene, 
1.32 mmol, 2.0 eq) in 95:5 toluene-THF (2.1 mL) at rt under Ar. The resulting solution was 
vigorously stirred at rt for 40 min. In a separate reaction flask, [(cinnamyl)PdCl2] (6.8 mg, 
0.013 mmol, 0.02 eq), t-Bu3P·HBF4 (7.5 mg, 0.026 mmol, 0.04 eq) and 4-bromoanisole 
(0.083 mL, 0.66 mmol, 1.0 eq) were added, followed by dry toluene (5 mL). The reaction 
flask was then evacuated under reduced pressure and back-filled with Ar three times. The 
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LiHMDS/ester solution was then added dropwise to the reaction flask and the resulting 
solution was stirred and heated at 50 °C for 16 h. The solution was poured into 1 M AcOH(aq) 
(10 mL) and the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined 
organics were washed with brine (20 mL) and sat NaHCO3(aq) (20 mL), dried (MgSO4) and 
evaporated under reduced pressure to give the crude product as an orange oil. Purification 
by flash column chromatography on silica with 70:30 hexane-EtOAc as eluent gave aryl 
THP-4-methyl ester 272 (104 mg, 63%) as a yellow solid, mp 56-58 °C; RF (70:30 hexane-
EtOAc) 0.25; IR (ATR) 2928, 1720 (C=O), 1512, 1100, 1027, 827 cm‒1; 1H NMR (400 
MHz, CDCl3) δ 7.28 (d, J = 9.0 Hz, 2H, Ar), 6.87 (d, J = 9.0 Hz, 2H, Ar), 3.91 (ddd, J = 
12.0, 4.0, 4.0 Hz, 2H, OCH), 3.79 (s, 3H, OMe), 3.65 (s, 3H, OMe), 3.53 (ddd, J = 12.0, 
12.0, 2.0 Hz, 2H, OCH), 2.57-2.44 (m, 2H, CH), 1.94 (ddd, J = 13.0, 12.0, 2.0 Hz, 2H, CH); 
13C NMR (100.6 MHz, CDCl3) δ 175.1 (C=O), 158.8 (ipso-Ar), 134.7 (ipso-Ar), 126.9 (Ar), 
114.1 (Ar), 65.8 (OCH2), 55.4 (OMe), 52.4 (OMe), 34.6 (CH2); MS (ESI) m/z 273 (M + 
Na)+; HRMS m/z calcd for C14H18O4 (M + Na)
+ 273.1097, found 273.1094 (+3.5 ppm error). 
and THP-keto-ester 269 (41 mg, 21%) as a colourless oil. 
Lab Book - PJ-07-26. 
 
Methyl 4-(pyridin-2-yl)tetrahydro-2H-pyran-4-carboxylate 273 
 
A solution of THP-4-methyl ester 263 (0.1 mL, 0.76 mmol, 1.2 eq), in toluene (1 mL) was 
added dropwise to a stirred solution of LiHMDS (1.32 mL of a 1.0 M solution in toluene, 
1.32 mmol, 2.0 eq) in 95:5 toluene-THF (2.1 mL) at rt under Ar. The resulting solution was 
vigorously stirred at rt for 40 min. Io a separate reaction flask, [(cinnamyl)PdCl2] (6.8 mg, 
0.013 mmol, 0.02 eq), t-Bu3P·HBF4 (7.5 mg, 0.026 mmol, 0.04 eq) and 2-bromopyridine 
(0.063 mL, 0.66 mmol, 1.0 eq) were added, followed by dry toluene (5 mL). The reaction 
flask was then evacuated under reduced pressure and back-filled with Ar three times. The 
LiHMDS/ester solution was then added dropwise to the reaction flask and the resulting 
solution was stirred and heated at 50 °C for 16 h. The solution was poured into 1 M AcOH(aq) 
(10 mL) and the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined 
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organics were washed with brine (20 mL) and sat NaHCO3(aq) (20 mL), dried (MgSO4) and 
evaporated under reduced pressure to give the crude product as an orange oil. Purification 
by flash column chromatography on silica with 70:30 hexane-EtOAc as eluent gave aryl 
THP-4-methyl ester 273 (77 mg, 53%) as a yellow oil, RF (80:20 hexane-EtOAc) 0.07; IR 
(ATR) 2954, 1726 (C=O), 1430, 1127, 1104 cm‒1; 1H NMR (400 MHz, CDCl3) δ 8.61-8.53 
(m, 1H, 6-py), 7.67 (ddd, J = 8.0, 8.0, 2.0 Hz, 1H, 4-py), 7.32 (m, 1H, 3-py), 7.17 (ddd, J = 
8.0, 5.0, 1.0 Hz, 1H, 5-py), 3.87 (ddd, J = 12.0, 4.0, 4.0 Hz, 2H, OCH), 3.70 (s, 3H, OMe), 
3.62 (ddd, J = 12.0, 10.0, 2.5 Hz, 2H, OCH), 2.47 (ddd, J = 14.0, 4.0, 2.5 Hz, 2H, CH), 2.16 
(ddd, J = 14.0, 10.0, 4.0 Hz, 2H, CH); 13C NMR (100.6 MHz, CDCl3) δ 174.4 (C=O), 161.3 
(ipso-Ar), 149.3 (Ar), 136.9 (Ar), 122.2 (Ar), 120.6 (Ar), 65.5 (OCH2), 52.5 (OMe), 33.8 
(CH2); MS (ESI) m/z 244 (M + Na)
+; HRMS m/z calcd for C12H15NO3 (M + Na)
+ 244.0944, 
found 244.0940 (+0.2 ppm error) and THP-keto-ester 269 (39 mg, 20%) as a colourless oil. 
Lab Book - PJ-07-30. 
 
Methyl 4-(p-tolyl)piperidine-4-carboxylate 274·HCl 
 
 
 
 
 
 
HCl (1 mL of a 4 M solution in dioxane) was added dropwise to N-Boc aryl piperidine-4-
methyl ester 253 (111 mg, 0.3 mmol, 1.0 eq) at rt under Ar. The resulting solution was stirred 
at rt for 16 h. Then, the solvent was evaporated under reduced pressure to give aryl 
piperidine-4-methyl ester 274·HCl (80 mg, 99%) as an orange solid, mp 230-232 °C; IR 
(ATR) 2934, 2730, 1725 (C=O), 1144, 495 cm‒1; 1H NMR (400 MHz, CDCl3) δ 9.67 (br s, 
1H, NH), 9.53 (br s, 1H, NCH), 7.22-7.10 (m, 4H, Ar), 3.67 (s, 3H, OMe), 3.45-3.36 (m, 
2H, NCH), 3.13-2.98 (m, 2H, NCH), 2.73 -2.61 (m, 2H, CH), 2.40-2.32 (m, 2H, CH), 2.31 
(s, 3H, Me); 13C NMR (100.6 MHz, CDCl3) δ 173.6 (C=O, CO2Me), 137.8 (ipso-Ar), 137.0 
(ipso-Ar), 129.8 (Ar), 125.5 (Ar), 52.9 (OMe), 47.9 (C), 41.8 (NCH2), 30.5 (CH2), 21.0 
(C6H4Me); MS (ESI) m/z 234 (M)
+; HRMS m/z calcd for C14H20NO2 (M)
+ 234.1489, found 
234.1493 (‒1.6 ppm error). 
Lab Book - PJ-07-98. 
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Methyl 3-(p-tolyl)piperidine-3-carboxylate 275·HCl 
 
 
 
 
HCl (1 mL of a 4 M solution in dioxane) was added dropwise to N-Boc aryl piperidine-3-
methyl ester 254 (60 mg, 0.18 mmol, 1.0 eq) at rt under Ar. The resulting solution was stirred 
at rt for 16 h. Then, the solvent was evaporated under reduced pressure to give aryl 
piperidine-3-methyl ester 275·HCl (47 mg, 97%) as an orange oil, IR (ATR) 2951, 1728 
(C=O, CO2Me), 1449, 1239, 1151, 728 cm
‒1; 1H NMR (400 MHz, CDCl3) δ 10.52 (s, 1H, 
NH), 8.65 (s, 1H, NH), 7.17 (s, 4H, Ar), 4.18 (d, J = 13.0 Hz, 1H, NCH), 3.82 (s, 3H, OMe), 
3.67-3.53 (m, 1H, NCH), 3.07-2.94 (m, 1H, NCH), 2.95-2.81 (m, 1H, NCH), 2.81-2.61 (m, 
1H, CH), 2.32 (s, 3H, C6H4Me), 2.09-1.80 (m, 3H, CH); 
13C NMR (100.6 MHz, CDCl3) δ 
172.8 (C=O), 138.4 (ipso-Ar), 135.6 (ipso-Ar), 129.9 (Ar), 125.3 (Ar), 53.7 (OMe), 49.7 
(NCH2), 48.6 (C), 43.6 (NCH2), 30.7 (CH2), 21.1 (C6H4Me), 20.4 (CH2); MS (ESI) m/z 234 
(M)+; HRMS m/z calcd for C14H21NO2 (M)
+ 234.1489, found 234.1490 (+0.4 ppm error). 
Lab Book - PJ-08-89. 
 
Methyl 3-(4-fluorophenyl)piperidine-3-carboxylate 276·HCl 
 
 
 
 
 
 
HCl (1 mL of a 2 M solution in Et2O) was added dropwise to N-Boc aryl piperidine-3-methyl 
ester 261 (100 mg, 0.3 mmol, 1.0 eq) at rt under Ar. The resulting solution was stirred at rt 
for 40 h. Then, the solvent was evaporated under reduced pressure to give aryl piperidine-3-
methyl ester 276·HCl (82 mg, 100%) as a brown solid, mp 122-124 °C; IR (ATR) 2955, 
1728 (C=O), 1513, 1145, 831 cm‒1; 1H NMR (400 MHz, CDCl3) δ 10.49-10.30 (m, 1H, 
NH), 8.93-8.56 (m, 1H, NH), 7.29 (dd, J = 9.0, 5.0 Hz, 2H, Ar), 7.05 (dd, J = 9.0, 9.0 Hz, 
2H, Ar), 4.18 (d, J = 13.0 Hz, 1H, NCH), 3.82 (s, 3H, OMe), 3.69-3.52 (m, 1H, NCH), 3.14-
2.95 (m, 1H, NCH), 2.98-2.83 (m, 1H, NCH), 2.80-2.70 (m, 1H, CH), 2.07-1.80 (m, 3H, 
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CH); 13C NMR (100.6 MHz, CDCl3) δ 172.5 (C=O), 162.5 (d, J = 248.5 Hz, ipso-Ar), 134.4 
(d, J = 3.5 Hz, ipso-Ar), 127.4 (d, J = 8.5 Hz, Ar), 116.2 (d, J = 21.5 Hz, Ar), 53.8 (OMe), 
49.6 (NCH2), 48.4 (C), 43.6 (NCH2), 30.8 (CH2), 20.3 (CH2); MS (ESI) m/z 238 (M)
+; 
HRMS m/z calcd for C13H17FNO2 (M)
+ 238.1238, found 238.1237 (‒0.3 ppm error). 
Lab Book - PJ-07-75. 
 
Methyl 3-(p-tolyl)pyrrolidine-3-carboxylate 277·HCl 
 
 
 
 
 
 
HCl (1 mL of a 4 M solution in dioxane) was added dropwise to N-Boc aryl pyrrolidine-3-
methyl ester 256 (72 mg, 0.23 mmol, 1.0 eq) at rt under Ar. The resulting solution was stirred 
at rt for 16 h. Then, the solvent was evaporated under reduced pressure to give aryl 
pyrrolidine-3-methyl ester 277·HCl (58 mg, 99%) as a cream solid, mp 50-52 °C; IR (ATR) 
2918, 1728 (C=O), 1212, 729 cm‒1; 1H NMR (400 MHz, CDCl3) δ 10.19-10.08 (m, 1H, 
NH), 10.00-9.87 (m, 1H, NH), 7.20-7.12 (m, 4H, Ar), 4.48-4.26 (m, 1H, NCH), 3.71 (s, 3H, 
OMe), 3.65-3.48 (m, 2H, NCH), 3.46-3.36 (m, 1H, NCH), 3.06-2.95 (m, 1H, CH), 2.40-2.21 
(m, 1H, CH), 2.31 (s, 3H, C6H4Me); 
13C NMR (100.6 MHz, CDCl3) δ 172.6 (C=O), 138.2 
(ipso-Ar), 134.7 (ipso-Ar), 129.8 (Ar), 126.4 (Ar), 57.5 (C), 53.6 (OMe), 51.8 (NCH2), 44.3 
(NCH2), 34.1 (CH2), 21.1 (C6H4Me); MS (ESI) m/z 220 (M)
+; HRMS m/z calcd for 
C13H18NO2 (M)
+ 220.1332, found 220.1333 (‒0.2 ppm error). 
Lab Book - PJ-07-92. 
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1-(tert-Butoxycarbonyl)-3-(4-fluorophenyl)piperidine-3-carboxylic acid 278 
 
 
 
 
 
KOH (476 mg, 8.47 mmol, 10.0 eq) was added to a stirred solution of N-Boc aryl piperidine-
3-methyl ester 261 (250 mg, 0.74 mmol, 1.0 eq) in EtOH (10 mL) at rt. The resulting mixture 
was stirred and heated at 100 °C for 16 h. The reaction mixture was allowed to cool to rt and 
evaporated under reduced pressure to give the crude product as an orange solid. The solid 
was taken up into water (20 mL) and washed with CH2Cl2 (3 x 10 mL). The aqueous layer 
was acidified with 1 M HCl(aq) (1 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined 
organics were washed with brine (20 mL), dried (Na2SO4) and evaporated under reduced 
pressure to give N-Boc aryl piperidine-3-carboxylic acid 278 (226 mg, 95%) as an orange 
solid, mp 178-180 °C; IR (ATR) 2978, 1717 (C=O, CO2H), 1663 (C=O, Boc), 1436, 1149, 
646 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.45-7.36 (m, 2H, Ar), 7.01 (dd, J = 9.0, 9.0 Hz, 
2H, Ar), 4.36-4.16 (m, 1H, NCH), 3.72-3.43 (m, 2H, NCH), 3.32-2.92 (m, 1H, NCH), 2.67-
2.23 (m, 1H, CH), 2.16-1.87 (m, 1H, CH), 1.72-1.51 (m, 2H, CH), 1.43 (s, 9H, CMe3); 
13C 
NMR (100.6 MHz, CDCl3) δ 178.9 (C=O, CO2H), 162.2 (d, J = 247.0 Hz, ipso-Ar), 154.8 
(C=O, Boc), 135.0 (d, J = 3.5 Hz, ipso-Ar), 128.4 (d, J = 8.0 Hz, Ar), 115.6 (d, J = 21.0 Hz, 
Ar), 80.2 (CMe3), 50.6 (NCH2), 49.5 (C), 43.1 (NCH2), 32.6 (CH2), 28.4 (CMe3), 22.2 (CH2); 
MS (ESI) m/z 346 (M + Na)+; HRMS m/z calcd for C17H22FNO4 (M + Na)
+ 346.1425, found 
346.1458 (‒4.8 ppm error). 
Lab Book - PJ-07-76. 
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3-(4-Fluorophenyl)piperidine-3-carboxamide 279 
 
 
 
 
 
 
T3P (0.31 mL of a 50% wt. solution in EtOAc, 1.07 mmol, 1.7 eq) was added dropwise to a 
stirred solution of N-Boc aryl piperidine-3-carboxylic acid 278 (200 mg, 0.62 mmol, 1.0 eq), 
35% NH3(aq) (0.031 mL, 0.78 mmol, 1.2 eq) and DIPEA (0.37 mL, 2.1 mmol, 3.4 eq) in 
CH2Cl2 (5 mL) at rt under Ar. The resulting solution was stirred at rt for 16 h. The reaction 
mixture was poured into water (10 mL) and acidified using 1 M HCl(aq) (5 mL) was added. 
The two layers were separated, and the aqueous layer was extracted with EtOAc (3 × 10 
mL). The combined organics were washed with 2 M NaOH(aq) (10 mL) and brine (10 mL), 
dried (MgSO4) and evaporated under reduced pressure to give the crude product as an orange 
oil. Purification by flash column chromatography on silica with 99:1 CH2Cl2-MeOH as 
eluent gave N-Boc aryl piperidine-3-amide (76 mg, 38%) as an orange solid, mp 150-152 
°C; RF (99:1 CH2Cl2-MeOH) 0.23, IR (ATR) 2951, 1666 (C=O), 1626 (C=O), 1434, 1156, 
830 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.48-7.32 (m, 2H, Ar), 7.03 (dd, J = 9.0, 9.0 Hz, 
3H, Ar and NH), 5.36-5.19 (m, 1H, NH), 4.63-4.44 (m, 1H, NCH), 4.05-3.78 (m, 1H, NCH), 
3.16-3.05 (m, 1H, NCH), 3.03-2.86 (m, 1H, NCH), 2.85-2.74 (m, 1H, CH), 1.87-1.69 (m, 
1H, CH), 1.67-1.58 (m, 2H, CH), 1.46 (s, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) δ 175.9 
(C=O, CONH2), 162.1 (d, J = 247.0 Hz, ipso-Ar), 155.5 (C=O, Boc), 137.2 (ipso-Ar), 127.8 
(Ar), 115.7 (d, J = 21.0 Hz, Ar), 80.8 (CMe3), 50.3 (C), 49.8 (NCH2), 44.5 (NCH2), 33.6 
(CH2), 28.5 (CMe3), 23.1 (CH2); MS (ESI) m/z 345 (M + Na)
+; HRMS m/z calcd for C17H23-
FN2O3 (M + Na)
+ 345.1585, found 345.1581 (+0.6 ppm error). HCl (1 mL of a 4 M solution 
in dioxane) was added dropwise to N-Boc aryl piperidine-3-amide (76 mg, 0.24 mmol, 1.0 
eq) at rt under Ar. The resulting solution was stirred at rt for 16 h. Then, the solvent was 
evaporated under reduced pressure to give aryl piperidine-3-amide 279·HCl (63 mg, 99%) 
as a cream solid, mp 230-231 °C; IR (ATR) 2954, 1650 (C=O, CONH2), 1510, 1229, 1165, 
814 cm‒1; 1H NMR (400 MHz, d4-MeOH) δ 7.46-7.39 (m, 2H, Ar), 7.14 (dd, J = 9.0, 9.0 
Hz, 2H, Ar), 3.87 (dd, J = 12.5, 2.5 Hz, 1H, NCH), 3.37-3.30 (m, 1H, NCH), 2.98 (ddd, J = 
12.5, 12.5, 3.5 Hz, 1H, NCH), 2.80 (d, J = 12.5 Hz, 1H, NCH), 2.61-2.44 (m, 1H, CH), 2.32 
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(ddd, J = 13.5, 13.5, 3.5 Hz, 1H, CH), 2.06 (ddddd, J = 15.0, 3.5, 3.5, 3.5, 3.5 Hz, 1H, CH), 
1.92-1.76 (m, 1H, CH); 13C NMR (100.6 MHz, d4-MeOH) δ 176.8 (C=O, CONH2), 162.6 
(d, J = 246.5 Hz, ipso-Ar), 135.6 (d, J = 3.0 Hz, ipso-Ar), 128.1 (d, J = 8.0 Hz, Ar), 115.5 
(d, J = 22.0 Hz, Ar), 50.5 (NCH2), 48.1 (C), 43.1 (NCH2), 29.2 (CH2), 19.7 (CH2); MS (ESI) 
m/z 223 (M)+; HRMS m/z calcd for C12H16FN2O (M)
+ 223.1241, found 223.1240 (+1.3 ppm 
error). 
Lab Book - PJ-07-79/PJ-08-01. 
 
4-(4-Methoxyphenyl)tetrahydro-2H-pyran-4-carboxylic acid 280 
 
 
 
 
 
KOH (444 mg, 7.92 mmol, 10.0 eq) was added to a stirred solution of aryl THP-4-methyl 
ester 272 (198 mg, 0.79 mmol, 1.0 eq) in EtOH (10 mL) at rt. The resulting mixture was 
stirred and heated at 100 °C for 16 h. The reaction mixture was allowed to cool to rt and 
evaporated under reduced pressure to give the crude product as an orange solid. The solid 
was taken up into water (20 mL) and washed with CH2Cl2 (3 x 10 mL). The aqueous layer 
was acidified with 1M HCl(aq) (1 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined 
organics were washed with brine (20 mL), dried (Na2SO4) and evaporated under reduced 
pressure to give aryl THP-4-carboxylic acid 280 (164 mg, 88%) as a cream solid, mp 160-
162 °C; IR (ATR) 2972, 1673 (C=O), 1511, 1257, 1239, 1027 cm‒1; 1H NMR (400 MHz, 
CDCl3) δ 7.33 (d, J = 9.0 Hz, 2H, Ar), 6.89 (d, J = 9.0 Hz, 2H, Ar), 3.91 (ddd, J = 12.0, 4.0, 
4.0 Hz, 2H, OCH), 3.80 (s, 3H, OMe), 3.66-3.56 (m, 2H, OCH), 2.62-2.42 (m, 2H, CH), 
1.96 (ddd, J = 14.0, 11.0, 4.0 Hz, 2H, CH); 13C NMR (100.6 MHz, CDCl3) δ 180.2 (C=O), 
159.0 (ipso-Ar), 133.8 (ipso-Ar), 127.2 (Ar), 114.2 (Ar), 65.6 (OCH2), 55.4 (OMe), 47.6 
(C), 34.2 (CH2); MS (ESI) m/z 259 (M + Na)
+; HRMS m/z calcd for C13H16O4 (M + Na)
+ 
259.0941, found 259.0929 (+2.9 ppm error). Spectroscopic data consistent with those 
reported in the literature.164  
Lab Book - PJ-07-83. 
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tert-Butyl 3-(4-fluorophenyl)-3-(hydroxymethyl)piperidine-1-carboxylate 281 
 
 
 
 
 
 
A solution of N-Boc aryl piperidine-3-methyl ester 261 (300 mg, 0.89 mmol, 1.0 eq) in THF 
(7 mL) was added dropwise to a stirred suspension of LiAlH4 (77 mg, 2.03 mmol, 2.0 eq) in 
THF (8 mL) at 0 °C under Ar. The resulting mixture was stirred at 0 °C for 2 h. Water (0.1 
mL), 20% NaOH(aq) (0.2 mL) and water (0.1 mL) were added sequentially (CARE – vigorous 
reaction). Then, MgSO4 was added and the solids were removed by filtration. The filtrate 
was evaporated under reduced pressure to give N-Boc aryl piperidine alcohol 281 (268 mg, 
98%) as a white solid, mp 98-100 °C; RF (70:30 hexane-EtOAc) 0.12; IR (ATR) 3517 (OH), 
2859, 1666 (C=O, Boc), 1431, 1156, 1060, 834 cm-1; 1H NMR (400 MHz, d4-MeOH) (50:50 
mixture of rotamers) δ 7.47 (dd, J = 9.0, 5.0 Hz, 2H, Ar), 7.13-6.99 (m, 2H, Ar), 4.30 (d, J 
= 13.5 Hz, 0.5H, NCH), 4.16 (d, J = 13.5 Hz, 0.5H, NCH), 3.83-3.59 (m, 1H, NCH), 3.61-
3.47 (m, 2H, OCH2), 3.30-3.22 (m, 1H, NCH), 3.18-3.13 (m, 0.5H, NCH), 3.07-2.94 (m, 
0.5H, NCH), 2.26-2.03 (m, 1H, CH), 1.95-1.78 (m, 1H, CH), 1.67-1.53 (m, 1H, CH), 1.54-
1.36 (m, 10H, CMe3 and CH); 
13C NMR (100.6 MHz, d4-MeOH) (rotamers) δ 161.48 (d, J 
= 243.5 Hz, ipso-Ar), 155.0 (C=O , Boc), 138.2 (ipso-Ar), 129.1 (Ar), 114.40 (d, J = 21.0 
Hz, Ar), 79.93 (CMe3), 79.92 (CMe3), 69.2 (OCH2), 68.8 (OCH2), 49.7 (NCH2), 48.4 
(NCH2), 44.4 (NCH2), 43.8 (C), 43.5 (NCH2), 30.9 (CH2), 30.5 (CH2), 27.4 (CMe3), 20.9 
(CH2); MS (ESI) m/z 332 (M + Na)
+; HRMS m/z calcd for C17H24FNO3 (M + Na)
+ 332.1632, 
found 332.1622 (+4.5 ppm error). 
Lab Book - PJ-07-78. 
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(3-(4-Fluorophenyl)piperidin-3-yl)methanol 282 
 
 
 
 
 
 
HCl (1 mL of a 4 M solution in dioxane) was added dropwise to N-Boc aryl piperidine 
alcohol 281 (90 mg, 0.29 mmol, 1.0 eq) at rt under Ar. The resulting solution was stirred at 
rt for 16 h. Then, the solvent was evaporated under reduced pressure to give aryl piperidine 
alcohol 282·HCl (70 mg, 99%) as a white solid, mp 100-102 °C; IR (ATR) 3346 (OH), 2950, 
1513, 1234, 832, 727 cm‒1; 1H NMR (400 MHz, CDCl3) δ 9.99-9.62 (m, 1H, NH), 8.98-8.65 
(m, 1H, NH), 7.35-7.28 (m, 2H, Ar), 7.04 (dd, J = 8.5, 8.5 Hz, 2H, Ar), 4.17 (d, J = 12.0 Hz, 
1H, OCH), 4.02 (d, J = 13.0 Hz, 1H, NCH), 3.71 (d, J = 12.0 Hz, 1H, OCH), 3.55-3.44 (m, 
1H, NCH), 3.02 (d, J = 13.0 Hz, 1H, NCH), 2.93-2.81 (m, 1H, NCH), 2.30-2.05 (m, 2H, 
CH), 1.98-1.77 (m, 2H, CH); 13C NMR (100.6 MHz, CDCl3) δ 161.9 (d, J = 247.0 Hz, ipso-
Ar), 138.6 (d, J = 3.0 Hz, ipso-Ar), 127.5 (d, J = 8.0 Hz, Ar), 115.7 (d, J = 21.0 Hz, Ar), 
66.4 (OCH2), 48.5 (NCH2), 43.7 (NCH2), 40.3 (C), 30.7 (CH2), 19.3 (CH2); MS (ESI) m/z 
210 (M)+; HRMS m/z calcd for C12H18FNO (M)
+ 210.1289, found 210.1287 (+0.7 ppm 
error). 
Lab Book - PJ-07-87. 
 
(1-(Pyridin-2-yl)cyclopentyl)ethanol 283 
 
A solution of aryl cyclopentane ester 248 (100 mg, 0.49 mmol, 1.0 eq) in THF (2.5 mL) was 
added dropwise to a stirred suspension of LiAlH4 (37 mg, 0.98 mmol, 2.0 eq) in THF (2.5 
mL) at 0 °C under Ar. The resulting mixture was stirred at 0 °C for 2 h. Water (0.1 mL), 
20% NaOH(aq) (0.2 mL) and water (0.1 mL) were added sequentially (CARE – vigorous 
reaction). Then, MgSO4 was added and the solids were removed by filtration. The filtrate 
was evaporated under reduced pressure to give aryl cyclopentane alcohol 283 (85 mg, 98%) 
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as an orange oil, IR (ATR) 3350 (OH), 2949, 1590, 1471, 1048, 748 cm‒1; 1H NMR (400 
MHz, CDCl3) δ 8.45-8.42 (m, 1H, 6-py), 7.67-7.60 (m, 1H, 4-py), 7.30-7.26 (m, 1H, 3-py), 
7.14-7.08 (m, 5-py), 3.73 (s, 2H, CH2OH), 2.01-1.93 (m, 2H, CH), 1.91-1.82 (m, 2H, CH), 
1.8-1.76 (m, 4H, CH); 13C NMR (100.6 MHz, CDCl3) δ 169.0 (ipso-Ar), 147.8 (Ar), 137.0 
(Ar), 121.2 (Ar), 121.0 (Ar), 69.2 (C), 53.6 (OCH2), 36.5 (CH2), 25.5 (CH2); MS (ESI) m/z 
178 (M + H)+; HRMS m/z calcd for C11H15NO (M + H)
+ 178.1226, found 178.1226 (+0.3 
ppm error). Spectroscopic data consistent with those reported in the literature.165  
Lab Book - PJ-07-23. 
 
(1-(Pyridin-2-yl)cyclopentyl)methyl methanesulfonate 284 
 
MsCl (0.026 mL, 0.34 mmol, 1.2 eq) was added dropwise to a stirred solution of aryl 
cyclopentane alcohol 283 (50 mg, 0.28 mmol, 1.0 eq) and Et3N (0.08 mL, 0.56 mmol, 2.0 
eq) in CH2Cl2 (5 mL)
 at rt under Ar. The resulting solution was stirred at rt for 16 h. The 
reaction mixture was evaporated under reduced pressure to give the crude product as a 
yellow oil. Purification by flash column chromatography on silica with 70:30 hexane-EtOAc 
as eluent gave aryl cyclopentane mesylate 284 (66 mg, 91%) as a colourless oil, RF (70:30 
hexane-EtOAc) 0.09; IR (ATR) 2960, 1350, 1171, 941, 748 cm‒1; 1H NMR (400 MHz, 
CDCl3) δ 8.56 (ddd, J = 5.0, 2.0, 1.0 Hz, 1H, 6-py), 7.63 (ddd, J = 7.5, 7.5, 2.0 Hz, 1H, 4-
py), 7.31 (m, 1H, 3-py), 7.13 (ddd, J = 7.5, 5.0, 1.0 Hz, 1H, 5-py), 4.42 (s, 2H, CH2O), 2.70 
(s, 3H, SO2Me), 2.31-2.00 (m, 2H, CH), 2.05-1.88 (m, 2H, CH), 1.85-1.64 (m, 4H, CH); 
13C 
NMR (100.6 MHz, CDCl3) δ 164.1 (ipso-Ar), 149.0 (Ar), 136.4 (Ar), 121.6 (Ar), 121.4 (Ar), 
76.1 (CH2O), 53.4 (C), 36.7 (Me), 34.7 (CH2), 24.5 (CH2); MS (ESI) m/z 256 (M + H)
+; 
HRMS m/z calcd for C12H17NO3S (M + H)
+ 256.1002, found 256.0998 (1.7 ppm error). 
Spectroscopic data consistent with those reported in the literature.165  
Lab Book - PJ-07-28. 
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2-(1-(Azidomethyl)cyclopentyl)pyridine 285 
 
A solution of aryl cyclopentane mesylate 284 (100 mg, 0.39 mmol, 1.0 eq) in DMF (1 mL) 
was added dropwise to a stirred solution of NaN3 (76 mg, 1.18 mmol, 3.0 eq) in DMF (1 
mL) at rt under Ar. The resulting mixture was stirred and heated at 60 °C for 24 h and then 
at 120 °C for 24 h. The reaction mixture was allowed to cool to rt and poured into water (10 
mL) and Et2O (10 mL). The two layers were separated, and the aqueous layer was extracted 
with Et2O (3 x 5 mL). The combined organics were dried (MgSO4) and evaporated under 
reduced pressure to give a colourless oil. Purification by flash column chromatography on 
silica with 90:10 hexane-EtOAc as eluent gave aryl cyclopentane azide 285 (68 mg, 86%) 
as a colourless oil, RF (70:30 hexane-EtOAc) 0.42; IR (ATR) 2956, 2093 (N3), 1587, 1469, 
747 cm‒1; 1H NMR (400 MHz, CDCl3) δ 8.62-8.53 (m, 1H, 6-py), 7.63 (ddd, J = 8.0, 8.0, 
2.0 Hz, 1H, 4-py), 7.37-7.27 (m, 1H, 3-py), 7.13 (ddd, J = 8.0, 5.0, 1.0 Hz, 1H, 5-py), 3.60 
(s, 2H, N3CH), 2.19-2.04 (m, 2H, CH), 2.00-1.86 (m, 2H, CH), 1.79-1.63 (m, 4H, CH); 
13C 
NMR (100.6 MHz, CDCl3) δ 165.2 (ipso-Ar), 149.1 (Ar), 136.3 (Ar), 121.5 (Ar), 121.3 (Ar), 
60.4 (N3CH2), 54.6 (C), 35.6 (CH2), 24.5 (CH2); MS (ESI) m/z 203 (M + H)
+; HRMS m/z 
calcd for C11H14N4 (M + H)
+ 203.1291, found 203.1292 (‒2.1 ppm error). 
Lab Book - PJ-07-74. 
 
(1-(Pyridin-2-yl)cyclopentyl)methanamine 286 
 
PPh3 (166 mg, 0.63 mmol, 2.0 eq) was added to a stirred solution of aryl cyclopentane azide 
285 (64 mg, 0.32 mmol, 1.0 eq) in 5:1 THF-water (6 mL) at rt. The resulting mixture was 
stirred and heated at 65 °C for 16 h. The reaction mixture was allowed to cool to rt and 
evaporated under reduced pressure to give the crude product as a colourless oil. Purification 
by flash column chromatography on silica with 85:14:1 CH2Cl2-MeOH-NH4OH(aq) as eluent 
gave aryl cyclopentane amine 286 (53 mg, 95%) as a green oil, RF (85:14:1 CH2Cl2-MeOH-
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NH4OH(aq)) 0.43; IR (ATR) 3066 (NH), 1474, 1430, 740, 690, 489 cm
‒1; 1H NMR (400 
MHz, CDCl3) δ 8.58-8.41 (m, 1H, 6-py), 7.70-7.54 (m, 1H, 4-py), 7.32-7.25 (m, 1H, 3-py), 
7.16-7.05 (m, 1H, 5-py), 2.97 (s, 2H, NCH2), 2.64 (br s, 2H, NH2) 2.12-2.02 (m, 2H, CH), 
1.97-1.84 (m, 2H, CH), 1.80-1.61 (m, 4H, CH); 13C NMR (100.6 MHz, CDCl3) δ 166.8 
(ipso-Ar), 148.7 (Ar), 136.6 (Ar), 121.4 (Ar), 121.2 (Ar), 54.3 (NCH2), 50.9 (C), 35.9 (CH2), 
24.6 (CH2); MS (ESI) m/z 177 (M + H)
+; HRMS m/z calcd for C11H16N2 (M + H)
+ 177.1386, 
found 177.1386 (‒0.4 ppm error). 
Lab Book - PJ-07-81. 
 
(4-(Pyridin-2-yl)tetrahydro-2H-pyran-4-yl)methanol 287 
 
 
 
 
A solution of aryl THP-4-methyl ester 273 (430 mg, 1.95 mmol, 1.0 eq) in THF (7 mL) was 
added dropwise to a stirred suspension of LiAlH4 (147 mg, 3.89 mmol, 2.0 eq) in THF (8 
mL) at 0 °C under Ar. The resulting mixture was stirred at 0 °C for 2 h. Water (0.1 mL), 
20% NaOH(aq) (0.2 mL) and water (0.1 mL) were added sequentially (CARE – vigorous 
reaction). Then, MgSO4 was added and the solids were removed by filtration. The filtrate 
was evaporated under reduced pressure to give the crude product as an orange oil. 
Purification by flash column chromatography on silica with 100% EtOAc as eluent gave aryl 
THP alcohol 287 (312 mg, 82%) as a colourless oil, RF (EtOAc) 0.17; IR (ATR) 3378 (OH), 
2952, 1432, 1043, 561 cm‒1; 1H NMR (400 MHz, CDCl3) δ 8.59-8.49 (m, 1H, 6-py), 8.01-
7.62 (m, 1H, 4-py), 7.48-7.29 (m, 1H, 3-py), 7.22-7.09 (m, 1H, 5-py), 4.10-3.95 (m, 1H, 
OH), 3.91-3.75 (m, 4H, OCH), 3.73-3.54 (m, 2H, OCH), 2.38-2.11 (m, 2H, CH), 1.95-1.81 
(m, 2H, CH); 13C NMR (100.6 MHz, CDCl3) δ 165.4 (ipso-Ar), 148.8 (Ar), 137.1 (Ar), 121.7 
(Ar), 120.9 (Ar), 68.4 (OCH2), 64.3 (OCH2), 42.5 (C), 32.4 (CH2); MS (ESI) m/z 194 (M + 
H)+; HRMS m/z calcd for C11H15NO2 (M + H)
+ 194.1176, found 194.1176 (+0.2 ppm error). 
Lab Book - PJ-07-82. 
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(4-(Pyridin-2-yl)tetrahydro-2H-pyran-4-yl)methyl methanesulfonate 288 
 
 
 
 
 
MsCl (0.07 mL, 0.93 mmol, 1.2 eq) was added dropwise to a stirred solution of aryl THP 
alcohol 287 (150 mg, 0.78 mmol, 1.0 eq) and Et3N (0.11 mL, 1.55 mmol, 2.0 eq) in CH2Cl2 
(5 mL) at rt under Ar. The resulting solution was stirred at rt for 16 h. The reaction mixture 
was evaporated under reduced pressure to give the crude product as an orange oil. 
Purification by flash column chromatography on silica with 80:20 EtOAc-heaxane as eluent 
gave aryl THP mesylate 288 (143 mg, 67%) as a colourless oil, RF (80:20 EtOAc-heaxane) 
0.26; IR (ATR) 2958, 1350, 1172, 952, 729 cm‒1; 1H NMR (400 MHz, CDCl3) δ 8.62 (ddd, 
J = 5.0, 2.0, 1.0 Hz, 1H, 6-py), 7.76-7.65 (m, 1H, 4-py), 7.35 (ddd, J = 8.0, 1.0, 1.0 Hz, 1H, 
3-py), 7.19 (ddd, J = 7.5, 5.0, 1.0 Hz, 1H, 5-py), 4.33 (s, 2H, OCH2), 3.83 (ddd, J = 12.0, 
4.5, 4.5 Hz, 2H, OCH), 3.50 (ddd, J = 12.0, 9.5, 3.0 Hz, 2H, OCH), 2.66 (s, 3H, Me), 2.36 
(dddd, J = 13.5, 4.5, 3.0 Hz, 2H, CH), 1.95 (ddd, J = 13.5, 9.5, 4.5 Hz, 2H, CH); 13C NMR 
(100.6 MHz, CDCl3) δ 160.8 (ipso-Ar), 149.7 (Ar), 136.6 (Ar), 122.4 (Ar), 122.1 (Ar), 76.9 
(MsOCH2), 64.1 (OCH2), 42.8 (C), 36.8 (Me), 31.8 (CH2); MS (ESI) m/z 272 (M + H)
+; 
HRMS m/z calcd for C12H17NO4S (M + H)
+ 272.0951, found 272.0944 (+2.1 ppm error). 
Lab Book - PJ-07-85. 
 
2-(4-(Azidomethyl)tetrahydro-2H-pyran-4-yl)pyridine 289 
 
 
 
 
 
A solution of aryl THP mesylate 288 (120 mg, 0.44 mmol, 1.0 eq) in DMF (2 mL) was added 
dropwise to a stirred solution of NaN3 (86 mg, 1.33 mmol, 3.0 eq) in DMF (1 mL) at rt under 
Ar. The resulting mixture was stirred and heated at 120 °C for 24 h. The reaction mixture 
was allowed to cool to rt and poured into water (10 mL) and Et2O (10 mL). The two layers 
were separated, and the aqueous layer was extracted with Et2O (3 x 5 mL). The combined 
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organics were dried (MgSO4) and evaporated under reduced pressure to give the crude 
product as a colourless oil. Purification by flash column chromatography on silica with 90:10 
hexane-EtOAc as eluent gave aryl THP azide 289 (80 mg, 84%) as a yellow oil, RF (50:50 
hexane-EtOAc) 0.32; IR (ATR) 2954, 2095 (N3), 1587, 1105, 748 cm
‒1; 1H NMR (400 MHz, 
CDCl3) δ 8.64 (ddd, J = 5.0, 2.0, 1.0 Hz, 1H, 6-py), 7.70 (ddd, J = 7.5, 7.5, 2.0 Hz, 1H, 4-
py), 7.34 (ddd, J = 7.5, 1.0, 1.0 Hz, 1H, 3-py), 7.19 (ddd, J = 7.5, 5.0, 1.0 Hz, 1H, 5-py), 
3.82 (ddd, J = 12.0, 4.5, 4.5 Hz, 2H, OCH), 3.52 (s, 2H, N3CH2), 3.48 (ddd, J = 12.0, 10.0, 
2.5 Hz, 2H, OCH), 2.42-2.33 (m, 2H, CH), 1.89 (ddd, J = 14.0, 10.0, 4.5 Hz, 2H, CH); 13C 
NMR (100.6 MHz, CDCl3) δ 161.8 (ipso-Ar), 149.7 (Ar), 136.5 (Ar), 122.1 (Ar), 121.9 (Ar), 
64.4 (OCH2), 62.0 (N3CH2), 43.6 (C), 33.1 (CH2); MS (ESI) m/z 219 (M + H)
+; HRMS m/z 
calcd for C11H14N4O (M + H)
+ 219.1240, found 219.1239 (+0.8 ppm error). 
Lab Book - PJ-07-88. 
 
(4-(Pyridin-2-yl)tetrahydro-2H-pyran-4-yl)methanamine 290 
 
 
 
 
 
PPh3 (194 mg, 0.74 mmol, 2.0 eq) was added to a stirred solution of aryl THP azide 289 (80 
mg, 0.37 mmol, 1.0 eq) in 5:1 THF-water (6 mL) at rt. The resulting mixture was stirred and 
heated at 65 °C for 16 h. The reaction mixture was allowed to cool to rt and evaporated under 
reduced pressure to give the crude product as a colourless oil. Purification by flash column 
chromatography on silica with 90:9:1 CH2Cl2-MeOH-NH4OH(aq) as eluent gave aryl THP 
amine 290 (66 mg, 92%) as a yellow oil, RF (90:9:1 CH2Cl2-MeOH-NH4OH(aq)) 0.18, IR 
(ATR) 3368 (NH), 2926, 2852, 1587, 1105, 749 cm‒1; 1H NMR (400 MHz, CDCl3) δ 8.64-
8.59 (m, 1H, 6-py), 7.72-7.62 (m, 1H, 4-py), 7.32-7.27 (m, 1H, 3-py), 7.17-7.11 (m, 1H, 5-
py), 3.87-3.77 (m, 2H, OCH), 3.50-3.41 (m, 2H, OCH), 2.88 (s, 2H, NCH2), 2.38-2.29 (m, 
2H, CH), 1.84-1.75 (m, 2H, CH); 13C NMR (100.6 MHz, CDCl3) δ 163.5 (ipso-Ar), 149.4 
(Ar), 136.5 (Ar), 121.8 (Ar), 121.3 (Ar), 64.7 (OCH2), 53.5 (NCH2), 44.1 (C), 33.4 (CH2); 
MS (ESI) m/z 193  (M + H)+; HRMS m/z calcd for C11H16N2O (M + H)
+ 193.1335, found 
193.1333 (+1.6 ppm error). Spectroscopic data consistent with those reported in the 
literature.166 
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Lab Book - PJ-07-94. 
 
(1-(Pyridin-2-yl)cyclopentyl)methyl pyridine-2-sulfonate 291 
 
 
 
 
 
DBU (0.08 mL, 0.56 mmol, 2.0 eq) was added dropwise to a stirred solution of aryl 
cyclopentane alcohol 283 (50 mg, 0.28 mmol, 1.0 eq) and PyFluor (50 mg, 0.31 mmol, 1.1 
eq) at rt under Ar. The resulting solution was stirred at rt for 48 h. The reaction mixture was 
evaporated under reduced pressure to give the crude product as a yellow oil. Purification by 
flash column chromatography on silica with 60:40 EtOAc-hexane as eluent gave aryl 
cyclopentane sulfonate 291 (89 mg, 99%) as a white solid, mp 64-66 °C; RF (60:40 EtOAc-
hexane) 0.07; IR (ATR) 2959, 1354, 1182, 936, 595 cm‒1; 1H NMR (400 MHz, CDCl3) δ 
8.64 (ddd, J = 5.0, 1.5, 1.5 Hz, 1H, 6-py), 8.38 (ddd, J = 5.0, 2.0, 1.0 Hz, 1H, 6-py), 7.86-
7.80 (m, 2H, 4-py and 3-py), 7.55 (ddd, J = 7.5, 7.5, 2.0  1H, 4-py), 7.49 (ddd, J = 6.0, 5.0, 
2.0 Hz, 1H, 5-py), 7.26 (ddd, J = 7.5, 1.0, 1.0 Hz, 1H, 3-py), 7.03 (ddd, J = 7.5, 5.0, 1.0 Hz, 
1H, 5-py), 4.50 (s, 2H, OCH2), 2.18-1.98 (m, 2H, CH), 2.01-1.84 (m, 2H, CH), 1.80-1.57 
(m, 4H, CH); 13C NMR (100.6 MHz, CDCl3) δ 163.8 (ipso-Ar), 154.5 (ipso-Ar), 150.2 (Ar), 
148.9 (Ar), 138.1 (Ar), 136.2 (Ar), 127.4 (Ar), 123.1 (Ar), 121.6 (Ar), 121.4 (Ar), 78.1 
(OCH2), 53.6 (C), 34.5 (CH2), 24.4 (CH2); MS (ESI) m/z 341 (M + Na)
+; HRMS m/z calcd 
for C16H18N2O3S (M + Na)
+ 341.0930, found 341.0928 (+1.7 ppm error). 
Lab Book - PJ-07-27. 
 
2-(1-(Fluoromethyl)cyclopentyl)pyridine 292 
 
DBU (0.08 mL, 0.56 mmol, 2.0 eq) was added dropwise to a stirred solution of aryl 
cyclopentane alcohol 283 (50 mg, 0.28 mmol, 1.0 eq) and PyFluor (50 mg, 0.31 mmol, 1.1 
eq) in toluene (5 mL) at rt under Ar. The resulting solution was stirred and heated at 80 °C 
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for 48 h. The reaction mixture was allowed to cool to rt and evaporated under reduced 
pressure to give the crude product as a yellow solid. Purification by flash column 
chromatography on silica with 60:40 hexane-EtOAc as eluent gave aryl cyclopentane 
fluoride 292 (35 mg, 70%) as a yellow oil, RF (60:40 hexane-EtOAc) 0.57; IR (ATR) 2954, 
1588, 1470, 1431, 991, 747 cm‒1; 1H NMR (400 MHz, CDCl3) δ 8.57 (ddd, J = 5.0, 2.0, 1.0 
Hz, 1H, 6-py), 7.61 (ddd, J = 8.0, 8.0, 2.0 Hz, 1H, 4-py), 7.44-7.29 (m, 1H, 3-py), 7.11 (ddd, 
J = 8.0, 5.0, 1.0 Hz, 1H, 5-py), 4.51 (d, J = 48.0 Hz, 2H, FCH2), 2.26-2.03 (m, 2H, CH), 
2.03-1.85 (m, 2H, CH), 1.80-1.68 (m, 4H, CH); 13C NMR (100.6 MHz, CDCl3) δ 165.0 (d, 
J = 2.0 Hz, ipso-Ar), 149.0 (Ar), 136.2 (Ar), 121.7 (Ar), 121.4. (Ar), 88.7 (d, J = 175.0 Hz, 
FCH2), 54.4 (d, J = 16.5 Hz, C), 34.1 (d, J = 4.5 Hz, CH2), 25.0 (CH2); MS (ESI) m/z 179 
(M + H)+; HRMS m/z calcd for C11H14FN (M + H)
+ 180.1183, found 180.1180 (+2.0 ppm 
error). 
Lab Book - PJ-07-34. 
 
2-(4-(Fluoromethyl)tetrahydro-2H-pyran-4-yl)pyridine 293 
 
 
 
 
 
DBU (0.25 mL, 1.03 mmol, 2.0 eq) was added dropwise to a stirred solution of aryl THP 
alcohol 287 (100 mg, 0.52 mmol, 1.0 eq) and PyFluor (92 mg, 0.57 mmol, 1.1 eq) at rt under 
Ar. The resulting solution was stirred and heated at 80 °C for 48 h. The reaction mixture was 
allowed to cool to rt and evaporated under reduced pressure to give the crude product as an 
orange solid. Purification by flash column chromatography on silica with 60:40 hexane-
EtOAc as eluent gave aryl THP fluoride 293 (86 mg, 85%) as a colourless oil, RF (60:40 
hexane-EtOAc) 0.35; IR (ATR) 2956, 1588, 1469, 1235, 1106, 729 cm‒1; 1H NMR (400 
MHz, CDCl3) δ 8.64 (ddd, J = 5.0, 2.0, 1.0 Hz, 1H, 6-py), 7.69 (ddd, J = 7.5, 7.5, 2.0 Hz, 
1H, 4-py), 7.39-7.33 (m, 1H, 3-py), 7.18 (ddd, J = 7.5, 5.0, 1.0 Hz, 1H, 5-py), 4.45 (d, J = 
47.5 Hz, 2H, FCH2), 3.84 (ddd, J = 12.0, 4.0, 4.0 Hz, 2H, OCH), 3.50 (ddd, J = 12.0, 10.0, 
2.5 Hz, 2H, OCH), 2.41-2.31 (m, 2H, CH), 1.96 (ddd, J = 14.0, 10.0, 4.0 Hz, 2H, CH); 13C 
NMR (100.6 MHz, CDCl3) δ 161.2 (ipso-Ar), 149.6 (Ar), 136.4 (Ar), 122.4 (Ar), 121.8 (Ar), 
90.3 (d, J = 176.5 Hz, FCH2), 64.3 (OCH2), 43.8 (d, J = 17.5 Hz, C), 31.2 (d, J = 5.0 Hz, 
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CH2); MS (ESI) m/z 196 (M + H)
+; HRMS m/z calcd for C11H14FNO (M + H)
+ 196.1132, 
found 196.1127 (+3.1 ppm error). 
Lab Book - PJ-07-84. 
 
tert-Butyl 3-(4-fluorophenyl)-3-(((pyridin-2-ylsulfonyl)oxy)methyl)piperidine-1-
carboxylate 294 
 
 
 
 
 
DBU (0.12 mL, 0.80 mmol, 2.0 eq) was added dropwise to a stirred solution of N-Boc aryl 
piperidine alcohol 281 (124 mg, 0.40 mmol, 1.0 eq) and PyFluor (71 mg, 0.44 mmol, 1.1 eq) 
at rt under Ar. The resulting solution was stirred and heated at 80 °C for 48 h. The reaction 
mixture was allowed to cool to rt and evaporated under reduced pressure to give the crude 
product as an orange oil. Purification by flash column chromatography on silica with 99:1 
CH2Cl2-acetone as eluent gave N-Boc aryl piperidine sulfonate 294 (137 mg, 76%) as a 
colourless oil, RF (99:1 CH2Cl2-acetone) 0.17; IR (ATR) 2976, 1638 (C=O), 1427, 1364, 
1154, 830, 593 cm‒1; 1H NMR (400 MHz, CDCl3) δ 8.62 (ddd, J = 5.0, 1.0, 1.0 Hz, 1H, 6-
py), 7.90-7.76 (m, 1H, 4-py and 3-py), 7.50 (ddd, J = 7.0, 5.0, 1.0 Hz, 1H, 5-py), 7.32-7.20 
(m, 2H, Ar), 6.89 (dd, J = 8.5, 8.5 Hz, 2H, Ar), 4.33 (s, 2H, OCH2), 4.11-3.91 (m, 1H, NCH), 
3.61-3.37 (m, 2H, NCH), 3.27-3.17 (m, 1H, NCH), 2.19-1.84 (m, 2H, CH), 1.64-1.50 (m, 
1H, CH), 1.51-1.30 (m, 10H, CMe3 and CH); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 
161.7 (d, J = 246.0 Hz, ipso-Ar), 154.8 (C=O or ipso-Ar), 154.4 (C=O or ipso-Ar), 150.2 
(Ar), 138.2 (Ar), 136.0 (d, J = 3.5 Hz, Ar), 128.7 (d, J = 8.0 Hz, Ar), 127.6 (Ar), 123.0 (Ar), 
115.29 (d, J = 21.0 Hz, Ar), 80.1 (CMe3), 77.4 (OCH2), 49.4 (NCH2), 48.4 (NCH2), 44.4 
(NCH2), 43.5 (NCH2), 42.2 (C), 31.0 (CH2), 28.5 (CMe3), 21.0 (CH2); MS (ESI) m/z 473 (M 
+ Na)+; HRMS m/z calcd for C22H27FN2O5S (M + Na)
+ 473.1517, found 473.1512 (+1.7 
ppm error).  
Lab Book - PJ-07-80. 
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(3-(4-Fluorophenyl)piperidin-3-yl)methanamine 295·HCl 
 
 
 
 
 
 
A solution of N-Boc aryl piperidine sulfonate 294 (137 mg, 0.30 mmol, 1.0 eq) in DMF (3 
mL) was added dropwise to a stirred solution of NaN3 (59 mg, 0.91 mmol, 3.0 eq) in DMF 
(1 mL) at rt under Ar. The resulting mixture was stirred and heated at 120 °C for 24 h. The 
reaction mixture was allowed to cool to rt and poured into water (10 mL) and Et2O (10 mL). 
The two layers were separated, and the aqueous layer was extracted with Et2O (3 x 5 mL). 
The combined organics were dried (MgSO4) and evaporated under reduced pressure to give 
a yellow oil. Purification by flash column chromatography on silica with 95:5-80:20 hexane-
EtOAc as eluent gave N-Boc aryl piperidine azide (66 mg, 65%) as a colourless oil, RF (95:5 
hexane-EtOAc) 0.06; IR (ATR) 2935, 2098 (N3), 1683 (C=O), 1425, 1153, 832 cm
‒1; 1H 
NMR (400 MHz, CDCl3) δ 7.40-7.29 (m, 2H, Ar), 7.03 (dd, J = 9.0, 9.0 Hz, 2H, Ar), 3.89 
(d, J = 13.5 Hz, 1H, NCH), 3.51-3.42 (m, 2H, NCH), 3.40-3.36 (m, 2H, N3CH), 3.36-3.25 
(m, 1H, NCH), 2.07-1.96 (m, 1H, CH), 1.94-1.83 (m, 1H, CH), 1.72-1.52 (m, 2H, CH), 1.52-
1.35 (m, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 161.8 (d, J = 246.0 Hz, 
ipso-Ar), 155.2 (C=O or ipso-Ar) 154.6 (C=O or ipso-Ar), 137.6 (d, J = 2.5 Hz, ipso-Ar), 
128.54 (d, J = 8.0 Hz, Ar), 115.45 (d, J = 21.0 Hz, Ar), 80.1 (CMe3), 59.7 (N3CH2), 50.3 
(NCH2), 49.5 (NCH2), 44.5 (NCH2), 43.5 (NCH2), 42.5 (C), 32.5 (CH2), 32.2 (CH2), 28.5 
(CMe3), 21.3 (CH2); MS (ESI) m/z 357 (M + Na)
+; HRMS m/z calcd for C17H23FN4O2 (M + 
Na)+ 357.1697, found 357.1695 (+0.0 ppm error). PPh3 (103 mg, 0.40 mmol, 2.0 eq) was 
added to a stirred solution of N-Boc aryl piperidine azide (66 mg, 0.20 mmol, 1.0 eq) in 5:1 
THF-water (6 mL) at rt. The resulting mixture was stirred and heated at 65 °C for 16 h. The 
reaction mixture was allowed to cool to rt and evaporated under reduced pressure to give the 
crude product as a colourless oil. Purification by flash column chromatography on silica with 
95:5 CH2Cl2-MeOH as eluent gave N-Boc aryl piperidine amine (49 mg, 79%) as a white 
solid, mp 82-84 °C; RF (95:5 CH2Cl2-MeOH) 0.05; IR (ATR) 3360 (NH), 2979, 1676 (C=O), 
1431, 1120, 836 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.29 (dd, J = 9.0, 5.5 Hz, 2H, Ar), 7.01 
(dd, J = 9.0, 9.0 Hz, 2H, Ar), 3.85-3.70 (m, 1H, NCH), 3.68-3.45 (m, 1H, NCH), 3.45-3.19 
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(m, 2H, NCH), 2.92-2.58 (m, 2H, NCH), 2.10-1.87 (m, 1H, CH), 1.86-1.73 (m, 1H, CH), 
1.66-1.54 (m, 1H, CH), 1.54-1.31 (m, 10H, CMe3 and CH); 
13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 161.4 (d, J = 245.5 Hz, ipso-Ar), 155.2 (C=O, Boc), 154.6 (C=O, Boc), 139.1 
(ipso-Ar), 138.8 (ipso-Ar), 128.5 (d, J = 6.0 Hz, Ar), 115.4 (d, J = 21.0 Hz, Ar), 79.8 (CMe3), 
50.5 (NCH2), 50.1 (NCH2), 49.0 (NCH2), 44.8 (NCH2), 43.9 (NCH2), 43.3 (C), 33.6 (CH2), 
33.2 (CH2), 28.5 (CMe3), 21.6 (CH2), 21.5 (CH2); MS (ESI) m/z 309 (M + H)
+; HRMS m/z 
calcd for C17H25FN2O2 (M + H)
+ 309.1973, found 309.1974 (‒0.6 ppm error). HCl (1 mL of 
a 4 M solution in dioxane) was added dropwise to N-Boc aryl piperidine amine (49 mg, 0.15 
mmol, 1.0 eq) at rt under Ar. The resulting solution was stirred at rt for 16 h. Then, the 
solvent was evaporated under reduced pressure to give aryl piperidine amine 295·HCl (36 
mg, 99%) as a white solid, mp 242-244 °C; IR (ATR) 3391 (NH), 2827, 1607, 1513, 1227, 
1173, 842 cm‒1; 1H NMR (400 MHz, d4-MeOD) δ 7.57 (dd, J = 9.0, 5.0 Hz, 2H, Ar), 7.27 
(dd, J = 9.0, 9.0 Hz, 2H, Ar), 3.87 (d, J = 13.5 Hz, 1H, NCH), 3.46 (d, J = 13.5 Hz, 1H, 
NCH), 3.26 (s, 2H, NCH), 3.18-3.12 (m, 2H, NCH), 2.57-2.47 (m, 1H, CH), 2.05-1.90 (m, 
2H, CH), 1.88-1.74 (m, 1H, CH); 13C NMR (100.6 MHz, d4-MeOH) δ 164.1 (d, J = 247.0 
Hz, ipso-Ar), 133.6 (d, J = 3.0 Hz, ipso-Ar), 130.5 (d, J = 8.5 Hz, Ar), 117.9 (d, J = 21.5 Hz, 
Ar), 50.3 (NCH2), 49.9 (NCH2) 45.3 (NCH2), 40.8 (C), 29.8 (CH2), 19.7 (CH2); MS (ESI) 
m/z 209 (M)+; HRMS m/z calcd for C12H18FN2 (M)
+ 209.1449, found 209.1449 (+2.9 ppm 
error). 
Lab Book - PJ-07-91/PJ-08-02/PJ-08-11. 
 
Methyl 1-acetyl-3-(p-tolyl)pyrrolidine-3-carboxylate 297 
 
 
 
 
 
 
Et3N (0.32 mL, 2.3 mmol, 10.0 eq) was added dropwise to a stirred solution of aryl 
pyrrolidine-3-methyl ester 296·HCl (59 mg, 0.23 mmol, 1.0 eq) in CH2Cl2 (5 mL)
 at rt under 
Ar. The resulting solution was stirred at rt for 30 min. Then, AcCl (0.02 mL, 0.34 mmol, 1.5 
eq) was added dropwise and the solution was stirred at rt for 16 h. The solution was poured 
into water (10 mL) and the two layers were separated. The aqueous layer was extracted with 
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CH2Cl2 (3 x 10 mL) and the combined organics were dried (MgSO4) and evaporated under 
reduced pressure to give the crude product as an orange oil. Purification by flash column 
chromatography on silica with 70:29:1-50:49:1 hexane-EtOAc-NH4OH(aq) as eluent gave N-
acyl aryl pyrrolidine-3-methyl ester 297 (60 mg, 99%) as a yellow solid, mp 64-66 °C, RF 
(70:29:1 hexane-EtOAc- NH4OH(aq)) 0.07; IR (ATR) 2957, 1723 (C=O, CO2Me), 1634 
(C=O, MeCO), 1416, 1193, 1115 cm‒1; 1H NMR (400 MHz, CDCl3) (50:50 mixture of 
rotamers) δ 7.23-7.03 (m, 4H, Ar), 4.51 (d, J = 11.5 Hz, 0.5H, NCH), 4.48 (d, J = 11.5 Hz, 
0.5H, NCH), 3.70 (d, J = 11.5 Hz, 0.5H, NCH), 3.65 (s, 1.5H, OMe), 3.68-3.61 (m, 0.5H, 
NCH), 3.62 (s, 1.5H, OMe), 3.57-3.49 (m, 1.5H, OMe), 3.43 (ddd, J = 12.5, 10.0, 7.0 Hz, 
0.5H, NCH), 3.03-2.91 (m, 0.5H, CH), 2.95-2.83 (m, 0.5H, CH), 2.33 (s, 1.5H, C6H4Me), 
2.32 (s, 1.5H, C6H4Me), 2.2- 2.13 (m, 1H, CH), 2.10 (s, 1.5H, MeCO), 2.03 (s, 1.5H, MeCO); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 174.0 (C=O, CO2Me), 173.8 (C=O, CO2Me), 
169.5 (C=O, COMe), 169.3 (C=O, COMe), 137.9 (ipso-Ar), 137.7 (ipso-Ar), 136.4 (ipso-
Ar), 136.0 (ipso-Ar), 129.6 (Ar), 129.6 (Ar), 126.5 (Ar), 126.3 (Ar), 57.5 (C), 55.7 (NCH2), 
55.2 (OMe), 53.1 (NCH2), 53.0 (OMe), 46.1 (NCH2), 44.4 (NCH2), 35.1 (CH2), 33.2 (CH2), 
22.6 (COMe), 22.2 (COMe), 21.2 (C6H4Me); MS (ESI) m/z 284 (M + Na)
+; HRMS m/z calcd 
for C15H19NO3 (M + Na)
+ 284.1257, found 284.1253 (+1.8 ppm error). 
Lab Book - PJ-07-95. 
 
(1-Methyl-3-(p-tolyl)pyrrolidin-3-yl)methanol 298 
 
 
 
 
 
A solution of N-Boc aryl pyrolidine-3-tert-butyl ester 260 (120 mg, 0.33 mmol, 1.0 eq) in 
THF (5 mL) was added dropwise to a stirred suspension of LiAlH4 (63 mg, 1.66 mmol, 5 eq) 
in THF (5 mL) at 0 °C under Ar. The resulting suspension was stirred at 0 °C for 2 h. Then, 
the reaction mixture was allowed to warm to rt. The reaction mixture was then stirred and 
heated at reflux for 16 h. After the reaction mixture was cooled to 0 °C, water (0.1 mL), 20% 
NaOH(aq) (0.2 mL) and water (0.1 mL) were added sequentially (CARE – vigorous reaction). 
Then, MgSO4 was added and the solids were removed by filtration. The filtrate was 
evaporated under reduced pressure to give the crude product as a green oil. Purification by 
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flash column chromatography on silica with 90:9:1 CH2Cl2-MeOH-NH4OH(aq) as eluent 
gave N-methyl aryl pyrrolidine alcohol 298 (20 mg, 31%) as a colourless oil, RF (90:9:1 
CH2Cl2-MeOH-NH4OH(aq)) 0.17, IR (ATR) 3347 (OH), 2921, 1515, 1449, 1049, 818 cm
‒1; 
1H NMR (400 MHz, CDCl3) δ 7.13 (d, J = 8.0 Hz, 2H, Ar), 7.07 (d, J = 8.0 Hz, 2H, Ar), 
3.69 (d, J = 10.0 Hz, 1H, OCH), 3.51 (dd, J = 10.0, 2.0 Hz, 1H, OCH), 3.40 (d, J = 9.0 Hz, 
1H, NCH), 3.27-3.20 (m, 1H, NCH), 2.64 (dd, J = 9.0, 2.0 Hz, 1H, NCH), 2.52-2.43 (m, 1H, 
CH), 2.40 (s, 3H, NMe), 2.32 (s, 3H, C6H4Me), 2.31-2.19 (m, 2H, CH and NCH); 
13C NMR 
(100.6 MHz, CDCl3) δ 141.9 (ipso-Ar), 136.2 (ipso-Ar), 129.2 (Ar), 126.6 (Ar), 75.3 
(OCH2), 66.0 (NCH2), 55.9 (NCH2), 51.1 (C), 41.8 (NMe), 34.3 (CH2), 21.0 (C6H4Me); MS 
(ESI) m/z 206 (M + H)+; HRMS m/z calcd for C13H19NO (M + H)
+ 206.1539, found 206.1537 
(+1.0 ppm error). 
Lab Book - PJ-07-90. 
 
Methyl 1-acetyl-3-(p-tolyl)piperidine-3-carboxylate 299 
 
 
 
 
 
Et3N (0.4 mL, 2.89 mmol, 10.0 eq) was added dropwise to a stirred solution of aryl 
piperidine-3-methyl ester 275·HCl (78 mg, 0.28 mmol, 1.0 eq) in CH2Cl2 (5 mL)
 at rt under 
Ar. The resulting solution was stirred at rt for 30 min. Then, AcCl (0.03 mL, 0.43 mmol, 1.5 
eq) was added dropwise and the solution was stirred at rt for 16 h. The solution was poured 
into water (10 mL) and the two layers were separated. The aqueous layer was extracted with 
CH2Cl2 (3 x 10 mL) and the combined organics were dried (MgSO4) and evaporated under 
reduced pressure to give the crude product as an orange oil. Purification by flash column 
chromatography on silica with 50:50-70:30 EtOAc-hexane as eluent gave N-acyl aryl 
piperidine-3-methyl ester 299 (68 mg, 88%) as a yellow oil, RF (70:30 EtOAc-hexane) 0.1; 
IR (ATR) 2949, 1726 (C=O, CO2Me), 1631 (C=O, MeCO), 1430, 1271, 1233, 1142 cm
‒1; 
1H NMR (400 MHz, CDCl3) (70:30 mixture of rotamers) δ 7.34-7.29 (m, 0.6H, Ar), 7.25-
7.22 (m, 1.4H, Ar), 7.1-7.11 (m, 2H, Ar), 4.65-4.58 (m, 0.7H, NCH), 4.59-4.48 (m, 1H, 
NCH), 3.71 (d, J = 13.5 Hz, 0.3H, NCH), 3.67 (s, 2.1H, OMe), 3.61 (s, 0.9H, OMe), 3.55-
3.46 (m, 0.3H, NCH), 3.23 (ddd, J = 13.0, 8.5, 4.0 Hz, 0.3H, NCH), 3.09 (d, J = 13.5 Hz, 
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0.7H, NCH), 2.74-2.66 (m, 0.7H, CH), 2.54 (ddd, J = 13.0, 13.0, 3.0 Hz, 0.7H, NCH), 2.33 
(s, 2.1H, C6H4Me), 2.31 (s, 0.9H, C6H4Me), 2.27 (s, 2.1H, MeCO), 2.11-2.02 (m, 0.3H, CH), 
2.07 (s, MeCO), 1.91-1.75 (m, 1.4H, CH), 1.70-1.60 (m, 0.6H, CH), 1.61-1.46 (m, 1H, CH); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 174.2 (C=O, CO2Me), 173.8 (C=O, CO2Me), 
170.0 (C=O, MeCO), 169.3 (C=O, MeCO), 137.8 (ipso-Ar), 137.2 (ipso-Ar), 136.8 (ipso-
Ar), 129.7 (Ar), 129.5 (Ar), 126.3 (Ar), 125.6 (Ar), 53.9 (NCH2), 52.5 (OMe), 52.4 (OMe), 
51.0 (C), 49.9 (C), 47.4 (NCH2), 46.6 (NCH2), 41.3 (NCH2), 33.1 (CH2), 32.6 (CH2), 23.1 
(CH2), 22.8 (CH2), 21.9 (MeCO), 21.4 (MeCO), 21.1 (C6H4Me); MS (ESI) m/z 298 (M + 
Na)+; HRMS m/z calcd for C16H21NO3 (M + Na)
+ 298.1414, found 298.1408 (+1.6 ppm 
error). 
Lab Book - PJ-07-97. 
 
1-Acetyl-3-(p-tolyl)piperidine-3-carboxylic acid 300 
 
 
 
 
 
KOH (139 mg, 2.47 mmol, 10.0 eq) was added to a stirred solution of N-acyl aryl piperidine-
3-methyl ester 299 (68 mg, 0.24 mmol, 1.0 eq) in EtOH (10 mL) at rt. The resulting mixture 
was stirred and heated at 100 °C for 16 h. The reaction mixture was allowed to cool to rt and 
evaporated under reduced pressure to give the crude product as an orange solid. The solid 
was taken up into water (10 mL) and washed with CH2Cl2 (3 x 10 mL). The aqueous layer 
was acidified with 1 M HCl(aq) (1 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined 
organics were washed with brine (20 mL), dried (Na2SO4) and evaporated under reduced 
pressure to give N-acyl aryl piperidine-3-carboxylic acid 300 (63 mg, 100%) as a white solid, 
mp 58-60 °C; IR (ATR) 2933, 2863, 1714 (C=O, CO2H), 1591 (C=O, MeCO), 726 cm
‒1; 1H 
NMR (400 MHz, CDCl3) (70:30 mixture of rotamers) δ 7.33 (d, J = 8.0 Hz, 0.6H, Ar), 7.30 
(d, J = 8.0 Hz, 1.4H, Ar), 7.16 (d, J = 8.0 Hz, 1.4H, Ar), 7.13 (d, J = 8.0 Hz, 0.6H, Ar), 4.72 
(d, J = 13.5 Hz, 0.3H, NCH), 4.67-4.60 (m, 0.7H, NCH), 4.54 (dd, J = 13.5, 2.0 Hz, 0.7H, 
NCH), 3.58 (ddd, J = 13.0, 4.5, 4.5 Hz, 0.3H, NCH), 3.45 (d, J = 13.5 Hz, 0.3H, NCH), 3.17 
(ddd, J = 13.0, 9.0, 4.0 Hz,0.3H, NCH), 3.07 (d, J = 13.5 Hz, 0.7H, NCH), 2.75.2.67 (m, 
0.7H, CH), 2.58-2.46 (m, 1.0H, NCH and CH), 2.32 (s, 2.1H, C6H4Me), 2.30 (s, 0.9H, 
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C6H4Me), 2.26 (s, 2.1H, MeCO), 2.07 (s, 0.9H, MeCO), 1.99 (ddd, J = 13.5, 10.0, 4.5 Hz, 
0.3H, CH), 1.86-1.73 (m, 1.7H, CH), 1.73-1.57 (m, 1H, CH); 13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 176.9 (C=O, CO2H), 176.6 (C=O, CO2H), 171.3 (C=O, MeCO), 170.3 (C=O, 
MeCO), 137.8 (ipso-Ar), 137.4 (ipso-Ar), 137.1 (ipso-Ar), 136.6 (ipso-Ar), 129.7 (Ar), 
129.5 (Ar), 126.3 (Ar), 125.7 (Ar), 53.8 (NCH2), 50.7 (C), 47.8 (NCH2), 46.7 (NCH2), 41.7 
(NCH2), 32.6 (CH2), 23.0 (CH2), 21.8 (MeCO), 21.3 (MeCO), 21.1 (C6H4Me); MS (ESI) m/z 
284 (M + Na)+; HRMS m/z calcd for C15H19NO3 (M + Na)
+ 284.1257, found 284.1255 (+1.2 
ppm error). 
Lab Book - PJ-07-100. 
 
Methyl 2-(4-fluorobenzyl)tetrahydrofuran-2-carboxylate 303 
 
Using general procedure H, LiHMDS (1.08 mL of a 1.0 M solution in toluene, 1.08 mmol, 
1.4 eq), THF-2-methyl ester 267 (0.09 mL, 0.77 mmol, 1.0 eq) and 4-fluorobenzyl bromide 
(0.13 mL, 1.08 mmol, 1.4 eq) in THF (5 mL) gave the crude product as a colourless oil. 
Purification by flash column chromatography on silica with 90:10 hexane-EtOAc as eluent 
gave aryl THF-2-methyl ester 303 (89 mg, 49%) as a colourless oil, RF (90:10 hexane-
EtOAc) 0.14; IR (ATR) 2952, 1729 (C=O), 1508, 1218, 1098, 837 cm‒1; 1H NMR (400 
MHz, CDCl3) δ 7.22-7.16 (m, 2H, Ar), 6.99-6.90 (m, 2H, Ar), 3.98-3.82 (m, 2H, OCH), 3.66 
(s, 3H, OMe), 3.17 (d, J = 14.0 Hz, 1H, CHAr), 2.93 (d, J = 14.0 Hz, 1H, CHAr), 2.31-2.20 
(m, 1H, CH), 1.94-1.76 (m, 2H, CH), 1.74-1.61 (m, 1H, CH); 13C NMR (100.6 MHz, CDCl3) 
δ 175.2 (C=O), 162.0 (d, J = 244.5 Hz, ipso-Ar), 132.2 (d, J = 3.5 Hz, ipso-Ar), 131.8 (d, J 
= 8.0 Hz, Ar), 115.0 (d, J = 21.0 Hz, Ar), 86.8 (C), 69.4 (OCH2), 52.3 (OMe), 42.6 (CH2Ar), 
35.0 (CH2), 25.4 (CH2); MS (ESI) m/z 261 (M + Na)
+; HRMS m/z calcd for C13H15FO3 (M 
+ Na)+ 261.0897, found 261.0892 (+2.3 ppm error). 
Lab Book - PJ-07-22. 
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Methyl 2-(4-fluorobenzyl)tetrahydro-2H-pyran-2-carboxylate 304 
 
Using general procedure H, LiHMDS (1.08 mL of a 1.0 M solution in toluene, 1.08 mmol, 
1.4 eq), THP-2-methyl ester 263 (0.1 mL, 0.77 mmol, 1.0 eq) and 4-fluorobenzyl bromide 
(0.13 mL, 1.08 mmol, 1.4 eq) in THF (5 mL) gave the crude product as a colourless oil. 
Purification by flash column chromatography on silica with 90:10 hexane-EtOAc as eluent 
gave aryl THP-2-methyl ester 304 (151 mg, 77%) as a colourless oil, RF (90:10 hexane-
EtOAc) 0.19; IR (ATR) 2947, 1729 (C=O), 1508, 1218, 1073, 1047 cm‒1; 1H NMR (400 
MHz, CDCl3) δ 7.16-7.09 (m, 2H, Ar), 6.98-6.89 (m, 2H, Ar), 3.93-3.86 (m, 1H, OCH), 
3.68-3.59 (m, 4H, OMe and OCH), 2.91 (s, 2H, CHAr), 2.20-2.12 (m, 1H, CH), 1.76-1.67 
(m, 1H, CH), 1.56-1.31 (m, 4H, CH); 13C NMR (100.6 MHz, CDCl3) δ 173.9 (C=O), 162.0 
(d, J = 244.5 Hz, ipso-Ar), 131.8 (d, J = 8.0 Hz, Ar), 131.6 (d, J = 3.5 Hz, ipso-Ar), 114.9 
(d, J = 21.0 Hz, Ar), 81.0 (C), 65.2 (OCH2), 51.9 (OMe), 45.8 (CH2Ar), 32.5 (CH2), 25.2 
(CH2), 20.8 (CH2); MS (ESI) m/z 275 (M + Na)
+; HRMS m/z calcd for C14H17FO3 (M + Na)
+ 
275.1054, found 275.1051 (+1.2 ppm error). 
Lab Book - PJ-07-35. 
 
1-(tert-Butyl) 2-methyl 2-(4-fluorobenzyl)pyrrolidine-1,2-dicarboxylate 305 
 
Using general procedure H, LiHMDS (0.42 mL of a 1.0 M solution in toluene, 0.42 mmol, 
1.4 eq), N-Boc pyrrolidine-2-methyl ester 257 (69 mg, 0.3 mmol, 1.0 eq) and 4-fluorobenzyl 
bromide (0.052 mL, 0.42 mmol, 1.4 eq) in THF (5 mL) gave the crude product as a colourless 
oil. Purification by flash column chromatography on silica with 90:10 hexane-EtOAc as 
eluent gave N-Boc aryl pyrrolidine-2-methyl ester 305 (89 mg, 86%) as a colourless oil, RF 
(90:10 hexane-EtOAc) 0.14; IR (ATR) 2976, 1739 (C=O, CO2Me), 1692 (C=O, Boc), 1509, 
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1386, 1158 cm‒1; 1H NMR (400 MHz, CDCl3) (60:40 mixture of rotamers) δ 7.13-7.06 (m, 
2H, Ar), 7.01-6.92 (m, 2H, Ar), 3.75 (s, 1.8H, OMe), 3.74 (s, 1.2H, OMe), 3.74-3.68 (m, 
0.4H, CHAr), 3.56-3.45 (m, 1.2H, CHAr and NCH), 3.40 (ddd, J = 10.5, 7.0, 7.0 Hz, 0.4H, 
NCH), 3.08-2.96 (m, 1.6H, CHAr and NCH), 2.89 (ddd, J = 10.5, 7.5, 5.5 Hz, 0.4H, NCH), 
2.12-1.97 (m, 2H, CH), 1.69-1.54 (m, 1H, CH), 1.50 (s, 3.6H, CMe3), 1.48 (s, 5.4H, CMe3), 
1.06-0.96 (m, 0.4H, CH), 0.96-0.86 (m, 0.6H, CH); 13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 175.3 (C=O, CO2Me), 175.1 (C=O, CO2Me), 162.1 (d, J = 245.0 Hz, ipso-Ar), 
161.9 (d, J = 244.5 Hz ipso-Ar), 154.3 (C=O, Boc), 153.7 (C=O, Boc), 133.07 (d, J = 3.0 
Hz, ipso-Ar), 132.7 (d, J = 3.0 Hz, ipso-Ar), 132.3 (d, J = 7.5 Hz, Ar), 132.2 (d, J = 7.5 Hz, 
Ar), 115.3 (d, J = 21.0 Hz, Ar), 115.0 (d, J = 21.0 Hz, Ar), 80.6 (CMe3), 79.8 (CMe3), 68.4 
(C), 68.0 (C), 52.5 (OMe), 52.4 (OMe), 48.4 (NCH2), 48.4 (NCH2), 39.1 (CH2Ar), 37.8 
(CH2Ar), 36.7 (CH2), 35.5 (CH2), 28.6 (CMe3), 28.5 (CMe3), 22.9 (CH2), 22.3 (CH2); MS 
(ESI) m/z 360 (M + Na)+; HRMS m/z calcd for C18H24FNO4 (M + Na)
+ 360.1582, found 
360.1574 (+1.9 ppm error). 
Lab Book - PJ-07-29. 
 
1-(tert-Butyl) 3-methyl 3-(4-fluorobenzyl)pyrrolidine-1,3-dicarboxylate 306 
 
Using general procedure H, LiHMDS (0.61 mL of a 1.0 M solution in toluene, 0.61 mmol, 
1.4 eq), N-Boc pyrrolidine-3-methyl ester 252 (100 mg, 0.43 mmol, 1.0 eq) and 4-
fluorobenzyl bromide (0.08 mL, 0.61 mmol, 1.4 eq) in THF (5 mL) gave the crude product 
as a colourless oil. Purification by flash column chromatography on silica with 90:10 
hexane-EtOAc as eluent gave N-Boc aryl pyrrolidine-3-methyl ester 306 (97 mg, 67%) as a 
colourless oil, RF (90:10 hexane-EtOAc) 0.16; IR (ATR) 2976, 1732 (C=O, CO2Me), 1691 
(C=O, Boc), 1509, 1398, 1168 cm‒1; 1H NMR (400 MHz, CDCl3) (50:50 mixture of 
rotamers) δ 7.06-6.98 (m, 2H, Ar), 6.96-6.88 (m, 2H, Ar), 3.83-3.73 (m, 0.5H, NCH), 3.70-
3.58 (m, 3.5H, OMe and NCH), 3.51-3.41 (m, 0.5H. NCH), 3.40-3.25 (m, 2.5H, NCH), 3.03-
2.85 (m, 2H, CH2Ar), 2.33-2.17 (m, 1H, CH), 1.92-1.79 (m, 1H, CH), 1.46-1.41 (m, 9H, 
CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 174.7 (C=O, CO2Me), 174.6 (C=O, 
CO2Me), 162.1 (d, J = 245.5 Hz, ipso-Ar), 154.5 (C=O, Boc), 154.4 (C=O, Boc), 132.7 
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(ipso-Ar), 131.0 (d, J = 8.0 Hz, Ar), 115.4 (d, J = 21.0 Hz, Ar), 79.7 (CMe3), 79.9 (CMe3), 
54.7 (C), 54.0 (C), 53.1 (NCH2), 52.3 (OMe), 44.8 (NCH2), 44.3 (NCH2), 41.2 (CH2Ar), 
41.0 (CH2Ar), 33.7 (CH2), 32.8 (CH2), 28.6 (CMe3); MS (ESI) m/z 360 (M + Na)
+; HRMS 
m/z calcd for C18H24FNO4 (M + Na)
+ 360.1582, found 360.1577 (+1.5 ppm error). 
Lab Book - PJ-07-71. 
 
1-(tert-Butyl) 2-methyl 2-(3-fluorobenzyl)pyrrolidine-1,2-dicarboxylate 307 
 
Using general procedure H, LiHMDS (0.61 mL of a 1.0 M solution in toluene, 0.61 mmol, 
1.4 eq), N-Boc pyrrolidine-2-methyl ester 257 (100 mg, 0.43 mmol, 1.0 eq) and 3-
fluorobenzyl bromide (0.075 mL, 0.61 mmol, 1.4 eq) in THF (5 mL) gave the crude product 
as a colourless oil. Purification by flash column chromatography on silica with 90:10 
hexane-EtOAc as eluent gave N-Boc aryl pyrrolidine-2-methyl ester 307 (133 mg, 92%) as 
a colourless oil, RF (90:10 hexane-EtOAc) 0.13; IR (ATR) 2976, 1739 (C=O, CO2Me), 1691 
(C=O, Boc), 1386, 1247, 1163 cm‒1; 1H NMR (400 MHz, CDCl3) (60:40 mixture of 
rotamers) δ 7.29-7.15 (m, 1H, Ar), 6.98-6.89 (m, 2H, Ar), 6.88-6.82 (m, 1H, Ar), 3.79-3.72 
(m, 0.4H, CHAr), 3.74 (s, 3H, OMe), 3.54 (d, J = 14.0 Hz, 0.6H, CHAr), 3.51-3.45 (m, 0.6H, 
NCH), 3.40 (ddd, J = 10.5, 7.0, 7.0 Hz, 0.4H, NCH), 3.08-2.98 (m, 1.6H, CHAr and NCH), 
2.91 (ddd, J = 10.5, 7.5, 6.0 Hz, 0.4H, NCH), 2.09-1.98 (m, 2H, CH), 1.68-1.55 (m, 1H, 
CH), 1.49 (s, 3.6H, CMe3), 1.47 (s, 5.4H, CMe3), 1.09-0.87 (m, 1H, CH); 
13C NMR (100.6 
MHz, CDCl3) (rotamers) δ 175.2 (C=O, CO2Me), 175.1 (C=O, CO2Me), 162.8 (d, J = 245.5 
Hz, ipso-Ar), 154.3 (C=O, Boc), 153.6 (C=O, Boc), 140.0 (d, J = 7.5 Hz, ipso-Ar), 139.6 (d, 
J = 7.5 Hz, ipso-Ar), 129.9 (d, J = 8.0 Hz, Ar), 129.4 (d, J = 8.0 Hz, Ar), 126.6 (d, J = 3.0 
Hz, Ar), 126.5 (d, J = 3.0 Hz, Ar), 117.8 (d, J = 2.5 Hz, Ar), 117.6 (d, J = 2.5 Hz, Ar), 113.8 
(d, J = 21.0 Hz, Ar), 113.5 (d, J = 21.0 Hz, Ar), 80.6 (CMe3), 79.9 (CMe3), 68.3 (C), 68.0 
(C), 52.5 (OMe), 52.4 (OMe), 48.4 (NCH2), 39.8 (CH2Ar), 38.4 (CH2Ar), 36.8 (CH2), 35.5 
(CH2), 28.6 (CMe3), 28.5 (CMe3), 22.9 (CH2), 22.4 (CH2); MS (ESI) m/z 360 (M + Na)
+; 
HRMS m/z calcd for C18H24FNO4 (M + Na)
+ 360.1582, found 360.1579 (+0.1 ppm error). 
Lab Book - PJ-07-68. 
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1-(tert-Butyl) 2-methyl 2-(2-fluorobenzyl)pyrrolidine-1,2-dicarboxylate 308 
 
Using general procedure H, LiHMDS (0.61 mL of a 1.0 M solution in toluene, 0.61 mmol, 
1.4 eq), N-Boc pyrrolidine-2-methyl ester 257 (100 mg, 0.43 mmol, 1.0 eq) and 2-
fluorobenzyl bromide (0.07 mL, 0.61 mmol, 1.4 eq) in THF (5 mL) gave the crude product 
as a colourless oil. Purification by flash column chromatography on silica with 90:10 
hexane-EtOAc as eluent gave N-Boc aryl pyrrolidine-2-methyl ester 308 (130 mg, 90%) as 
a colourless oil, RF (90:10 hexane-EtOAc) 0.11; IR (ATR) 2976, 1740 (C=O, CO2Me), 1693 
(C=O, Boc), 1385, 1165, 1103, 757 cm‒1; 1H NMR (400 MHz, CDCl3) (60:40 mixture of 
rotamers δ 7.27-7.13 (m, 1H, Ar), 7.17-7.06 (m, 1H, Ar), 7.10-6.94 (m, 2H, Ar), 3.74 (s, 
1.2H, OMe), 3.74 (s, 1.8H, OMe), 3.58 (d, J = 13.5 Hz, 0.8H, CHAr), 3.51-3.32 (m, 2.6H, 
CHAr and NCH), 3.05-2.98 (m, 0.6H, NCH), 2.97-2.89 (m, 0.4H, NCH), 2.14-1.97 (m, 2H, 
CH), 1.67-1.57 (m, 1H, CH), 1.49-1.45 (m, 9H, CMe3), 1.10-0.89 (m, 1H, CH); 
13C NMR 
(100.6 MHz, CDCl3) (rotamers) δ 175.2 (C=O, CO2Me), 175.0 (C=O, CO2Me), 161.8 (d, J 
= 245.0 Hz, ipso-Ar), 154.3 (C=O, Boc), 153.7 (C=O, Boc), 133.2 (d, J = 4.5 Hz, Ar), 132.9 
(d, J = 4.5 Hz, Ar), Ar, 128.6 (d, J = 8.0 Hz, Ar), 128.4 (d, J = 8.0 Hz, Ar), 124.5 (ipso-Ar), 
124.3 (ipso-Ar), 124.1 (d, J = 4.0 Hz, Ar), 123.9 (d, J = 4.0 Hz, Ar), 115.4 (d, J = 22.5 Hz, 
Ar), 115.1 (d, J = 22.5 Hz, Ar), 80.5 (CMe3), 79.7 (CMe3), 68.6 (C), 68.2 (C), 52.4 (OMe), 
52.3 (OMe), 48.3 (NCH2), 48.2 (NCH2), 36.7 (CH2), 35.6 (CH2), 32.5 (CH2Ar), 31.4 
(CH2Ar), 28.5 (CMe3), 28.4 (CMe3), 23.1 (CH2), 22.5 (CH2); MS (ESI) m/z 360 (M + Na)
+; 
HRMS m/z calcd for C18H24FNO4 (M + Na)
+ 360.1582, found 360.1576 (+1.7 ppm error). 
Lab Book - PJ-07-64. 
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1-(tert-Butyl) 2-methyl 2-(4-methoxybenzyl)pyrrolidine-1,2-dicarboxylate 309 
 
Using general procedure H, LiHMDS (0.61 mL of a 1.0 M solution in toluene, 0.61 mmol, 
1.4 eq), N-Boc pyrrolidine-2-methyl ester 257 (100 mg, 0.43 mmol, 1.0 eq) and 4-
methoxybenzyl bromide (123 mg, 0.61 mmol, 1.4 eq) in THF (5 mL) gave the crude product 
as a colourless oil. Purification by flash column chromatography on silica with 90:10 
hexane-EtOAc as eluent gave N-Boc aryl pyrrolidine-2-methyl ester 309 (137 mg, 91%) as 
a colourless oil, RF (90:10 hexane-EtOAc) 0.09; IR (ATR) 2973, 1738 (C=O, CO2Me), 1691 
(C=O, Boc) 1512, 1387, 1246, 1166 cm‒1; 1H NMR (400 MHz, d4-MeOD) (55:45 mixture 
of rotamers) δ 7.06-7.02 (m, 2H, Ar), 6.86-6.80 (m, 2H, Ar), 3.76 (s, 1.35H, OMe), 3.754 
(s, 1.65H, OMe), 3.749 (s, 1.65H, OMe), 3.72 (s, 1.35H, OMe), 3.58 (d, J = 14.0 Hz, 0.45H, 
CHAr), 3.46 (d, J = 14.0 Hz, 0.55H, CHAr), 3.42-3.33 (m, 1H, NCH), 2.97 (d, J = 14.0 Hz, 
0.55H, CHAr), 2.95 (d, J = 14.0 Hz, 0.45H, CHAr), 2.88 (ddd, J = 10.0, 7.5, 5.0, Hz, 1H, 
NCH), 2.20-1.93 (m, 2H, CH), 1.66-1.52 (m, 1H, CH), 1.50 (s, 4.05H, CMe3), 1.48 (s, 4.95H, 
CMe3), 1.05-0.88 (m, 1H, CH); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 175.5 (C=O, 
CO2Me), 175.3 (C=O, CO2Me), 158.5 (ipso-Ar), 158.3 (ipso-Ar), 154.2 (C=O, Boc), 153.6 
(C=O, Boc), 131.8 (Ar), 131.6 (Ar), 129.3 (ipso-Ar), 128.8 (ipso-Ar), 113.8 (Ar), 113.5 (Ar), 
80.4 (CMe3), 79.6 (CMe3), 68.5 (C), 68.1 (C), 55.3 (OMe), 52.4 (OMe), 52.3 (OMe), 48.3 
(NCH2), 48.3 (NCH2), 38.9 (CH2Ar), 37.6 (CH2Ar), 36.6 (CH2), 35.4 (CH2), 28.6 (CMe3), 
28.5 (CMe3), 22.9 (CH2), 22.3 (CH2); MS (ESI) m/z 372 (M + Na)
+; HRMS m/z calcd for 
C19H27NO5 (M + Na)
+ 372.1781, found 372.1775 (+1.5 ppm error). 
Lab Book - PJ-08-15. 
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1-(tert-Butyl) 2-methyl 2-(3-methoxybenzyl)pyrrolidine-1,2-dicarboxylate 310 
 
Using general procedure H, LiHMDS (0.61 mL of a 1.0 M solution in toluene, 0.61 mmol, 
1.4 eq), N-Boc pyrrolidine-2-methyl ester 257 (100 mg, 0.43 mmol, 1.0 eq) and 3-
methoxybenzyl bromide (0.085 mL, 0.61 mmol, 1.4 eq) in THF (5 mL) gave the crude 
product as a colourless oil. Purification by flash column chromatography on silica with 90:10 
hexane-EtOAc as eluent gave N-Boc aryl pyrrolidine-2-methyl ester 310 (103 mg, 68%) as 
a colourless oil, RF (90:10 hexane-EtOAc) 0.12; IR (ATR) 2974, 1739 (C=O, CO2Me), 1692 
(C=O, Boc), 1388, 1249, 1166, 1118 cm‒1; 1H NMR (400 MHz, CDCl3) (60:40 mixture of 
rotamers) δ 7.21-7.15 (m, 1H, Ar), 6.81-6.66 (m, 3H, Ar), 3.79 (s, 1.2H, OMe), 3.77 (s, 1.8H, 
OMe), 3.75 (s, 3H, OMe), 3.75-3.70 (m, 0.4H, CHAr), 3.56 (d, J = 14.0 Hz, 0.6H, CHAr), 
3.49 (ddd, J = 10.5, 7.5, 7.5 Hz, 0.6H, NCH), 3.41 (ddd, J = 10.5, 7.5, 7.5 Hz, 0.4H, NCH), 
3.05-2.97 (m, 1.6H, CHAr and NCH), 2.97-2.90 (m, 0.4H, NCH), 2.14-1.93 (m, 2H, CH), 
1.64-1.53 (m, 1H, CH), 1.50 (s, 3.6H, CMe3), 1.49 (s, 5.4H, CMe3), 1.07-0.90 (m, 1H, CH); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 175.4 (C=O, CO2Me), 175.3 (C=O, CO2Me), 
159.5 (ipso- Ar), 159.4 (ipso-Ar), 154.2 (C=O, Boc), 153.6 (C=O, Boc), 138.9 (ipso-Ar), 
138.5 (ipso-Ar), 129.2 (Ar), 128.9 (Ar), 123.4 (Ar), 123.2 (Ar), 116.4 (Ar), 116.1 (Ar), 112.4 
(Ar), 112.1 (Ar), 80.4 (CMe3), 79.7 (CMe3), 68.4 (C), 68.0 (C), 55.3 (OMe), 55.2 (OMe), 
52.4 (OMe), 52.3 (OMe), 48.4 (NCH2), 48.3 (NCH2), 39.8 (CH2Ar), 38.6 (CH2Ar), 36.7 
(CH2), 35.4 (CH2), 28.6 (CMe3), 28.5 (CMe3), 22.9 (CH2), 22.3 (CH2); MS (ESI) m/z 372 
(M + Na)+; HRMS m/z calcd for C19H27NO5 (M + Na)
+ 372.1781, found 372.1780 (+0.5 
ppm error). 
Lab Book - PJ-07-59. 
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1-(tert-Butyl) 2-methyl 2-(2-bromobenzyl)pyrrolidine-1,2-dicarboxylate 311 
 
Using general procedure H, LiHMDS (3.19 mL of a 1.0 M solution in toluene, 3.19 mmol, 
1.4 eq), N-Boc pyrrolidine-2-methyl ester 257 (500 mg, 2.28 mmol, 1.0 eq) and 2-
bromobenzyl bromide (796 mL, 3.19 mmol, 1.4 eq) in THF (5 mL) gave the crude product 
as a colourless oil. Purification by flash column chromatography on silica with 90:10 
hexane-EtOAc as eluent gave N-Boc aryl pyrrolidine-2-methyl ester 311 (813 mg, 89%) as 
a colourless oil, RF (90:10 hexane-EtOAc) 0.19; IR (ATR) 2974, 1739 (C=O, CO2Me), 1692 
(C=O, Boc), 1384, 1163, 1024, 759 cm‒1; 1H NMR (400 MHz, CDCl3) (60:40 mixture of 
rotamers) δ 7.58-7.51 (m, 1H, Ar), 7.25-7.18 (m, 1H, Ar), 7.17-7.12 (m, 1H, Ar), 7.12-7.05 
(m, 1H, Ar), 3.79-3.72 (m, 3H, OMe), 3.73-3.61 (m, 1.4H, CHAr and NCH), 3.58-3.39 (m, 
1.6H, CHAr and NCH), 3.08-3.00 (m, 0.6H, NCH), 2.99-2.91 (m, 0.4H, NCH), 2.26-2.12 
(m, 1H, CH), 2.10-1.96 (m, 1H, CH), 1.72-1.57 (m, 1H, CH), 1.53-1.48 (m, 3.6H, CMe3), 
1.49-1.45 (m, 5.4H, CMe3), 1.09-0.90 (m, 1H, CH); 
13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 175.0 (C=O, CO2Me), 174.9 (C=O, CO2Me), 154.4 (C=O, Boc), 153.7 (C=O, 
Boc), 137.5 (ipso-Ar), 137.1 (ipso-Ar), 133.1 (Ar), 132.9 (Ar), 132.9 (Ar), 132.6 (Ar), 128.5 
(Ar), 128.2 (Ar), 127.6 (Ar), 127.3 (Ar), 126.4 (ipso-Ar), 80.6 (CMe3), 79.9 (CMe3), 69.2 
(C), 68.8 (C), 52.5 (OMe), 52.5 (OMe), 48.3 (NCH2), 48.2 (NCH2), 38.2 (CH2Ar), 37.1 
(CH2Ar), 36.4 (CH2), 35.3 (CH2), 28.6 (CMe3), 28.5 (CMe3), 23.2 (CH2), 22.6 (CH2); MS 
(ESI) m/z 420 (M + Na)+; HRMS m/z calcd for C18H24
79BrNO4 (M + Na)
+ 420.0781, found 
420.0774 (+0.6 ppm error). 
Lab Book - PJ-08-09. 
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1-(tert-Butyl) 2-methyl 2-(pyridin-2-ylmethyl)pyrrolidine-1,2-dicarboxylate 312 
 
LiHMDS (0.61 mL of a 1.0 M solution in toluene, 0.61 mmol, 1.4 eq) was added dropwise 
to a stirred solution of N-Boc pyrrolidine-2-methyl ester 257 (100 mg, 0.43 mmol, 1.0 eq) in 
THF (4 mL) at ‒78 °C under Ar. The resulting solution was stirred at ‒78 °C for 1.5 h. In a 
separate flask sat NaHCO3(aq) (5 mL) was added to 2(bromomethyl)pyridine·HBr (153 mg, 
0.61 mmol) and the solution was extracted with CH2Cl2 (3 x 5 mL). The combined organics 
were dried (Na2CO3) and evaporated under reduced pressure to give a red oil. The oil was 
taken up into THF (2 mL) and added dropwise to the enolate reaction mixture at ‒78 °C 
under Ar. The resulting solution was stirred at ‒78 °C and slowly warmed up to rt over 16 
h. The solution was poured into sat NH4Cl(aq) (10 mL) and the two layers were separated. 
The aqueous layer was extracted with EtOAc (3 x 10 mL) and the combined organics were 
dried (MgSO4) and evaporated under reduced pressure to give the crude product as an orange 
oil. Purification by flash column chromatography on silica with 60:40 hexane-EtOAc as 
eluent gave N-Boc aryl pyrrolidine-2-methyl ester 312 (45 mg, 33%) as a colourless oil, RF 
(90:10 hexane-EtOAc) 0.11; IR (ATR) 2974, 1739 (C=O, CO2Me), 1691 (C=O, Boc), 1387, 
1162, 1131 cm‒1; 1H NMR (400 MHz, CDCl3) (60:40 mixture of rotamers) δ 8.54-8.48 (m, 
1H, 6-py), 7.61-7.53 (m, 1H, 4-py), 7.17-7.12 (m, 1H, 3-py), 7.12-7.06 (m, 1H, 5-py), 3.83 
(d, J = 13.5 Hz, 0.4H, CHAr), 3.74 (s, 3H, OMe), 3.64 (d, J = 13.5 Hz, 0.6H, CHAr), 3.48 
(ddd, J = 10.5, 7.0, 7.0 Hz, 0.6H, NCH), 3.40 (ddd, J = 10.5, 7.0, 7.0 Hz, 0.4H, NCH), 3.32 
(d, J = 13.5 Hz, 0.6H, CHAr), 3.30 (d, J = 13.5 Hz, 0.4H, CHAr), 2.88 (ddd, J = 10.5, 7.5, 
6.0 Hz, 0.6H, NCH), 2.81 (ddd, J = 10.5, 7.0, 7.0 Hz, 0.4H, NCH), 2.63-2.49 (m, 1H, CH), 
2.12-1.99 (m, 1H, CH), 1.70-1.60 (m, 1H, CH), 1.49 (s, 5.6H, CMe3), 1.46 (s, 3.4H, CMe3), 
1.08 (ddddd, J = 13.5, 7.0, 7.0, 7.0, 7.0 Hz, 0.4H, CH), 0.98-0.84 (m, 0.6H, CH); 13C NMR 
(100.6 MHz, CDCl3) (rotamers) δ 175.1 (C=O, CO2Me), 157.9 (ipso-Ar), 153.7 (C=O, Boc), 
149.1 (Ar), 148.8 (Ar), 136.3 (Ar), 136.0 (Ar), 125.6 (Ar), 125.3 (Ar), 121.8 (Ar), 121.6 
(Ar), 80.6 (CMe3), 79.7 (CMe3), 68.4 (C), 68.0 (C), 52.5 (OMe), 52.4 (OMe), 48.4 (NCH2), 
48.3 (NCH2), 42.2 (CH2Ar), 41.0 (CH2Ar), 36.4 (CH2), 35.3 (CH2), 28.6 (CMe3), 22.9 (CH2), 
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22.4 (CH2); MS (ESI) m/z 321 (M + H)
+; HRMS m/z calcd for C17H25N2O4 (M + H)
+ 
321.1809, found 321.1807 (+0.7 ppm error). 
Lab Book - PJ-07-48. 
 
Methyl 3-(4-fluorobenzyl)pyrrolidine-3-carboxylate 314·HCl 
 
HCl (1 mL of a 4 M solution in dioxane) was added dropwise to N-Boc aryl pyrrolidine-3-
methyl ester 306 (50 mg, 0.15 mmol, 1.0 eq) at rt under Ar. The resulting solution was stirred 
at rt for 16 h. Then, the solvent was evaporated under reduced pressure to give aryl 
pyrrolidine-3-methyl ester 314·HCl (40 mg, 99%) as a red oil, IR (ATR) 3406 (NH), 2906, 
2725, 1729 (C=O), 1509, 1216 cm‒1; 1H NMR (400 MHz, CDCl3) δ 10.02 (br s, 1H, NH), 
9.74 (br s, 1H, NH), 7.17-7.00 (m, 2H, Ar), 7.00-6.86 (m, 2H, Ar), 3.68 (s, 3H, OMe), 3.68-
3.63 (m, 1H, NCH), 3.55-3.46 (m, 1H, NCH), 3.37-3.25 (m, 2H, NCH), 3.12 (d, J = 14.0 
Hz, 1H, CHAr), 3.03 (d, J = 14.0 Hz, 1H, CHAr), 2.41 (ddd, J = 13,0, 7.5, 5.0 Hz, 1H, CH), 
2.07 (ddd, J = 13.5, 8.5, 8.5 Hz, 1H, CH Ar); 13C NMR (100.6 MHz, CDCl3) δ 173.1 (C=O), 
162.2 (d, J = 246.0 Hz, ipso-Ar), 131.7 (d, J = 3.5 Hz, ipso-Ar), 131.0 (d, J = 8.0 Hz, Ar), 
115.7 (d, J = 21.5 Hz, Ar), 55.1 (C), 52.9 (OMe), 50.8 (NCH2), 44.4 (NCH2), 40.9 (CH2Ar), 
33.9 (CH2); MS (ESI) m/z 238 (M)
+; HRMS m/z calcd for C13H17FNO2 (M)
+ 238.1238, found 
238.1238 (+0.4 ppm error). 
Lab Book - PJ-08-16. 
 
Methyl 2-(4-methoxybenzyl)pyrrolidine-2-carboxylate 313·HCl 
 
HCl (1 mL of a 4 M solution in dioxane) was added dropwise to N-Boc aryl pyrrolidine-2-
methyl ester 309 (50 mg, 0.14 mmol, 1.0 eq) at rt under Ar. The resulting solution was stirred 
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at rt for 16 h. Then, the solvent was evaporated under reduced pressure to give aryl 
pyrrolidine-2-methyl ester 313·HCl (39 mg, 99%) as a white solid, mp 172-174 °C; IR 
(ATR) 2884, 2704, 1755 (C=O), 1513, 1255, 1202, 1031 cm‒1; 1H NMR (400 MHz, CDCl3) 
δ 11.55 (s, 1H, NH), 8.24 (s, 1H, NH), 7.32-7.27 (m, 2H, Ar), 6.84-6.79 (m, 2H, Ar), 3.80-
3.68 (m, 8H, OMe, NCH and CHAr), 3.47-3.34 (m, 2H, NCH and CHAr), 2.57-2.46 (m, 1H, 
CH), 2.35-2.15 (m, 2H, CH), 1.95-1.81 (m, 1H, CH); 13C NMR (100.6 MHz, CDCl3) δ 170.5 
(C=O), 159.3 (ipso-Ar), 130.8 (Ar), 125.8 (ipso-Ar), 114.4 (Ar), 74.7 (C), 55.3 (OMe), 53.7 
(OMe), 45.5 (NCH2), 39.5 (CH2Ar), 34.1 (CH2), 22.3 (CH2); MS (ESI) m/z 250 (M)
+; HRMS 
m/z calcd for C14H20NO3 (M)
+ 250.1438, found 250.1436 (+0.7 ppm error). 
Lab Book - PJ-08-15. 
 
1-(tert-Butoxycarbonyl)-2-(4-fluorobenzyl)pyrrolidine-2-carboxylic acid 321 
 
KOH (90 mg, 1.6 mmol, 10.0 eq) was added to a stirred solution of N-Boc aryl pyrrolidine-
2-methyl ester 305 (55 mg, 0.16 mmol, 1.0 eq) in EtOH (10 mL) at rt. The resulting mixture 
was stirred and heated at 100 °C for 16 h. The reaction mixture was allowed to cool to rt and 
evaporated under reduced pressure to give the crude product as an orange solid. The solid 
was taken up into water (10 mL) and washed with CH2Cl2 (3 x 50 mL). The aqueous layer 
was then acidified with 1 M HCl(aq) (1 mL) and extracted with CH2Cl2 (3 x 10 mL). The 
combined organics were washed with brine (10 mL), dried (Na2SO4) and evaporated under 
reduced pressure to give N-Boc aryl pyrrolidine-2-carboxylic acid 321 (50 mg, 98%) as a 
white solid, mp 178-180 °C; IR (ATR) 2984, 1739 (C=O, CO2H), 1636 (C=O, Boc), 1419, 
1219, 1148, 847, 770 cm‒1; 1H NMR (400 MHz, d4-MeOH) (60:40 mixture of rotamers) δ 
7.19-7.14 (m, 2H, Ar), 7.05-6.98 (m, 2H, Ar), 3.68 (d, J = 14.0 Hz, 0.4H, CHAr), 3.52 (d, J 
= 14.0 Hz, 0.6H, CHAr), 3.46-3.36 (m, 1H, NCH), 3.05-2.99 (m, 1H, CHAr), 2.95-2.86 (m, 
1H, NCH), 2.18-2.04 (m, 2H, CH), 1.70-1.58 (m, 1H, CH), 1.51 (s, 3.4H, CMe3), 1.50 (s, 
5.6H, CMe3), 1.07-0.88 (m, 1H, CH); 
13C NMR (100.6 MHz, d4-MeOH) (rotamers) δ 177.8 
(C=O, CO2H), 177.7 (C=O, CO2H), 163.4 (d, J = 244.0 Hz, ipso-Ar), 163.3 (d, J = 244.0 
Hz, ipso-Ar) 155.8 (C=O, Boc), 155.7 (C=O, Boc), 134.5 (d, J = 3.5 Hz, ipso-Ar), 134.4 (d, 
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J = 3.5 Hz, ipso-Ar), 133.4 (d, J = 8.0 Hz, Ar), 133.3 (d, J = 8.0 Hz, Ar), 115.9 (d, J = 21.5 
Hz, Ar), 115.7 (d, J = 21.5 Hz, Ar), 82.2 (CMe3), 81.1 (CMe3), 69.5 (C), 69.5 (C), 49.7 
(NCH2), 49.5 (NCH2), 39.8 (CH2Ar), 38.5 (CH2Ar), 37.8 (CH2), 36.7 (CH2), 28.9 (CMe3), 
28.7 (CMe3), 23.6 (CH2), 23.1 (CH2); MS (ESI) m/z 346 (M + Na)
+; HRMS m/z calcd for 
C17H22FNO4 (M + Na)
+ 346.1425, found 346.1420 (+1.5 ppm error). 
Lab Book - PJ-07-44. 
 
tert-Butyl 2-carbamoyl-2-(4-fluorobenzyl)pyrrolidine-1-carboxylate 322 
 
T3P (0.07 mL of a 50% wt solution in EtOAc, 0.23 mmol, 1.5 eq) was added dropwise to a 
stirredsolution of N-Boc aryl pyrrolidine-2-carboxylix acid 321 (50 mg, 0.15 mmol, 1.0 eq), 
DIPEA (0.08 mL, 0.46 mmol, 3.0 eq) and 35% NH3(aq) (0.018 mL, 0.47 mmol, 3.0 eq) in 
CH2Cl3 (3 mL) at rt under Ar. The resulting solution was stirred at rt for 16 h. Then, water 
(10 mL) was added and the layers were separated. The aqueous layer was extracted with 
CH2Cl2 (3 x 5 mL) and the combined organics were washed with 2 M NaOH(aq) (10 mL) and 
brine (10 mL), dried (Na2SO4) and evaporated under redued pressure to give the crude 
product as a colourless oil. Purification by flash column chromatography on silica with 
EtOAc as eluent gave N-Boc aryl pyrrolidine amide 322 (21 mg, 45%) as a colourless oil, 
RF (EtOAc) 0.36; IR (ATR) 3381 (NH), 2982, 1658 (C=O), 1509, 1395, 1159 cm
‒1; 1H NMR 
(400 MHz, CDCl3) (60:40 mixture of rotamers) δ 7.41 (br s, 0.6H, NH), 7.15-7.04 (m, 2H, 
Ar), 7.01-6.92 (m, 2H, Ar), 5.80 (br s, 0.4H, NH). 5.39 (br s, 1H, NH), 3.70 (d, J = 14.0 Hz, 
0.6H, CHAr), 3.54 (d, J = 14.0 Hz, 0.4H, CHAr), 3.51-3.45 (m, 0.4H, NCH), 3.40 (ddd, J = 
11.0, 8.0, 3.0 Hz, 0.6H, NCH), 3.16 (d, J = 14.0 Hz, 0.4H, CHAr), 3.11 (d, J = 14.0 Hz, 
0.6H, CHAr), 3.02-2.86 (m, 1H, NCH), 2.44 (ddd, J = 12.5, 6.5, 3.5 Hz, 0.6H, CH), 2.17-
2.10 (m, 0.6H, CH), 1.81 (ddd, J = 13.0, 11.0, 7.0 Hz, 0.6H, CH), 1.60-1.56 (m, 1.2H, CH), 
1.53 (s, 3.6H, CMe3), 1.52 (s, 5.4H, CMe3), 1.38-1.29 (m, 0.6H, CH), 1.04-0.94 (m, 0.4H, 
CH); 13C NMR (100.6 MHz, CDCl3) (rotamers) δ 177.8 (C=O, CONH), 176.9 (C=O, 
CONH), 161.94 (d, J = 245.0 Hz, ipso-Ar), 155.5 (C=O, Boc), 153.6 (C=O, Boc), 132.9 (d, 
J = 3.0 Hz, ipso-Ar), 132.4 (d, J = 3.0 Hz, ipso-Ar), 132.1 (d, J = 8.0 Hz, Ar), 131.9 (d, J = 
317 
 
8.0 Hz, Ar), 115.4 (d, J = 21.0 Hz, Ar), 115.1 (d, J = 21.0 Hz,  Ar), 81.5 (CMe3), 80.6 
(CMe3), 70.8 (C), 69.1 (C), 49.5 (NCH2), 48.5 (NCH2), 37.9 (CH2Ar), 37.8 (CH2Ar), 37.4 
(CH2), 34.2 (CH2), 28.6 (CMe3), 22.2 (CMe3), 22.0 (CH2); MS (ESI) m/z 345 (M + Na)
+; 
HRMS m/z calcd for C17H23FN2O3 (M + Na)
+ 345.1585, found 345.1581 (+1.0 ppm error). 
Lab Book - PJ-07-61. 
 
1-(tert-Butoxycarbonyl)-3-(4-fluorobenzyl)pyrrolidine-3-carboxylic acid 323 
 
KOH (83 mg, 1.5 mmol, 10.0 eq) was added to a stirred solution of N-Boc aryl pyrrolidine-
3-methyl ester 306 (50 mg, 0.15 mmol, 1.0 eq) in EtOH (10 mL) at rt. The resulting mixture 
was stirred and heated at 100 °C for 16 h. The reaction mixture was allowed to cool to rt and 
evaporated under reduced pressure to give the crude product as an orange solid. The solid 
was taken up into water (10 mL) and washed with CH2Cl2 (3 x 50 mL). The aqueous layer 
was then acidified with 1 M HCl(aq) (1 mL) and extracted with CH2Cl2 (3 x 10 mL). The 
combined organics were washed with brine (10 mL), dried (Na2SO4) and evaporated under 
reduced pressure to give N-Boc aryl pyrrolidine-3-carboxylic acid 323 (48 mg, 100%) as a 
white solid, mp 122-124 °C; IR (ATR) 2915, 1717 (C=O, CO2H), 1632 (C=O, Boc), 1433, 
1141, 893 cm‒1; 1H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 7.17-7.04 (m, 
2H, Ar), 7.02-6.89 (m, 2H, Ar), 3.82 (d, J = 11.5 Hz, 0.5H, CHAr), 3.71 (d, J = 11.5 Hz, 
0.5H, CHAr), 3.55-3.28 (m, 3H, NCH and CHAr), 3.09-2.91 (m, 2H, CH), 2.35-2.25 (m, 
1H, CH), 1.96-1.83 (m, 1H, CH), 1.46 (s, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 179.3 (C=O, CO2H), 179.2 (C=O, CO2H), 162.1 (d, J = 246.0 Hz, ipso-Ar), 
154.6 (C=O, Boc), 132.4 (ipso-Ar), 131.1 (d, J = 8.0 Hz, Ar), 115.4 (d, J = 21.0 Hz, Ar), 
80.0 (CMe3), 79.9 (CMe3), 54.4 (C), 53.7 (C), 52.9 (CH2Ar), 44.8 (NCH2), 44.3 (NCH2), 
40.8 (CH2), 40.6 (CH2), 33.5 (CH2), 32.9 (CH2), 28.6 (CMe3); MS (ESI) m/z 346 (M + Na)
+; 
HRMS m/z calcd for C17H22FNO4 (M + Na)
+ 346.1425, found 346.1427 (‒1.4 ppm error). 
Lab Book - PJ-08-07. 
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tert-Butyl 3-((tert-butoxycarbonyl)-l2-azanyl)-3-(4-fluorobenzyl)pyrrolidine-1-
carboxylate 324 
 
Et3N (0.06 mL, 0.44 mmol, 2.0 eq) was added dropwise to a stirred solution of N-Boc 
pyrrolidine-3-carboxylic acid 323 (72 mg, 0.22 mmol, 1.0 eq), DPPA (0.06 mL, 0.27 mmol, 
1.2 eq) and 3Å MS (50 mg) in tBuOH (10 mL) at rt under Ar. The resulting solution was 
stirred and heated at 40 °C for 1 h and then at 100 °C for 16 h. The reaction mixture was 
allowed to cool to rt and the solids were removed by filtration through Celite and washed 
with MeOH (10 mL). The filtrate was evaporated under redued pressure to give the crude 
product as a yellow oil. Purification by flash column chromatography on silica with 95:5-
80:20 hexane-EtOAc as eluent gave N-Boc aryl pyrrolidine amine 324 (44 mg, 51%) as a 
colourless oil, RF (80:20 hexane-EtOAc) 0.25; IR (ATR) 2977, 1627 (C=O), 1509, 1404, 
1216, 1156 cm‒1; 1H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 7.11-7.02 (m, 
2H, Ar), 7.00-6.90 (m, 2H, Ar), 3.61-3.06 (m, 5H, NCH and CHAr), 3.00-2.83 (m, 1H, 
CHAr), 2.43-2.22 (m, 0.5H, CH), 2.04-1.92 (m, 0.5H, CH), 1.86 (ddd, J = 12.5, 8.5, 8.5 Hz, 
1H, CH), 1.53-1.37 (m, 18H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 161.9 (d, 
J = 244.5 Hz, ipso-Ar), 154.7 (C=O, Boc), 133.2 (ipso-Ar), 131.4 (d, J = 7.0 Hz, Ar), 115.2 
(d, J = 21.0 Hz, Ar), 79.7 (CMe3), 79.6 (CMe3), 61.9 (C), 61.5 (C), 56.1 (NCH2), 44.3 
(NCH2), 43.7 (NCH2), 39.5 (CH2Ar), 39.2 (CH2Ar), 35.3 (CH2), 34.9 (CH2), 28.6 (CMe3), 
28.6 (CMe3), 28.5 (CMe3); MS (ESI) m/z 417 (M + Na)
+; HRMS m/z calcd for C21H31FN2O4 
(M + Na)+ 417.2160, found 417.2160 (+0.0 ppm error). 
Lab Book - PJ-07-70. 
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1-(tert-Butyl) 2-methyl 2-(2-aminobenzyl)pyrrolidine-1,2-dicarboxylate 327 
 
Pd(OAc)2 (2.8 mg, 0.013 mmol, 0.05 eq) was added to a stirred solution of N-Boc aryl 
pyrrolidine-3-methyl ester 311 (100 mg, 0.25 mmol, 1.0 eq), benzophenone imine (0.063 
mL, 0.38 mmol, 1.5 eq), Cs2CO3 (246 mg, 0.76 mmol, 3.0 eq) and Xantphos (14.5 mg, 0.025 
mmol) in dioxane (6 mL) at rt. The reaction flask was evacuated under reduced pressure and 
back-filled with Ar three times. The resulting mixture was stirred and heated at 95 °C for 16 
h. The reaction mixture was allowed to cool to rt and 1 M HCl(aq) (3 mL) was added. The 
resulting solution was stirred at rt for 10 min. 2 M NaOH(aq) (1 mL) was then added and the 
two layers were separated. The aqueous layer was extracted with CH2Cl2 (3 x 10 mL) and 
the combined organics were dried (Na2CO3) and evaporated under reduced pressure to give 
the crude product as a black oil. Purification by flash column chromatography on silica with 
80:20 hexane-EtOAc as eluent gave aniline N-Boc pyrrolidine-2-methyl ester 327 (73 mg, 
87%) as a yellow solid, mp 80-82 °C; RF (80:20 hexane-EtOAc) 0.11; IR (ATR) 3488 (NH), 
3371 (NH). 2976, 1741 (C=O, CO2Me), 1692 (C=O, Boc), 1395, 1250, 1121, 748 cm
‒1; 1H 
NMR (400 MHz, CDCl3) (60:40 mixture of rotamers) δ 7.05-6.99 (m, 1H, Ar), 6.70-6.59 
(m, 1H, Ar), 6.71-6.58 (m, 2H, Ar), 3.74 (s, 1.8H, OMe), 3.73 (s, 1.2H, OMe), 3.63 (d, J = 
14.5 Hz, 0.4H, CHAr), 3.51 (ddd, J = 10.5, 7.5, 7.5 Hz, 0.6H, NCH), 3.43-3.34 (m, 1H, 
CHAr and NCH), 3.18 (ddd, J = 10.5, 7.5, 4.5 Hz, 0.6H, NCH), 3.11-3.01 (m, 1.4H, CHAr 
and NCH), 2.28-2.15 (m, 1H, CH), 2.08-1.96 (m, 1H, CH), 1.73-1.57 (m, 1H, CH), 1.45 (s, 
3.6H, CMe3), 1.41 (s, 5.4H, CMe3), 1.27-1.14 (m, 1H, CH); 
13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 175.7 (C=O, CO2Me), 175.5 (C=O, CO2Me), 155.2 (C=O, Boc), 153.7 (C=O, 
Boc), 146.5 (ipso-Ar), 145.9 (ipso-Ar), 132.8 (Ar), 132.6 (Ar), 127.9 (Ar), 127.8 (Ar), 121.4 
(ipso-Ar), 121.1 (ipso-Ar), 118.7 (Ar), 117.9 (Ar), 116.1 (Ar), 115.7 (Ar), 80.7 (CMe3), 79.9 
(CMe3), 69.2 (C), 68.9 (C), 52.5 (OMe), 52.4 (OMe), 48.4 (NCH2), 37.1 (CH2), 35.9 (CH2), 
35.3 (CH2Ar), 34.5 (CH2Ar), 28.5 (CMe3), 28.4 (CMe3), 23.3 (CH2), 22.7 (CH2); MS (ESI) 
m/z 335 (M + H)+; HRMS m/z calcd for C18H26N2O4 (M + H)
+ 335.1965, found 335.1973 (‒
2.1 ppm error). 
Lab Book - PJ-08-10. 
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1',4'-Dihydro-2'H-spiro[pyrrolidine-2,3'-quinolin]-2'-one 328 
 
p-TsOH (36 mg, 0.21 mmol, 1.0 eq) was added to a stirred solution of aniline N-Boc 
pyrrolidine-2-methyl ester 327 (70 mg, 0.21 mmol, 1.0 eq) in EtOH (5 mL) at rt. The 
resulting solution was stirred and heated at 90 °C for 16 h. The reaction mixture was allowed 
to cool to rt and evaporated under reduced pressure to give an orange oil. Sat NaHCO3(aq) 
(10 mL) was added and the mixture was extracted with EtOAc (3 x 10 mL). The combined 
organics were dried (Na2SO4) and evaporated under reduced pressure to give the crude 
product as an orange oil. Purification by flash column chromatography on silica with 95:5 
CH2Cl2-MeOH as eluent gave 5,6-spirocycle 328 (31 mg, 74%) as a cream soild, mp 116-
118 °C, RF (95:5 CH2Cl2-MeOH) 0.11; IR (ATR) 3057 (NH), 2927, 1668 (C=O), 1492, 
1369, 750 cm‒1; 1H NMR (400 MHz, CDCl3) δ 9.04 (br s, 1H, NH) 7.22-7.09 (m, 2H, Ar), 
6.97 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 6.83 (dd, J = 7.5, 1.0 Hz, 1H, Ar), 3.29-3.18 (m, 1H, 
NCH), 3.11-2.99 (m, 2H, NCH and CHAr), 2.86 (d, J = 15.5 Hz, 1H, CHAr), 1.91-1.69 (m, 
4H, CH). 13C NMR (100.6 MHz, CDCl3) δ 175.8 (C=O), 136.8 (ipso-Ar), 128.7 (Ar), 127.7 
(Ar), 123.8 (ipso-Ar), 123.2 (Ar), 115.2 (Ar), 63.9 (C), 47.6 (NCH2), 39.8 (CH2Ar), 35.5 
(CH2), 26.1 (CH2); MS (ESI) m/z 203 (M + H)
+; HRMS m/z calcd for C12H14N2O (M + H)
+ 
203.1179, found 203.1179 (‒0.4 ppm error). 
Lab Book - PJ-08-13. 
 
Methyl 4-(2-bromobenzyl)tetrahydro-2H-pyran-4-carboxylate 329 
 
Using general procedure H, LiHMDS (2.1 mL of a 1.0 M solution in toluene, 2.1 mmol, 1.4 
eq), THP-4-methyl ester 265 (0.2 mL, 1.5 mmol, 1.0 eq) in THF (10 mL) and 2-bromobenzyl 
bromide (525 mg, 2.1 mmol, 1.4 eq) in THF (5 mL) gave the crude product as a colourless 
oil. Purification by flash column chromatography on silica with 19:1 CH2Cl2-acetone as 
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eluent gave aryl THP-4-methyl ester 329 (368 mg, 76%) as a white solid, mp 44-46 °C; RF 
(19:1 CH2Cl2-acetone) 0.25; IR (ATR) 2956, 1713 (C=O), 1438, 1210, 1134, 1104, 774 cm
‒
1; 1H NMR (400 MHz, CDCl3) δ 7.55-7.48 (m, 1H, Ar), 7.23-7.17 (m, 1H, Ar), 7.09-7.01 
(m, 2H, Ar), 3.88-3.80 (m, 2H, OCH), 3.69 (s, 3H, OMe), 3.35 (ddd, J = 12.0, 12.0, 2.0 Hz, 
2H, OCH), 3.06 (s, 2H, CH2Ar), 2.11-2.04 (m, 2H, CH), 1.72 (ddd, J = 13.5, 12.0, 4.5 Hz, 
2H, CH); 13C NMR (100.6 MHz, CDCl3) δ 175.4 (C=O), 136.2 (ipso-Ar), 133.2 (Ar), 131.8 
(Ar), 128.5 (Ar), 127.1 (Ar), 125.8 (ipso-Ar), 65.6 (OCH2), 52.0 (OMe), 47.2 (C), 45.3 
(CH2Ar), 34.1 (CH2); MS (ESI) m/z 335 (M + Na)
+; HRMS m/z calcd for C14H17
79BrO3 (M 
+ Na)+ 335.0253, found 335.0249 (‒1.7 ppm error). 
Lab Book - PJ-08-12. 
 
1',2,3,4',5,6-Hexahydro-2'H-spiro[pyran-4,3'-quinolin]-2'-one 331 
 
Pd(OAc)2 (3.5 mg, 0.016 mmol, 0.05 eq) was added to a stirred solution of aryl THP-4-
methyl ester 329 (100 mg, 0.31 mmol, 1.0 eq), benzophenone imine (0.08 mL, 0.46 mmol, 
1.5 eq), Cs2CO3 (304 mg, 0.93 mmol, 3.0 eq) and Xantphos (18 mg, 0.031 mmol) in dioxane 
(6 mL) at rt. The reaction flask was evacuated under reduced pressure and back-filled with 
Ar three times. The resulting mixture was stirred and heated at 95 °C for 16 h. The reaction 
mixture was allowed to cool to rt and 1 M HCl(aq) (3 mL) was added. The resulting solution 
was stirred at rt for 10 min. 2 M NaOH(aq) (1 mL) was then added and the two the layers 
were separated. The aqueous layer was extracted with CH2Cl2 (3 x 10 mL) and the combined 
organics were dried (Na2CO3) and evaporated under reduced pressure to give the crude 
product as a black oil. Purification by flash column chromatography on silica with 80:20-
60:40 hexane-EtOAc as eluent gave a 65:35 mixture (by 1H NMR spectroscopy) of 
spirocycle 331 and aniline THP-4-methyl ester 330 (66 mg) as a white solid. The solid was 
taken up into MeOH (5 mL) and the resulting solution was stirred and heated at 50 °C for 
16 h. The reaction mixture was allowed to cool to rt and evaporated under reduced pressure 
to afford spirocycle THP 330 (61 mg, 91%) as a white solid, mp 188-190 °C; RF (80:20 
hexane-EtOAc) 0.04; IR (ATR) 3058 (NH), 2984, 1662 (C=O), 1490, 1239, 747, 486 cm‒1; 
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1H NMR (400 MHz, CDCl3) δ 8.44 (s, 1H, NH), 7.23-7.11 (m, 2H, Ar), 7.05-6.92 (m, 1H, 
Ar), 6.86-6.64 (m, 1H, Ar), 3.90 (ddd, J = 11.5, 7.5, 3.5 Hz, 2H, OCH), 3.74 (ddd, J = 11.5, 
7.0, 4.0 Hz, 2H, OCH), 2.92 (s, 2H, CH2Ar), 2.01 (ddd, J = 14.0, 7.0, 4.0 Hz, 2H, CH), 1.47 
(ddd, J = 14.0, 7.5, 3.5 Hz, 1H); 13C NMR (100.6 MHz, CDCl3) δ 175.4 (C=O), 136.5 (ipso-
Ar), 128.7 (Ar), 127.8 (Ar), 123.3 (Ar), 122.3 (ipso-Ar), 114.8 (Ar), 64.0 (OCH2), 37.7 (C), 
37.3 (CH2Ar), 32.2 (CH2); MS (ESI) m/z 240 (M + Na)
+; HRMS m/z calcd for C13H15NO2 
(M + Na)+ 240.0995, found 240.0996 (‒1.6 ppm error). 
Lab Book – PJ-08-14. 
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Abbreviations 
 
Aq - Aqueous  
Bn - Benzyl  
Br - Broad  
Cbz - Carboxybenzyl   
cm‒1 - Wavenumber  
d - Doublet  
DBU - 1,8-Diazabicyclo[5.4.0]undec-7-ene  
DDQ - 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DIPEA - N,N-Diisopropylethylamine 
DMAP - 4-Dimethylaminopyridine 
DOS - Diversity Orientated Synthesis 
DPPA - Diphenyl phosphoryl azide 
dppf - 1,1'-Bis(diphenylphosphino)ferrocene 
DTPF - 1,1’-Bis(di-o-tolylphosphino)ferrocene 
Eq. - Equivalents  
ESI - Electrospray ionisation  
FBDD - Fragment based drug discovery  
FDA - Food and drug administration  
FG - Functional group 
g - Gram(s)  
GSK3β - Glycogen synthase kinase 3β 
h - Hour(s)  
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H bond - Hydrogen bond  
HAC - Heavy atom count  
HBA - Hydrogen bond acceptor 
HBD - Hydrogen bond donor 
HRMS - High resolution mass spectrometry  
HTS - High throughput screening  
Hz - Hertz  
ICR - Institute of Cancer Research 
IP - Intellectual properties 
IR - Infra-red  
J - Coupling constant in Hz  
kcal mol‒1 - Kilocalories per mole  
KHMDS - Potassium hexamethyldisilazide 
LLAMA - Lead-likeness and Molecular Analysis 
m - Multiplet  
M - Molar  
MAP - Mitogen protein kinase  
m-CPBA - meta-Chloroperoxybenzoic acid 
m/z - Mass to charge ratio  
M+ - Molecular ion  
mg - Milligrams  
μM - Micromolar  
min - Minute(s)  
mL - Millilitre(s)  
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mmol - Millimole(s)  
MS - Mass spectrometry  
MW - Molecular weight 
MW - Microwave 
NCA - N-carboxyanhydrides  
nM - Nanomolar  
NMR - Nuclear Magnetic Resonance  
NMP - N-Methyl-2-pyrrolidone 
NPR - Normalised PMI ratio  
Ns - Nosyl 
Oxyma - Ethyl cyanohydroxyiminoacetate 
PAINS - Pan-assay interference compounds  
PBF - Plane of Best Fit  
PHIP - Pleckstrin homology domain interacting protein 
PMI - Principal moment of inertia  
ppm - Parts per million  
PSA - Polar Surface Area 
p-TSA - para-Toluenesulfonic acid 
q - Quartet  
Rf - Retention Factor  
RO3 - Rule of three 
RMSD - Root-mean-square deviation 
rt - Room Temperature  
s - Singlet  
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SAR - Structure Activity Relationship 
SeeD - Selection of Experimental Exploitable Drug Starting Point 
SEM - [2-(Trimethylsilyl)ethoxy]methyl acetal 
SMILES - Simplified molecular-input line-entry system  
SPR - Surface plasmon resonance  
t - Triplet 
TFA - Trifluoroacetic acid 
TMEDA - N',N',N',N'-Tetramethylethylenediamine 
QC - Quality control 
3-D FIT - 3-D Fragment idea Tool  
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